US6630328B2
(en)
|
1909-07-15 |
2003-10-07 |
Genencor International, Inc. |
Increasing production of proteins in gram-positive microorganisms
|
GB8308235D0
(en)
*
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
EP0957167A1
(en)
*
|
1983-11-02 |
1999-11-17 |
Applied Research Systems ARS Holding N.V. |
Production of heterodimeric human fertility hormones
|
US5639639A
(en)
*
|
1983-11-02 |
1997-06-17 |
Genzyme Corporation |
Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
|
US5229272A
(en)
*
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
JPS6147500A
(ja)
*
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
US5807715A
(en)
*
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
EP0173494A3
(en)
*
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
US6808901B1
(en)
*
|
1984-09-03 |
2004-10-26 |
Celltech R&D Limited |
Production of chimeric antibodies
|
GB8422238D0
(en)
*
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
JPS61134325A
(ja)
*
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
US5169939A
(en)
*
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
US5672502A
(en)
*
|
1985-06-28 |
1997-09-30 |
Celltech Therapeutics Limited |
Animal cell culture
|
US5369010A
(en)
*
|
1985-08-16 |
1994-11-29 |
Genetic Systems Corporation |
Monoclonal antibody to polymorphic HLA determinant -B27
|
DE3689123T2
(de)
*
|
1985-11-01 |
1994-03-03 |
Xoma Corp |
Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
|
EP0536566A1
(en)
*
|
1985-11-01 |
1993-04-14 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5576195A
(en)
*
|
1985-11-01 |
1996-11-19 |
Xoma Corporation |
Vectors with pectate lyase signal sequence
|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US4935233A
(en)
*
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
JPS62153300A
(ja)
*
|
1985-12-26 |
1987-07-08 |
Teijin Ltd |
ヒト免疫グロブリンGFc領域蛋白質およびその製造方法
|
EP0234592A1
(en)
*
|
1986-02-28 |
1987-09-02 |
Teijin Limited |
Plasmid containing DNA fragment coding for human immunoglobulin G Fc region protein and use thereof for production of said protein
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5225539A
(en)
*
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
*
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5955584A
(en)
*
|
1986-03-31 |
1999-09-21 |
Charter Ventures |
Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
|
US5811248A
(en)
*
|
1986-03-31 |
1998-09-22 |
Charter Ventures |
Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
|
US6025477A
(en)
*
|
1986-03-31 |
2000-02-15 |
Calenoff; Emanuel |
Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
|
US4859609A
(en)
*
|
1986-04-30 |
1989-08-22 |
Genentech, Inc. |
Novel receptors for efficient determination of ligands and their antagonists or agonists
|
JPS63112995A
(ja)
*
|
1986-07-07 |
1988-05-18 |
セントコ−・インコ−ポレ−テッド |
腫瘍関連抗原に特異的なキメラ齧歯類/ヒト免疫グロブリン
|
JPH0698021B2
(ja)
*
|
1986-08-01 |
1994-12-07 |
帝人株式会社 |
マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラdna配列、プラスミド及び細胞
|
JPS6336786A
(ja)
*
|
1986-07-31 |
1988-02-17 |
Teijin Ltd |
抗体l鎖発現型核酸塩基配列,プラスミド,細胞及びキメラ抗体l鎖
|
US5958678A
(en)
*
|
1986-08-21 |
1999-09-28 |
The Trustees Of Columbia University In The City Of New York |
DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
|
US6673896B1
(en)
*
|
1986-08-21 |
2004-01-06 |
The Trustees Of Columbia University In The City Of New York |
Derivatives of soluble T-4
|
AU616639B2
(en)
|
1986-08-21 |
1991-11-07 |
Trustees Of Columbia University In The City Of New York, The |
Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
|
US5126433A
(en)
*
|
1986-08-21 |
1992-06-30 |
The Trustees Of Columbia University In The City Of New York |
Soluble forms of the t cell surface protein cd4
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
DE3785186T2
(de)
*
|
1986-09-02 |
1993-07-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US6893625B1
(en)
*
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL84285A
(en)
*
|
1986-10-27 |
1993-03-15 |
Int Genetic Engineering |
Chimeric antibody with specificity to human tumor antigen
|
CA1339445C
(en)
*
|
1986-11-12 |
1997-09-09 |
The General Hospital Corporation |
Recombinant hybrid immunoglobulin molecules and method of use
|
IL85035A0
(en)
*
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5169752A
(en)
*
|
1987-02-19 |
1992-12-08 |
Nissin Shokuhin Kabushiki Kaisha |
Methods and materials for HIV detection
|
US5140105A
(en)
*
|
1987-02-19 |
1992-08-18 |
Nissin Shokuhin Kabushiki Kaisha |
Methods and materials for HIV detection
|
US5217895A
(en)
*
|
1987-02-19 |
1993-06-08 |
Nissin Shokuhin Kabushiki Kaisha |
Monoclonal anti-idiotypic antibodies specific for anti-T4 antibodies and cross-reactive with HIV
|
US5180660A
(en)
*
|
1987-02-19 |
1993-01-19 |
Nissin Shokuhin Kabushiki Kaisha |
Methods and materials for HIV detection
|
DE3855869T2
(de)
|
1987-02-20 |
1997-10-02 |
Genentech Inc |
Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
|
EP0307434B2
(en)
*
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5610034A
(en)
*
|
1987-04-29 |
1997-03-11 |
Alko Group Ltd. |
Immunoglobulin production by trichoderma
|
DE3856559T2
(de)
*
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunktionelle Proteine mit vorbestimmter Zielsetzung
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US5132405A
(en)
*
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5981278A
(en)
*
|
1987-05-29 |
1999-11-09 |
Tanox, Inc. |
Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
|
US5834599A
(en)
*
|
1987-05-29 |
1998-11-10 |
Tanox Biosystems, Inc. |
Immunoconjugates which neutralize HIV-1 infection
|
US6657050B1
(en)
|
1987-05-29 |
2003-12-02 |
Tanox, Inc. |
Chimeric viral-neutralizing immunoglobulins
|
CA1341235C
(en)
*
|
1987-07-24 |
2001-05-22 |
Randy R. Robinson |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5677425A
(en)
*
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
JPH02501533A
(ja)
*
|
1987-09-09 |
1990-05-31 |
セルテック リミテッド |
ポリペプチド製造
|
US5336603A
(en)
*
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
US6710169B2
(en)
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
FI884924A
(fi)
*
|
1987-10-28 |
1989-04-29 |
Oncogen |
Humanimmuglobulin som producerats med hybrid-dna-teknik.
|
US4978745A
(en)
*
|
1987-11-23 |
1990-12-18 |
Centocor, Inc. |
Immunoreactive heterochain antibodies
|
AU625613B2
(en)
*
|
1988-01-05 |
1992-07-16 |
Novartis Ag |
Novel chimeric antibodies
|
GB8800077D0
(en)
*
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel chimeric antibodies
|
US5843708A
(en)
*
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US6004781A
(en)
*
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
US6018026A
(en)
*
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
ZA89430B
(en)
*
|
1988-01-22 |
1989-10-25 |
Gen Hospital Corp |
Cloned genes encoding ig-cd4 fusion proteins and the use thereof
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
JP2646007B2
(ja)
|
1988-01-30 |
1997-08-25 |
財団法人 化学及血清療法研究所 |
抗hiv抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗hivキメラ抗体ならびにその製法
|
JP3095168B2
(ja)
*
|
1988-02-05 |
2000-10-03 |
エル. モリソン,シェリー |
ドメイン‐変性不変部を有する抗体
|
US5846534A
(en)
*
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
IL89489A0
(en)
*
|
1988-03-09 |
1989-09-10 |
Hybritech Inc |
Chimeric antibodies directed against human carcinoembryonic antigen
|
AU3342689A
(en)
*
|
1988-03-24 |
1989-10-16 |
Igen Incorporated |
Luminescent chimeric proteins
|
US5582862A
(en)
|
1988-04-04 |
1996-12-10 |
General Hospital Corporation |
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
|
US5372812A
(en)
*
|
1988-04-04 |
1994-12-13 |
The General Hospital Corporation |
Composition and method for acceleration of clot lysis
|
EP0362371A4
(en)
*
|
1988-04-15 |
1990-10-24 |
Protein Design Labs, Inc. |
Il-2 receptor-specific chimeric antibodies
|
US4975369A
(en)
*
|
1988-04-21 |
1990-12-04 |
Eli Lilly And Company |
Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|
US5171666A
(en)
*
|
1988-04-22 |
1992-12-15 |
Eli Lilly And Company |
Monoclonal antibodies reactive with a cell-surface gylcoprotein expressed on human carcinomas
|
US5770198A
(en)
*
|
1988-05-18 |
1998-06-23 |
The Research Foundation Of The State Of New York |
Platelet-specific chimeric 7E3 immunoglobulin
|
JP2749167B2
(ja)
|
1988-06-21 |
1998-05-13 |
ジェネンテク,インコーポレイテッド |
心筋梗塞の処置のための方法および治療用組成物
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
WO1990002762A1
(en)
|
1988-09-02 |
1990-03-22 |
The Rockefeller University |
Macrophage-derived inflammatory mediator (mip-2)
|
US5576184A
(en)
*
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
DE68929167T2
(de)
*
|
1988-09-06 |
2000-11-16 |
Xoma Corp |
Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
|
DE3835350A1
(de)
*
|
1988-10-17 |
1990-04-19 |
Boehringer Mannheim Gmbh |
Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
|
US6051225A
(en)
|
1988-10-19 |
2000-04-18 |
The Dow Chemical Company |
Family of high affinity, modified antibodies for cancer treatment
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
US20030229208A1
(en)
*
|
1988-12-28 |
2003-12-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
IL162181A
(en)
*
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1990007713A1
(en)
*
|
1988-12-29 |
1990-07-12 |
Cytogen Corporation |
Molecular recognition units
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
ES2082850T3
(es)
*
|
1989-02-24 |
1996-04-01 |
Univ California |
Inmunoglobulinas preparadas geneticamente.
|
US5599538A
(en)
*
|
1989-04-25 |
1997-02-04 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US5658753A
(en)
*
|
1989-04-25 |
1997-08-19 |
Paul; Sudhir |
Catalytic antibody components
|
US5318897A
(en)
*
|
1989-04-25 |
1994-06-07 |
Igen, Inc. |
Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
|
US5236836A
(en)
*
|
1989-04-25 |
1993-08-17 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US6048717A
(en)
*
|
1989-04-25 |
2000-04-11 |
Igen International, Inc. |
Inhibitors of catalytic antibodies
|
US5602015A
(en)
*
|
1989-04-25 |
1997-02-11 |
Igen, Inc. |
Autoantibodies which enhance the rate of a chemical reaction
|
US6291161B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US5897861A
(en)
*
|
1989-06-29 |
1999-04-27 |
Medarex, Inc. |
Bispecific reagents for AIDS therapy
|
US6020145A
(en)
*
|
1989-06-30 |
2000-02-01 |
Bristol-Myers Squibb Company |
Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
|
US5081235A
(en)
*
|
1989-07-26 |
1992-01-14 |
City Of Hope |
Chimeric anti-cea antibody
|
US7247475B2
(en)
*
|
1989-07-28 |
2007-07-24 |
Wyeth |
Method for producing monoclonal antibodies
|
US6475787B1
(en)
*
|
1989-07-28 |
2002-11-05 |
Wyeth |
Method for producing monoclonal antibodies
|
US5580774A
(en)
*
|
1989-07-31 |
1996-12-03 |
Eli Lilly And Company |
Chimeric antibodies directed against a human glycoprotein antigen
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
CA2064915C
(en)
|
1989-08-07 |
2001-05-29 |
Deborah A. Rathjen |
Tumour necrosis factor binding ligands
|
CA2022959C
(en)
*
|
1989-08-10 |
2001-03-20 |
Hiroaki Maeda |
Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
|
DK0491878T3
(da)
|
1989-08-16 |
1997-06-23 |
Chiron Corp |
Præparater til inhibering af proteinhormondannelse og anvendelser deraf
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
CA2065010A1
(en)
*
|
1989-08-23 |
1991-02-24 |
Brian Seed |
Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
EP0417563B1
(de)
|
1989-09-12 |
2000-07-05 |
F. Hoffmann-La Roche Ag |
TNF-bindende Proteine
|
JP2852705B2
(ja)
*
|
1989-09-15 |
1999-02-03 |
タノックス バイオシステムズ インコーポレイテッド |
自己免疫疾患の治療
|
CA2066720A1
(en)
*
|
1989-09-19 |
1991-03-20 |
David M. Knight |
Method for improving human monoclonal antibody production
|
US5196320A
(en)
*
|
1989-09-20 |
1993-03-23 |
Abbott Biotech, Inc. |
Method of producing engineered binding proteins
|
US6018031A
(en)
*
|
1989-10-20 |
2000-01-25 |
Trustees Of Dartmouth College |
Binding agents specific for IgA receptor
|
US5959177A
(en)
*
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US7005560B1
(en)
|
1989-10-27 |
2006-02-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6995014B1
(en)
|
1989-10-27 |
2006-02-07 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US7037722B1
(en)
|
1989-10-27 |
2006-05-02 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5202422A
(en)
*
|
1989-10-27 |
1993-04-13 |
The Scripps Research Institute |
Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
|
CA2045150A1
(en)
*
|
1989-11-07 |
1991-05-08 |
Walt W. Shuford |
Oligomeric immunoglobulins
|
WO1991007418A1
(en)
*
|
1989-11-13 |
1991-05-30 |
Xoma Corporation |
Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
|
GB8928874D0
(en)
*
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
US7037496B2
(en)
|
1989-12-27 |
2006-05-02 |
Centocor, Inc. |
Chimeric immunoglobulin for CD4 receptors
|
US6232444B1
(en)
*
|
1990-01-29 |
2001-05-15 |
The Regents Of The University Of California |
Conserved anti-DNA antibody idiotype associated with nephritis in murine and human lupus
|
JP3319594B2
(ja)
*
|
1990-03-20 |
2002-09-03 |
ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク |
定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
|
GB9009548D0
(en)
*
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Chimeric antibody and method
|
GB9009549D0
(en)
*
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Recombinant antibody and method
|
AU7796291A
(en)
*
|
1990-05-04 |
1991-11-27 |
Baxter Diagnostics Inc. |
High affinity antibodies to small peptides
|
US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
US7253264B1
(en)
|
1990-06-28 |
2007-08-07 |
Sanofi-Arentideutschland GmbH |
Immunoglobulin fusion proteins, their production and use
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6916605B1
(en)
*
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
JP3283041B2
(ja)
*
|
1990-07-13 |
2002-05-20 |
学校法人藤田学園 |
人工抗体
|
EP0539395A1
(en)
*
|
1990-07-16 |
1993-05-05 |
Alko Group Ltd. |
IMMUNOGLOBULIN PRODUCTION BY $i(TRICHODERMA)
|
DE4107154A1
(de)
*
|
1990-10-11 |
1992-04-16 |
Boehringer Mannheim Gmbh |
Monoklonale antikoerper gegen melanom
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
CA2095842A1
(en)
*
|
1990-11-09 |
1992-05-10 |
Stephen D. Gillies |
Bridging antibody fusion constructs
|
IE914075A1
(en)
*
|
1990-11-23 |
1992-06-03 |
Gen Hospital Corp |
Inhibition of cell adhesion protein-carbohydrate¹interactions
|
US5709859A
(en)
*
|
1991-01-24 |
1998-01-20 |
Bristol-Myers Squibb Company |
Mixed specificity fusion proteins
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
US5547853A
(en)
*
|
1991-03-12 |
1996-08-20 |
Biogen, Inc. |
CD2-binding domain of lymphocyte function associated antigen 3
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
US20040120952A1
(en)
*
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
*
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US6277969B1
(en)
*
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US20020032313A1
(en)
*
|
1991-03-29 |
2002-03-14 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US20030206899A1
(en)
*
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
*
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US5223396A
(en)
*
|
1991-05-03 |
1993-06-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for detecting organ transplant rejection
|
US20050196400A1
(en)
*
|
1991-05-06 |
2005-09-08 |
Xoma Technology Ltd. |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
US5834229A
(en)
|
1991-05-24 |
1998-11-10 |
Genentech, Inc. |
Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
ES2145004T3
(es)
*
|
1991-08-21 |
2000-07-01 |
Novartis Ag |
Derivados de anticuerpos.
|
EP0861893A3
(en)
*
|
1991-09-19 |
1999-11-10 |
Genentech, Inc. |
High level expression of immunoglobulin polypeptides
|
US20070031409A1
(en)
*
|
1991-09-26 |
2007-02-08 |
Stichting Rega Vzw |
Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US6025165A
(en)
*
|
1991-11-25 |
2000-02-15 |
Enzon, Inc. |
Methods for producing multivalent antigen-binding proteins
|
ATE275198T1
(de)
*
|
1991-12-02 |
2004-09-15 |
Medical Res Council |
Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
|
US5766886A
(en)
*
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
ATE150319T1
(de)
†
|
1992-01-13 |
1997-04-15 |
Biogen Inc |
Behandlung von asthma
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
ATE255902T1
(de)
*
|
1992-03-09 |
2003-12-15 |
San Diego Regional Cancer Ct |
Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
|
US5518887A
(en)
*
|
1992-03-30 |
1996-05-21 |
Abbott Laboratories |
Immunoassays empolying generic anti-hapten antibodies and materials for use therein
|
US7754211B2
(en)
*
|
1992-04-10 |
2010-07-13 |
Research Development Foundation |
Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
|
US6599505B1
(en)
*
|
1992-04-10 |
2003-07-29 |
Research Development Foundation |
Immunotoxins directed against CD33 related surface antigens
|
AU4283793A
(en)
*
|
1992-04-16 |
1993-11-18 |
Albert Einstein College Of Medicine Of Yeshiva University |
Monocyte adhesion protein and monoclonal antibody thereto
|
US5851787A
(en)
*
|
1992-04-20 |
1998-12-22 |
The General Hospital Corporation |
Nucleic acid encoding amyloid precursor-like protein and uses thereof
|
US5643570A
(en)
*
|
1992-05-19 |
1997-07-01 |
Xoma Corporation |
BPI-immunoglobulin fusion proteins
|
US6274348B1
(en)
|
1992-05-19 |
2001-08-14 |
Xoma Corporation |
Methods for the preparation of positively charged proteins
|
US5397703A
(en)
*
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
US5437951A
(en)
*
|
1992-09-03 |
1995-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Self-assembling recombinant papillomavirus capsid proteins
|
US5573924A
(en)
*
|
1992-09-08 |
1996-11-12 |
Immunex Corporation |
CD27 ligand
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
RO119721B1
(ro)
|
1992-10-28 |
2005-02-28 |
Genentech Inc. |
Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
EP0752248B1
(en)
*
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US6652863B1
(en)
|
1992-11-16 |
2003-11-25 |
Centocor, Inc. |
Method of reducing the immunogenicity of compounds
|
WO1994012520A1
(en)
*
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
DE69419721T2
(de)
*
|
1993-01-12 |
2000-04-27 |
Biogen Inc |
Rekombinante anti-vla4 antikörpermoleküle
|
WO1994015969A1
(en)
*
|
1993-01-14 |
1994-07-21 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Recombinant anti-hiv antibody and preparation thereof
|
US20050255104A1
(en)
*
|
1993-01-29 |
2005-11-17 |
Centocor, Inc. |
Methods of treating psoriasis using anti-TNF receptor fusion proteins
|
EP0621338A3
(en)
*
|
1993-04-21 |
1997-10-29 |
Ajinomoto Kk |
The interleukin-2 response blocking immunosuppressor.
|
AU6796094A
(en)
|
1993-04-29 |
1994-11-21 |
Raymond Hamers |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
|
JPH08510240A
(ja)
|
1993-05-12 |
1996-10-29 |
カイロン コーポレイション |
C型肝炎ウイルスe2/ns1領域の保存モチーフ
|
US6562333B1
(en)
|
1993-06-14 |
2003-05-13 |
Schering Corporation |
Purified mammalian CTLA-8 antigens and related reagents
|
US20040067157A1
(en)
*
|
1993-07-22 |
2004-04-08 |
Clearant, Inc. |
Methods for sterilizing biological materials
|
US5684144A
(en)
*
|
1993-07-28 |
1997-11-04 |
University Of North Texas |
Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof
|
US5491071A
(en)
*
|
1993-08-03 |
1996-02-13 |
Abbott Laboratories |
Reagents and methods for the detection and quantification of testosterone in fluid samples
|
ATE234855T1
(de)
*
|
1993-09-20 |
2003-04-15 |
Anadis Ltd |
Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
|
AU7732894A
(en)
*
|
1993-09-22 |
1995-04-10 |
Nichols Institute Diagnostics |
Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
|
US5827690A
(en)
*
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
DK145493D0
(da)
*
|
1993-12-23 |
1993-12-23 |
Dako As |
Antistof
|
US5476939A
(en)
*
|
1993-12-30 |
1995-12-19 |
Abbott Laboratories |
Certain pyridyl and isoquinolyl carbinolamine derivatives
|
US6660256B1
(en)
|
1994-01-03 |
2003-12-09 |
Genetech, Inc. |
Porcine mpl ligand
|
US6335160B1
(en)
|
1995-02-17 |
2002-01-01 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US6165793A
(en)
|
1996-03-25 |
2000-12-26 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5605793A
(en)
*
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US6406855B1
(en)
|
1994-02-17 |
2002-06-18 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
US6395547B1
(en)
|
1994-02-17 |
2002-05-28 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US6995017B1
(en)
|
1994-02-17 |
2006-02-07 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
EP0749488A1
(en)
*
|
1994-03-03 |
1996-12-27 |
Genentech, Inc. |
Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
|
US5874080A
(en)
*
|
1994-03-03 |
1999-02-23 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of asthma
|
WO1995024501A1
(en)
|
1994-03-07 |
1995-09-14 |
Cetus Oncology Corporation |
Compositions for the inhibition of tnf formation and uses thereof
|
DK0746613T3
(da)
*
|
1994-03-08 |
2006-09-25 |
Sloan Kettering Inst Cancer |
Rekombinante humaniserede antistoffer mod FB5
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6992175B1
(en)
*
|
1994-04-15 |
2006-01-31 |
Amgen Inc. |
Nucleic acids encoding Eph-like receptor tyrosine kinases
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
GB9412230D0
(en)
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
USRE39548E1
(en)
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
US5686600A
(en)
*
|
1994-06-28 |
1997-11-11 |
Novartis Finance Corporation |
Antibodies which bind to insect gut proteins and their use
|
CU22615A1
(es)
|
1994-06-30 |
2000-02-10 |
Centro Inmunologia Molecular |
Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
|
US6576236B1
(en)
|
1994-07-01 |
2003-06-10 |
Dana Farber Cancer Institute |
Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
|
US6080560A
(en)
*
|
1994-07-25 |
2000-06-27 |
Monsanto Company |
Method for producing antibodies in plant cells
|
US6140075A
(en)
*
|
1994-07-25 |
2000-10-31 |
Monsanto Company |
Method for producing antibodies and protein toxins in plant cells
|
US5885574A
(en)
*
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
AU691331B2
(en)
|
1994-08-12 |
1998-05-14 |
Myriad Genetics, Inc. |
Method for diagnosing a predisposition for breast and ovarian cancer
|
AU686004B2
(en)
|
1994-08-12 |
1998-01-29 |
Myriad Genetics, Inc. |
In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
|
CA2195557C
(en)
*
|
1994-08-12 |
2006-10-17 |
Shui-On Leung |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
EP0789575B8
(en)
|
1994-11-02 |
2009-01-14 |
Allelix Neuroscience, Inc. |
Peripheral nervous system specific sodium channels, dna encoding therefor, drug screening, and methods of making and using thereof
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6017697A
(en)
|
1994-11-14 |
2000-01-25 |
Eli Lilly And Company |
Excitatory amino acid receptor protein and related nucleic acid compounds
|
US20030086922A1
(en)
*
|
1994-12-02 |
2003-05-08 |
David B. Ring |
Method of promoting an immune response with a bispecific antibody
|
US6692920B1
(en)
*
|
1994-12-07 |
2004-02-17 |
Incyte Corporation |
Antibodies to a chemokine expressed in inflamed adenoid
|
US5633149A
(en)
|
1994-12-07 |
1997-05-27 |
Incyte Pharmaceuticals, Inc. |
Polynucleotide encoding novel chemokine expressed in inflamed adenoid
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
US5876950A
(en)
*
|
1995-01-26 |
1999-03-02 |
Bristol-Myers Squibb Company |
Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
|
US6551593B1
(en)
*
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
US7803904B2
(en)
*
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US7005509B1
(en)
|
1995-02-17 |
2006-02-28 |
Incyte Corporation |
Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
|
US5795966A
(en)
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US6091001A
(en)
*
|
1995-03-29 |
2000-07-18 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US20060193862A1
(en)
*
|
1995-03-30 |
2006-08-31 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
IL117645A
(en)
*
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US6214344B1
(en)
|
1995-06-02 |
2001-04-10 |
Genetech, Inc. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
US5646036A
(en)
*
|
1995-06-02 |
1997-07-08 |
Genentech, Inc. |
Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
|
WO1996040726A1
(en)
|
1995-06-07 |
1996-12-19 |
Genta Incorporated |
Novel carbamate-based cationic lipids
|
AU6267896A
(en)
|
1995-06-07 |
1996-12-30 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth oftumors
|
EP0833911B1
(en)
*
|
1995-06-07 |
2004-05-12 |
Ortho Pharmaceutical Corporation |
Cdr-grafted anti-tissue factor antibodies and methods of use thereof
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
GB0112226D0
(en)
*
|
2001-05-18 |
2001-07-11 |
Danisco |
Method of improving dough and bread quality
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
EP2258726A1
(en)
|
1995-06-14 |
2010-12-08 |
The Regents of the University of California |
High affinity human antibodies to c-erbB-2
|
US5925351A
(en)
*
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US20040197326A1
(en)
*
|
1995-07-27 |
2004-10-07 |
Genentech, Inc. |
Method for treatment of allergic asthma
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
AU716785B2
(en)
|
1995-07-27 |
2000-03-09 |
Genentech Inc. |
Stabile isotonic lyophilized protein formulation
|
US6248555B1
(en)
|
1995-08-31 |
2001-06-19 |
The General Hospital Corporation |
Genetic alterations related to familial alzheimer's disease
|
WO1997010505A1
(en)
*
|
1995-09-14 |
1997-03-20 |
The Regents Of The University Of California |
ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc¿
|
ES2341864T3
(es)
|
1995-09-29 |
2010-06-29 |
Universita Degli Studi Di Siena |
Genes regulados y usos de los mismos.
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
US6440418B1
(en)
*
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
NZ326525A
(en)
|
1995-12-18 |
1999-11-29 |
Endorecherche Inc |
Chromosome 13-linked breast cancer susceptibility gene
|
US5837492A
(en)
|
1995-12-18 |
1998-11-17 |
Myriad Genetics, Inc. |
Chromosome 13-linked breast cancer susceptibility gene
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6046048A
(en)
*
|
1996-01-09 |
2000-04-04 |
Genetech, Inc. |
Apo-2 ligand
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
*
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
AU730816B2
(en)
*
|
1996-02-12 |
2001-03-15 |
Cedars-Sinai Medical Center |
Vitamin D response element binding protein
|
US20040006018A1
(en)
*
|
1996-02-14 |
2004-01-08 |
Genentech, Inc. |
Cardiotrophin and uses therefor
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
US6730300B2
(en)
*
|
1996-03-20 |
2004-05-04 |
Immunomedics, Inc. |
Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
|
US7964190B2
(en)
*
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
JP2000507245A
(ja)
*
|
1996-03-22 |
2000-06-13 |
ユニバーシティー オブ ジョージア リサーチ ファウンデーション,インコーポレイテッド |
Porphyromonas gingivalisペプチドを含む免疫原性組成物および方法
|
US6506602B1
(en)
|
1996-03-25 |
2003-01-14 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US6469144B1
(en)
|
1996-04-01 |
2002-10-22 |
Genentech, Inc. |
Apo-2LI and Apo-3 polypeptides
|
US20020165157A1
(en)
*
|
1996-04-01 |
2002-11-07 |
Genentech, Inc. |
Apo-2LI and Apo-3 polypeptides
|
US7241568B2
(en)
*
|
1996-04-03 |
2007-07-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-fibroblast growth factor-8 monoclonal antibody
|
EP0966971A1
(en)
|
1996-04-23 |
1999-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
|
US6107090A
(en)
|
1996-05-06 |
2000-08-22 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
EP0918858A1
(en)
*
|
1996-05-10 |
1999-06-02 |
Biogen, Inc. |
Common gamma chain blocking agents
|
GB9610967D0
(en)
|
1996-05-24 |
1996-07-31 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
US6716974B1
(en)
|
1996-05-31 |
2004-04-06 |
Maine Medical Center Research Institute |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
CA2256481A1
(en)
|
1996-05-31 |
1997-12-04 |
The National American Red Cross |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
DE69724428T3
(de)
*
|
1996-06-07 |
2009-07-23 |
Poniard Pharmaceuticals, Inc., Seattle |
Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
|
AU729029B2
(en)
|
1996-07-03 |
2001-01-25 |
Genentech Inc. |
Hepatocyte growth factor receptor agonists and uses thereof
|
GB9712818D0
(en)
*
|
1996-07-08 |
1997-08-20 |
Cambridge Antibody Tech |
Labelling and selection of specific binding molecules
|
DE69737326T2
(de)
|
1996-07-12 |
2007-11-22 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Transkriptions zwischen faktor-2 tif2
|
DE69734397T2
(de)
|
1996-08-07 |
2006-07-06 |
Biogen Idec Ma Inc., Cambridge |
Tumor-nekrose-faktor ähnliches ligand
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
DK0961831T3
(da)
|
1996-08-16 |
2009-01-12 |
Human Genome Sciences Inc |
Humant alfa-endokin
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US20030044859A1
(en)
*
|
1996-08-19 |
2003-03-06 |
Henslee Jerry G. |
Reagents and methods useful for detecting diseases of the breast
|
JP2001502895A
(ja)
*
|
1996-09-20 |
2001-03-06 |
ザ・ジェネラル・ホスピタル・コーポレイション |
アルファ―2―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
|
US6462176B1
(en)
*
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US6903194B1
(en)
*
|
1996-09-26 |
2005-06-07 |
Chungai Seiyaku Kabushiki Kaisha |
Antibody against human parathormone related peptides
|
US5990281A
(en)
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
US6136958A
(en)
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
ATE245194T1
(de)
*
|
1996-10-01 |
2003-08-15 |
Geron Corp |
Katalytische untereinheit der menschlichen telomerase
|
US6093809A
(en)
*
|
1996-10-01 |
2000-07-25 |
University Technology Corporation |
Telomerase
|
US6808880B2
(en)
*
|
1996-10-01 |
2004-10-26 |
Geron Corporation |
Method for detecting polynucleotides encoding telomerase
|
US7585622B1
(en)
|
1996-10-01 |
2009-09-08 |
Geron Corporation |
Increasing the proliferative capacity of cells using telomerase reverse transcriptase
|
US6475789B1
(en)
*
|
1996-10-01 |
2002-11-05 |
University Technology Corporation |
Human telomerase catalytic subunit: diagnostic and therapeutic methods
|
US6610839B1
(en)
*
|
1997-08-14 |
2003-08-26 |
Geron Corporation |
Promoter for telomerase reverse transcriptase
|
US6261836B1
(en)
|
1996-10-01 |
2001-07-17 |
Geron Corporation |
Telomerase
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6420140B1
(en)
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
US6395276B1
(en)
|
1997-05-02 |
2002-05-28 |
Immunomedics, Inc. |
Immunotoxins directed against malignant cells
|
US5977319A
(en)
*
|
1996-10-21 |
1999-11-02 |
Cambridge Antibody Technology Limited |
Specific binding members for estradiol; materials and methods
|
US7255854B1
(en)
|
1996-10-25 |
2007-08-14 |
Biogen, Inc. |
Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
|
PT939804E
(pt)
|
1996-10-25 |
2005-11-30 |
Human Genome Sciences Inc |
Neutroquina alfa
|
US6348581B1
(en)
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
US20040146507A1
(en)
*
|
1996-11-27 |
2004-07-29 |
Genentech, Inc. |
Antibody mutants
|
US6037454A
(en)
*
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
ATE399861T1
(de)
|
1996-12-13 |
2008-07-15 |
Schering Corp |
Oberflächenantigene aus säugern
|
US20070009930A1
(en)
*
|
1996-12-18 |
2007-01-11 |
Maxygen, Inc. |
Methods and compositions for polypeptide engineering
|
SI1019500T1
(sl)
|
1997-01-15 |
2007-02-28 |
Yeda Res & Dev |
Proteini, ki vezejo receptor 1 za ifn, dna, ki jih kodira, in postopki za regulacijo celicnega odziva na interferone
|
US20040241645A1
(en)
*
|
1997-01-31 |
2004-12-02 |
Genentech, Inc. |
O-fucosyltransferase
|
JP3394540B2
(ja)
|
1997-01-31 |
2003-04-07 |
ジェネンテク・インコーポレイテッド |
O−フコシルトランスフェラーゼ
|
US6100076A
(en)
*
|
1997-01-31 |
2000-08-08 |
Genentech, Inc. |
O-fucosyltransferase
|
EP2172478A3
(en)
|
1997-02-07 |
2010-07-28 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Activity-dependent neurotrophic factor III (ADNF III)
|
US7528239B1
(en)
*
|
1997-02-13 |
2009-05-05 |
Immunex Corporation |
Receptor that binds trail
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
WO1998054206A1
(en)
|
1997-05-30 |
1998-12-03 |
Human Genome Sciences, Inc. |
32 human secreted proteins
|
US7749498B2
(en)
*
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20030109680A1
(en)
*
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
*
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US5986065A
(en)
*
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
WO1998041641A1
(en)
*
|
1997-03-20 |
1998-09-24 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
|
ES2312184T3
(es)
|
1997-03-21 |
2009-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
|
US5939316A
(en)
*
|
1997-03-27 |
1999-08-17 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5866412A
(en)
*
|
1997-03-27 |
1999-02-02 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5914394A
(en)
*
|
1997-03-27 |
1999-06-22 |
Millenium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
|
US5955355A
(en)
*
|
1997-03-27 |
1999-09-21 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US20020137890A1
(en)
*
|
1997-03-31 |
2002-09-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20020102706A1
(en)
*
|
1997-06-18 |
2002-08-01 |
Genentech, Inc. |
Apo-2DcR
|
US7083786B2
(en)
|
1997-04-03 |
2006-08-01 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
ATE476664T1
(de)
|
1997-04-07 |
2010-08-15 |
Genentech Inc |
Anti-vegf antikörper
|
US7365166B2
(en)
*
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
*
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
EP1325932B9
(en)
|
1997-04-07 |
2006-07-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
JP3816111B2
(ja)
|
1997-04-09 |
2006-08-30 |
インテレクト・ニューロサイエンシズ・インコーポレーテッド |
β−アミロイド末端に特異的な組換え抗体、それをコードするDNA及びその使用法
|
ES2402947T3
(es)
|
1997-04-10 |
2013-05-10 |
Stichting Katholieke Universiteit University Medical Centre Nijmegen |
PCA3, genes PCA3 y métodos de uso
|
AU6954398A
(en)
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Antagonistic anti-avb3 integrin antibodies
|
US6193968B1
(en)
|
1997-04-11 |
2001-02-27 |
The Burnham Institute |
Methods for using anti-αvβ3 integrin antibody
|
JP2001524824A
(ja)
|
1997-04-16 |
2001-12-04 |
ミレニアム・フアーマシユーチカルズ・インコーポレーテツド |
Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途
|
SI0975754T2
(sl)
|
1997-04-16 |
2016-04-29 |
Amgen Inc., |
Vezivni proteini in receptorji osteoprotegerina
|
US6316408B1
(en)
*
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
US7413864B2
(en)
*
|
1997-04-18 |
2008-08-19 |
Geron Corporation |
Treating cancer using a telomerase vaccine
|
US20050013825A1
(en)
*
|
1997-04-18 |
2005-01-20 |
Geron Corporation |
Vaccine containing the catalytic subunit of telomerase for treating cancer
|
US7622549B2
(en)
*
|
1997-04-18 |
2009-11-24 |
Geron Corporation |
Human telomerase reverse transcriptase polypeptides
|
EP0915980B1
(en)
|
1997-04-25 |
2009-08-05 |
Antigenics Inc. |
Characterization of granulocytic ehrlichia and methods of use
|
WO1998049311A2
(en)
*
|
1997-04-30 |
1998-11-05 |
De Novo Enzyme Corporation |
Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
ES2246069T3
(es)
*
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
*
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
ES2279572T3
(es)
|
1997-05-07 |
2007-08-16 |
Schering Corporation |
Proteinas receptoras humanas de tipo toll, reactivos y metodos relacionados.
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
CA2287911C
(en)
|
1997-05-15 |
2014-05-06 |
Genentech, Inc. |
Apo-2 receptor
|
US7541151B2
(en)
|
1997-06-05 |
2009-06-02 |
Duke University |
Single-cell biosensor for the measurement of GPCR ligands in a test sample
|
US6291643B1
(en)
|
1997-06-05 |
2001-09-18 |
Board Of Reports, The University Of Texas System |
Apaf-1 an activator of caspase-3
|
US5891646A
(en)
*
|
1997-06-05 |
1999-04-06 |
Duke University |
Methods of assaying receptor activity and constructs useful in such methods
|
US6528271B1
(en)
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
CA2289665C
(en)
|
1997-06-13 |
2005-08-09 |
Genentech, Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
CA2206774A1
(en)
|
1997-06-16 |
1998-12-16 |
Rick E. Preddie |
"prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
|
AU740227B2
(en)
*
|
1997-06-18 |
2001-11-01 |
Genentech Inc. |
Apo-2DcR
|
EP1754490A3
(en)
|
1997-06-20 |
2010-01-20 |
Biogen Idec MA Inc. |
CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
|
US7147854B2
(en)
*
|
1997-06-23 |
2006-12-12 |
Yes Biotech Laboratories Ltd. |
Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
CN1493597A
(zh)
|
1997-07-09 |
2004-05-05 |
���鹫˾ |
分离树突状细胞膜蛋白基因
|
US6187564B1
(en)
|
1997-07-10 |
2001-02-13 |
Beth Israel Deaconess Medical Center |
DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
|
US6242570B1
(en)
|
1997-07-10 |
2001-06-05 |
Beth Israel Deaconess Medical Center |
Production and use of recombinant protein multimers with increased biological activity
|
US6165476A
(en)
*
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
EP0927266A1
(en)
|
1997-07-11 |
1999-07-07 |
The University Of North Texas Health Science Center At Fort Worth |
THE $i(ESCHERICHIA COLI csrB) GENE, RNA ENCODED THEREBY, AND METHODS OF USE THEREOF
|
US20070067859A1
(en)
*
|
1997-07-14 |
2007-03-22 |
Michel Georges |
Double-muscling in mammals
|
EP1002068B1
(en)
|
1997-07-14 |
2009-09-09 |
University of Liège |
Mutations in the myostatin gene cause double-muscling in mammals
|
US6103466A
(en)
*
|
1997-07-14 |
2000-08-15 |
University Of Liege |
Double-muscling in mammals
|
US6723550B1
(en)
|
1997-07-15 |
2004-04-20 |
Genencor International, Inc. |
Proteases from gram-positive organisms
|
US20030157642A1
(en)
|
1997-07-15 |
2003-08-21 |
Caldwell Robert M. |
Increasing production of proteins in gram-positive microorganisms
|
US6506579B1
(en)
|
1997-07-15 |
2003-01-14 |
Genencor International, Inc. |
Increasing production of proteins in gram-positive microorganisms using SecG
|
US6762039B2
(en)
*
|
1997-07-15 |
2004-07-13 |
Genencor International, Inc. |
Bacillus subtillis with an inactivated cysteine protease-1
|
US6521421B1
(en)
|
1997-07-16 |
2003-02-18 |
Genencor International, Inc. |
Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
|
PE20000183A1
(es)
|
1997-07-25 |
2000-03-11 |
Schering Corp |
Citoquinas de mamiferos y reactivos relacionados
|
EP1003861B1
(en)
|
1997-08-01 |
2006-10-04 |
Schering Corporation |
Mammalian cell membrane proteins; related reagents
|
WO1999008707A1
(fr)
|
1997-08-15 |
1999-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Preventifs et/ou medicaments contre le lupus erythemateux systemique, contenant un anticorps anti-recepteur d'il-6 comme ingredient actif
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US20030175856A1
(en)
*
|
1997-08-26 |
2003-09-18 |
Genetech, Inc. |
Rtd receptor
|
CA2301847A1
(en)
*
|
1997-08-26 |
1999-03-04 |
Genentech, Inc. |
Rtd receptor
|
WO1999012965A2
(en)
*
|
1997-09-12 |
1999-03-18 |
Biogen, Inc. |
April- a novel protein with growth effects
|
US6300117B1
(en)
*
|
1997-09-15 |
2001-10-09 |
Genencor International, Inc. |
Proteases from gram-positive organisms
|
US6521440B1
(en)
|
1997-09-15 |
2003-02-18 |
Genencor International, Inc. |
Proteases from gram-positive organisms
|
US20020192209A1
(en)
*
|
1997-09-17 |
2002-12-19 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US6635443B1
(en)
|
1997-09-17 |
2003-10-21 |
Human Genome Sciences, Inc. |
Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
|
US20030170794A1
(en)
*
|
1997-09-18 |
2003-09-11 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20040231011A1
(en)
*
|
2001-06-28 |
2004-11-18 |
Genentech, Inc. |
DcR3 polypeptide, a TNFR homolog
|
IL134578A0
(en)
|
1997-09-18 |
2001-04-30 |
Genentech Inc |
DcR3 POLYPEPTIDE, A TNFR HOMOLOG
|
US7378244B2
(en)
*
|
1997-10-01 |
2008-05-27 |
Geron Corporation |
Telomerase promoters sequences for screening telomerase modulators
|
EP1967587A1
(en)
|
1997-10-10 |
2008-09-10 |
Genentech, Inc. |
APO-3 Ligand
|
KR100362974B1
(ko)
|
1997-10-14 |
2002-11-30 |
츄가이 세이야꾸 가부시키가이샤 |
림프구계 종양에 대한 항체의 증진제
|
AU1070399A
(en)
|
1997-10-17 |
1999-05-10 |
Genentech Inc. |
Human toll homologues
|
US6639051B2
(en)
*
|
1997-10-20 |
2003-10-28 |
Curis, Inc. |
Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
|
ATE350472T1
(de)
|
1997-10-21 |
2007-01-15 |
Univ Glasgow |
Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
|
ES2316173T3
(es)
|
1997-10-29 |
2009-04-01 |
Genentech, Inc. |
Genes inducibles por wnt-1.
|
DK1027437T3
(da)
|
1997-10-29 |
2008-11-24 |
Genentech Inc |
Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
|
EP1042343B1
(en)
|
1997-11-03 |
2008-01-23 |
Human Genome Sciences, Inc. |
Vegi, an inhibitor of angiogenesis and tumor growth
|
WO1999023867A2
(en)
*
|
1997-11-07 |
1999-05-20 |
Biogen, Inc. |
Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use
|
GB9724629D0
(en)
*
|
1997-11-20 |
1998-01-21 |
Genencor Int Bv |
Alpha/beta hydrolase-fold enzymes
|
GB9724627D0
(en)
|
1997-11-20 |
1998-01-21 |
Genencor Int Bv |
Gram positive microorganism formate pathway
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
WO1999027078A1
(en)
|
1997-11-21 |
1999-06-03 |
Human Genome Sciences, Inc. |
Chemokine alpha-5
|
EP1481990B1
(en)
|
1997-11-21 |
2007-06-06 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
EP1036198B1
(en)
|
1997-12-08 |
2012-09-26 |
California Institute Of Technology |
Method for creating polynucleotide and polypeptide sequences
|
EP1037927B1
(en)
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US6248542B1
(en)
*
|
1997-12-09 |
2001-06-19 |
Massachusetts Institute Of Technology |
Optoelectronic sensor
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
GB9727470D0
(en)
*
|
1997-12-30 |
1998-02-25 |
Genencor Int Bv |
Proteases from gram positive organisms
|
US6465186B1
(en)
*
|
1997-12-30 |
2002-10-15 |
Genecor International, Inc. |
Proteases from gram positive organisms
|
US6599731B1
(en)
*
|
1997-12-30 |
2003-07-29 |
Genencor International, Inc. |
Proteases from gram positive organisms
|
US6528255B1
(en)
*
|
1997-12-30 |
2003-03-04 |
Genencor International, Inc. |
Proteases from gram positive organisms
|
CA2317702A1
(en)
*
|
1998-01-07 |
1999-07-15 |
Human Genome Sciences, Inc. |
36 human secreted proteins
|
PT1045906E
(pt)
|
1998-01-15 |
2009-01-27 |
Genentech Inc |
Ligando apo-2
|
US6673914B1
(en)
|
1998-01-22 |
2004-01-06 |
John Wayne Cancer Institute |
Human tumor-associated gene
|
US6764830B1
(en)
|
1998-01-23 |
2004-07-20 |
The Regents Of The University Of California |
Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins
|
US7060667B1
(en)
|
1998-01-30 |
2006-06-13 |
Biogen Idec Ma, Inc. |
Treatment of follicular lymphomas using inhibitors of the LT pathway
|
JP2002502977A
(ja)
|
1998-02-04 |
2002-01-29 |
インビトロジェン コーポレイション |
マイクロアレイとその使用
|
US20020136721A1
(en)
*
|
1998-02-17 |
2002-09-26 |
Schwall Ralph H. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
US6727079B1
(en)
*
|
1998-02-25 |
2004-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
EP1060253A2
(en)
|
1998-03-04 |
2000-12-20 |
Genencor International, Inc. |
Modified forms of pullulanase
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
US20040176572A1
(en)
*
|
1998-03-16 |
2004-09-09 |
Freimer Nelson B. |
Methods of compositions for diagnosing and treating chromosome-18p related disorders
|
US6342351B1
(en)
|
1998-03-16 |
2002-01-29 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for diagnosing and treating chromosome-18p related disorders
|
AU758353B2
(en)
*
|
1998-03-17 |
2003-03-20 |
Genentech Inc. |
Polypeptides homologous to VEGF and BMP1
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
JP4974408B2
(ja)
|
1998-03-24 |
2012-07-11 |
中外製薬株式会社 |
血管形成抑制剤
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
US6337200B1
(en)
*
|
1998-03-31 |
2002-01-08 |
Geron Corporation |
Human telomerase catalytic subunit variants
|
WO1999051620A1
(en)
*
|
1998-04-03 |
1999-10-14 |
Invitrogen Corporation |
Libraries of expressible gene sequences
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
US6709838B1
(en)
|
1998-04-15 |
2004-03-23 |
Genentech, Inc. |
Nucleic acid encoding patched-2
|
US6348575B1
(en)
|
1998-04-15 |
2002-02-19 |
Genentech, Inc. |
Patched-2
|
US20020029391A1
(en)
*
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
ES2267263T3
(es)
*
|
1998-04-15 |
2007-03-01 |
Emd Lexigen Research Center Corp. |
Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
|
US7157083B2
(en)
*
|
1998-04-17 |
2007-01-02 |
Surrogate Pharmaceutical Pathways, Llc |
Compositions and methods for treating retroviral infections
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
DE69936382T3
(de)
|
1998-05-15 |
2011-07-07 |
Genentech, Inc., Calif. |
Therapeutische verwendungen von il-17 homologe polypeptide
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
US6197947B1
(en)
|
1998-06-01 |
2001-03-06 |
The Rockefeller University |
Translation initiation factor 4AIII and methods of use thereof
|
US6252050B1
(en)
*
|
1998-06-12 |
2001-06-26 |
Genentech, Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
ES2331901T3
(es)
|
1998-06-12 |
2010-01-19 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
|
JP2000000097A
(ja)
*
|
1998-06-15 |
2000-01-07 |
Nippon Zoki Pharmaceut Co Ltd |
Nef結合蛋白質、該蛋白質をコードするDNA並びに該蛋白質に対するモノクローナル抗体
|
US6365408B1
(en)
|
1998-06-19 |
2002-04-02 |
Maxygen, Inc. |
Methods of evolving a polynucleotides by mutagenesis and recombination
|
IL140701A0
(en)
|
1998-07-13 |
2002-02-10 |
Univ Texas |
Cancer treatment methods using antibodies to aminophospholipids
|
US20020119579A1
(en)
*
|
1998-07-14 |
2002-08-29 |
Peter Wagner |
Arrays devices and methods of use thereof
|
US6406921B1
(en)
*
|
1998-07-14 |
2002-06-18 |
Zyomyx, Incorporated |
Protein arrays for high-throughput screening
|
US6780582B1
(en)
*
|
1998-07-14 |
2004-08-24 |
Zyomyx, Inc. |
Arrays of protein-capture agents and methods of use thereof
|
EP1098988B9
(en)
*
|
1998-07-21 |
2007-10-24 |
Danisco A/S |
Foodstuff
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
US6312689B1
(en)
*
|
1998-07-23 |
2001-11-06 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR2 antibodies and methods of use therefor
|
US6727349B1
(en)
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
CN1689646A
(zh)
|
1998-08-11 |
2005-11-02 |
拜奥根Idec公司 |
包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
HUP0103563A3
(en)
*
|
1998-08-31 |
2004-04-28 |
Biogen Idec Ma Inc Cambridge |
Method of modulating memory effector t-cells and compositions
|
EP1112087B1
(en)
*
|
1998-09-11 |
2010-02-24 |
Curis, Inc. |
Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor
|
AU6394399A
(en)
|
1998-09-18 |
2000-04-10 |
Rockefeller University, The |
Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
|
AU6246199A
(en)
|
1998-09-21 |
2000-04-10 |
Schering Corporation |
Human interleukin-b50, therapeutic uses
|
EP0997476A3
(en)
|
1998-09-25 |
2000-07-19 |
Schering-Plough |
Antibodies to a mammalian Langerhans cell antigen and their uses
|
CA2344653A1
(en)
*
|
1998-09-29 |
2000-04-06 |
Gamida Cell Ltd. |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
DE69931944T2
(de)
*
|
1998-10-09 |
2007-02-08 |
Biogen Idec Ma Inc., Cambridge |
Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US20030027998A1
(en)
*
|
1998-10-30 |
2003-02-06 |
Holtzman Douglas A. |
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
|
US20060205034A1
(en)
*
|
1998-10-30 |
2006-09-14 |
Millennium Pharmaceuticals, Inc. |
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
|
US6818749B1
(en)
*
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
CA2350064C
(en)
*
|
1998-11-09 |
2012-05-08 |
Idec Pharmaceuticals Corporation |
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
|
DK2055313T3
(en)
|
1998-11-09 |
2015-07-27 |
Biogen Inc |
Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody
|
AU1727500A
(en)
*
|
1998-11-17 |
2000-06-05 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
CA2355976C
(en)
|
1998-12-22 |
2012-07-17 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
CA2450402A1
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Methods and compositions for inhibiting cancer cell growth comprising pro224
|
EP2319929A1
(en)
|
1998-12-23 |
2011-05-11 |
Genentech, Inc. |
IL-1 related polypeptides
|
PT1141297E
(pt)
|
1999-01-11 |
2010-01-06 |
Schering Corp |
Citoquinas de mamíferos relacionadas com a interleucina-17. polinucleótidos que as codificam. utilizações
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
CN100340292C
(zh)
|
1999-01-25 |
2007-10-03 |
比奥根艾迪克Ma公司 |
Baff,其封闭剂以及它们在b细胞应答的调节中的应用
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
JP5000804B2
(ja)
|
1999-02-03 |
2012-08-15 |
アムジエン・インコーポレーテツド |
免疫応答に関与する新規ポリペプチド
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
US7708993B2
(en)
*
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
US6972125B2
(en)
*
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
PL350909A1
(en)
*
|
1999-02-12 |
2003-02-10 |
Genetics Inst |
Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
|
EP2301947A3
(en)
|
1999-02-26 |
2011-11-23 |
Millennium Pharmaceuticals, Inc. |
Secreted proteins and uses thereof
|
EP2357192A1
(en)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
MY133346A
(en)
*
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
AU770952B2
(en)
*
|
1999-03-01 |
2004-03-11 |
Genentech Inc. |
Antibodies for cancer therapy and diagnosis
|
US6531125B1
(en)
|
1999-03-02 |
2003-03-11 |
Twinstrand Therapeutics Inc. |
Antiviral ricin-like proteins
|
DE60045240D1
(de)
*
|
1999-03-02 |
2010-12-30 |
Centocor Inc |
Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
|
US6599710B1
(en)
|
1999-03-10 |
2003-07-29 |
The General Hospital Corporation |
Treatment of autoimmune disease
|
AU3873200A
(en)
|
1999-03-11 |
2000-09-28 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
EP1854480A3
(en)
|
1999-03-19 |
2009-04-01 |
Genentech, Inc. |
Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6911429B2
(en)
*
|
1999-04-01 |
2005-06-28 |
Transition Therapeutics Inc. |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
DE19915057A1
(de)
|
1999-04-01 |
2000-10-19 |
Forschungszentrum Borstel |
Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
|
ES2571230T3
(es)
*
|
1999-04-09 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
GB9908533D0
(en)
|
1999-04-14 |
1999-06-09 |
Novartis Ag |
Organic compounds
|
US6492497B1
(en)
*
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
EP1645292A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
EP1637160A3
(en)
*
|
1999-05-07 |
2006-05-03 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
US6831060B2
(en)
|
1999-05-07 |
2004-12-14 |
Genentech, Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
JP2002543838A
(ja)
|
1999-05-13 |
2002-12-24 |
メディカル リサーチ カウンシル |
Ox2レセプターホモログ
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
EE200100603A
(et)
|
1999-05-14 |
2003-02-17 |
Imclone Systems Incorporated |
Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6221597B1
(en)
|
1999-05-21 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6200803B1
(en)
|
1999-05-21 |
2001-03-13 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6197517B1
(en)
|
1999-05-21 |
2001-03-06 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
CA2305716A1
(en)
|
1999-05-28 |
2000-11-28 |
University Of Guelph |
Method for assay of wbpm
|
US7166573B1
(en)
*
|
1999-05-28 |
2007-01-23 |
Ludwig Institute For Cancer Research |
Breast, gastric and prostate cancer associated antigens and uses therefor
|
IL130225A0
(en)
|
1999-05-31 |
2000-06-01 |
Yissum Res Dev Co |
Novel uses of antibodies against ache and peptides thereof
|
WO2000073451A1
(en)
|
1999-06-01 |
2000-12-07 |
Schering Corporation |
Mammalian receptor proteins; related reagents and methods
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7534605B2
(en)
|
1999-06-08 |
2009-05-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
|
EP1978029A3
(en)
|
1999-06-15 |
2008-10-15 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
GB9914210D0
(en)
|
1999-06-17 |
1999-08-18 |
Danisco |
Promoter
|
US20030166561A1
(en)
*
|
1999-06-18 |
2003-09-04 |
Cooper Garth J. S. |
Peptide
|
AU784045B2
(en)
|
1999-06-25 |
2006-01-19 |
Genentech Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
CN100482281C
(zh)
|
1999-06-25 |
2009-04-29 |
基因技术股份有限公司 |
抗ErbB抗体-类美坦素偶联物在制备药物中的应用
|
AU5632500A
(en)
|
1999-06-30 |
2001-01-31 |
Ludwig Institute For Cancer Research |
Cancer associated antigens and uses therefor
|
US20040001826A1
(en)
*
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
*
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
FR2797402B1
(fr)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
|
US7001766B2
(en)
*
|
1999-07-20 |
2006-02-21 |
Curagen Corporation |
Nucleic acid sequences encoding human angiopoietin-like polypeptides
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
SI1200592T1
(sl)
|
1999-07-30 |
2010-01-29 |
Schering Corp |
Sesalski citokini; sorodni reagenti
|
DK1200479T3
(da)
*
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
EP2314694A3
(en)
|
1999-08-17 |
2013-12-11 |
Biogen Idec MA Inc. |
BAFF receptor (BCMA), an immunoregulatory agent
|
US6927203B1
(en)
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
US7192698B1
(en)
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
MXPA02001877A
(es)
|
1999-08-23 |
2002-08-20 |
Dana Farber Cancer Inst Inc |
Pd-1, un receptor para b7-4, y usos del mismo.
|
ES2307526T3
(es)
|
1999-08-23 |
2008-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Potenciadores de la expresion del antigeno hm1.24.
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
US6627196B1
(en)
*
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
NZ523206A
(en)
*
|
1999-08-31 |
2004-12-24 |
Genentech Inc |
Antibodies that bind to tumor gene sequences
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
*
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
EP1905832A3
(en)
|
1999-09-09 |
2009-09-09 |
Schering Corporation |
Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
|
US6900043B1
(en)
|
1999-09-21 |
2005-05-31 |
Amgen Inc. |
Phosphatases which activate map kinase pathways
|
DE60041821D1
(de)
|
1999-09-24 |
2009-04-30 |
Cybios Llc |
Pluripotent embryonale stammzellen-ähnliche zellen, zusammensetzungen und ihre vervendungen
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
ATE321857T1
(de)
|
1999-09-29 |
2006-04-15 |
Diagnocure Inc |
Pca3 mrna in gutartigen und bösartigen prostatageweben
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
US8062638B1
(en)
|
1999-10-01 |
2011-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
UA74798C2
(uk)
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US6855806B1
(en)
*
|
1999-10-15 |
2005-02-15 |
Curagen Corporation |
Thymosin beta 10-like proteins and nucleic acids encoding same
|
CA2386088A1
(en)
|
1999-10-19 |
2001-04-26 |
Ludwig Institute For Cancer Research |
Mage-a12 antigenic peptides and uses thereof
|
WO2001029071A2
(en)
*
|
1999-10-19 |
2001-04-26 |
Curagen Corporation |
Genes associated with obesity and methods for using the same
|
AU1095001A
(en)
*
|
1999-10-20 |
2001-04-30 |
Genentech Inc. |
Type i cytokine receptor tccr
|
US6342587B1
(en)
|
1999-10-22 |
2002-01-29 |
Ludwig Institute For Cancer Research |
A33 antigen specific immunoglobulin products and uses thereof
|
US6346249B1
(en)
|
1999-10-22 |
2002-02-12 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
|
US7078382B1
(en)
|
1999-11-02 |
2006-07-18 |
Genentech, Inc. |
Modulation of eNOS activity and therapeutic uses thereof
|
WO2001034636A1
(en)
|
1999-11-05 |
2001-05-17 |
The General Hospital Corporation |
Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
JP2003516324A
(ja)
|
1999-11-24 |
2003-05-13 |
シェーリング コーポレイション |
転移を阻害する方法
|
US7425437B2
(en)
*
|
1999-11-26 |
2008-09-16 |
Crucell Holland B.V. |
Vaccines against West Nile Virus
|
WO2001039722A2
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
CA2492070A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same
|
US6544792B1
(en)
*
|
1999-12-21 |
2003-04-08 |
Genencor International, Inc. |
Production of secreted polypeptides
|
DK1897944T3
(da)
|
1999-12-23 |
2011-10-24 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutisk anvendelse deraf
|
BR0016886A
(pt)
|
1999-12-30 |
2002-10-08 |
Genencor Int |
Xilanase de tricoderma reesei
|
US6979537B2
(en)
*
|
2000-01-10 |
2005-12-27 |
Scios, Inc. |
Methods for identifying inhibitors of neuronal degeneration
|
DK1246917T3
(da)
|
2000-01-13 |
2009-06-08 |
Genentech Inc |
Humane Stra6-polypeptider
|
WO2003074738A1
(en)
*
|
2000-01-18 |
2003-09-12 |
Quantom Dot Corporation |
Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization
|
WO2001058949A2
(en)
|
2000-02-11 |
2001-08-16 |
Biogen, Inc. |
Heterologous polypeptide of the tnf family
|
CA2399832C
(en)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
DE60028830T2
(de)
|
2000-02-16 |
2007-01-18 |
Genentech, Inc., South San Francisco |
Anti-april antikörper und hybridomazellen
|
EP1255550A2
(en)
*
|
2000-02-17 |
2002-11-13 |
Cv Therapeutics, Inc. |
Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
|
US7153701B1
(en)
*
|
2000-02-17 |
2006-12-26 |
Hamamatsu Photonics K.K. |
Method for quantitatively detecting antigen
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
JP2003524018A
(ja)
|
2000-02-24 |
2003-08-12 |
アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ |
フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
|
US8623373B2
(en)
*
|
2000-02-24 |
2014-01-07 |
Philogen S.P.A. |
Compositions and methods for treatment of angiogenesis in pathological lesions
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU2001247294A1
(en)
*
|
2000-03-03 |
2001-09-17 |
Curagen Corporation |
Proteins named FCTRX and nucleic acids encoding same
|
IL151499A0
(en)
|
2000-03-03 |
2003-04-10 |
Cambridge Antibody Tech |
Human antibodies against eotaxin and their use
|
US6630584B1
(en)
*
|
2000-03-16 |
2003-10-07 |
Ramot At Tel-Aviv University Ltd. |
Single chain antibody against mutant p53
|
US6740520B2
(en)
*
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
US20040086970A1
(en)
*
|
2000-03-22 |
2004-05-06 |
Genentech, Inc. |
Novel cytokine receptors and nucleic acids encoding the same
|
CA2403708A1
(en)
|
2000-03-22 |
2001-09-27 |
Quantum Dot Corporation |
Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
ATE343562T1
(de)
*
|
2000-03-23 |
2006-11-15 |
Elan Pharm Inc |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
US20030212022A1
(en)
*
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
ES2551164T3
(es)
|
2000-03-24 |
2015-11-16 |
Biosphere Medical, Inc. |
Microesferas para embolización activa
|
US20030185796A1
(en)
*
|
2000-03-24 |
2003-10-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
US20030144236A1
(en)
*
|
2000-03-29 |
2003-07-31 |
Weiss Robert H |
Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
|
US20050043262A1
(en)
*
|
2000-03-29 |
2005-02-24 |
Weiss Robert H. |
Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
|
US20030108927A1
(en)
*
|
2000-04-03 |
2003-06-12 |
Kathryn Leishman |
Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
|
AU2001253140A1
(en)
*
|
2000-04-03 |
2001-10-15 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Tumor markers in ovarian cancer
|
NZ521540A
(en)
|
2000-04-11 |
2004-09-24 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
EP2267026A1
(en)
|
2000-04-12 |
2010-12-29 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
IL151348A0
(en)
|
2000-04-13 |
2003-04-10 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
US20010046496A1
(en)
*
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
DE60136921D1
(de)
|
2000-04-18 |
2009-01-22 |
Schering Corp |
Medizinische Verwendung von IL-174 Agonisten und Antagonisten
|
US7632929B2
(en)
|
2000-04-20 |
2009-12-15 |
The Board Of Trustees Of The University Of Arkansas |
Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
|
US20020009444A1
(en)
*
|
2000-04-25 |
2002-01-24 |
Idec Pharmaceuticals Corporation |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
EP1278065A4
(en)
*
|
2000-04-25 |
2004-09-15 |
Tokuyama Dental Corp |
METHOD FOR DETECTION OF STREPTOCOCCUS SOBRINUS AND ANTIBODIES AGAINST THE SAME
|
US20040013674A1
(en)
*
|
2001-04-27 |
2004-01-22 |
Christine Ambrose |
Taci as an anti-tumor agent
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
TWI318983B
(en)
*
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
US6696620B2
(en)
*
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
JP2004511753A
(ja)
*
|
2000-05-04 |
2004-04-15 |
イエール ユニバーシティー |
タンパク質活性のスクリーニング用タンパク質チップ
|
US6835545B2
(en)
|
2000-05-08 |
2004-12-28 |
President And Fellows Of Harvard College |
Methods, products and treatments for diabetes
|
US20040005554A1
(en)
*
|
2000-05-08 |
2004-01-08 |
Tayar Nabil El |
Novel glycoproteins and methods of use thereof
|
US20030219786A1
(en)
*
|
2000-08-11 |
2003-11-27 |
Applied Research Systems Ars Holding N.V. |
Novel glycoproteins and methods of use thereof
|
US7439330B2
(en)
*
|
2000-05-08 |
2008-10-21 |
President And Fellows Of Harvard College |
Anti-glycated CD59 antibodies and uses thereof
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
US7422743B2
(en)
|
2000-05-10 |
2008-09-09 |
Schering Corporation |
Mammalian receptor protein DCRS5;methods of treatment
|
ATE536375T1
(de)
|
2000-05-10 |
2011-12-15 |
Mayo Foundation |
Menschliche igm antikörper, welche die fähigkeit besitzen, den wiederaufbau der myelinstruktur zu induzieren und deren diagnostische und therapeutische anwendung im zentralen nervensystem
|
AU6135101A
(en)
|
2000-05-10 |
2001-11-20 |
Schering Corp |
Mammalian receptor proteins; related reagents and methods
|
CA2408617A1
(en)
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
EP1714661A3
(en)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
|
NZ522327A
(en)
|
2000-05-25 |
2004-09-24 |
Schering Corp |
Mammalian DNAX Toll-like receptor protein, DTLR 10, antibodies and medicaments made therefrom and use in treating immunological disorders
|
US20030009016A1
(en)
*
|
2000-05-25 |
2003-01-09 |
Shimkets Richard A. |
Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US6649359B2
(en)
|
2000-06-01 |
2003-11-18 |
The Brigham & Women's Hospital, Inc. |
Diagnosis of endometrial precancers
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
WO2001094586A2
(en)
*
|
2000-06-06 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
|
EP2251026A1
(en)
|
2000-06-08 |
2010-11-17 |
Immune Disease Institute, Inc. |
Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
AU6842701A
(en)
|
2000-06-16 |
2002-01-14 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
EP1299128A2
(en)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
AU2001268633A1
(en)
*
|
2000-06-21 |
2002-01-02 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating breast cancer
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
WO2002000710A2
(en)
*
|
2000-06-28 |
2002-01-03 |
Amgen, Inc. |
B7-like molecules and uses thereof
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
ES2317917T3
(es)
|
2000-06-28 |
2009-05-01 |
Amgen Inc. |
Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
|
US20060257399A1
(en)
*
|
2000-06-28 |
2006-11-16 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
DK1294401T3
(da)
*
|
2000-06-29 |
2007-10-08 |
Merck Patent Gmbh |
Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
DE60112942T2
(de)
*
|
2000-06-30 |
2006-06-22 |
Elan Pharmaceuticals, Inc., South San Francisco |
Verbindungen zur behandlung der alzheimerischen krankheit
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
US6852510B2
(en)
|
2000-07-03 |
2005-02-08 |
Gala Design Inc |
Host cells containing multiple integrating vectors
|
CA2413156C
(en)
*
|
2000-07-03 |
2009-08-18 |
Gala Design, Inc. |
Expression vectors
|
US20040235173A1
(en)
*
|
2000-07-03 |
2004-11-25 |
Gala Design, Inc. |
Production of host cells containing multiple integrating vectors by serial transduction
|
US20030224415A1
(en)
*
|
2001-06-29 |
2003-12-04 |
Gala Design, Inc. |
Selection free growth of host cells containing multiple integrating vectors
|
FR2811323B1
(fr)
*
|
2000-07-07 |
2006-10-06 |
Fuma Tech Gmbh |
Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
|
US7176037B2
(en)
|
2000-07-13 |
2007-02-13 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US6951947B2
(en)
*
|
2000-07-13 |
2005-10-04 |
The Scripps Research Institute |
Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
AU2001279055A1
(en)
|
2000-07-27 |
2002-02-13 |
Genentech, Inc. |
Apo-2L receptor agonist and CPT-11 synergism
|
AU2001283507A1
(en)
|
2000-07-27 |
2002-02-13 |
Mayo Foundation For Medical Education And Research |
B7-h3 and b7-h4, novel immunoregulatory molecules
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US20050249735A1
(en)
*
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US20110195063A1
(en)
*
|
2000-08-07 |
2011-08-11 |
Centocor, Inc. |
Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
|
US20060018907A1
(en)
*
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US20030114410A1
(en)
|
2000-08-08 |
2003-06-19 |
Technion Research And Development Foundation Ltd. |
Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
|
ES2286133T3
(es)
|
2000-08-08 |
2007-12-01 |
St. Jude Children's Research Hospital |
Acidos nucleicos de polipeptidos de estreptococos del grupo b y composiciones terapeuticas y vacunas de los mismos.
|
WO2002011677A2
(en)
*
|
2000-08-09 |
2002-02-14 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
JP4799801B2
(ja)
|
2000-08-11 |
2011-10-26 |
協和発酵キリン株式会社 |
リン酸代謝、カルシウム代謝、石灰化及びビタミンd代謝を調節するポリペプチド並びにそれをコードするdna
|
SG143058A1
(en)
*
|
2000-08-11 |
2008-06-27 |
Favrille Inc |
Method and composition for altering a t cell mediated pathology
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
EP2014298A3
(en)
|
2000-08-24 |
2009-10-07 |
Genentech, Inc. |
Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
EP1197550A3
(en)
*
|
2000-08-25 |
2002-11-20 |
Pfizer Products Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
AU2001288478B2
(en)
|
2000-08-25 |
2006-11-02 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding prenyl proteases
|
US6803211B2
(en)
*
|
2000-08-25 |
2004-10-12 |
Pfizer Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DE60140457D1
(de)
|
2000-09-01 |
2009-12-24 |
Blood Res Center |
Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
|
AU8867501A
(en)
*
|
2000-09-01 |
2002-03-13 |
Biogen Inc |
Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
|
MXPA03002049A
(es)
|
2000-09-08 |
2003-07-24 |
Schering Corp |
Genes de mamiferos: reactivos y metodos relacionados.
|
WO2002022661A2
(en)
*
|
2000-09-12 |
2002-03-21 |
Beavo Joseph A |
NOVEL PDEs AND USES THEREOF
|
EP1327638A4
(en)
*
|
2000-09-12 |
2004-09-29 |
Kirin Brewery |
NEW WALL MEMBRANE OF DENDRITIC CELLS AND THEIR USE
|
US6673623B1
(en)
|
2000-09-12 |
2004-01-06 |
Novocure, Inc. |
Methods and compositions that control lipid production
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
CA2422095A1
(en)
|
2000-09-14 |
2002-03-21 |
Biogen, Inc. |
Tweak receptor agonists as anti-angiogenic agents
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
EP1356060B1
(en)
*
|
2000-09-18 |
2005-12-14 |
Genencor International, Inc. |
Twin-arginine translocation in bacillus
|
US20020058029A1
(en)
*
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
US20020164576A1
(en)
*
|
2000-09-22 |
2002-11-07 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
|
US20020115058A1
(en)
*
|
2000-09-22 |
2002-08-22 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
|
US20030044803A1
(en)
*
|
2000-09-22 |
2003-03-06 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
|
AU2001293187A1
(en)
*
|
2000-09-28 |
2002-04-08 |
Uab Research Foundation |
Chimeric retroviral gag genes and screening assays
|
EP1717251B1
(en)
|
2000-10-02 |
2012-01-18 |
Novartis Vaccines and Diagnostics, Inc. |
Therapy for B-cell malignancies using human anti-CD40 antibodies
|
US20030022247A1
(en)
*
|
2000-10-03 |
2003-01-30 |
Masabumi Shibuya |
Substance which inhibits binding of information transfer molecule for 1175-tyrosine phosphorylated KDR/FLK-1 and usages of the same
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
AU2002226876A1
(en)
|
2000-10-06 |
2002-04-15 |
Quantum Dot Corporation |
Cells having a spectral signature, and methods of preparation and use thereof
|
US6946292B2
(en)
*
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP2113516B1
(en)
|
2000-10-10 |
2014-05-21 |
Genentech, Inc. |
Antibodies against C5 inhibiting type II endothelial cell activation
|
US20020155460A1
(en)
*
|
2000-10-10 |
2002-10-24 |
Genencor International Inc. |
Information rich libraries
|
EP2336166A1
(en)
|
2000-10-12 |
2011-06-22 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
DE60139944D1
(de)
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
DE60140903D1
(de)
|
2000-10-18 |
2010-02-04 |
Brigham & Womens Hospital |
E-selectin/l-selectin-liganden-polypeptide hämatopoetischer zellen und verfahren zu deren verwendung
|
US7393532B1
(en)
|
2000-10-18 |
2008-07-01 |
Genentech, Inc. |
Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
|
US20020128448A1
(en)
*
|
2000-10-20 |
2002-09-12 |
Idec Pharmaceuticals Corporation |
Variant IgG3 Rituxan and therapeutic use thereof
|
US7259232B1
(en)
|
2000-10-27 |
2007-08-21 |
Nymox Pharmaceutical Corporation |
Preferred segments of neural thread protein
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
AU4155602A
(en)
*
|
2000-11-01 |
2002-06-18 |
Elusys Therapeutics Inc |
Method of producing biospecific molecules by protein trans-splicing
|
US20050136431A1
(en)
*
|
2000-11-03 |
2005-06-23 |
Oakley Robert H. |
Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
|
US7163800B2
(en)
*
|
2000-11-03 |
2007-01-16 |
Molecular Devices Corporation |
Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
|
US7018812B2
(en)
*
|
2000-11-03 |
2006-03-28 |
Duke University |
Modified G-protein coupled receptors
|
WO2002043658A2
(en)
|
2000-11-06 |
2002-06-06 |
The Jackson Laboratory |
Fcrn-based therapeutics for the treatment of auto-immune disorders
|
US6890734B2
(en)
|
2000-11-10 |
2005-05-10 |
Schering Corporation |
Nucleic acids encoding a cytokine receptor complex
|
EP1343973B2
(en)
|
2000-11-16 |
2020-09-16 |
California Institute Of Technology |
Apparatus and methods for conducting assays and high throughput screening
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
JP4368196B2
(ja)
*
|
2000-11-17 |
2009-11-18 |
ユニバーシティー オブ ロチェスター |
真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
|
EP2027874B1
(en)
|
2000-11-28 |
2013-10-16 |
Medimmune, Inc. |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
EP2295606A1
(en)
|
2000-11-28 |
2011-03-16 |
Wyeth LLC |
Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
BR0115715A
(pt)
|
2000-11-28 |
2004-02-03 |
Wyeth Corp |
Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
|
JP4236925B2
(ja)
|
2000-11-28 |
2009-03-11 |
アムジエン・インコーポレーテツド |
免疫応答に関与する新規ポリペプチド
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US7534429B2
(en)
*
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
WO2002044366A2
(en)
*
|
2000-11-29 |
2002-06-06 |
Lynkeus Biotech Gmbh |
Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
US20030124534A1
(en)
|
2000-12-08 |
2003-07-03 |
Luca Rastelli |
Method of detecting and treating Tuberous Sclerosis Complex associated disorders
|
ATE329026T1
(de)
*
|
2000-12-08 |
2006-06-15 |
Genentech Inc |
In knorpelgeweben stark exprimiertes gen
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
DK1341899T3
(da)
*
|
2000-12-14 |
2006-04-10 |
Genentech Inc |
Bakterieværtsstammer
|
US6979556B2
(en)
*
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
US20020187100A1
(en)
*
|
2000-12-21 |
2002-12-12 |
David Rizzieri |
Anti-tenascin monoclonal antibody therapy for lymphoma
|
US7892730B2
(en)
|
2000-12-22 |
2011-02-22 |
Sagres Discovery, Inc. |
Compositions and methods for cancer
|
US7645441B2
(en)
*
|
2000-12-22 |
2010-01-12 |
Sagres Discovery Inc. |
Compositions and methods in cancer associated with altered expression of PRLR
|
US7700274B2
(en)
*
|
2000-12-22 |
2010-04-20 |
Sagres Discovery, Inc. |
Compositions and methods in cancer associated with altered expression of KCNJ9
|
US20030099963A1
(en)
*
|
2000-12-22 |
2003-05-29 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of TBX21
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
US7820447B2
(en)
|
2000-12-22 |
2010-10-26 |
Sagres Discovery Inc. |
Compositions and methods for cancer
|
US20030087252A1
(en)
*
|
2000-12-22 |
2003-05-08 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of PRDM11
|
US20030165878A1
(en)
*
|
2000-12-22 |
2003-09-04 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of MCM3AP
|
US20030232334A1
(en)
*
|
2000-12-22 |
2003-12-18 |
Morris David W. |
Novel compositions and methods for cancer
|
WO2002052005A1
(fr)
|
2000-12-22 |
2002-07-04 |
Kazusa Dna Research Institute Foundation |
Genes et proteines codees par ceux-ci
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
CN1911965B
(zh)
|
2001-01-17 |
2013-05-29 |
新兴产品开发西雅图有限公司 |
结合域-免疫球蛋白融合蛋白
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7279324B2
(en)
*
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
JP4463475B2
(ja)
|
2001-01-31 |
2010-05-19 |
バイオジェン アイデック インコーポレイテッド |
腫瘍疾患の治療における免疫調節性抗体の使用
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
WO2002062850A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
US20040077081A1
(en)
*
|
2001-02-07 |
2004-04-22 |
Egbert Oosterwijk |
Hybridoma cell line g250 and its use for producing monoclonal antibodies
|
US8216797B2
(en)
|
2001-02-07 |
2012-07-10 |
Massachusetts Institute Of Technology |
Pathogen detection biosensor
|
JP3986439B2
(ja)
|
2001-02-07 |
2007-10-03 |
中外製薬株式会社 |
造血器腫瘍の治療剤
|
AU2002238537B8
(en)
*
|
2001-02-07 |
2006-08-24 |
Wilex Ag |
Hybridoma cell line G250 and its use for producing monoclonal antibodies
|
AU2002256992B2
(en)
*
|
2001-02-07 |
2007-06-07 |
Massachusetts Institute Of Technology |
Optoelectronic detection system
|
US7422860B2
(en)
|
2001-02-07 |
2008-09-09 |
Massachusetts Institute Of Technology |
Optoelectronic detection system
|
CA2437811A1
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
AU2002240336A1
(en)
*
|
2001-02-14 |
2002-08-28 |
Tularik Inc. |
Methods for the diagnosis and treatment of tumors employing the hepsin gene
|
ATE488576T1
(de)
|
2001-02-20 |
2010-12-15 |
Univ Georgia |
Schnellproduktion monoklonaler antikörper
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
US6815166B2
(en)
|
2001-02-23 |
2004-11-09 |
Dana-Farber Cancer Institute, Inc. |
HIN-1, a tumor suppressor gene
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
WO2002070668A2
(en)
*
|
2001-03-06 |
2002-09-12 |
Sierra Sciences, Inc. |
Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
US6936449B2
(en)
*
|
2001-03-14 |
2005-08-30 |
Genencor International, Inc. |
Regulatable growth of filamentous fungi
|
ES2328796T3
(es)
|
2001-03-14 |
2009-11-18 |
Myriad Genetics, Inc. |
Interaccion tsg101-gag y uso de la misma.
|
JP2004537976A
(ja)
*
|
2001-03-15 |
2004-12-24 |
インターナショナル バイオイムン システムズ,インコーポレーテッド |
膵癌のモノクローナル抗体治療
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US20020177239A1
(en)
|
2001-03-16 |
2002-11-28 |
Thomas Gregory Brian |
Anti-GPE antibodies, their uses, and analytical methods for GPE
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
WO2002076507A2
(en)
*
|
2001-03-23 |
2002-10-03 |
Genentech, Inc. |
Uses of opg ligand to modulate immune responses
|
JP2005508838A
(ja)
*
|
2001-03-23 |
2005-04-07 |
アフトン コーポレーション |
膵癌の組合せ治療
|
WO2002079415A2
(en)
*
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
MXPA03008959A
(es)
|
2001-04-02 |
2004-10-15 |
Wyeth Corp |
Pd-1, un receptor para b7-4 y sus usos.
|
US20030148298A1
(en)
*
|
2001-04-03 |
2003-08-07 |
O''toole Margot |
Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
|
WO2002081640A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene shinc-1 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
JP2005501518A
(ja)
|
2001-04-16 |
2005-01-20 |
ワイス・ホールディングズ・コーポレイション |
ポリペプチド抗原をコードしている新規ストレプトコッカスニューモニアエオープンリーディングフレームおよびその使用
|
RU2316337C2
(ru)
|
2001-04-24 |
2008-02-10 |
Мерк Патент Гмбх |
КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
CA2715570A1
(en)
|
2001-04-26 |
2002-11-07 |
Biogen Idec Ma Inc. |
Cripto blocking antibodies and uses thereof
|
DE10121255A1
(de)
*
|
2001-04-30 |
2002-11-07 |
Switch Biotech Ag |
Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
|
US7256257B2
(en)
*
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20030017159A1
(en)
*
|
2001-05-02 |
2003-01-23 |
Jerome Ritz |
Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
US20090191232A1
(en)
*
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
US7803382B2
(en)
*
|
2001-05-04 |
2010-09-28 |
Ludwig Institute For Cancer Research Ltd. |
Method for inducing immune response to NY-CO-58
|
US6794501B2
(en)
*
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
US20050013810A1
(en)
*
|
2001-05-08 |
2005-01-20 |
Waller Edmund K |
Regulating immune response using dendritic cells
|
RS51708B
(sr)
|
2001-05-11 |
2011-10-31 |
Amgen Inc. |
Peptidi i njima srodni molekuli koji se vezuju za tall-1
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
EP1392359B2
(en)
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
GB0111628D0
(en)
*
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
AU2002339115B2
(en)
|
2001-05-18 |
2007-03-15 |
Dupont Nutrition Biosciences Aps |
Method of preparing a dough with an enzyme
|
US6972324B2
(en)
*
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
ATE413884T1
(de)
|
2001-05-22 |
2008-11-15 |
Merck & Co Inc |
Beta-secretase-substrat und seine verwendung
|
WO2002094376A2
(en)
*
|
2001-05-22 |
2002-11-28 |
Duke University |
Compositions and methods for promoting or inhibiting ndpk
|
CA2448018A1
(en)
*
|
2001-05-22 |
2002-11-28 |
Duke University |
Compositions and methods for inhibiting metastasis
|
JP4309758B2
(ja)
|
2001-05-25 |
2009-08-05 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
Trailレセプターに免疫特異的に結合する抗体
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
US7279274B2
(en)
*
|
2001-05-29 |
2007-10-09 |
Pride Proteomics A/S |
Method for diagnosing diabetes in a mammal
|
CN101653604A
(zh)
|
2001-05-30 |
2010-02-24 |
基因技术股份有限公司 |
抗ngf抗体用于治疗各种疾病
|
US20030007974A1
(en)
*
|
2001-05-30 |
2003-01-09 |
Nanus David M. |
Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
MXPA03011094A
(es)
*
|
2001-05-31 |
2004-12-06 |
Medarex Inc |
Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
|
WO2002098897A2
(en)
|
2001-06-01 |
2002-12-12 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
US7553484B2
(en)
*
|
2001-06-05 |
2009-06-30 |
The Regents Of The University Of California |
Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
EP1604688B1
(de)
|
2001-06-05 |
2010-02-03 |
CureVac GmbH |
Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
|
US20090324612A1
(en)
*
|
2001-06-05 |
2009-12-31 |
Kaufman Daniel L |
Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
|
CA2449649A1
(en)
*
|
2001-06-07 |
2002-12-19 |
Wyeth |
A g-protein coupled receptor and uses therefor
|
US7468253B2
(en)
*
|
2001-06-07 |
2008-12-23 |
Chemocentryx, Inc. |
Method for multiple chemokine receptor screening for antagonists using RAM assay
|
KR100635703B1
(ko)
*
|
2001-06-07 |
2006-10-17 |
케모센트릭스, 인크. |
세포 이동성 검사
|
CN100359327C
(zh)
*
|
2001-06-15 |
2008-01-02 |
英希比泰克斯公司 |
识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体
|
EP2000545B1
(en)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of lung tumor
|
JP2005500034A
(ja)
*
|
2001-06-20 |
2005-01-06 |
プロション バイオテク リミテッド |
受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
|
WO2003000916A2
(en)
*
|
2001-06-21 |
2003-01-03 |
Sierra Sciences, Inc. |
Telomerase expression repressor proteins and methods of using the same
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
US6886964B2
(en)
*
|
2001-06-26 |
2005-05-03 |
Allan Gardiner |
Illuminator with filter array and bandwidth controller
|
NZ530765A
(en)
|
2001-06-26 |
2006-11-30 |
Amgen Fremont Inc |
Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
|
MXPA04000140A
(es)
*
|
2001-06-27 |
2004-06-03 |
Elan Pharm Inc |
Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
|
CA2451854A1
(en)
|
2001-06-28 |
2003-01-09 |
Kyowa Hakko Kogyo Co., Ltd. |
Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
|
US20030129613A1
(en)
*
|
2001-07-05 |
2003-07-10 |
Fernandes Elma R. |
Novel human proteins and polynucleotides encoding them
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
WO2003004607A2
(en)
*
|
2001-07-05 |
2003-01-16 |
Wyeth |
Aggrecanase molecules
|
KR20040049830A
(ko)
*
|
2001-07-09 |
2004-06-12 |
애프톤 코포레이션 |
간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
|
US7393656B2
(en)
|
2001-07-10 |
2008-07-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for risk stratification
|
US20030113940A1
(en)
*
|
2001-07-16 |
2003-06-19 |
Erlanger Bernard F. |
Antibodies specific for nanotubes and related methods and compositions
|
AU2002354947B2
(en)
|
2001-07-17 |
2008-04-17 |
The General Hospital Corporation |
Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
|
CA2454397A1
(en)
*
|
2001-07-20 |
2003-06-05 |
The University Of Georgia Research Foundation, Inc. |
Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns
|
CA2454618C
(en)
*
|
2001-07-24 |
2012-04-03 |
Biogen Idec Ma, Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
AU2002319703A1
(en)
*
|
2001-07-27 |
2003-02-17 |
Wyeth |
Aggrecanase molecules
|
AUPR673001A0
(en)
|
2001-07-31 |
2001-08-23 |
Prince Henry's Institute Of Medical Research |
Pregnancy-related enzyme activity
|
US7413870B2
(en)
|
2001-08-01 |
2008-08-19 |
Rigel Pharmaceuticals, Incorporated |
SAK: modulation of cellular proliferation for treatment of cancer
|
TWI334439B
(en)
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
EA007984B1
(ru)
*
|
2001-08-03 |
2007-02-27 |
Дженентек, Инк. |
ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ
|
EP1551972A4
(en)
*
|
2001-08-09 |
2005-08-31 |
Curagen Corp |
NUCLEIC ACIDS, POLYPEPTIDES, SINGLE NUCLEOTIDE POLYMORPHISMS AND METHOD OF USE THEREOF
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
US20030035802A1
(en)
*
|
2001-08-14 |
2003-02-20 |
Dewan Zeng |
Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
|
EP1878441B1
(en)
|
2001-08-17 |
2018-01-24 |
Genentech, Inc. |
Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
|
US6861231B2
(en)
*
|
2001-08-17 |
2005-03-01 |
Qiagen Gmbh |
Suppression of cross-reactivity and non-specific binding by antibodies using protein A
|
AU2002331720B2
(en)
*
|
2001-08-24 |
2007-10-11 |
Johns Hopkins University |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
EP1421214A4
(en)
*
|
2001-08-27 |
2005-11-02 |
Tularik Inc |
AMPLIFIED ONCOGENE AND THEIR ROLE IN CANCER
|
MXPA04001566A
(es)
*
|
2001-08-27 |
2004-05-17 |
Genentech Inc |
Un sistema para expresion y ensamblado de anticuerpos.
|
US20030099985A1
(en)
*
|
2001-08-27 |
2003-05-29 |
Jing Li |
Amplified gene involved in cancer
|
US7270960B2
(en)
|
2001-08-29 |
2007-09-18 |
Pacific Northwest Research Institute |
Diagnosis of ovarian carcinomas
|
NZ543755A
(en)
|
2001-08-29 |
2008-04-30 |
Genentech Inc |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US20040142325A1
(en)
*
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
US20070082337A1
(en)
*
|
2004-01-27 |
2007-04-12 |
Compugen Ltd. |
Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
EP3187592B1
(en)
|
2001-09-20 |
2018-12-12 |
Immunex Corporation |
Selection of cells expressing heteromeric polypeptides
|
US6982159B2
(en)
*
|
2001-09-21 |
2006-01-03 |
Genencor International, Inc. |
Trichoderma β-glucosidase
|
US20070098728A1
(en)
*
|
2001-09-24 |
2007-05-03 |
Pedersen Finn S |
Novel compositions and methods in cancer
|
EP1431310A4
(en)
|
2001-09-25 |
2005-03-23 |
Immuno Biological Lab Co Ltd |
ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
MXPA04002817A
(es)
|
2001-09-27 |
2004-07-05 |
Pioneer Hi Bred Int |
Polinucleotidos de fitato y metodos de uso.
|
US20050053935A1
(en)
|
2001-10-01 |
2005-03-10 |
Fishman Mark C. |
Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
|
DK1432431T3
(en)
|
2001-10-04 |
2017-07-10 |
Genetics Inst Llc |
Methods and compositions for modulating interleukin-21 activity
|
US7084257B2
(en)
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
MXPA04003291A
(es)
|
2001-10-12 |
2004-07-23 |
Schering Corp |
Uso de anticuerpos biespecificos para ragular respuestas inmunes.
|
MXPA04003533A
(es)
*
|
2001-10-15 |
2005-06-20 |
Immunomedics Inc |
Agentes de intensificacion de afinidad.
|
ATE524196T1
(de)
*
|
2001-10-16 |
2011-09-15 |
Macrogenics West Inc |
An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
|
DE10151511A1
(de)
|
2001-10-18 |
2003-05-08 |
Basf Lynx Bioscience Ag |
ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
|
US20040151721A1
(en)
|
2001-10-19 |
2004-08-05 |
O'keefe Theresa |
Humanized anti-CCR2 antibodies and methods of use therefor
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7445925B2
(en)
*
|
2001-10-27 |
2008-11-04 |
Sanofi-Aventis Deutschland Gmbh |
Aequorin as a reporter gene in yeast
|
US20030190705A1
(en)
*
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
WO2003040341A2
(en)
|
2001-11-07 |
2003-05-15 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-hepatitis a virus antibodies
|
IL161968A0
(en)
|
2001-11-14 |
2005-11-20 |
Centocor Inc |
Anti-il-6 antibodies, compositions, methods and uses
|
AU2002356898A1
(en)
*
|
2001-11-15 |
2003-06-10 |
Tularik Inc. |
Gene amplification and overexpression in cancer
|
US20030113813A1
(en)
*
|
2001-11-15 |
2003-06-19 |
Heidaran Mohammad A. |
Methods and devices for the integrated discovery of cell culture environments
|
US6952704B2
(en)
*
|
2001-11-26 |
2005-10-04 |
Microsoft Corporation |
Extending a directory schema independent of schema modification
|
US7052860B2
(en)
|
2001-11-28 |
2006-05-30 |
University Of Florida Research Foundation |
Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
TW200408407A
(en)
*
|
2001-11-30 |
2004-06-01 |
Dana Farber Cancer Inst Inc |
Methods and compositions for modulating the immune system and uses thereof
|
DK1461300T3
(da)
|
2001-11-30 |
2011-10-24 |
Biogen Idec Inc |
Antistoffer mod kemotaktiske monocytproteiner
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US7871619B2
(en)
|
2001-11-30 |
2011-01-18 |
Chemocentryx, Inc. |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
|
EP2354791A1
(en)
*
|
2001-12-04 |
2011-08-10 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
CN1630514A
(zh)
|
2001-12-05 |
2005-06-22 |
贝勒医学院 |
通过调节交感神经紧张性控制骨形成的方法和组合物
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
US8178128B2
(en)
*
|
2001-12-05 |
2012-05-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Nanoparticles containing polymeric nucleic acid homologs
|
US20070037147A1
(en)
*
|
2001-12-07 |
2007-02-15 |
Pablo Garcia |
Endogenous retrovirus polypeptides linked to oncogenic transformation
|
US20060275747A1
(en)
*
|
2001-12-07 |
2006-12-07 |
Hardy Stephen F |
Endogenous retrovirus up-regulated in prostate cancer
|
US8080554B2
(en)
|
2001-12-12 |
2011-12-20 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
|
AU2002361385B2
(en)
*
|
2001-12-18 |
2009-11-19 |
Centre National De La Recherche Scientifique Cnrs |
Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
|
US7045332B2
(en)
|
2001-12-18 |
2006-05-16 |
Genencor International, Inc. |
BGL4 β-glucosidase and nucleic acids encoding the same
|
US7049125B2
(en)
|
2001-12-18 |
2006-05-23 |
Genencor International, Inc. |
EGVIII endoglucanase and nucleic acids encoding the same
|
US7858297B2
(en)
*
|
2001-12-18 |
2010-12-28 |
Centre National De La Recherche Scientifique Cnrs |
Chemokine-binding protein and methods of use
|
US7056721B2
(en)
*
|
2001-12-18 |
2006-06-06 |
Genencor International, Inc. |
EGVI endoglucanase and nucleic acids encoding the same
|
US7045331B2
(en)
*
|
2001-12-18 |
2006-05-16 |
Genencor International, Inc. |
EGVII endoglucanase and nucleic acids encoding the same
|
US7005289B2
(en)
*
|
2001-12-18 |
2006-02-28 |
Genencor International, Inc. |
BGL5 β-glucosidase and nucleic acids encoding the same
|
AU2002359721A1
(en)
*
|
2001-12-19 |
2003-07-09 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
CA2470088A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Tularik Inc. |
Identification of an amplified gene and target for drug intervention
|
GB0130543D0
(en)
|
2001-12-20 |
2002-02-06 |
Univ Cambridge Tech |
Human antibodies and their use
|
PT1463751E
(pt)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Proteínas de fusão de albumina
|
US20060024292A1
(en)
*
|
2001-12-27 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
|
US20060034829A1
(en)
*
|
2001-12-27 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
|
CA2471656C
(en)
|
2001-12-28 |
2012-07-31 |
Kirin Beer Kabushiki Kaisha |
Antibody against fibroblast growth factor-23
|
JP4063769B2
(ja)
|
2001-12-28 |
2008-03-19 |
中外製薬株式会社 |
タンパク質安定化方法
|
US20030228676A1
(en)
*
|
2001-12-31 |
2003-12-11 |
Agostino Michael J. |
Aggrecanase molecules
|
WO2003057159A2
(en)
|
2001-12-31 |
2003-07-17 |
Dana-Farber Cancer Institute, Inc. |
Psoriasin expression by breast epithelial cells
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
EP1461001A4
(en)
*
|
2002-01-03 |
2010-03-31 |
Scripps Research Inst |
EPITOPE ASSOCIATED WITH CANCER
|
US20040009498A1
(en)
*
|
2002-01-14 |
2004-01-15 |
Diversa Corporation |
Chimeric antigen binding molecules and methods for making and using them
|
EP1534739A4
(en)
*
|
2002-01-18 |
2006-05-31 |
Bristol Myers Squibb Co |
IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS THAT INTERACT WITH TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
WO2003062404A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
WO2003064622A2
(en)
*
|
2002-01-31 |
2003-08-07 |
Wyeth |
Aggrecanase molecules
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
NZ533987A
(en)
|
2002-02-01 |
2007-04-27 |
Schering Corp |
Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells
|
ATE417858T1
(de)
|
2002-02-05 |
2009-01-15 |
Genentech Inc |
Proteinaufreinigung
|
KR20040088059A
(ko)
*
|
2002-02-05 |
2004-10-15 |
와이어쓰 |
절두된 아그레카나제 분자
|
EP1572168B1
(en)
|
2002-02-06 |
2010-05-26 |
Vicor Technologies, Inc. |
Anti-infarction molecules
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
EP1563302B1
(en)
|
2002-02-13 |
2011-09-14 |
American Diagnostica, Inc. |
Methods for selecting treatment regimens and predicting outcomes in cancer patients
|
ATE482719T1
(de)
|
2002-02-21 |
2010-10-15 |
Univ Duke |
Behandlungsverfahren unter verwendung von anti- cd22-antikörpern
|
DK2508596T3
(en)
|
2002-02-21 |
2015-10-19 |
Inst Virology |
MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
|
AU2003217693A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
NZ534947A
(en)
|
2002-02-22 |
2008-03-28 |
Progenics Pharm Inc |
Anti-CCR5 antibody that binds to CCR5 on the surface of a human cell.
|
US7662924B2
(en)
*
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
CA2476518A1
(en)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP1534729A2
(en)
*
|
2002-02-26 |
2005-06-01 |
University of Utah Research Foundation |
Variants of nedd4l associated with hypertension and viral budding
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
CN102174108B
(zh)
*
|
2002-03-01 |
2016-06-29 |
免疫医疗公司 |
内在化抗-cd74抗体和使用方法
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
EP2277522B1
(en)
|
2002-03-01 |
2012-11-21 |
UCB Manufacturing, Inc. |
Methods for increasing or decreasing bone density and identifying molecules
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
GB0205022D0
(en)
|
2002-03-04 |
2002-04-17 |
Univ Cambridge Tech |
Materials and methods for the treatment of cns damage
|
DE60325564D1
(de)
|
2002-03-05 |
2009-02-12 |
Univ Texas |
Biospezifische kontrastmittel
|
WO2003076455A2
(en)
|
2002-03-05 |
2003-09-18 |
Ramot At Tel-Aviv University Ltd. |
Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
|
ES2337566T3
(es)
|
2002-03-11 |
2010-04-27 |
Philogen S.P.A. |
Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US6703216B2
(en)
|
2002-03-14 |
2004-03-09 |
The Regents Of The University Of California |
Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
US20030182669A1
(en)
*
|
2002-03-19 |
2003-09-25 |
Rockman Howard A. |
Phosphoinositide 3-kinase mediated inhibition of GPCRs
|
CA2475529A1
(en)
*
|
2002-03-19 |
2003-10-02 |
Abgenix, Inc. |
Methods for treating chronic obstructive pulmonary disease (copd)
|
US6974672B2
(en)
*
|
2002-03-19 |
2005-12-13 |
Amgen Inc. |
Gene amplification in cancer
|
WO2003081211A2
(en)
*
|
2002-03-19 |
2003-10-02 |
Cengent Therapeutics, Inc. |
Discrete bayesian analysis of data
|
EP1490399A2
(en)
|
2002-03-20 |
2004-12-29 |
Syddansk Universitet |
Human diabetes-mediating proteins
|
EP2093233A1
(en)
|
2002-03-21 |
2009-08-26 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7317087B2
(en)
*
|
2002-03-25 |
2008-01-08 |
The Uab Research Foundation |
Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
|
US7384738B2
(en)
*
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
US20040038304A1
(en)
*
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
WO2003085093A2
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
EP2314316A1
(en)
|
2002-04-05 |
2011-04-27 |
Amgen, Inc |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
US7786278B2
(en)
|
2002-04-09 |
2010-08-31 |
Sanofi Pasteur Limited |
Modified CEA nucleic acid and expression vectors
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
AU2003224916B2
(en)
|
2002-04-10 |
2009-01-08 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
US7138512B2
(en)
*
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
*
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
US20040048312A1
(en)
*
|
2002-04-12 |
2004-03-11 |
Ronghao Li |
Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
US20040016010A1
(en)
*
|
2002-04-17 |
2004-01-22 |
Marion Kasaian |
IL-21 receptor knockout animal and methods of use thereof
|
PL209696B1
(pl)
|
2002-04-19 |
2011-10-31 |
Univ Toronto |
Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
|
JP4319979B2
(ja)
|
2002-04-26 |
2009-08-26 |
ジェネンテック・インコーポレーテッド |
タンパク質の非アフィニティ精製
|
US8088889B2
(en)
|
2002-05-02 |
2012-01-03 |
David Lovejoy |
Teneurin c-terminal associated peptides (TCAP) and uses thereof
|
AU2003225294A1
(en)
*
|
2002-05-03 |
2003-11-17 |
Raven Biotechnologies, Inc. |
Alcam and alcam modulators
|
EP1504034B1
(en)
|
2002-05-06 |
2012-12-12 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
PT3072978T
(pt)
|
2002-05-09 |
2018-10-15 |
Brigham & Womens Hospital Inc |
1l1rl-1 como um marcador de doença cardiovascular
|
JP4585968B2
(ja)
*
|
2002-05-10 |
2010-11-24 |
パーデュー・リサーチ・ファウンデーション |
EphA2アゴニストモノクローナル抗体およびその使用法
|
US20050152899A1
(en)
*
|
2002-05-10 |
2005-07-14 |
Kinch Michael S. |
EphA2 agonistic monoclonal antibodies and methods of use thereof
|
WO2003094859A2
(en)
*
|
2002-05-10 |
2003-11-20 |
Medimmune, Inc. |
Epha2 monoclonal antibodies and methods of use thereof
|
US20030228317A1
(en)
*
|
2002-05-22 |
2003-12-11 |
Prafulla Gokhale |
Gene BRCC-1 and diagnostic and therapeutic uses thereof
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
AU2003239544A1
(en)
*
|
2002-05-24 |
2003-12-12 |
Tularik Inc. |
Amplification and overexpression of oncogenes
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
EP1513554B9
(en)
*
|
2002-05-30 |
2011-11-09 |
Macrogenics, Inc. |
Cd16a binding proteins and use for the treatment of immune disorders
|
US7290215B2
(en)
*
|
2002-06-03 |
2007-10-30 |
Microsoft Corporation |
Dynamic wizard interface system and method
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
NZ556507A
(en)
*
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
US7563882B2
(en)
*
|
2002-06-10 |
2009-07-21 |
University Of Rochester |
Polynucleotides encoding antibodies that bind to the C35 polypeptide
|
US20050221326A1
(en)
*
|
2002-06-12 |
2005-10-06 |
Avi Orr-Urtreger |
Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
|
AU2003276679A1
(en)
*
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
DE60239566D1
(de)
|
2002-06-14 |
2011-05-05 |
Brigham And Women S Hospital Boston |
Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
|
US7893218B2
(en)
|
2003-06-16 |
2011-02-22 |
Stowers Institute For Medical Research |
Antibodies that specifically bind SOST peptides
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2003247551C1
(en)
|
2002-06-17 |
2010-12-09 |
Thrasos Innovation, Inc. |
Single domain TDF-related compounds and analogs thereof
|
CA2490399C
(en)
|
2002-06-19 |
2015-10-06 |
Raven Biotechnologies, Inc. |
Novel raag10 cell surface target and a family of antibodies recognizing that target
|
US7144950B2
(en)
|
2003-09-17 |
2006-12-05 |
The Regents Of The University Of California |
Conformationally flexible cationic conjugated polymers
|
US8029803B2
(en)
|
2002-06-20 |
2011-10-04 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US8025873B2
(en)
|
2002-06-20 |
2011-09-27 |
Paladin Labs, Inc. |
Chimeric antigens for eliciting an immune response
|
US7628988B2
(en)
|
2002-06-27 |
2009-12-08 |
The General Hospital Corporation |
Methods and compositions for treating type 1 diabetes
|
US7582313B2
(en)
|
2002-06-27 |
2009-09-01 |
The General Hospital Corporation |
Methods of organ regeneration using Hox 11-expressing pluripotent cells
|
AU2003248744C1
(en)
*
|
2002-06-28 |
2009-12-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
|
US7455834B2
(en)
|
2002-06-29 |
2008-11-25 |
Genentech, Inc. |
Methods and compositions for modulating and detecting WISP activity
|
WO2004002526A1
(en)
*
|
2002-07-01 |
2004-01-08 |
Wilex Ag |
Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
|
EP2332956A1
(en)
*
|
2002-07-08 |
2011-06-15 |
Genentech, Inc. |
Antibody binding to PRO71238
|
ES2358730T3
(es)
|
2002-07-15 |
2011-05-13 |
Board Of Regents, The University Of Texas System |
Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
EA011686B1
(ru)
*
|
2002-07-15 |
2009-04-28 |
Уайт |
Способ модуляции развития и функций т-клеток-хелперов
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
CA2872136C
(en)
*
|
2002-07-18 |
2017-06-20 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
US7435419B2
(en)
|
2002-07-19 |
2008-10-14 |
Beth Israel Deaconess Medical Center |
Methods of diagnosing and treating pre-eclampsia or eclampsia
|
ES2534926T3
(es)
|
2002-07-19 |
2015-04-30 |
Beth Israel Deaconess Medical Center |
Métodos para tratar la preeclampsia
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
WO2004009619A2
(en)
*
|
2002-07-19 |
2004-01-29 |
Cellzome Ag |
Protein complexes of the tip60 transcriptional activator protein
|
US7250551B2
(en)
*
|
2002-07-24 |
2007-07-31 |
President And Fellows Of Harvard College |
Transgenic mice expressing inducible human p25
|
JP2005533863A
(ja)
*
|
2002-07-25 |
2005-11-10 |
ジェネンテック・インコーポレーテッド |
Taci抗体とその用途
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
US20040018497A1
(en)
*
|
2002-07-26 |
2004-01-29 |
Warden Craig H |
Human obesity LIPIN3 polynucleotide and polypeptide sequences and methods of use thereof
|
CA2492444A1
(en)
*
|
2002-07-29 |
2004-02-05 |
Wyeth |
Modified adamts4 molecules and method of use thereof
|
WO2004010957A2
(en)
|
2002-07-31 |
2004-02-05 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
WO2005016232A2
(en)
|
2002-08-01 |
2005-02-24 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
WO2004013290A2
(en)
*
|
2002-08-05 |
2004-02-12 |
Invitrogen Corporation |
Compositions and methods for molecular biology
|
EP1575992A4
(en)
|
2002-08-05 |
2007-02-21 |
Univ Rochester |
CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES
|
US20050059011A1
(en)
*
|
2002-08-07 |
2005-03-17 |
Sin Wun Chey |
Amplification and overexpression of oncogenes
|
EA200500330A1
(ru)
*
|
2002-08-10 |
2006-06-30 |
Йейл Юниверсити |
Антагонисты nogo рецепторов
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
WO2004016740A2
(en)
*
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
EP1569514A4
(en)
|
2002-08-16 |
2007-10-31 |
|
SPECIFIC ANTIGEN OF TUMORS, PEPTIDES ASSOCIATED THERETO AND USE THEREOF AS IMMUNOMINAL VACCINES
|
EP2322607B1
(en)
|
2002-08-16 |
2015-09-16 |
Danisco US Inc. |
Novel variant Hyprocrea jecorina CBH1 cellulases with increase thermal stability comprising substitution or deletion at position S113
|
US20050233473A1
(en)
*
|
2002-08-16 |
2005-10-20 |
Zyomyx, Inc. |
Methods and reagents for surface functionalization
|
JP2006514823A
(ja)
|
2002-08-20 |
2006-05-18 |
ミレニアム ファーマスーティカルズ インク |
子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
|
GB0219524D0
(en)
|
2002-08-21 |
2002-10-02 |
Queen Mary & Westfield College |
Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
|
US20040247588A1
(en)
*
|
2002-08-28 |
2004-12-09 |
Johnson Robert E. |
Formulations of modified antibodies and methods of making the same
|
AU2003265361A1
(en)
*
|
2002-08-28 |
2004-03-19 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
EP1575515A4
(en)
*
|
2002-08-29 |
2007-08-08 |
Genentech Inc |
ACHAETE-SCUTE-SIMILAR 2 POLYPEPTIDES AND CODING NUCLEIC ACIDS AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF A TUMOR
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
AU2002328429A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
|
CA2497628A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
MXPA05002514A
(es)
|
2002-09-06 |
2005-05-27 |
Amgen Inc |
Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
|
US20080260744A1
(en)
*
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
AU2003267124A1
(en)
|
2002-09-09 |
2004-03-29 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
CA2498264A1
(en)
*
|
2002-09-09 |
2004-05-13 |
Nura, Inc. |
G protein coupled receptors and uses thereof
|
HUE033623T2
(en)
|
2002-09-11 |
2017-12-28 |
Genentech Inc |
protein purification
|
ATE493433T1
(de)
|
2002-09-11 |
2011-01-15 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
US20060199181A1
(en)
|
2002-09-11 |
2006-09-07 |
Genentch, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003291625B2
(en)
|
2002-09-16 |
2009-10-08 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CA2499081A1
(en)
*
|
2002-09-16 |
2004-04-22 |
Elusys Therapeutics, Inc. |
Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
|
US20040053359A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
US20040053363A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
EP1545575A4
(en)
|
2002-09-19 |
2006-04-05 |
Us Gov Health & Human Serv |
POLYPEPTIDES OF P. ARIASI POLYPEPTIDES P. PERNICIOSUS AND METHODS OF USE
|
EP2500438A3
(en)
|
2002-09-25 |
2012-11-28 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
WO2004029246A2
(en)
|
2002-09-26 |
2004-04-08 |
K.U.Leuven Research And Development |
Integrase cofactor
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
KR20050046751A
(ko)
*
|
2002-09-27 |
2005-05-18 |
오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 |
폴리펩티드 및 이들을 암호화하는 핵산 및 간질환 및 상피세포암을 예방, 진단 또는 치료하기 위한 이들의 용도
|
US7541440B2
(en)
*
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
WO2004029284A2
(en)
*
|
2002-09-30 |
2004-04-08 |
Protein Design Labs, Inc. |
Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
|
WO2004031362A2
(en)
*
|
2002-10-03 |
2004-04-15 |
Large Scale Biology Corporation |
Multimeric protein engineering
|
WO2004033631A2
(en)
*
|
2002-10-04 |
2004-04-22 |
Regents Of The University Of Minnesota |
Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
|
CA2500901A1
(en)
*
|
2002-10-04 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
US7255860B2
(en)
|
2002-10-08 |
2007-08-14 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
WO2004032870A2
(en)
*
|
2002-10-08 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
|
EP1633786A4
(en)
*
|
2002-10-09 |
2007-07-25 |
Rinat Neuroscience Corp |
METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
|
GB0228832D0
(en)
|
2002-12-10 |
2003-01-15 |
Novartis Ag |
Organic compound
|
US7396913B2
(en)
*
|
2002-10-14 |
2008-07-08 |
Abbott Laboratories |
Erythropoietin receptor binding antibodies
|
US7229762B2
(en)
*
|
2002-10-15 |
2007-06-12 |
Duke University Medical Center |
Proteomic screening for redox state dependent protein—protein interactions
|
WO2004035537A2
(en)
|
2002-10-16 |
2004-04-29 |
Euro-Celtique S.A. |
Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
|
AU2003304203A1
(en)
*
|
2002-10-29 |
2005-01-04 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
EP1572968B1
(en)
|
2002-10-29 |
2009-04-22 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Lutzomyia longipalpis polypeptides and methods of use
|
WO2004039956A2
(en)
|
2002-10-29 |
2004-05-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
MXPA05004677A
(es)
*
|
2002-10-31 |
2005-11-17 |
Genentech Inc |
Metodos y composiciones para aumentar la produccion de anticuerpos.
|
WO2004044161A2
(en)
*
|
2002-11-06 |
2004-05-27 |
Fraunhofer Usa |
Expression of foreign sequences in plants using trans-activation system
|
US8278079B2
(en)
|
2002-11-07 |
2012-10-02 |
Danisco Us Inc. |
BGL6 β-glucosidase and nucleic acids encoding the same
|
JP4744879B2
(ja)
*
|
2002-11-07 |
2011-08-10 |
ジェネンコー・インターナショナル・インク |
BGL6β−グルコシダーゼ及びそれをエンコードする核酸
|
EP1581169A4
(en)
|
2002-11-08 |
2008-09-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
|
US20050054054A1
(en)
*
|
2002-11-12 |
2005-03-10 |
Foss Francine M. |
Interleukin-7 molecules with altered biological properties
|
US7683238B2
(en)
*
|
2002-11-12 |
2010-03-23 |
iBio, Inc. and Fraunhofer USA, Inc. |
Production of pharmaceutically active proteins in sprouted seedlings
|
US7692063B2
(en)
*
|
2002-11-12 |
2010-04-06 |
Ibio, Inc. |
Production of foreign nucleic acids and polypeptides in sprout systems
|
CA2505633A1
(en)
*
|
2002-11-13 |
2004-05-27 |
Raven Biotechnologies, Inc. |
Antigen pipa and antibodies that bind thereto
|
US20060009378A1
(en)
*
|
2002-11-14 |
2006-01-12 |
Itshak Golan |
Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
|
JP4915980B2
(ja)
|
2002-11-15 |
2012-04-11 |
エムユーエスシー ファウンデーション フォー リサーチ デベロップメント |
補体レセプター2標的化補体調節因子
|
US9233120B2
(en)
|
2002-11-15 |
2016-01-12 |
Jyant Technologies |
Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
|
US8512701B2
(en)
|
2002-11-15 |
2013-08-20 |
Morehouse School Of Medicine |
Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
|
US8658377B2
(en)
|
2002-11-15 |
2014-02-25 |
Morehouse School Of Medicine |
Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
|
DE60332483D1
(de)
|
2002-11-15 |
2010-06-17 |
Novartis Vaccines & Diagnostic |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
US20110091451A1
(en)
*
|
2002-11-15 |
2011-04-21 |
Kavanaugh William M |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
AU2003290948A1
(en)
*
|
2002-11-15 |
2004-06-15 |
The General Hospital Corporation |
Screening methods to identify treatments for autoimmune disease
|
US20040171037A1
(en)
*
|
2002-11-19 |
2004-09-02 |
Jing Li |
Amplified genes involved in cancer
|
ATE481422T1
(de)
|
2002-11-21 |
2010-10-15 |
Celltech R & D Inc |
Modulieren von immunantworten
|
US7407788B2
(en)
|
2002-11-21 |
2008-08-05 |
Danisco A/S, Genencor Division |
BGL7 beta-glucosidase and nucleic acids encoding the same
|
EP2112229A3
(en)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Methods for identifying risk of breast cancer and treatments thereof
|
JP4741242B2
(ja)
|
2002-11-26 |
2011-08-03 |
アボット バイオセラピューティクス コーポレイション |
新脈管形成を調節するα5β1インテグリンへのキメラ及びヒト化抗体
|
EP1576351A4
(en)
*
|
2002-11-26 |
2010-06-23 |
Univ Utah Res Found |
MICROPOROUS MATERIALS, METHODS, AND ARTICLES FOR LOCATING AND QUANTIFYING ANALYTES
|
EP2311870A1
(en)
|
2002-11-26 |
2011-04-20 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7597936B2
(en)
*
|
2002-11-26 |
2009-10-06 |
University Of Utah Research Foundation |
Method of producing a pigmented composite microporous material
|
JP2007531505A
(ja)
|
2002-11-27 |
2007-11-08 |
ミネルバ バイオオテクノロジーズ コーポレーション |
癌(muc1)の診断および治療のための技術および組成物
|
EP1581629B1
(en)
|
2002-12-06 |
2015-04-01 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
US7491699B2
(en)
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7056702B2
(en)
*
|
2002-12-16 |
2006-06-06 |
Kimberly Clark Co |
Detecting lipocalin
|
BRPI0316779B1
(pt)
|
2002-12-16 |
2020-04-28 |
Genentech Inc |
anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
|
BRPI0317376B8
(pt)
*
|
2002-12-17 |
2021-05-25 |
Merck Patent Gmbh |
proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
|
US20070042978A1
(en)
*
|
2002-12-19 |
2007-02-22 |
Jean-Philippe Girard |
Nf-hev compositions and methods of use
|
AU2002953431A0
(en)
*
|
2002-12-19 |
2003-01-09 |
Murdoch University |
BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof
|
ES2388280T3
(es)
|
2002-12-20 |
2012-10-11 |
Abbott Biotherapeutics Corp. |
Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
|
EP2474632B1
(en)
|
2002-12-20 |
2015-08-12 |
Celera Corporation |
Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
|
US9487823B2
(en)
*
|
2002-12-20 |
2016-11-08 |
Qiagen Gmbh |
Nucleic acid amplification
|
ATE471335T1
(de)
|
2002-12-23 |
2010-07-15 |
Vical Inc |
Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
|
AU2003300397A1
(en)
*
|
2002-12-23 |
2004-07-22 |
Rinat Neuroscience Corp. |
Methods for treating taxol-induced sensory neuropathy
|
ATE515514T1
(de)
|
2002-12-23 |
2011-07-15 |
Schering Corp |
Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
|
PT2270048E
(pt)
*
|
2002-12-24 |
2016-02-10 |
Rinat Neuroscience Corp |
Anticorpos anti-ngf e métodos de utilização dos mesmos
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2509568A1
(en)
*
|
2002-12-26 |
2004-07-15 |
Applied Research Systems Ars Holding N.V. |
Spliced variants of lgr6
|
JP2006517191A
(ja)
*
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
US20050265992A1
(en)
|
2003-01-03 |
2005-12-01 |
The Research Foundation Of State University Of New York |
F11 receptor (F11R) antagonists as therapeutic agents
|
US8557957B2
(en)
|
2003-01-03 |
2013-10-15 |
Elizabeth Kornecki |
Methods of treating disorders by administration of F11 receptor antagonists
|
DE602004020179D1
(de)
|
2003-01-07 |
2009-05-07 |
Univ Ramot |
Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
JP4773947B2
(ja)
*
|
2003-01-09 |
2011-09-14 |
マクロジェニクス,インコーポレーテッド |
細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系
|
WO2004065416A2
(en)
*
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20050196766A1
(en)
*
|
2003-12-24 |
2005-09-08 |
Soe Jorn B. |
Proteins
|
MXPA05007653A
(es)
|
2003-01-17 |
2005-09-30 |
Danisco |
Metodo.
|
JP4778887B2
(ja)
|
2003-01-17 |
2011-09-21 |
ダニスコ エイ/エス |
脂質アシルトランスフェラーゼの使用
|
US7955814B2
(en)
*
|
2003-01-17 |
2011-06-07 |
Danisco A/S |
Method
|
CA2513675A1
(en)
|
2003-01-17 |
2004-08-05 |
The Johns Hopkins University |
Methods of identifying modulators of cellular glycosylation using gtrap3-18
|
US20040197629A1
(en)
*
|
2003-01-20 |
2004-10-07 |
Yasuo Arishima |
Electric power generating element for fuel cell and fuel cell using the same
|
JP2006518997A
(ja)
*
|
2003-01-21 |
2006-08-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規アシルコエンザイムa:モノアシルグリセロールアシルトランスフェラーゼ−3(mgat3)をコードするポリヌクレオチドおよびその用途
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
WO2004065417A2
(en)
*
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
CA2514062A1
(en)
*
|
2003-01-27 |
2004-08-12 |
Biogen Idec Ma Inc. |
Compositions and methods for treating cancer using igsf9 and liv-1
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
EP1592777A4
(en)
|
2003-02-01 |
2008-06-04 |
Tanox Inc |
METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
|
CA2513722A1
(en)
*
|
2003-02-01 |
2004-08-19 |
Neuralab Limited |
Active immunization to generate antibodies to soluble a-beta
|
EP2192172B1
(en)
*
|
2003-02-03 |
2014-12-03 |
iBio, Inc. |
System for expression of genes in plants
|
AU2004209578A1
(en)
|
2003-02-07 |
2004-08-19 |
Diagnocure Inc. |
Method to detect prostate cancer in a sample
|
EP2325301B1
(en)
|
2003-02-11 |
2015-09-02 |
Shire Human Genetic Therapies, Inc. |
Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
|
WO2004074321A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US20040170982A1
(en)
*
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
CA2516028C
(en)
*
|
2003-02-14 |
2012-10-16 |
University Of Southern California |
Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine
|
EP1596858A1
(en)
*
|
2003-02-14 |
2005-11-23 |
Medical Research Council |
Ip receptor antagonists for the treatment of pathological uterine conditions
|
EP2241330A1
(en)
|
2003-02-14 |
2010-10-20 |
The Curators Of The University Of Missouri |
Contraceptive methods and compositions related to proteasomal interference
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
US7655231B2
(en)
|
2003-02-19 |
2010-02-02 |
Pfizer Inc. |
Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
|
US7662387B2
(en)
|
2003-02-20 |
2010-02-16 |
Seattle Genetics |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US7723075B2
(en)
*
|
2003-02-21 |
2010-05-25 |
The Queens's Medical Center |
Methods of screening for TRPM5 modulators
|
CN101897969B
(zh)
|
2003-02-21 |
2014-04-02 |
健泰科生物技术公司 |
补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
|
US20070065433A1
(en)
*
|
2003-02-21 |
2007-03-22 |
Mollnes Tom E |
Methods and compositions for the treatment of meconium aspiration syndrome
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
RU2349642C2
(ru)
|
2003-03-12 |
2009-03-20 |
Исихара Сангио Кайся, Лтд. |
Растительные клетки и организмы растений с модифицированным клеточным ростом, развитием и дифференцировкой
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
US8017113B2
(en)
|
2003-03-12 |
2011-09-13 |
Rappaport Family Institute For Research In The Medical Sciences |
Compositions and methods for diagnosing and treating an inflammation
|
US7741065B2
(en)
*
|
2003-03-13 |
2010-06-22 |
Ramot At Tel Aviv University Ltd. |
Non-invasive marker for liver function and disease
|
US20040180387A1
(en)
|
2003-03-13 |
2004-09-16 |
Fujirebio Diagnostics, Inc. |
Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
|
DE10311248A1
(de)
*
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper
|
MXPA05009556A
(es)
*
|
2003-03-14 |
2005-11-16 |
Wyeth Corp |
Anticuerpos contra receptor de il-21 humano y sus usos.
|
EP1606409B1
(en)
|
2003-03-19 |
2010-09-01 |
Biogen Idec MA Inc. |
Nogo receptor binding protein
|
JP2006520597A
(ja)
|
2003-03-20 |
2006-09-14 |
ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ |
細胞運動性に関する物質および方法
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
WO2004084836A2
(en)
*
|
2003-03-20 |
2004-10-07 |
Rinat Neuroscience Corp. |
Methods for treating taxol-induced gut disorder
|
US7235376B2
(en)
*
|
2003-03-28 |
2007-06-26 |
Receptor Biologix, Inc. |
Gastrin hormone immunoassays
|
US8043834B2
(en)
*
|
2003-03-31 |
2011-10-25 |
Qiagen Gmbh |
Universal reagents for rolling circle amplification and methods of use
|
AU2003237792A1
(en)
|
2003-04-01 |
2004-11-23 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ATE517926T1
(de)
|
2003-04-04 |
2011-08-15 |
Yeda Res & Dev |
Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
|
EP1618897A4
(en)
|
2003-04-04 |
2010-09-29 |
Eisai R&D Man Co Ltd |
LIPID MEMBRANE STRUCTURE COMPRISING AN ANTI-MT-MMP MONOCLONAL ANTIBODY
|
JP4869064B2
(ja)
|
2003-04-04 |
2012-02-01 |
ジェネンテック, インコーポレイテッド |
高濃度抗体及びタンパク質製剤
|
ES2322267T3
(es)
|
2003-04-09 |
2009-06-18 |
Genentech, Inc. |
Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
|
EP1618184A4
(en)
*
|
2003-04-11 |
2006-06-21 |
Medimmune Inc |
EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
|
CA2521594A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Epha2 and non-neoplastic hyperproliferative cell disorders
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
SE0301087D0
(sv)
*
|
2003-04-14 |
2003-04-14 |
Cartela Ab |
New monoclonal antibody
|
US20080213169A1
(en)
*
|
2003-04-14 |
2008-09-04 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20080025977A1
(en)
*
|
2003-04-14 |
2008-01-31 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20060140963A1
(en)
*
|
2003-04-14 |
2006-06-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
EP1615654A2
(en)
*
|
2003-04-16 |
2006-01-18 |
Yale University |
Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
|
AT500650B1
(de)
|
2003-04-17 |
2009-11-15 |
Altropus Gmbh |
Immunogener rekombinanter antikörper
|
CN100409897C
(zh)
*
|
2003-04-23 |
2008-08-13 |
梅达雷克斯公司 |
1型干扰素拮抗剂在制备治疗患有炎症性肠病的患者的药物中的用途
|
CA2523142A1
(en)
*
|
2003-04-23 |
2004-11-04 |
Medarex, Inc. |
Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
|
US8613922B2
(en)
|
2003-04-24 |
2013-12-24 |
The University Of North Carolina At Chapel Hill |
Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
CN100417414C
(zh)
|
2003-04-30 |
2008-09-10 |
苏黎世大学 |
免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用
|
WO2004098634A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health |
Protein arginine n-methyltransferase 2 (prmt-2)
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
KR101412271B1
(ko)
|
2003-05-09 |
2014-06-25 |
듀크 유니버시티 |
Cd20-특이적 항체 및 이를 이용한 방법
|
SI2374819T1
(sl)
*
|
2003-05-12 |
2017-09-29 |
Helion Biotech Aps |
Protitelesa proteina MASP-2
|
US8394379B2
(en)
*
|
2003-05-15 |
2013-03-12 |
Iogenetics, Llc |
Targeted cryptosporidium biocides
|
US20050014932A1
(en)
|
2003-05-15 |
2005-01-20 |
Iogenetics, Llc |
Targeted biocides
|
US8703134B2
(en)
|
2003-05-15 |
2014-04-22 |
Iogenetics, Llc |
Targeted cryptosporidium biocides
|
US7566447B2
(en)
|
2003-05-15 |
2009-07-28 |
Iogenetics, Llc |
Biocides
|
CA2524534C
(en)
|
2003-05-15 |
2012-12-11 |
Sek Chung Fung |
Methods and compositions for the prevention and treatment of sepsis
|
US20070104722A1
(en)
*
|
2003-05-15 |
2007-05-10 |
Iogenetics |
Targeted biocides
|
US8080642B2
(en)
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
US7892563B2
(en)
|
2003-05-20 |
2011-02-22 |
Wyeth Holdings Corporation |
Methods for treatment of severe acute respiratory syndrome (SARS)
|
CN103074316B
(zh)
|
2003-05-22 |
2015-10-21 |
美国弗劳恩霍夫股份有限公司 |
用于表达、传递及纯化目标多肽的重组载体分子
|
WO2004111192A2
(en)
*
|
2003-05-29 |
2004-12-23 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
CA2527694C
(en)
*
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
KR20180132969A
(ko)
|
2003-05-30 |
2018-12-12 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
WO2005017149A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
KR20060027801A
(ko)
*
|
2003-06-05 |
2006-03-28 |
제넨테크, 인크. |
B 세포 장애에 대한 조합 요법
|
PL1636593T3
(pl)
|
2003-06-06 |
2009-08-31 |
Genentech Inc |
Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
|
CN1279056C
(zh)
*
|
2003-06-06 |
2006-10-11 |
马菁 |
肿瘤相关抗原sm5-1的特异性抗体及其应用
|
US20050232926A1
(en)
*
|
2003-06-06 |
2005-10-20 |
Oncomax Acquisition Corp. |
Antibodies specific for cancer associated antigen SM5-1 and uses thereof
|
US20040248323A1
(en)
*
|
2003-06-09 |
2004-12-09 |
Protometrix, Inc. |
Methods for conducting assays for enzyme activity on protein microarrays
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
GB0313259D0
(en)
|
2003-06-09 |
2003-07-16 |
Consejo Superior Investigacion |
Magnetic nanoparticles
|
AU2004249155B2
(en)
|
2003-06-13 |
2009-11-19 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Monitoring immunologic, hematologic and inflammatory diseases
|
IL156495A0
(en)
*
|
2003-06-17 |
2004-01-04 |
Prochon Biotech Ltd |
Use of fgfr3 antagonists for treating t cell mediated diseases
|
AU2004255553B2
(en)
*
|
2003-06-19 |
2009-08-20 |
Genentech, Inc. |
Compositions and methods for treating coagulation related disorders
|
ES2862206T3
(es)
|
2003-06-19 |
2021-10-07 |
Genzyme Corp |
Viriones de AAV con inmunorreactividad disminuida y sus usos
|
WO2004112575A2
(en)
*
|
2003-06-20 |
2004-12-29 |
Amgen Inc. |
Gene amplification and overexpression in cancer
|
EP1641826A2
(en)
*
|
2003-06-27 |
2006-04-05 |
Biogen Idec MA Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
EP1638517A4
(en)
|
2003-06-30 |
2010-01-06 |
Univ Tel Aviv Future Tech Dev |
PEPTIDES, ANTIBODIES AGAINST DISEASES ASSOCIATED WITH AMYLOID AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF THESE DISEASES
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0315450D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
US20090191213A9
(en)
*
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
JP4871125B2
(ja)
*
|
2003-07-02 |
2012-02-08 |
イナート・ファルマ |
Nk細胞活性を調節するための組成物および方法
|
SI2784084T2
(sl)
|
2003-07-08 |
2024-02-29 |
Novartis Pharma Ag |
Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
|
US20050058658A1
(en)
*
|
2003-07-15 |
2005-03-17 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
|
EP1644408A1
(en)
*
|
2003-07-15 |
2006-04-12 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
IL161903A0
(en)
*
|
2003-07-17 |
2005-11-20 |
Gamida Cell Ltd |
Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
|
EP1498133A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Use of a pak inhibitor for the treatment of a joint disease
|
TWI476206B
(zh)
|
2003-07-18 |
2015-03-11 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
WO2005007878A2
(en)
*
|
2003-07-22 |
2005-01-27 |
Dana-Farber Cancer Institute, Inc. |
Method of modulating apoptosis and compositions thereof
|
DK1648507T3
(en)
|
2003-07-24 |
2017-05-01 |
Innate Pharma Sa |
PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
HUE050171T2
(hu)
|
2003-07-28 |
2020-11-30 |
Genentech Inc |
Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
|
US20050026881A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
|
US20090263381A1
(en)
*
|
2003-07-31 |
2009-10-22 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
|
WO2005010039A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Pfizer Products Inc. |
Bsep polypeptide variants and uses thereof
|
EP1648500B1
(en)
|
2003-07-31 |
2014-07-09 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for streptococcus pyogenes
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
*
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
EP1939779A3
(en)
|
2003-08-01 |
2009-04-01 |
Dna Twopointo Inc. |
Systems and methods for biopolymer engineering
|
EP2434420A3
(en)
|
2003-08-01 |
2012-07-25 |
Dna Twopointo Inc. |
Systems and methods for biopolymer engineering
|
AU2004261980A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody CDR polypeptide sequences with restricted diversity
|
WO2005012526A1
(en)
|
2003-08-04 |
2005-02-10 |
The Hospital For Sick Children |
Lafora's disease gene
|
AU2004263896A1
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
EP1651276A4
(en)
*
|
2003-08-08 |
2009-05-06 |
Barnes Jewish Hospital |
EMULSION PARTICLES FOR IMAGING AND THERAPY AND USE METHOD THEREFOR
|
EP1652923B1
(en)
|
2003-08-08 |
2011-10-12 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
US8007805B2
(en)
*
|
2003-08-08 |
2011-08-30 |
Paladin Labs, Inc. |
Chimeric antigens for breaking host tolerance to foreign antigens
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
CA2535897A1
(en)
|
2003-08-14 |
2005-02-24 |
Exelixis, Inc. |
Sulfs as modifiers of the beta catenin pathway and methods of use
|
CA2535799A1
(en)
|
2003-08-15 |
2005-03-03 |
University Of Florida |
Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
|
CN1864068B
(zh)
*
|
2003-08-18 |
2010-10-13 |
特提斯生物科学公司 |
用小表位抗体降低样品复杂度的方法
|
EP1660534A2
(en)
*
|
2003-08-22 |
2006-05-31 |
MedImmune, Inc. |
Humanization of antibodies
|
EP3168304A1
(en)
|
2003-08-27 |
2017-05-17 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
US7589181B2
(en)
*
|
2003-08-29 |
2009-09-15 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
|
DE602004008658T2
(de)
*
|
2003-09-05 |
2008-06-12 |
Cellzome Ag |
Behandlung neurodegenerativer krankheiten
|
EP1668026A1
(en)
*
|
2003-09-05 |
2006-06-14 |
The Scripps Research Institute |
Detection of cholesterol ozonation products
|
AU2004273791A1
(en)
*
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
TR200600945T1
(tr)
*
|
2003-09-05 |
2006-10-26 |
The Scripps Research Institute |
Terapötik usuller.
|
EP1514561A1
(en)
|
2003-09-10 |
2005-03-16 |
Philogen S.p.A. |
Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
|
US7046714B2
(en)
*
|
2003-09-10 |
2006-05-16 |
Intel Corporation |
Method and apparatus for Raman ring resonator based laser/wavelength converter
|
GB0321997D0
(en)
|
2003-09-19 |
2003-10-22 |
Novartis Ag |
Organic compound
|
EP1664082B1
(en)
*
|
2003-09-18 |
2014-03-05 |
MacroGenics West, Inc. |
Kid3 and anti-kid3 antibodies
|
JP2007521015A
(ja)
|
2003-09-18 |
2007-08-02 |
ジェンマブ エー/エス |
癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド
|
EP1668034A1
(en)
*
|
2003-09-19 |
2006-06-14 |
Leukotech A/S |
Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
|
US20050282177A1
(en)
*
|
2003-09-22 |
2005-12-22 |
Aichi Prefecture |
Types of lymphoma and method for prognosis thereof
|
WO2006101474A1
(en)
*
|
2005-03-15 |
2006-09-28 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin k-dependent proteins
|
EP2336360A1
(en)
*
|
2003-09-23 |
2011-06-22 |
University Of North Carolina At Chapel Hill |
Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage
|
EP1673394A4
(en)
*
|
2003-09-23 |
2008-03-26 |
Favrille Inc |
MODIFICATION OF A LYMPHOCYTE B PATHOLOGY USING AUTODERATED ANTIGENS IN CONJUGATION WITH A SPECIFICALLY BINDING CYTOREDUCING AGENT
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7803624B2
(en)
|
2003-09-30 |
2010-09-28 |
Cytyc Corporation |
Automated cytological sample classification
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
WO2005031362A2
(en)
*
|
2003-10-02 |
2005-04-07 |
Ramot At Tel Aviv University Ltd. |
Novel antibacterial agents and methods of identifying and utilizing same
|
IL158287A0
(en)
|
2003-10-07 |
2004-05-12 |
Yeda Res & Dev |
Antibodies to nik, their preparation and use
|
CN1964986A
(zh)
|
2003-10-07 |
2007-05-16 |
千年药品公司 |
用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
|
US20050226867A1
(en)
*
|
2003-10-08 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
IL-5R-specific antibody composition
|
US20050287138A1
(en)
*
|
2003-10-08 |
2005-12-29 |
Kyowa Hakko Kogyo Co., Ltd. |
CCR4-specific antibody composition
|
US7691810B2
(en)
*
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
US20060021071A1
(en)
*
|
2003-10-09 |
2006-01-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell in which genome is modified
|
US7662929B2
(en)
|
2003-10-10 |
2010-02-16 |
Alchemia Oncology Pty Limited |
Antibody that specifically binds hyaluronan synthase
|
ES2344413T3
(es)
|
2003-10-14 |
2010-08-26 |
Baxter International Inc. |
Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
|
US9382322B2
(en)
|
2003-10-17 |
2016-07-05 |
Rehab Al-Jamal |
Tissue repair by modulation of beta-1 integrin biological function
|
IL158599A0
(en)
*
|
2003-10-26 |
2004-05-12 |
Yeda Res & Dev |
Methods of modulating hematopoiesis
|
US7304139B2
(en)
*
|
2003-10-28 |
2007-12-04 |
University Of Florida Research Foundation, Inc. |
Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
|
CA2544852A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
|
DE602004028272D1
(de)
|
2003-11-04 |
2010-09-02 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
|
DE602004028270D1
(de)
|
2003-11-04 |
2010-09-02 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
|
DK1682178T3
(da)
|
2003-11-04 |
2010-10-04 |
Novartis Vaccines & Diagnostic |
Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
|
JP4810431B2
(ja)
|
2003-11-04 |
2011-11-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
B細胞に関連する癌に対する治療方法
|
RS58420B1
(sr)
|
2003-11-05 |
2019-04-30 |
Roche Glycart Ag |
Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
SG148161A1
(en)
*
|
2003-11-05 |
2008-12-31 |
Palingen Inc |
Enhanced b cell cytotoxicity of cdim binding antibody
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
US20060199194A1
(en)
*
|
2003-11-10 |
2006-09-07 |
Q-Rna, Inc. |
Methods of detection using immuno-Q-Amp technology
|
PE20090046A1
(es)
|
2003-11-10 |
2009-01-26 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
US20050214805A1
(en)
*
|
2003-11-10 |
2005-09-29 |
Q-Rna, Inc. |
Methods of detection employing immuno-Q-Amp technology
|
US20070276049A1
(en)
|
2003-11-11 |
2007-11-29 |
Schlievert Patrick M |
Regulation of Cell Membrane-Mediated Effects
|
JP2007514413A
(ja)
*
|
2003-11-12 |
2007-06-07 |
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド |
C型肝炎ウイルス糖タンパク質をコードする新規配列
|
CA2541709C
(en)
*
|
2003-11-13 |
2013-06-04 |
California Pacific Medical Center |
Anti-pecam therapy for metastasis suppression
|
DK1687066T3
(da)
|
2003-11-14 |
2012-11-26 |
Brigham & Womens Hospital |
Fremgangsmåder til immunmodulering
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
US7750123B2
(en)
*
|
2003-11-25 |
2010-07-06 |
Dana Farber Cancer Institute, Inc. |
Antibodies against SARS-CoV and methods of use thereof
|
EP1689783B1
(en)
|
2003-11-25 |
2010-05-19 |
The Government Of The United States, As Represented by The Secretary Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
EP1711622A2
(en)
|
2003-11-26 |
2006-10-18 |
Applera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
ES2469670T3
(es)
|
2003-11-30 |
2014-06-18 |
Yeda Research And Development Co., Ltd. |
Métodos y agentes para inmunomodulaci�n y métodos para identificar inmunomoduladores
|
DE602004028506D1
(de)
|
2003-12-02 |
2010-09-16 |
Pasteur Institut |
Neuer mit sars verbunden coronavirus stamm und seine verwendungen
|
EP1708751B1
(en)
*
|
2003-12-04 |
2011-09-28 |
Vaccinex, Inc. |
Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
|
US20060047436A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for magnifying an immune response
|
US20060116824A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Ishikawa Muriel Y |
System and method for modulating a humoral immune response
|
US20060122783A1
(en)
*
|
2004-08-24 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for heightening a humoral immune response
|
US20060047434A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to improving an immune system
|
US20060095211A1
(en)
*
|
2003-12-05 |
2006-05-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for modulating a cell mediated immune response
|
US20060122784A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Ishikawa Muriel Y |
System and method for augmenting a humoral immune response
|
US20060047437A1
(en)
*
|
2004-08-25 |
2006-03-02 |
Ishikawa Muriel Y |
System and method for heightening an immune response
|
US20060182742A1
(en)
*
|
2004-08-24 |
2006-08-17 |
Ishikawa Muriel Y |
System and method for magnifying a humoral immune response
|
US20060047435A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Ishikawa Muriel Y |
System and method related to augmenting an immune system
|
US20060003412A1
(en)
*
|
2003-12-08 |
2006-01-05 |
Xencor, Inc. |
Protein engineering with analogous contact environments
|
US20070249809A1
(en)
*
|
2003-12-08 |
2007-10-25 |
Xencor, Inc. |
Protein engineering with analogous contact environments
|
DK2418220T3
(da)
|
2003-12-10 |
2017-11-06 |
Squibb & Sons Llc |
Interferon-alpha-antistoffer og anvendelser deraf
|
JP2007521248A
(ja)
|
2003-12-10 |
2007-08-02 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
ヒト化抗ccr2抗体および該抗体を使用する方法
|
KR101374514B1
(ko)
|
2003-12-10 |
2014-03-13 |
메다렉스, 인코포레이티드 |
Ip―10 항체 및 그의 용도
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
AU2004298483A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
WO2005058961A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
US7427670B2
(en)
*
|
2003-12-19 |
2008-09-23 |
Cytochroma Inc. |
Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
|
PT1718677E
(pt)
*
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
AU2004308439A1
(en)
*
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
SG166768A1
(en)
*
|
2003-12-23 |
2010-12-29 |
Rinat Neuroscience Corp |
Agonist anti-trkc antibodies and methods using same
|
US7541185B2
(en)
*
|
2003-12-23 |
2009-06-02 |
Cythera, Inc. |
Methods for identifying factors for differentiating definitive endoderm
|
US8647873B2
(en)
*
|
2004-04-27 |
2014-02-11 |
Viacyte, Inc. |
PDX1 expressing endoderm
|
US7985585B2
(en)
|
2004-07-09 |
2011-07-26 |
Viacyte, Inc. |
Preprimitive streak and mesendoderm cells
|
WO2007059007A2
(en)
|
2005-11-14 |
2007-05-24 |
Cythera, Inc. |
Markers of definitive endoderm
|
US20050266554A1
(en)
*
|
2004-04-27 |
2005-12-01 |
D Amour Kevin A |
PDX1 expressing endoderm
|
US7625753B2
(en)
*
|
2003-12-23 |
2009-12-01 |
Cythera, Inc. |
Expansion of definitive endoderm cells
|
SG10201404273QA
(en)
|
2003-12-23 |
2014-10-30 |
Genentech Inc |
Novel anti-il 13 antibodies and uses thereof
|
AU2004309421B2
(en)
*
|
2003-12-23 |
2011-04-21 |
Viacyte, Inc. |
Definitive endoderm
|
US7718408B2
(en)
*
|
2003-12-24 |
2010-05-18 |
Danisco A/S |
Method
|
WO2008090395A1
(en)
|
2007-01-25 |
2008-07-31 |
Danisco A/S |
Production of a lipid acyltransferase from transformed bacillus licheniformis cells
|
GB0716126D0
(en)
*
|
2007-08-17 |
2007-09-26 |
Danisco |
Process
|
JP5697294B2
(ja)
|
2003-12-24 |
2015-04-08 |
デュポン ニュートリション バイオサイエンシーズ エーピーエス |
糖脂質アシル基転移酵素変異体及びその製造方法
|
EP1710310A4
(en)
|
2003-12-30 |
2007-02-21 |
Suntory Ltd |
NEW SERUM-TYPE STREPTOCOCCUS MUTANS AND USE THEREOF
|
AU2004309063B2
(en)
*
|
2003-12-31 |
2010-10-28 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
PL2311873T3
(pl)
*
|
2004-01-07 |
2019-01-31 |
Novartis Vaccines And Diagnostics, Inc. |
Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania
|
US20050221429A1
(en)
*
|
2004-01-16 |
2005-10-06 |
Cardinal Health Pts, Llc |
Host cells containing multiple integrating vectors comprising an amplifiable marker
|
EP1737971B1
(en)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Mixtures of binding proteins
|
ATE466596T1
(de)
|
2004-01-20 |
2010-05-15 |
Sunnybrook & Womens College |
Hochfrequenz-ultraschall-darstellung mit kontrastmitteln
|
US7670771B2
(en)
|
2004-01-21 |
2010-03-02 |
University Of Utah Research Foundation |
Mutant sodium channel Nav1.7 nucleic acid methods
|
EP1716168A4
(en)
*
|
2004-01-21 |
2009-06-24 |
Fujirebio America Inc |
DETECTION OF PEPTIDES RELATING TO THE FACTOR FOR THE POTENTIATION OF URINARY MESOTHELIN- / MEGACARYOCYTES FOR THE EVALUATION OF MESOTHELIOMA
|
EP1711529A1
(en)
*
|
2004-01-21 |
2006-10-18 |
Novozymes A/S |
Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
|
EP2444805A3
(en)
|
2004-01-21 |
2012-06-20 |
Fujirebio America, Inc. |
Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
|
WO2005070967A2
(en)
|
2004-01-22 |
2005-08-04 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
CA2554729A1
(en)
*
|
2004-01-27 |
2005-08-11 |
University Of Southern California |
Polymer-bound antibody cancer therapeutic agent
|
US7323551B2
(en)
*
|
2004-01-27 |
2008-01-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inhibiting squamous cell carcinoma
|
US7875277B2
(en)
*
|
2004-01-27 |
2011-01-25 |
The Dept. of Veterans Affairs Office of The General Counsel |
Compositions and methods for inhibiting squamous cell carcinoma
|
EP1713900A4
(en)
*
|
2004-01-27 |
2009-06-17 |
Compugen Ltd |
METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
|
EP1718741A2
(en)
*
|
2004-01-29 |
2006-11-08 |
Cellzome Ag |
Treatment of neurodegenerative diseases by the use of atp7a
|
AU2004315111B2
(en)
*
|
2004-01-29 |
2010-03-04 |
Cellzome Ag |
Treatment of neurodegenerative diseases by the use of GPR49
|
CA2554526A1
(en)
*
|
2004-01-29 |
2005-08-18 |
Genentech, Inc. |
Variants of the extracellular domain of bcma and uses thereof
|
CA2553946C
(en)
|
2004-02-06 |
2019-02-26 |
University Of Massachusetts |
Antibodies against clostridium difficile toxins and uses thereof
|
US20050226883A1
(en)
*
|
2004-02-06 |
2005-10-13 |
Paul Averback |
Humanized antibody
|
CA2555144A1
(en)
*
|
2004-02-06 |
2005-08-25 |
Astellas Us Llc |
Methods of treating skin disorders
|
PL1729795T3
(pl)
|
2004-02-09 |
2016-08-31 |
Human Genome Sciences Inc |
Białka fuzyjne albuminy
|
US7481997B1
(en)
|
2004-02-12 |
2009-01-27 |
Montana State University |
Snow mountain virus genome sequence, virus-like particles and methods of use
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
EP1730173A4
(en)
*
|
2004-02-18 |
2008-10-08 |
Merck & Co Inc |
NUCLEIC ACID MOLECULES ENCODING NEW MURINE PROTEINS WITH ACTIVE LOW VOLTAGE CALCIUM CHANNEL, 1H SPECIALIZED ALPHA, ENCODED PROTEINS AND METHODS OF USE THEREOF
|
CA2555820C
(en)
|
2004-02-19 |
2016-01-19 |
Genentech, Inc. |
Cdr-repaired antibodies
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
WO2005081905A2
(en)
*
|
2004-02-20 |
2005-09-09 |
Fraunhofer Usa Inc. |
Systems and methods for clonal expression in plants
|
EP1717250A4
(en)
|
2004-02-20 |
2008-10-01 |
Immuno Biological Lab Co Ltd |
MONOCLONAL ANTIBODY AND ITS USE
|
CA2560066A1
(en)
|
2004-03-01 |
2005-09-15 |
The Cbr Institute For Biomedical Research, Inc. |
Natural igm antibodies and inhibitors thereof
|
GB0405637D0
(en)
|
2004-03-12 |
2004-04-21 |
Danisco |
Protein
|
WO2005090406A2
(en)
|
2004-03-12 |
2005-09-29 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
JP2007529718A
(ja)
*
|
2004-03-12 |
2007-10-25 |
ザ スクリップス リサーチ インスティチュート |
蛋白質活性の検出および定量のための蛍光シグナル発光型生細胞バイオセンサー分子ならびに色素
|
EP1735348B1
(en)
*
|
2004-03-19 |
2012-06-20 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
EP1756162A1
(en)
|
2004-03-23 |
2007-02-28 |
Biogen Idec MA Inc. |
Receptor coupling agents and therapeutic uses thereof
|
EP1737890A2
(en)
*
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
EP1786463A4
(en)
*
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
ANTIBODY AGAINST NOGO RECEPTOR
|
US20070161554A1
(en)
*
|
2004-03-26 |
2007-07-12 |
Cellzome Ag |
Treatment of neurodegenerative diseases by the use of laptm4b
|
JP5576592B2
(ja)
*
|
2004-03-29 |
2014-08-20 |
キャンサー アドヴァンシズ インコーポレイテッド |
ガストリンホルモンに対するモノクローナル抗体
|
US20050260710A1
(en)
*
|
2004-03-31 |
2005-11-24 |
Sekisui Chemical Co. Ltd. |
Methods for producing recombinant polyclonal immunoglobulins
|
CN101426812B
(zh)
|
2004-03-31 |
2013-01-02 |
森托科尔公司 |
用于改变蛋白生产速率的方法
|
WO2005097832A2
(en)
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
WO2005095458A1
(en)
*
|
2004-04-02 |
2005-10-13 |
The Talwar Research Foundation |
CHIMERIC MONOCLONAL ANTIBODY FOR BINDING WITH HIGH AFFINITY SELECTIVELY TO hCG
|
CN1964740A
(zh)
|
2004-04-02 |
2007-05-16 |
加利福尼亚大学董事会 |
治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
|
US7794713B2
(en)
*
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
HUE037549T2
(hu)
|
2004-04-07 |
2018-09-28 |
Rinat Neuroscience Corp |
Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
|
US20050227289A1
(en)
|
2004-04-09 |
2005-10-13 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP2216650A1
(en)
|
2004-04-09 |
2010-08-11 |
University of Pittsburgh |
Real time method of detecting acute inflammatory conditions
|
US20060018902A1
(en)
*
|
2004-04-09 |
2006-01-26 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
US20080038265A1
(en)
*
|
2004-04-09 |
2008-02-14 |
Reilly Edward B |
Antibodies to Erythropoietin Receptor and Uses Thereof
|
JP4659025B2
(ja)
|
2004-04-15 |
2011-03-30 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質
|
BRPI0509412A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
EP1745288A2
(en)
*
|
2004-04-16 |
2007-01-24 |
Genentech, Inc. |
Assay for antibodies
|
JP2007532681A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
CA2563433C
(en)
*
|
2004-04-30 |
2010-07-13 |
Bas Medical, Inc. |
Methods and compositions for control of fetal growth via modulation of relaxin
|
US7311906B2
(en)
*
|
2004-04-30 |
2007-12-25 |
Brigham Young University |
Anti-viral activity of an anti-thymidine kinase monoclonal antibody
|
EP1747291A2
(en)
*
|
2004-05-04 |
2007-01-31 |
Genaissance Pharmaceuticals, Inc. |
Haplotype markers and methods of using the same to determine response to treatment
|
WO2005115436A1
(en)
*
|
2004-05-07 |
2005-12-08 |
Astellas Us Llc |
Soluble lfa-3 polypeptide for treating viral disorders
|
JP5236286B2
(ja)
|
2004-05-07 |
2013-07-17 |
セレラ コーポレーション |
肝線維症に関連する遺伝的多型、その検出方法および使用
|
AU2005242719B2
(en)
|
2004-05-11 |
2011-02-24 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
AU2005246289A1
(en)
*
|
2004-05-15 |
2005-12-01 |
Genentech, Inc. |
Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
US20060292554A1
(en)
*
|
2004-05-18 |
2006-12-28 |
Genentech, Inc. |
Major coat protein variants for C-terminal and bi-terminal display
|
US8586294B2
(en)
|
2004-05-18 |
2013-11-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Detection of protein translocation by beta-galactosidase reporter fragment complementation
|
WO2005116270A2
(en)
|
2004-05-18 |
2005-12-08 |
Vical Incorporated |
Influenza virus vaccine composition and method of use
|
US7517903B2
(en)
*
|
2004-05-19 |
2009-04-14 |
Medarex, Inc. |
Cytotoxic compounds and conjugates
|
AU2005244942A1
(en)
*
|
2004-05-19 |
2005-12-01 |
Wyeth |
Modulation of immunoglobulin production and atopic disorders
|
US7691962B2
(en)
*
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
US7837998B2
(en)
*
|
2004-05-21 |
2010-11-23 |
Nathaniel Lallatin |
Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
|
US8551486B2
(en)
*
|
2004-05-21 |
2013-10-08 |
Savoy Pharmaceuticals, Inc. |
Monoclonal antibodies to human thymidine kinase to treat cancer
|
EP1765065B1
(en)
*
|
2004-05-21 |
2012-06-27 |
University of Utah Research Foundation |
Methods and compositions related to delivery of chemical compounds to invertebrate embryos
|
US20100266495A1
(en)
*
|
2004-05-21 |
2010-10-21 |
Brigham Young University |
Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
|
AU2005250370B2
(en)
|
2004-05-28 |
2010-04-01 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
KR101200133B1
(ko)
|
2004-06-01 |
2012-11-13 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
EA012622B1
(ru)
|
2004-06-01 |
2009-10-30 |
Домэнтис Лимитед |
Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
|
EP2169060B1
(en)
|
2004-06-02 |
2011-12-07 |
TSS Biotech Inc. |
Novel polypeptide useful for diagnosis and treatment of cancer
|
KR20070029733A
(ko)
|
2004-06-04 |
2007-03-14 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
EP1765868B1
(en)
|
2004-06-07 |
2016-04-20 |
MacroGenics, Inc. |
Transferrin receptor antibodies
|
US7604947B2
(en)
*
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
GB0412966D0
(en)
|
2004-06-10 |
2004-07-14 |
Univ Leicester |
Genetically modified non-human mammals and cells
|
US7919094B2
(en)
*
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US20080226639A1
(en)
*
|
2004-06-10 |
2008-09-18 |
Enkan Pharmaceuticals A/S |
Heparin Binding Peptide
|
US20060002937A1
(en)
|
2004-06-10 |
2006-01-05 |
University Of Leicester |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US20060018896A1
(en)
*
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
CA2570296A1
(en)
*
|
2004-06-12 |
2005-12-29 |
Oregon Health And Science University |
Compositions and methods for diagnosis and treatment of orthopoxviruses
|
EP2789342A1
(en)
|
2004-06-17 |
2014-10-15 |
Thrasos Innovation, Inc. |
TDF-related compounds and analogs thereof
|
BRPI0512254A
(pt)
*
|
2004-06-18 |
2008-02-19 |
Enkam Pharmaceuticals As |
peptìdeos ligantes ao fgfr
|
LT2662390T
(lt)
|
2004-06-21 |
2017-10-10 |
E. R. Squibb & Sons, L.L.C. |
Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas
|
AU2005253776B8
(en)
|
2004-06-21 |
2012-02-02 |
King's College London |
Screening methods using c-Abl, Fyn and Syk in combination with tau protein
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
JP4960865B2
(ja)
|
2004-06-24 |
2012-06-27 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄に関連する状態の処置
|
JP5112863B2
(ja)
*
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー/エス |
ヒト抗−kir抗体
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US7598071B2
(en)
*
|
2004-07-09 |
2009-10-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Infectious clone of human parvovirus B19 and methods
|
MY145073A
(en)
|
2004-07-09 |
2011-12-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
PT1789593T
(pt)
|
2004-07-09 |
2017-04-24 |
Henry M Jackson Found Advancement Military Medicine Inc |
Formas solúveis de glicoproteína g de vírus hendra
|
CA3052445C
(en)
|
2004-07-10 |
2023-08-22 |
Kerry S. Campbell |
Genetically modified human natural killer cell lines
|
WO2006092669A2
(en)
*
|
2004-07-12 |
2006-09-08 |
Rappaport Family Institute For Research In The Medical Sciences |
Methods of detecting a phenotype of a polymorphic protein
|
US7714119B2
(en)
*
|
2004-07-13 |
2010-05-11 |
Biosante Pharmaceuticals, Inc. |
AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
EP1814876A2
(en)
*
|
2004-07-15 |
2007-08-08 |
The General Hospital Corporation |
Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer's disease
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
KR101226156B1
(ko)
|
2004-07-16 |
2013-01-24 |
듀폰 뉴트리션 바이오사이언시즈 에이피에스 |
효소적 오일-탈검 방법
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
US7740846B2
(en)
|
2004-07-20 |
2010-06-22 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
US20070264277A1
(en)
|
2004-07-22 |
2007-11-15 |
Dirk Behrens |
Compositions and Methods of Use for Mgd-Csf in Disease Treatment
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
EP2298807A3
(en)
*
|
2004-07-30 |
2011-05-18 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
CA2575901C
(en)
|
2004-08-02 |
2015-01-27 |
Amrad Operations Pty. Ltd. |
A method of treating cancer comprising a vegf-b antagonist
|
WO2006013552A2
(en)
|
2004-08-02 |
2006-02-09 |
Ramot At Tel Aviv University Ltd. |
Articles of peptide nanostructures and method of forming the same
|
WO2006026051A2
(en)
*
|
2004-08-03 |
2006-03-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma
|
CN101014245A
(zh)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
神经元功能中的taj
|
CA2575607C
(en)
|
2004-08-03 |
2017-07-11 |
Innate Pharma |
Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
|
US7709611B2
(en)
|
2004-08-04 |
2010-05-04 |
Amgen Inc. |
Antibodies to Dkk-1
|
US7572600B2
(en)
*
|
2004-08-04 |
2009-08-11 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
WO2006135385A2
(en)
*
|
2004-08-05 |
2006-12-21 |
Wyeth |
Antagonizing interleukin-21 receptor activity
|
MX2007001470A
(es)
*
|
2004-08-05 |
2007-03-26 |
Genentech Inc |
Antagonistas anti-cmet humanizados.
|
WO2006017859A2
(en)
|
2004-08-06 |
2006-02-16 |
Genentech, Inc. |
Assays and methods using biomarkers
|
ATE508205T1
(de)
|
2004-08-06 |
2011-05-15 |
Genentech Inc |
Tests und verfahren unter verwendung von biomarkern
|
DE602004013202T2
(de)
*
|
2004-08-09 |
2009-05-28 |
Cellzome Ag |
Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
|
US20080181892A1
(en)
*
|
2004-08-11 |
2008-07-31 |
Trubion Pharmaceuticals |
Binding Domain Fusion Protein
|
US20060073168A1
(en)
*
|
2004-08-11 |
2006-04-06 |
Stephens David S |
Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
US20070265817A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to fortifying an immune system
|
US20070207492A1
(en)
*
|
2004-08-24 |
2007-09-06 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to adjust a humoral immune response
|
US20070198196A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational systems and methods relating to ameliorating an immune system
|
US20070265787A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc,A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for magnifying cell-mediated immune response
|
US20070288173A1
(en)
*
|
2004-08-24 |
2007-12-13 |
Searete Llc, A Limited Liability Corporation Of The State Of Delware |
Computational methods and systems to reinforce a humoral immune response
|
US20060047439A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for improving a humoral immune response
|
US20070265788A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for augmenting cell-mediated immune response
|
US20070265819A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for improving cell-mediated immune response
|
US20070196362A1
(en)
*
|
2004-08-24 |
2007-08-23 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems to bolster an immune response
|
US20070265818A1
(en)
*
|
2004-08-24 |
2007-11-15 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational methods and systems for heightening cell-mediated immune response
|
US7300773B2
(en)
*
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
TWI374935B
(en)
|
2004-08-27 |
2012-10-21 |
Pfizer Ireland Pharmaceuticals |
Production of α-abeta
|
WO2006033768A2
(en)
|
2004-08-27 |
2006-03-30 |
Novartis Vaccines And Diagnostics Inc. |
Hcv multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
US7655229B2
(en)
*
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
AU2005282700A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
US7662926B2
(en)
*
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
PT2322556E
(pt)
|
2004-09-03 |
2016-02-15 |
Genentech Inc |
Antagonistas humanizados anti-beta7 e suas utilizações
|
US7432359B2
(en)
|
2004-09-06 |
2008-10-07 |
Kirin Pharma Kabushiki Kaisha |
Anti-A33 antibody
|
CN101010427B
(zh)
|
2004-09-06 |
2011-07-27 |
协和发酵麒麟株式会社 |
抗a33抗体
|
WO2006027780A2
(en)
|
2004-09-08 |
2006-03-16 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
|
JP2008518586A
(ja)
*
|
2004-09-09 |
2008-06-05 |
ユニバーシティ オブ ワシントン |
オールトランスレチノールすなわちオールトランス13,14−ジヒドロレチノールサチュラーゼ及びその使用方法
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
WO2006030442A2
(en)
*
|
2004-09-16 |
2006-03-23 |
Gamida-Cell Ltd. |
Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1794586B1
(en)
|
2004-09-22 |
2013-01-30 |
Cancer Advances, Inc., |
Monoclonal antibodies to progastrin
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
DE602005024850D1
(de)
|
2004-09-24 |
2010-12-30 |
Beth Israel Hospital |
Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
|
WO2006037048A2
(en)
*
|
2004-09-27 |
2006-04-06 |
The Uab Research Foundation |
Fc RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF
|
GB0422052D0
(en)
|
2004-10-04 |
2004-11-03 |
Dansico As |
Enzymes
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
BRPI0516572A
(pt)
*
|
2004-10-05 |
2008-09-16 |
Wyeth Corp |
métodos e composições para melhorar a produção de proteìnas recombinantes
|
EP3428191A1
(en)
|
2004-10-06 |
2019-01-16 |
Mayo Foundation for Medical Education and Research |
B7-h1 and pd-1 in treatment of renal cell carcinoma
|
AU2005294150B2
(en)
|
2004-10-07 |
2011-06-16 |
Coimmune, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
WO2006044335A2
(en)
*
|
2004-10-14 |
2006-04-27 |
The Board Of Trustees Of The University Of Arkansas |
Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
|
WO2006041048A1
(ja)
|
2004-10-15 |
2006-04-20 |
Mie University |
肝再生・修復制御剤
|
GB0423139D0
(en)
|
2004-10-18 |
2004-11-17 |
Danisco |
Enzymes
|
AU2005332655A1
(en)
*
|
2004-10-20 |
2006-12-14 |
Iogenetics, Llc |
Biocides
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006047417A2
(en)
|
2004-10-21 |
2006-05-04 |
University Of Florida Research Foundation, Inc. |
Detection of cannabinoid receptor biomarkers and uses thereof
|
EP2311433A3
(en)
|
2004-10-21 |
2011-08-10 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
AU2005299716B2
(en)
*
|
2004-10-22 |
2012-09-06 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
US7910101B2
(en)
|
2004-10-25 |
2011-03-22 |
Centocor, Inc. |
Melanocortin receptor binding mimetibodies, compositions, methods and uses
|
ES2389562T3
(es)
|
2004-10-25 |
2012-10-29 |
Statens Seruminstitut |
Antígenos de Chlamydia trachomatis para uso en vacuna y diagnóstico
|
CN101115846A
(zh)
|
2004-10-27 |
2008-01-30 |
范德比尔特大学 |
与感染相关的哺乳动物基因
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
TW200636064A
(en)
*
|
2004-10-28 |
2006-10-16 |
Centocor Inc |
Anti-respiratory syncytial virus antibodies, antigens and uses thereof
|
EP1814568A4
(en)
*
|
2004-10-29 |
2009-08-12 |
Univ Southern California |
ANTI-CANCER POLYIMMUNOTHERAPY IN WHICH CO-STIMULATING MOLECULES ARE USED
|
EP1814918A1
(en)
*
|
2004-10-29 |
2007-08-08 |
Elusys Therapeutics, Inc. |
Use of cr1-binding molecules in clearance and induction of immune responses
|
MX2007005378A
(es)
*
|
2004-11-04 |
2008-02-14 |
Genentech Inc |
Polipeptidos que ligan a baff y/o april.
|
EP1824513A4
(en)
*
|
2004-11-04 |
2010-06-09 |
Fibron Ltd |
TREATMENT OF B-CELL TUMORS
|
EP1814913B1
(en)
|
2004-11-05 |
2015-08-19 |
IGM Biosciences, Inc. |
Antibody induced cell membrane wounding
|
US7462697B2
(en)
*
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
US20060099144A1
(en)
|
2004-11-08 |
2006-05-11 |
Schering Corporation |
Tumor association of MDL-1 and methods
|
US7709208B2
(en)
*
|
2004-11-08 |
2010-05-04 |
New York University |
Methods for diagnosis of major depressive disorder
|
WO2006052900A2
(en)
*
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
AU2005304031B2
(en)
|
2004-11-09 |
2009-04-23 |
Philogen Spa |
Antibodies against tenascin-C
|
GB0424940D0
(en)
|
2004-11-11 |
2004-12-15 |
Danisco |
Transcription factors
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
KR101027427B1
(ko)
|
2004-11-12 |
2011-04-11 |
젠코어 인코포레이티드 |
FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
ES2715776T3
(es)
|
2004-11-12 |
2019-06-06 |
Seattle Genetics Inc |
Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CA2588087A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Obe Therapy Biotechnology S.A.S. |
Methods of reducing body fat
|
CA2588093A1
(en)
*
|
2004-11-16 |
2006-05-26 |
Rony Seger |
Variants of pigment epithelium derived factor and uses thereof
|
PL2343380T3
(pl)
|
2004-11-16 |
2020-03-31 |
Humanigen, Inc. |
Wymiana kasety dla regionu zmiennego immunoglobuliny
|
CA2587903A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen Fremont Inc. |
Fully human monoclonal antibodies to il-13
|
US20060115862A1
(en)
*
|
2004-11-17 |
2006-06-01 |
Duke University |
Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
|
US20060127311A1
(en)
*
|
2004-11-17 |
2006-06-15 |
Duke University |
Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
|
EP1812064A4
(en)
|
2004-11-19 |
2009-07-08 |
Cornell Res Foundation Inc |
USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS
|
CN103169965A
(zh)
*
|
2004-11-19 |
2013-06-26 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
US20060141504A1
(en)
*
|
2004-11-23 |
2006-06-29 |
Willman Cheryl L |
Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults
|
US7459529B2
(en)
|
2004-11-24 |
2008-12-02 |
Seoul National University Industry Foundation |
AIMP2-DX2 and its uses
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
TWI487535B
(zh)
|
2004-11-30 |
2015-06-11 |
Centocor Inc |
類鐸受體3(toll like receptor3)拮抗劑,方法及用途
|
EP1819730A2
(en)
*
|
2004-11-30 |
2007-08-22 |
Novo Nordisk A/S |
Method of producing antibodies
|
NZ555464A
(en)
|
2004-12-02 |
2010-03-26 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
JP2008521907A
(ja)
|
2004-12-03 |
2008-06-26 |
シェーリング コーポレイション |
抗igf1r治療について患者を予め選択するためのバイオマーカー
|
WO2006061723A2
(en)
|
2004-12-06 |
2006-06-15 |
Kirin Beer Kabushiki Kaisha |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
CN102618642B
(zh)
|
2004-12-08 |
2014-12-31 |
安万特药物公司 |
测量对多西他赛抗药性或敏感性的方法
|
BRPI0520207A2
(pt)
|
2004-12-08 |
2012-09-25 |
Revision Therapeutics Inc |
uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
|
WO2006063292A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Icos Corporation |
Recombinant method for making multimeric proteins
|
EP1838854B1
(en)
*
|
2004-12-15 |
2012-10-31 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize Beta Amyloid Peptide
|
WO2006066089A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
TW200635608A
(en)
*
|
2004-12-15 |
2006-10-16 |
Neuralab Ltd |
Aβ antibodies for use in improving cognition
|
RU2007126985A
(ru)
*
|
2004-12-16 |
2009-01-27 |
Дженентек, Инк. (Us) |
Способы лечения аутоиммунных заболеваний
|
US7504769B2
(en)
*
|
2004-12-16 |
2009-03-17 |
E. I. Du Pont De Nemours + Company |
Aromatic chalcogen compounds and their use
|
SV2006002342A
(es)
*
|
2004-12-17 |
2006-06-01 |
Genentech Inc |
Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
|
US20080003617A1
(en)
*
|
2004-12-20 |
2008-01-03 |
Xiaomin Fan |
Methods for the identification and the isolation of epitope specific antibodies
|
CA2591665C
(en)
*
|
2004-12-20 |
2015-05-05 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US7741275B2
(en)
*
|
2004-12-22 |
2010-06-22 |
Lipopeptide Ab |
Agents and use thereof
|
NZ588430A
(en)
|
2004-12-22 |
2012-10-26 |
Genentech Inc |
Methods for producing soluble multi-membrane-spanning proteins
|
WO2006066912A2
(en)
*
|
2004-12-23 |
2006-06-29 |
F. Hoffmann-La Roche Ag |
Detection of a therapeutic antibody in an experimental animal
|
CA2491067A1
(en)
|
2004-12-24 |
2006-06-24 |
Stichting Katholieke Universiteit |
Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
|
CA2531616A1
(en)
*
|
2004-12-28 |
2006-06-28 |
Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.) |
High strength thin steel sheet having high hydrogen embrittlement resisting property and high workability
|
CA2591059C
(en)
|
2004-12-28 |
2018-11-06 |
Innate Pharma |
Monoclonal antibodies against nkg2a
|
US20060154285A1
(en)
*
|
2004-12-29 |
2006-07-13 |
Robishaw Janet D |
Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
|
US7850960B2
(en)
|
2004-12-30 |
2010-12-14 |
University Of Washington |
Methods for regulation of stem cells
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
SI1836225T1
(sl)
|
2005-01-06 |
2012-06-29 |
Novo Nordisk As |
Kir vezujoäśa sredstva in postopki za njihovo rabo
|
WO2006086098A2
(en)
*
|
2005-01-06 |
2006-08-17 |
President And Fellows Of Harvard College |
Mass spectrometric methods and products
|
ES2384466T3
(es)
|
2005-01-06 |
2012-07-05 |
Novo Nordisk A/S |
Composiciones y procedimientos de tratamiento de una infección viral
|
EP2230517A1
(en)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
AU2006203882B2
(en)
|
2005-01-07 |
2011-05-12 |
Regeneron Pharmaceuticals, Inc. |
IGF-1 fusion polypeptides and therapeutic uses thereof
|
WO2006076594A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
EP1846767B1
(en)
*
|
2005-01-12 |
2012-06-06 |
MacroGenics West, Inc. |
Kid31 and antibodies that bind thereto
|
US20080102054A1
(en)
*
|
2005-01-18 |
2008-05-01 |
Faustman Denise L |
Compositions Containing Agm Cells And Methods Of Use Thereof
|
ZA200706017B
(en)
|
2005-01-21 |
2008-12-31 |
Genentech Inc |
Fixed dosing of her antibodies
|
CA2589860A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
US7700738B2
(en)
|
2005-01-27 |
2010-04-20 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
EP1846032A4
(en)
*
|
2005-01-31 |
2009-01-28 |
Raven Biotechnologies Inc |
LUCA2 AND ANTIBODY BINDING
|
WO2006084078A2
(en)
*
|
2005-02-02 |
2006-08-10 |
Raven Biotechnologies, Inc. |
Jam-3 and antibodies that bind thereto
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
EP1841794B1
(en)
|
2005-02-02 |
2013-11-20 |
MacroGenics West, Inc. |
Adam-9 modulators
|
US7402730B1
(en)
|
2005-02-03 |
2008-07-22 |
Lexicon Pharmaceuticals, Inc. |
Knockout animals manifesting hyperlipidemia
|
US7572896B2
(en)
|
2005-02-03 |
2009-08-11 |
Raven Biotechnologies, Inc. |
Antibodies to oncostatin M receptor
|
US7569672B2
(en)
|
2005-02-04 |
2009-08-04 |
Raven Biotechnologies, Inc. |
Antibodies that bind to EphA2 and methods of use thereof
|
JP5265923B2
(ja)
|
2005-02-07 |
2013-08-14 |
ジーンニュース インコーポレーテッド |
軽度の変形性関節症のバイオマーカーおよびその使用
|
RU2488597C2
(ru)
|
2005-02-07 |
2013-07-27 |
Гликарт Биотехнологи Аг |
Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
|
CN104151427B
(zh)
|
2005-02-08 |
2017-09-08 |
根茨美公司 |
针对TGFβ的抗体
|
BRPI0608210A2
(pt)
*
|
2005-02-14 |
2010-11-09 |
Wyeth Corp |
métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
|
JP2008532936A
(ja)
*
|
2005-02-14 |
2008-08-21 |
ワイス |
インターロイキン−17f抗体及び他のil−17fシグナル伝達拮抗物質並びにそれらの使用
|
CN105535967B
(zh)
|
2005-02-15 |
2022-05-03 |
杜克大学 |
抗cd19抗体及其在肿瘤学中的应用
|
US20080019905A9
(en)
*
|
2005-02-18 |
2008-01-24 |
Strome Scott E |
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
|
US7731965B2
(en)
*
|
2005-02-17 |
2010-06-08 |
Abbott Lab |
Human ring specific BNP antibodies
|
WO2006089141A2
(en)
|
2005-02-18 |
2006-08-24 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
AU2006214031A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
US20060193849A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
WO2006096565A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
US20090238820A1
(en)
|
2005-03-08 |
2009-09-24 |
Allan Corey M |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
CA2597325A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
CN101147066A
(zh)
|
2005-03-11 |
2008-03-19 |
塞诺菲-安万特股份有限公司 |
Mgc4504的用途
|
EP2113572B1
(en)
|
2005-03-11 |
2012-12-05 |
Celera Corporation |
Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
|
ES2716874T3
(es)
|
2005-03-23 |
2019-06-17 |
Genmab As |
Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
|
EP1868647A4
(en)
|
2005-03-24 |
2009-04-01 |
Millennium Pharm Inc |
OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
|
DK2343320T3
(da)
|
2005-03-25 |
2018-01-29 |
Gitr Inc |
Anti-gitr-antistoffer og anvendelser deraf
|
KR20070114324A
(ko)
*
|
2005-03-25 |
2007-11-30 |
글리카트 바이오테크놀로지 아게 |
Mcsp 에 향하며 증가된 fc 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
|
JP2008543276A
(ja)
|
2005-03-30 |
2008-12-04 |
ミネルバ バイオテクノロジーズ コーポレーション |
Muc1発現細胞の増殖
|
ES2720288T3
(es)
|
2005-03-30 |
2019-07-19 |
Minerva Biotechnologies Corp |
Proliferación de células que expresan MUC1
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
WO2006105488A2
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
US8309303B2
(en)
*
|
2005-04-01 |
2012-11-13 |
Qiagen Gmbh |
Reverse transcription and amplification of RNA with simultaneous degradation of DNA
|
WO2006107924A2
(en)
|
2005-04-04 |
2006-10-12 |
Idexx Laboratories, Inc. |
Ehrlichia canis diva (differentiate infected from vaccinated animals)
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
WO2006110581A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
NZ563273A
(en)
|
2005-04-09 |
2010-02-26 |
Fusion Antibodies Ltd |
Cathepsin S antibody
|
ES2856881T3
(es)
|
2005-04-11 |
2021-09-28 |
Horizon Pharma Rheumatology Llc |
Formas variantes de urato oxidasa y su uso
|
ES2374419T3
(es)
|
2005-04-11 |
2012-02-16 |
National Research Council Of Canada |
Identificación de una beta-1,3-n-acetilgalactosaminiltranferasa (cgte) de campylobacter jejuni lio87.
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
CN102603770A
(zh)
*
|
2005-04-15 |
2012-07-25 |
免疫基因公司 |
消除肿瘤中的异质或混合细胞群体
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
RU2403261C2
(ru)
|
2005-04-15 |
2010-11-10 |
Дженентек, Инк. |
Варианты бета-цепи hgf
|
AU2006236225C1
(en)
|
2005-04-19 |
2013-05-02 |
Seagen Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
WO2006112737A1
(en)
*
|
2005-04-20 |
2006-10-26 |
Protemix Discovery Limited |
Vesiculins
|
AR054260A1
(es)
*
|
2005-04-26 |
2007-06-13 |
Rinat Neuroscience Corp |
Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
CA2607327A1
(en)
|
2005-04-29 |
2006-11-09 |
The Regents Of The University Of California |
Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
|
US8034902B2
(en)
*
|
2005-05-04 |
2011-10-11 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against CD55 and CD59 and uses thereof
|
US20060257317A1
(en)
*
|
2005-05-04 |
2006-11-16 |
Duke University |
Combination therapy in the treatment of cancer
|
AU2006244445B2
(en)
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
CN101198624B
(zh)
|
2005-05-06 |
2012-10-10 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
CA2605781A1
(en)
*
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
AU2006245950B2
(en)
|
2005-05-09 |
2012-01-12 |
Biosphere Medical S.A. |
Compositions and methods using microspheres and non-ionic contrast agents
|
EP2377884A1
(en)
|
2005-05-10 |
2011-10-19 |
Neoloch Aps |
Neuritogenic peptides
|
US8084198B2
(en)
*
|
2005-05-11 |
2011-12-27 |
Sanofi-Aventis |
Use of a GIP promoter polymorphism
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
US7622560B2
(en)
*
|
2005-05-11 |
2009-11-24 |
Dinona Inc. |
Monoclonal antibody specific for CD43 epitope
|
BRPI0611044A2
(pt)
|
2005-05-11 |
2010-12-14 |
Dinona Inc |
polipeptÍdio isolado, anticorpos ou respectivos fragmentos, cÉlula, mÉtodos de diagnàstico e de tratamento da leucemia aguda, da leucemia crânica com crise de blastos e do linfoma linfoblÁstico, composiÇÕes farmacÊuticas e kits de diagnàstico
|
CN101175856A
(zh)
|
2005-05-12 |
2008-05-07 |
诺瓦提斯公司 |
猪痢疾短螺旋体的基因和蛋白质及其用于诊断和治疗的用途
|
AU2006245734C1
(en)
|
2005-05-12 |
2012-05-24 |
Crucell Holland B.V. |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
|
US8333970B2
(en)
|
2005-05-18 |
2012-12-18 |
Novartis Ag |
Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
|
ES2431315T3
(es)
|
2005-05-19 |
2013-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Epítopos funcionales del antígeno PsaA de Streptococcus pneumoniae y usos de los mismos
|
CA2726759C
(en)
*
|
2005-05-25 |
2016-02-16 |
Curedm Group Holdings, Llc |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
US8454511B2
(en)
*
|
2005-05-27 |
2013-06-04 |
Board Of Regents, The University Of Texas System |
Magneto-motive ultrasound detection of magnetic nanoparticles
|
US8355776B2
(en)
*
|
2005-05-27 |
2013-01-15 |
Board Of Regents, The University Of Texas System |
Hemoglobin contrast in magneto-motive optical doppler tomography, optical coherence tomography, and ultrasound imaging methods and apparatus
|
US20100074884A1
(en)
*
|
2005-05-31 |
2010-03-25 |
Duska Scientific Co. |
Inhibition of neuronal damage
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
TW200643171A
(en)
|
2005-06-07 |
2006-12-16 |
Temasek Life Sciences Lab Ltd |
Porcine circovirus type 2 vaccines
|
TW200718780A
(en)
|
2005-06-10 |
2007-05-16 |
Chugai Pharmaceutical Co Ltd |
Sc(Fv)2 site-directed mutant
|
AU2006257664B2
(en)
|
2005-06-14 |
2013-01-10 |
Protox Therapeutics Incorporated |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
|
EP1899376A2
(en)
|
2005-06-16 |
2008-03-19 |
The Feinstein Institute for Medical Research |
Antibodies against hmgb1 and fragments thereof
|
EP1895947A2
(en)
*
|
2005-06-17 |
2008-03-12 |
Abbott Laboratories |
Improved method of treating degenerative spinal disorders
|
CN104926938B
(zh)
|
2005-06-17 |
2019-06-04 |
惠氏有限责任公司 |
纯化含Fc区蛋白的方法
|
CA2611519A1
(en)
*
|
2005-06-17 |
2006-12-28 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
US20070225242A1
(en)
*
|
2005-06-21 |
2007-09-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method and composition for treating and preventing tumor metastasis in vivo
|
ES2827247T3
(es)
|
2005-06-21 |
2021-05-20 |
Xoma Us Llc |
Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
|
WO2006136601A1
(en)
*
|
2005-06-23 |
2006-12-28 |
Crucell Holland B.V. |
Optimization of west nile virus antibodies
|
EP1893647A2
(en)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antibody formulations having optimized aggregation and fragmentation profiles
|
TW201444869A
(zh)
*
|
2005-06-30 |
2014-12-01 |
Abbvie Inc |
Il-12/p40結合蛋白
|
EP3501537A1
(en)
|
2005-06-30 |
2019-06-26 |
Janssen Biotech, Inc. |
Anti-il23 antibodies, compositions, methods and uses
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
US20070009976A1
(en)
|
2005-07-06 |
2007-01-11 |
Helmut Lenz |
Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
|
WO2007008848A2
(en)
*
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
US8343928B2
(en)
|
2005-07-07 |
2013-01-01 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
|
AU2006268227A1
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc |
Optimized anti-Ep-CAM antibodies
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
KR101245462B1
(ko)
|
2005-07-08 |
2013-03-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Sp35 항체 및 그의 용도
|
US7780969B2
(en)
*
|
2005-07-15 |
2010-08-24 |
University Of Georgia Research Foundation, Inc. |
Trypanosoma cruzi proteome compositions and methods
|
HUE057936T2
(hu)
|
2005-07-18 |
2022-06-28 |
Seagen Inc |
Béta-glükuronid-linker-hatóanyag konjugátumok
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
EP1910550A4
(en)
|
2005-07-21 |
2009-11-04 |
Abbott Lab |
MULTIGENIC EXPRESSION COMPRISING SORF CONSTRUCTS AND METHODS USING POLYPROTEINS, PRO-PROTEINS, AND PROTEOLYSIS
|
SG164379A1
(en)
|
2005-07-21 |
2010-09-29 |
Genmab As |
Potency assays for antibody drug substance binding to an fc receptor
|
US8211648B2
(en)
*
|
2005-07-22 |
2012-07-03 |
Kalobios Pharmaceuticals, Inc. |
Secretion of antibodies without signal peptides from bacteria
|
RU2486204C2
(ru)
*
|
2005-07-22 |
2013-06-27 |
Уай'З Терапьютикс Ко., Лтд. |
Антитела против сd26 и способы их применения
|
JP2009514790A
(ja)
*
|
2005-07-22 |
2009-04-09 |
プロジェニクス・ファーマスーティカルズ・インコーポレイテッド |
Hiv−1−感染患者におけるウイルス負荷を減少させる方法
|
UA97469C2
(uk)
*
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
WO2007016240A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Use of antibody to m-csf
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
US7452978B2
(en)
*
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7494648B2
(en)
*
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
US7456258B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456259B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7411046B2
(en)
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
KR101446025B1
(ko)
*
|
2005-08-03 |
2014-10-01 |
아이바이오, 인크. |
면역글로불린의 생산을 위한 조성물 및 방법
|
ATE549416T1
(de)
|
2005-08-05 |
2012-03-15 |
Genentech Inc |
Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten
|
CA2615460A1
(en)
*
|
2005-08-08 |
2007-02-15 |
Onconon, Llc |
Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
|
US8217147B2
(en)
|
2005-08-10 |
2012-07-10 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1913391B1
(en)
|
2005-08-11 |
2010-12-29 |
Siemens Healthcare Diagnostics Inc. |
QUANTITATIVE ASSAYS FOR PDGFR-beta IN BODY FLUIDS
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
JP2009504685A
(ja)
*
|
2005-08-15 |
2009-02-05 |
アラーナ・テラピューティクス・リミテッド |
新世界霊長類フレームワーク領域を用いる設計された抗体
|
ZA200800970B
(en)
|
2005-08-15 |
2009-10-28 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
ATE540318T1
(de)
|
2005-08-16 |
2012-01-15 |
Genentech Inc |
Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
BRPI0615397B1
(pt)
|
2005-08-26 |
2023-10-03 |
Roche Glycart Ag |
Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
|
BRPI0616600A2
(pt)
|
2005-08-31 |
2011-06-28 |
Centocor Inc |
linhagens de célula hospedeira para produção de região constante de anticorpo com função efetora aumentada
|
WO2007027906A2
(en)
*
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2007027867A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP2354160A1
(en)
|
2005-08-31 |
2011-08-10 |
Schering Corporation |
Engineered anti-IL-23-antibodies
|
WO2007028030A2
(en)
*
|
2005-09-02 |
2007-03-08 |
Picobella, Llc |
Oncogenic regulatory rnas for diagnostics and therapeutics
|
JP2009507835A
(ja)
|
2005-09-09 |
2009-02-26 |
ジョンズ ホプキンス ユニバーシティ |
抗体、アゴニストおよびアンタゴニストを用いてニューリチン遺伝子をターゲティングすることによる調節性t細胞およびdcの機能の操作
|
EP1762627A1
(de)
|
2005-09-09 |
2007-03-14 |
Qiagen GmbH |
Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
|
JP2009507482A
(ja)
*
|
2005-09-09 |
2009-02-26 |
グライコフィ, インコーポレイテッド |
主にman7glcnac2、man8glcnac2グリコフォームを含むイムノグロブリン
|
US20090162374A1
(en)
|
2005-09-14 |
2009-06-25 |
Geraghty Daniel E |
Specific removal of activated immune cells
|
ES2537527T3
(es)
|
2005-09-20 |
2015-06-09 |
Thrasos Innovation, Inc. |
Compuestos relacionados con el TDF y análogos de los mismos
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
BRPI0617546A2
(pt)
|
2005-09-26 |
2011-07-26 |
Medarex Inc |
conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
|
EA016186B1
(ru)
|
2005-09-26 |
2012-03-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к cd70 и их применение
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
AU2006294481B2
(en)
|
2005-09-28 |
2012-12-20 |
Becton, Dickinson And Company |
Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
|
EP1931999B1
(en)
|
2005-09-29 |
2011-10-26 |
Roche Diagnostics GmbH |
Release reagent for vitamin d compounds
|
EP1928905B1
(de)
*
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
EP2264058A3
(en)
|
2005-09-30 |
2011-03-23 |
Seattle Biomedical Research |
Plasmodium liver stage antigens
|
WO2007041635A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
IL172297A
(en)
|
2005-10-03 |
2016-03-31 |
Compugen Ltd |
Soluble vegfr-1 variants for the diagnosis of preeclampsia
|
US7422899B2
(en)
*
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
WO2007044607A2
(en)
*
|
2005-10-06 |
2007-04-19 |
Emthrax, Llc |
Methods and compositions relating to anthrax spore glycoproteins as vaccines
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
EP1973928A2
(en)
|
2005-10-11 |
2008-10-01 |
Ramot at Tel-Aviv University Ltd. |
Self-assembled fmoc-ff hydrogels
|
UA92504C2
(xx)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Антиміостатинове моноклональне антитіло$антимиостатиновое моноклональное антитело
|
DE102005048898A1
(de)
*
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
US20090238822A1
(en)
*
|
2005-10-13 |
2009-09-24 |
Virexx Medical Corp. |
Chimeric Hepatitis C Virus Antigens For Eliciting an Immune Response
|
US9447185B2
(en)
|
2005-10-14 |
2016-09-20 |
Innate Pharma, S.A. |
Compositions and methods for treating proliferative disorders
|
US20100029504A1
(en)
|
2007-01-16 |
2010-02-04 |
Phigenix, Inc. |
Detecting pax2 for the diagnosis of breast cancer
|
US8461126B2
(en)
|
2005-10-14 |
2013-06-11 |
Phigenix, Inc. |
Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
|
WO2007043641A1
(ja)
|
2005-10-14 |
2007-04-19 |
Fukuoka University |
膵島移植における移植膵島障害抑制剤
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
EP1947180B1
(en)
|
2005-10-18 |
2012-12-05 |
National Institute Of Agrobiological Sciences |
Antibody producing transgenic silkworms and method for producing the same
|
JP5328019B2
(ja)
*
|
2005-10-21 |
2013-10-30 |
レヴォ バイオロジクス インコーポレイテッド |
抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法
|
WO2007048074A1
(en)
|
2005-10-21 |
2007-04-26 |
Genenews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
BRPI0617664B8
(pt)
|
2005-10-21 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
|
EP1948827B1
(en)
|
2005-10-21 |
2016-03-23 |
The Regents of The University of California |
C-kit oncogene mutations in melanoma
|
JP5006330B2
(ja)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Il13に対するヒト抗体および治療的使用
|
AR058140A1
(es)
*
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
ES2526705T3
(es)
|
2005-10-25 |
2015-01-14 |
The Johns Hopkins University |
Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
|
PL1940789T3
(pl)
|
2005-10-26 |
2012-04-30 |
Squibb & Sons Llc |
Metody i związki do otrzymywania analogów cc-1065
|
DK1945820T3
(da)
|
2005-10-27 |
2013-11-11 |
Janssen Biotech Inc |
Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser
|
CN101351221A
(zh)
|
2005-10-28 |
2009-01-21 |
明治制果株式会社 |
绿脓杆菌的外膜蛋白pa5158
|
US20080213274A1
(en)
*
|
2005-10-28 |
2008-09-04 |
Sabbadini Roger A |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
|
US20090074720A1
(en)
*
|
2005-10-28 |
2009-03-19 |
Sabbadini Roger A |
Methods for decreasing immune response and treating immune conditions
|
CA2628116A1
(en)
|
2005-10-31 |
2007-12-13 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
EP1948235B1
(en)
|
2005-11-01 |
2013-08-28 |
AbbVie Biotechnology Ltd |
Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers
|
FR2892724B1
(fr)
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
US20070099246A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Sandy John D |
Antibodies, assays and kits to quantitate cartilage destruction
|
CA2628451A1
(en)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
KR20170002684A
(ko)
*
|
2005-11-04 |
2017-01-06 |
제넨테크, 인크. |
안질환 치료를 위한 보체 경로 억제제의 용도
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
US20080286819A1
(en)
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
EP1945261A4
(en)
|
2005-11-07 |
2010-05-12 |
Scripps Research Inst |
COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
|
US20070161089A1
(en)
*
|
2005-11-08 |
2007-07-12 |
Genentech, Inc. |
Method of Producing Pan-Specific Antibodies
|
UA96139C2
(xx)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)$антитело к нейропилину-1 (nrp1)
|
US7939069B2
(en)
|
2005-11-09 |
2011-05-10 |
Abbott Laboratories |
Human BNP immunospecific antibodies
|
EP1957535A1
(en)
*
|
2005-11-09 |
2008-08-20 |
Abbott Laboratories |
Human bnp immunospecific antibodies
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
EP1948238B1
(en)
|
2005-11-10 |
2013-08-28 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
|
ATE547709T1
(de)
*
|
2005-11-14 |
2012-03-15 |
Metamol Theranostics Llc |
Tumorinvasionsfördernde peptidsequenz
|
WO2007054949A2
(en)
|
2005-11-14 |
2007-05-18 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Improved variants of pigment epithelium derived factor and uses thereof
|
RS57194B1
(sr)
|
2005-11-14 |
2018-07-31 |
Teva Pharmaceuticals Int Gmbh |
Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
|
US20090162869A1
(en)
*
|
2005-11-14 |
2009-06-25 |
Riken |
Membrane molecule expressed specifically in activated plasmacytoid dendritic cell
|
US8128934B2
(en)
|
2005-11-14 |
2012-03-06 |
Ribomic, Inc. |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AU2006316629A1
(en)
*
|
2005-11-17 |
2007-05-31 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
|
EP1948798B1
(en)
|
2005-11-18 |
2015-04-01 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
EP1957541A2
(en)
|
2005-11-21 |
2008-08-20 |
Laboratoires Serono SA |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
AU2006318539B2
(en)
*
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
WO2007064759A2
(en)
*
|
2005-11-29 |
2007-06-07 |
The Scripps Research Institute |
Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
KR20080090408A
(ko)
|
2005-11-30 |
2008-10-08 |
아보트 러보러터리즈 |
항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
|
DK1976877T4
(en)
|
2005-11-30 |
2017-01-16 |
Abbvie Inc |
Monoclonal antibodies to amyloid beta protein and uses thereof
|
US8957187B2
(en)
*
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
AU2006342792A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
US20070237764A1
(en)
*
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
CA2632094C
(en)
|
2005-12-02 |
2015-01-27 |
Wayne A. Marasco |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
WO2007065273A1
(en)
*
|
2005-12-08 |
2007-06-14 |
The University Of British Columbia |
Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith
|
US20070134249A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Genitope Corporation |
Combination therapy and antibody panels
|
WO2007075308A2
(en)
|
2005-12-09 |
2007-07-05 |
Wisconsin Alumni Research Foundation (W.A.R.F.) |
Vaccine candidates against johne's disease
|
GB0525214D0
(en)
|
2005-12-12 |
2006-01-18 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
RS57255B1
(sr)
|
2005-12-13 |
2018-08-31 |
Lilly Co Eli |
Anti-il-17 antitela
|
JP5236488B2
(ja)
|
2005-12-14 |
2013-07-17 |
ハーモ ファーマ エルテーデー. |
新規な神経栄養因子タンパク質およびその用途
|
RU2008128134A
(ru)
|
2005-12-15 |
2010-01-20 |
Дженентек, Инк. (Us) |
Способы и композиции для получения направленности на полиубиквитин
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
US20070264687A1
(en)
|
2005-12-15 |
2007-11-15 |
Min-Yuan Chou |
Recombinant triplex scaffold-based polypeptides
|
US7625759B2
(en)
|
2005-12-19 |
2009-12-01 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
JP2009521685A
(ja)
*
|
2005-12-22 |
2009-06-04 |
ノバルティス アーゲー |
可溶性ヒトm−csf受容体およびその使用
|
EP1981535A2
(en)
*
|
2005-12-22 |
2008-10-22 |
IQ Corporation |
Compositions and methods of modulating the immune response
|
PL1971366T3
(pl)
|
2005-12-29 |
2015-01-30 |
Janssen Biotech Inc |
Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
|
CN101351477B
(zh)
|
2005-12-30 |
2011-11-16 |
默克专利有限公司 |
具有降低的免疫原性的抗cd19抗体
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
EP2982761B1
(en)
|
2006-01-04 |
2017-10-04 |
Fujirebio America, Inc. |
Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
|
RU2470665C2
(ru)
*
|
2006-01-05 |
2012-12-27 |
Новартис Аг |
Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
ES2586825T3
(es)
|
2006-01-12 |
2016-10-19 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos para OX-2/CD200 y usos de los mismos
|
CA2637267A1
(en)
|
2006-01-16 |
2007-07-19 |
Compugen Ltd. |
Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
|
US20070166306A1
(en)
*
|
2006-01-17 |
2007-07-19 |
Fey Georg H M |
Anti-CD19 antibody composition and method
|
EP1973569B1
(en)
|
2006-01-18 |
2013-05-22 |
Merck Patent GmbH |
Specific therapy using integrin ligands for treating cancer
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
EP1973946B1
(en)
|
2006-01-20 |
2015-03-25 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
EP3135298B1
(en)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
EP1981902B1
(en)
|
2006-01-27 |
2015-07-29 |
Biogen MA Inc. |
Nogo receptor antagonists
|
US20070178103A1
(en)
*
|
2006-01-30 |
2007-08-02 |
Fey Georg H |
CD19-specific immunotoxin and treatment method
|
EP1987361A4
(en)
*
|
2006-01-30 |
2009-03-04 |
Invitrogen Corp |
COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
|
AR059193A1
(es)
|
2006-01-31 |
2008-03-12 |
Bayer Schering Pharma Ag |
Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
|
NZ569988A
(en)
*
|
2006-02-01 |
2011-09-30 |
Cephalon Australia Pty Ltd |
Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
|
EP1982181B1
(en)
*
|
2006-02-06 |
2010-12-15 |
Rhode Island Hospital |
Gpr30 estrogen receptor in breast cancers
|
EP3438131B1
(en)
|
2006-02-10 |
2022-03-16 |
Life Technologies Corporation |
Oligosaccharide modification and labeling of proteins
|
US7790857B2
(en)
*
|
2006-02-10 |
2010-09-07 |
Sanofi Pasteur Limited |
Monoclonal antibodies and uses thereof
|
EP1994043A4
(en)
|
2006-02-10 |
2009-05-20 |
Univ Cincinnati |
PROTEIN-A PHOSPHATASE INHIBITOR AS REGULATOR OF CARDIAC FUNCTION
|
AU2007215080A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Fraunhofer Usa, Inc. |
Influenza antigens, vaccine compositions, and related methods
|
JP2009526780A
(ja)
*
|
2006-02-13 |
2009-07-23 |
フラウンホーファー ユーエスエー, インコーポレイテッド |
Hpv抗原、ワクチン組成物、および関連する方法
|
US8277816B2
(en)
*
|
2006-02-13 |
2012-10-02 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
US8618060B2
(en)
|
2006-02-14 |
2013-12-31 |
University Of Tasmania |
Metallothionein-derived peptide fragments
|
EP2050335A1
(en)
|
2006-02-17 |
2009-04-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
JP2009531295A
(ja)
|
2006-02-22 |
2009-09-03 |
ユニバーシティ オブ チューリッヒ |
自己免疫疾患又は脱髄疾患を処置するための方法
|
US7459280B2
(en)
*
|
2006-02-27 |
2008-12-02 |
Picobella, Llc |
Methods for diagnosing and treating kidney cancer
|
US8470965B2
(en)
*
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US9365622B2
(en)
*
|
2006-03-01 |
2016-06-14 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US7807364B2
(en)
|
2006-03-03 |
2010-10-05 |
University Of Southern California |
Angiogenesis pathway gene polymorphisms for therapy selection
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US7829086B2
(en)
*
|
2006-03-06 |
2010-11-09 |
Medimmune, Llc |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
ES2527695T3
(es)
|
2006-03-08 |
2015-01-28 |
Archemix Llc |
Aptámeros de unión a complemento y agentes anti-C5 útiles en el tratamiento de trastornos oculares
|
WO2008076139A1
(en)
*
|
2006-03-10 |
2008-06-26 |
Tethys Bioscience, Inc. |
Multiplex protein fractionation
|
EP2397856B1
(en)
|
2006-03-14 |
2013-11-13 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
US7504106B2
(en)
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
DK2359834T5
(en)
|
2006-03-15 |
2017-02-06 |
Alexion Pharma Inc |
Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2374472B9
(en)
|
2006-03-16 |
2019-06-12 |
Dyax Corp. |
Compositions and methods for treating ophthalmic disorders
|
US9121853B2
(en)
*
|
2006-03-20 |
2015-09-01 |
Mayo Foundation For Medical Education And Research |
B7-H4 expression on tumor vasculature
|
CA2646597A1
(en)
|
2006-03-21 |
2007-09-27 |
The Regents Of The University Of California |
N-cadherin and ly6 e: targets for cancer diagnosis and therapy
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
CA2646611A1
(en)
|
2006-03-21 |
2008-05-22 |
Genentech, Inc. |
Combinatorial therapy
|
EP2389946A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
PL1999152T3
(pl)
|
2006-03-27 |
2013-05-31 |
Medimmune Ltd |
Element wiążący receptor GM-CSF
|
US9868961B2
(en)
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
SG170804A1
(en)
|
2006-03-30 |
2011-05-30 |
Meiji Seika Kaisha |
Pseudomonas aeruginosa outer membrane protein pa0427
|
EP2008106A2
(en)
|
2006-03-31 |
2008-12-31 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
RU2429014C2
(ru)
|
2006-03-31 |
2011-09-20 |
Массачусетс Инститьют Оф Текнолоджи |
Лечение опухолей, экспрессирующих мутантные рецепторы egf
|
WO2007119623A1
(ja)
|
2006-03-31 |
2007-10-25 |
Riken |
G蛋白質共役型受容体およびそのリガンドの新規用途
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
WO2007115207A2
(en)
*
|
2006-03-31 |
2007-10-11 |
Regents Of The University Of Minnesota |
Irf-5 haplotypes in systemic lupus erythematosus
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
CN101432301B
(zh)
|
2006-04-05 |
2014-01-08 |
洛克菲勒大学 |
具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法
|
CN101495146B
(zh)
|
2006-04-07 |
2012-10-17 |
国立大学法人大阪大学 |
肌肉再生促进剂
|
RU2494108C2
(ru)
|
2006-04-07 |
2013-09-27 |
Аерпио Терапетикс, Инк. |
Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
|
US20070280935A1
(en)
*
|
2006-04-07 |
2007-12-06 |
Bernd Bohrmann |
Antibody that recognizes phosphorylated peptides
|
US8524454B2
(en)
|
2006-04-07 |
2013-09-03 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
WO2007118214A2
(en)
*
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
EP2007426A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
|
GB0620255D0
(en)
*
|
2006-10-12 |
2006-11-22 |
Fusion Antibodies Ltd |
Antibody and uses thereof
|
AU2007238186B2
(en)
|
2006-04-10 |
2014-01-09 |
Genentech, Inc. |
Disheveled PDZ modulators
|
US9321838B2
(en)
*
|
2006-04-10 |
2016-04-26 |
Fusion Antibodies Limited |
Therapy targeting cathepsin S
|
EP2666479A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
ES2532804T3
(es)
*
|
2006-04-12 |
2015-03-31 |
Crealta Pharmaceuticals Llc |
Purificación de proteínas con tensioactivo catiónico
|
HUE035732T2
(en)
|
2006-04-14 |
2018-05-28 |
Cell Signaling Technology Inc |
Gene defects and mutant ALK kinase in human solid tumors
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
US8293245B2
(en)
|
2006-04-20 |
2012-10-23 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods and compositions based on Shiga toxin type 1 protein
|
GEP20125628B
(en)
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
EP3147365B1
(en)
|
2006-04-21 |
2019-12-04 |
Intervet International B.V. |
Pestivirus species
|
US8492097B2
(en)
|
2006-04-24 |
2013-07-23 |
Diagnostic Hybrids, Inc. |
Compositions and methods for human metapneumovirus monoclonal antibodies
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
US20070254338A1
(en)
*
|
2006-04-24 |
2007-11-01 |
Amgen Inc. |
Method for making recombinant protein using complementation dependent DHFR mutants
|
EP2537943B1
(en)
|
2006-04-24 |
2014-03-12 |
Genentech, Inc. |
Methods and compositions for detecting autoimmune disorders
|
WO2007129457A1
(ja)
|
2006-04-25 |
2007-11-15 |
The University Of Tokyo |
アルツハイマー病および癌の治療薬
|
AU2007244705A1
(en)
*
|
2006-04-27 |
2007-11-08 |
Barnes-Jewish Hospital |
Detection and imaging of target tissue
|
US20090298093A1
(en)
*
|
2006-04-27 |
2009-12-03 |
Roberto Polakiewicz |
Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
|
US8592149B2
(en)
|
2006-04-27 |
2013-11-26 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
WO2007128757A2
(en)
|
2006-05-02 |
2007-11-15 |
Actogenix N.V. |
Microbial intestinal delivery of obesity related peptides
|
US20070258976A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Ward Keith W |
Combination Therapy for Diseases Involving Angiogenesis
|
DE102006020885A1
(de)
*
|
2006-05-05 |
2007-11-08 |
Qiagen Gmbh |
Einführung von Sequenzelementen in Nukleinsäuren
|
WO2007134050A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
US7727525B2
(en)
*
|
2006-05-11 |
2010-06-01 |
City Of Hope |
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
|
WO2007134132A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
WO2007145760A2
(en)
|
2006-05-12 |
2007-12-21 |
Oklahoma Medical Research Foundation |
Anthrax compositions and methods of use and production
|
WO2007133800A2
(en)
*
|
2006-05-15 |
2007-11-22 |
University Of Kentucky |
Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
|
EP2027284A2
(en)
*
|
2006-05-18 |
2009-02-25 |
Sanofi-Aventis |
Use of adamts4 gene and protein polymorphisms
|
EP3260863B1
(en)
|
2006-05-27 |
2021-03-10 |
Fluidigm Canada Inc. |
Method for performing multiplex analysis of two or more analytes
|
BRPI0711249A2
(pt)
|
2006-05-30 |
2012-03-13 |
Genentech, Inc. |
Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
|
US7862812B2
(en)
*
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US9217749B2
(en)
*
|
2006-05-31 |
2015-12-22 |
Lpath, Inc. |
Immune-derived moieties reactive against lysophosphatidic acid
|
US8796429B2
(en)
*
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US9274129B2
(en)
*
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
CA2654438A1
(en)
|
2006-06-01 |
2008-03-27 |
Genentech, Inc. |
Crystal structure of crig and c3b:crig complex
|
WO2007143121A2
(en)
*
|
2006-06-01 |
2007-12-13 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
EP2029627B1
(en)
|
2006-06-02 |
2011-11-16 |
Aveo Pharmaceuticals, Inc. |
Hepatocyte growth factor (hgf) binding proteins
|
SG158112A1
(en)
|
2006-06-02 |
2010-01-29 |
Aveo Pharmaceuticals Inc |
Hepatocyte growth factor (hgf) binding proteins
|
AU2007257162A1
(en)
|
2006-06-05 |
2007-12-13 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
EA018030B1
(ru)
|
2006-06-06 |
2013-05-30 |
Круселл Холланд Б.В. |
Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
|
EP2029159A2
(en)
*
|
2006-06-06 |
2009-03-04 |
Genentech, Inc. |
Compositions and methods for modulating vascular development
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
SG175615A1
(en)
*
|
2006-06-06 |
2011-11-28 |
Genentech Inc |
Anti-dll4 antibodies and methods using same
|
EP2044120B1
(en)
*
|
2006-06-07 |
2019-01-30 |
BioAlliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
JP2009539370A
(ja)
|
2006-06-07 |
2009-11-19 |
オタゴ イノベーション リミテッド |
診断方法およびマーカー
|
AT503690A1
(de)
|
2006-06-09 |
2007-12-15 |
Biomay Ag |
Hypoallergene moleküle
|
NZ573646A
(en)
*
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
AU2007259739B2
(en)
|
2006-06-14 |
2013-03-07 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for promoting the growth of hematopoietic stem cells
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
EP2046384A4
(en)
*
|
2006-06-15 |
2009-12-02 |
Fibron Ltd |
ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
|
ES2415655T3
(es)
|
2006-06-15 |
2013-07-26 |
The Board Of Trustees Of The University Of Arkansas |
Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
|
CA2655903A1
(en)
*
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
RU2412203C2
(ru)
|
2006-06-21 |
2011-02-20 |
Онкотерапи Сайенс, Инк. |
Направленные на опухоль моноклональные антитела против fzd10 и их применение
|
EP2377953A1
(en)
|
2006-06-23 |
2011-10-19 |
Myriad Genetics, Inc. |
DPYD gene variants and use thereof
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
EP2041283B1
(en)
|
2006-06-26 |
2013-02-20 |
The University Of British Columbia |
Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
ATE544468T1
(de)
|
2006-06-28 |
2012-02-15 |
Yeda Res & Dev |
Caspase-8 und wundheilung
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Igfbp2インヒビター
|
EP2043711A4
(en)
|
2006-06-30 |
2017-08-30 |
AbbVie Biotechnology Ltd |
Automatic injection device
|
NO346945B1
(no)
|
2006-06-30 |
2023-03-13 |
Novo Nordisk As |
Anti-NKG2A-antistoffer og anvendelser derav
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP5385135B2
(ja)
|
2006-07-03 |
2014-01-08 |
チャールズ デイビッド アデア, |
細胞接着分子の発現を調節するための組成物
|
JP5605895B2
(ja)
|
2006-07-04 |
2014-10-15 |
ゲンマブ エー/エス |
Copdを処置するためのcd20結合分子
|
US20080026376A1
(en)
|
2006-07-11 |
2008-01-31 |
Huaming Wang |
KEX2 cleavage regions of recombinant fusion proteins
|
US8198046B2
(en)
*
|
2006-07-11 |
2012-06-12 |
Danisco Us Inc. |
KEX2 cleavage regions of recombinant fusion proteins
|
KR101429783B1
(ko)
|
2006-07-12 |
2014-08-18 |
가부시키가이샤 진 테크노 사이언스 |
항 인간 α9 인테그린 항체와 그 용도
|
SG173371A1
(en)
|
2006-07-13 |
2011-08-29 |
Univ Iowa Res Found |
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
|
KR101495549B1
(ko)
|
2006-07-13 |
2015-02-25 |
와이어쓰 엘엘씨 |
당단백질의 생산
|
MY157757A
(en)
*
|
2006-07-18 |
2016-07-15 |
Sanofi Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
EP2046809B1
(en)
|
2006-07-19 |
2016-12-07 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/il-27 as a target for anti-inflammatory responses
|
EP1882697B1
(en)
|
2006-07-24 |
2010-04-21 |
Institut Pasteur |
Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
CA2659012A1
(en)
*
|
2006-07-26 |
2008-01-31 |
Diamedica Inc. |
Methods of diagnosis and treatment for metabolic disorders
|
ES2452067T3
(es)
*
|
2006-08-04 |
2014-03-31 |
Novartis Ag |
Anticuerpo específico para EPHB3 y usos del mismo
|
CA2660330A1
(en)
|
2006-08-08 |
2008-02-14 |
Kyoto University |
Novel monoclonal antibody and use of the same
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
EP2057465A4
(en)
|
2006-08-09 |
2010-04-21 |
Homestead Clinical Corp |
SPECIFIC ORGAN PROTEINS AND METHODS OF USE
|
WO2008022035A2
(en)
*
|
2006-08-10 |
2008-02-21 |
The Scripps Research Institute |
Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
|
WO2008019394A2
(en)
*
|
2006-08-11 |
2008-02-14 |
The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services |
Methods for treatment and diagnosis of psychiatric disorders
|
PL2056858T3
(pl)
|
2006-08-11 |
2015-01-30 |
Csl Ltd |
Leczenie stanów chorobowych płuc
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
WO2008018641A1
(en)
|
2006-08-11 |
2008-02-14 |
Ono Pharmaceutical Co., Ltd. |
Monoclonal antibodies against stromal derived factor-1 (sdf-1)
|
US20090269342A1
(en)
*
|
2006-08-14 |
2009-10-29 |
Massachusetts Institute Of Technology |
Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
|
EP2052340A4
(en)
*
|
2006-08-14 |
2010-11-17 |
Massachusetts Inst Technology |
SYSTEM FOR EXPLORING DATA ON GLYCANES
|
US9867530B2
(en)
|
2006-08-14 |
2018-01-16 |
Volcano Corporation |
Telescopic side port catheter device with imaging system and method for accessing side branch occlusions
|
PT2059536E
(pt)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Anticorpos otimizados que visam cd19
|
PT2059535E
(pt)
*
|
2006-08-18 |
2014-01-29 |
Novartis Ag |
Anticorpos específicos do prlr e suas utulizações
|
ES2570153T3
(es)
|
2006-08-22 |
2016-05-17 |
Novo Nordisk As |
Anticuerpos anti-C5aR con propiedades mejoradas
|
EP2423333A1
(en)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US20090203602A1
(en)
|
2006-09-01 |
2009-08-13 |
Cohava Gelber |
Compositions and methods for diagnosis and treatment of type 2 diabetes
|
EP2759549B1
(en)
|
2006-09-01 |
2015-08-19 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
US7951776B2
(en)
|
2006-09-01 |
2011-05-31 |
American Type Culture Collection |
Methods for treatment of type 1 diabetes
|
BRPI0714893A2
(pt)
|
2006-09-05 |
2013-05-28 |
Medarex Inc |
anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
|
ES2530428T3
(es)
|
2006-09-05 |
2015-03-02 |
Alexion Pharma Inc |
Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos
|
GB0617429D0
(en)
|
2006-09-05 |
2006-10-18 |
Electrophoretics Ltd |
Markers of renal transplant rejection and renal damage
|
CN101611318B
(zh)
|
2006-09-07 |
2015-03-04 |
奥塔哥创新有限公司 |
生物标记物
|
US20080064045A1
(en)
*
|
2006-09-07 |
2008-03-13 |
Huaiqin Wu |
Biomarker fragments for the detection of human BNP
|
SI3339445T1
(sl)
*
|
2006-09-08 |
2020-12-31 |
Abbvie Bahamas Ltd. |
Beljakovine za vezavo interlevkin-13
|
AU2007294909A1
(en)
|
2006-09-08 |
2008-03-20 |
Amgen Inc. |
IL-1 family variants
|
EP2386655B1
(en)
|
2006-09-12 |
2014-11-19 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of lung cancer using KIT or KDG gene as genetic marker
|
EP2500415A1
(en)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Cell culture improvements
|
TW201516149A
(zh)
|
2006-09-13 |
2015-05-01 |
Abbvie Inc |
細胞培養改良
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US8349801B2
(en)
*
|
2006-09-18 |
2013-01-08 |
Compugen Ltd. |
Peptide ligands for G-protein coupled receptors
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
WO2008036973A2
(en)
|
2006-09-22 |
2008-03-27 |
St. Jude Children's Research Hospital |
Modulating regulatory t cell activity via interleukin 35
|
DK2081595T3
(da)
|
2006-09-26 |
2019-07-15 |
Genmab As |
Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
|
FR2906533B1
(fr)
|
2006-09-28 |
2013-02-22 |
Pf Medicament |
Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
JP2010505123A
(ja)
|
2006-09-29 |
2010-02-18 |
トランスレーショナル セラピューティクス,インク. |
eIF4Eレギュロン・ベースの診断薬
|
EP3357932A1
(en)
|
2006-09-29 |
2018-08-08 |
OncoMed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
ES2625798T3
(es)
|
2006-10-02 |
2017-07-20 |
E. R. Squibb & Sons, L.L.C. |
Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
|
US20120282245A1
(en)
|
2006-10-03 |
2012-11-08 |
Biogen Idec Ma Inc. |
Biomarkers and assays for the treatment of cancer
|
CA2664567C
(en)
|
2006-10-04 |
2016-04-26 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
RS53387B
(en)
|
2006-10-04 |
2014-10-31 |
Genentech, Inc. |
ELISA FOR VEGF
|
CN101541834A
(zh)
|
2006-10-06 |
2009-09-23 |
武田药品工业株式会社 |
癌症的预防和/或治疗剂
|
US8541169B2
(en)
|
2006-10-10 |
2013-09-24 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
|
US20100222228A1
(en)
*
|
2006-10-11 |
2010-09-02 |
Janssen Pharmaceutica N.V. |
Compositions and methods for treating and diagnosing irritable bowel syndrome
|
JP5919593B2
(ja)
*
|
2006-10-11 |
2016-05-18 |
フージョン アンティボディーズ リミテッド |
併用療法
|
JP2010506839A
(ja)
*
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
TWI414531B
(zh)
*
|
2006-10-12 |
2013-11-11 |
Genentech Inc |
淋巴毒素α之抗體
|
JP5247106B2
(ja)
*
|
2006-10-13 |
2013-07-24 |
キヤノン株式会社 |
タンパク質、タンパク質の固定方法、構造体、バイオセンサー、核酸、ベクター及び標的物質検出用キット
|
WO2008048545A2
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
JP5238710B2
(ja)
|
2006-10-19 |
2013-07-17 |
シーエスエル、リミテッド |
インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
WO2008051511A2
(en)
|
2006-10-20 |
2008-05-02 |
Applera Corporation |
Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
|
KR20090083958A
(ko)
*
|
2006-10-20 |
2009-08-04 |
바이오겐 아이덱 엠에이 인코포레이티드 |
가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
|
US8108030B2
(en)
|
2006-10-20 |
2012-01-31 |
Board Of Regents, The University Of Texas System |
Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
EP1916259A1
(en)
|
2006-10-26 |
2008-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
|
DK2075258T3
(da)
|
2006-10-26 |
2012-09-17 |
Gene Techno Science Co Ltd |
Antistof mod RGD i en aminosyresekvens i et ekstracellulært matrixprotein samt fremgangsmåde til dets fremstilling og dets anvendelse
|
JP5732182B2
(ja)
*
|
2006-10-27 |
2015-06-10 |
エルパス・インコーポレイテッドLpath, Inc. |
眼疾患と症状を処置するための組成物および方法
|
PT2087002E
(pt)
*
|
2006-10-27 |
2014-11-26 |
Lpath Inc |
Composições e métodos para a ligação de esfingosina-1- fosfato
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
US7745148B2
(en)
|
2006-10-30 |
2010-06-29 |
Functional Genetics, Inc. |
Random homozygous gene perturbation to enhance antibody production
|
GB0621513D0
(en)
*
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
US8999317B2
(en)
|
2006-11-01 |
2015-04-07 |
University Of Rochester |
Methods and compositions related to the structure and function of APOBEC3G
|
WO2008070367A2
(en)
*
|
2006-11-01 |
2008-06-12 |
Facet Biotech Corporation |
Mammalian cell-based immunoglobulin display libraries
|
EP2092294B1
(en)
|
2006-11-02 |
2015-06-03 |
Mitchell A. Winnik |
Particles containing detectable elemental code
|
US20080254512A1
(en)
|
2006-11-02 |
2008-10-16 |
Capon Daniel J |
Hybrid immunoglobulins with moving parts
|
PE20121034A1
(es)
*
|
2006-11-02 |
2012-08-25 |
Genentech Inc |
Anticuerpos anti-factor d humanizados
|
US8394927B2
(en)
|
2006-11-03 |
2013-03-12 |
U3 Pharma Gmbh |
FGFR4 antibodies
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
ES2397186T3
(es)
*
|
2006-11-06 |
2013-03-05 |
Whitehead Institute |
Composiciones inmunomoduladoras y métodos para su uso
|
US9457047B2
(en)
|
2006-11-06 |
2016-10-04 |
Whitehead Institute |
Immunomodulating compositions and methods of use thereof
|
US7718774B2
(en)
*
|
2006-11-08 |
2010-05-18 |
Macrogenics, Inc. |
TES7 and antibodies that bind thereto
|
US20110294782A1
(en)
|
2006-11-10 |
2011-12-01 |
Massachusetts Institute Of Technology |
Small molecule pak inhibitors
|
JP2010509246A
(ja)
*
|
2006-11-13 |
2010-03-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
癌性疾患修飾抗体
|
RU2009122233A
(ru)
*
|
2006-11-13 |
2010-12-20 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Антитела, модифицирующие раковые заболевания
|
CA2668496A1
(en)
*
|
2006-11-13 |
2008-05-22 |
F. Hoffmann-La Roche Ag |
Cancerous disease modifying antibodies
|
JP2010509612A
(ja)
|
2006-11-14 |
2010-03-25 |
ジェネンテック インコーポレイテッド |
ニューロン再生の活性調節因子
|
US7492312B2
(en)
*
|
2006-11-14 |
2009-02-17 |
Fam Adly T |
Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
|
AU2007334264A1
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to BTLA and methods of use
|
EP2094282A4
(en)
*
|
2006-11-15 |
2010-05-05 |
Functional Genetics Inc |
ANTI-TSG101 ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS
|
CN101553506B
(zh)
|
2006-11-17 |
2013-08-07 |
诺瓦提斯公司 |
Lingo结合分子及其制药用途
|
EP2567975A3
(en)
|
2006-11-21 |
2013-07-03 |
The Regents of The University of California |
Modulation of RHAMM (CD168) for selective adipose tissue development
|
US20100062000A1
(en)
*
|
2006-11-21 |
2010-03-11 |
The Regents Of The University Of California |
Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
|
NZ598345A
(en)
|
2006-11-21 |
2013-09-27 |
Kalobios Pharmaceuticals Inc |
Methods of treating chronic inflammatory diseases using a gm-csf antagonist
|
US8785400B2
(en)
*
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
JP2010510772A
(ja)
|
2006-11-27 |
2010-04-08 |
パトリス リミテッド |
新生細胞における新規なグリコシル化ペプチド標的
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US20100047829A1
(en)
|
2006-11-28 |
2010-02-25 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
ATE555128T1
(de)
|
2006-11-30 |
2012-05-15 |
Res Dev Foundation |
Verbesserte immunglobulin-bibliotheken
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
PT2662091T
(pt)
|
2006-12-01 |
2018-12-03 |
Novartis Ag |
Anticorpos anti-p-selectina e métodos para os utilizar no tratamento de doenças inflamatórias
|
CN101626782B
(zh)
|
2006-12-01 |
2013-03-27 |
梅达雷克斯公司 |
结合cd22的人抗体及其用途
|
US7858752B2
(en)
|
2006-12-05 |
2010-12-28 |
Abbott Laboratories |
Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
KR20140119831A
(ko)
|
2006-12-07 |
2014-10-10 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
US20080139790A1
(en)
*
|
2006-12-08 |
2008-06-12 |
Jennings Philip A |
Chimeric antibodies
|
ZA200904022B
(en)
|
2006-12-08 |
2010-08-25 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against ANGPTL3
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
KR20090088950A
(ko)
|
2006-12-14 |
2009-08-20 |
쉐링 코포레이션 |
가공된 항-tslp 항체
|
BRPI0719409A2
(pt)
|
2006-12-18 |
2014-02-11 |
Genentch Inc |
"regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo"
|
US20090186034A1
(en)
*
|
2006-12-19 |
2009-07-23 |
Genetech, Inc. |
Gene expression markers for inflammatory bowel disease
|
TW200831538A
(en)
|
2006-12-19 |
2008-08-01 |
Genentech Inc |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
EP3124045A3
(en)
|
2006-12-20 |
2017-05-03 |
Xoma (Us) Llc |
Treatment of il-1 beta related diseases
|
US20100267933A1
(en)
|
2006-12-21 |
2010-10-21 |
Moya Wilson |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
*
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
TW200833711A
(en)
*
|
2006-12-22 |
2008-08-16 |
Genentech Inc |
Antibodies to insulin-like growth factor receptor
|
US7888069B2
(en)
*
|
2006-12-22 |
2011-02-15 |
Dow Agrosciences Llc |
Plant-made west nile virus (WNV) vaccines, vectors and plant codon optimized sequences
|
EP2913341A1
(en)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
EP3345607B1
(en)
|
2006-12-29 |
2022-10-26 |
Ossifi-Mab LLC |
Methods of altering bone growth by administration of sost or wise antagonist or agonist
|
CA2674378A1
(en)
|
2007-01-03 |
2008-07-17 |
Burnham Institute For Medical Research |
Methods and compositions related to clot binding compounds
|
AU2008205330B2
(en)
|
2007-01-08 |
2014-07-03 |
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
SLCO1B3 genotype
|
CN101636168B
(zh)
|
2007-01-09 |
2013-05-29 |
比奥根艾迪克Ma公司 |
Sp35抗体及其用途
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
US20080171710A1
(en)
|
2007-01-17 |
2008-07-17 |
University Of Rochester |
The Redox/Fyn/c-Cbl Pathway
|
PL2101805T3
(pl)
|
2007-01-18 |
2013-04-30 |
Merck Patent Gmbh |
Ligandy integryn do stosowania w leczeniu nowotworów
|
EP2126117A2
(en)
*
|
2007-01-18 |
2009-12-02 |
University Of Southern California |
Gene polymorphisms predictive for dual tki therapy
|
JP2010516259A
(ja)
|
2007-01-22 |
2010-05-20 |
レイベン バイオテクノロジーズ |
ヒトがん幹細胞
|
AU2008209404B2
(en)
|
2007-01-22 |
2012-08-16 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
TWI438208B
(zh)
|
2007-01-23 |
2014-05-21 |
Chugai Pharmaceutical Co Ltd |
抑制慢性排斥反應之藥劑
|
EP2106439B1
(en)
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US20100119526A1
(en)
*
|
2007-01-26 |
2010-05-13 |
Bioinvent International Ab |
DLL4 Signaling Inhibitors and Uses Thereof
|
FI20075059A0
(fi)
|
2007-01-29 |
2007-01-29 |
Valtion Teknillinen |
Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus
|
EP2077853A1
(en)
*
|
2007-01-29 |
2009-07-15 |
Wyeth |
Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
|
US8143046B2
(en)
|
2007-02-07 |
2012-03-27 |
Danisco Us Inc., Genencor Division |
Variant Buttiauxella sp. phytases having altered properties
|
EP2468776A3
(en)
|
2007-02-09 |
2012-11-14 |
Genentech, Inc. |
Anti-Robo4 antibodies and uses therefor
|
EP1958645A1
(en)
|
2007-02-13 |
2008-08-20 |
Biomay AG |
Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
|
US7883705B2
(en)
|
2007-02-14 |
2011-02-08 |
Kyowa Hakko Kirin Co., Ltd. |
Anti FGF23 antibody and a pharmaceutical composition comprising the same
|
WO2008100596A2
(en)
*
|
2007-02-15 |
2008-08-21 |
Burnham Institute For Medical Research |
Biomarkers of neurodegenerative disease
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
EP2130044B1
(en)
|
2007-02-16 |
2016-10-26 |
Genzyme Corporation |
Method of identifying risk for thyroid disorder
|
EP3248617A3
(en)
|
2007-02-16 |
2018-02-21 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against erbb3 and uses thereof
|
WO2008101184A2
(en)
*
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
WO2008103319A2
(en)
|
2007-02-16 |
2008-08-28 |
Ark Diagnostics, Inc. |
Compounds and methods for use in detecting gabapentin
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
BRPI0807952A2
(pt)
*
|
2007-02-20 |
2014-06-10 |
Anaptysbio Inc |
Sistemas de hipermutação somática
|
CN101616911A
(zh)
*
|
2007-02-21 |
2009-12-30 |
梅达莱克斯公司 |
具有单个氨基酸的化学连接物及其偶联物
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
BRPI0807710B1
(pt)
*
|
2007-02-23 |
2021-12-14 |
Merck Sharp & Dohme Corp |
Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
|
SG178804A1
(en)
|
2007-02-23 |
2012-03-29 |
Schering Corp |
Engineered anti-il-23p19 antibodies
|
CN104189885A
(zh)
|
2007-02-23 |
2014-12-10 |
纽约哥伦比亚大学理事会 |
通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径治疗免疫疾病的方法
|
EP3118221B1
(en)
|
2007-02-26 |
2019-08-21 |
Oxford BioTherapeutics Ltd |
Proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
US20100311767A1
(en)
*
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2056838B1
(en)
|
2007-02-28 |
2013-09-25 |
Merck Sharp & Dohme Corp. |
Combination therapy for treatment of immune disorders
|
US8188214B2
(en)
|
2007-02-28 |
2012-05-29 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
EP2134373A4
(en)
|
2007-02-28 |
2014-04-02 |
Yeda Res & Dev |
CORE TARGETING SEQUENCES
|
US8119133B2
(en)
|
2007-02-28 |
2012-02-21 |
Schering Corporation |
Engineered anti-IL-23R antibodies
|
AU2008223133A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Wyeth |
Use of copper and glutamate in cell culture for production of polypeptides
|
MX2009008981A
(es)
*
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
EP2243834A1
(en)
|
2007-03-05 |
2010-10-27 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
CN101641115B
(zh)
|
2007-03-08 |
2013-04-24 |
卡罗拜奥斯制药公司 |
用于实体瘤治疗的EphA3抗体
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
CA2680556A1
(en)
|
2007-03-12 |
2008-09-18 |
Miraculins Inc. |
Biomarkers of prostate cancer and uses thereof
|
JP2010521180A
(ja)
|
2007-03-14 |
2010-06-24 |
ノバルティス アーゲー |
癌を処置、診断または検出するためのapcdd1阻害剤
|
EP2546355A1
(en)
|
2007-03-14 |
2013-01-16 |
Washington University |
Methods for identifying diabetes and obesity therapeutics
|
US9023356B2
(en)
*
|
2007-03-15 |
2015-05-05 |
Ludwig Institute For Cancer Research Ltd |
Treatment method using EGFR antibodies and SRC inhibitors and related formulations
|
EP1972938B1
(de)
*
|
2007-03-19 |
2014-05-14 |
Ivoclar Vivadent |
Teststreifen für die Bestimmung des Kariesrisikos
|
PL2121919T3
(pl)
*
|
2007-03-22 |
2012-07-31 |
Heptares Therapeutics Ltd |
Zmutowane receptory związane z białkiem G i sposoby ich wyboru
|
CN103214577B
(zh)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP1975184A3
(en)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serine or threonine phosphorylation sites
|
EP2136832B1
(en)
|
2007-03-26 |
2015-09-02 |
General Regeneratives Limited |
Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
JP5779350B2
(ja)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
抗体代替軽鎖配列を含む構築物およびライブラリー
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
TW200902064A
(en)
*
|
2007-03-28 |
2009-01-16 |
Wyeth Corp |
Methods and compositions for modulating IL-17F/IL-17A biological activity
|
GB0706070D0
(en)
|
2007-03-28 |
2007-05-09 |
Scancell Ltd |
Nucleic acids
|
US8455189B2
(en)
*
|
2007-03-29 |
2013-06-04 |
Jeffrey W. Allard |
Use of HE4 for assessment of breast cancers
|
WO2008120202A2
(en)
|
2007-03-29 |
2008-10-09 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
US20100291024A1
(en)
*
|
2007-03-30 |
2010-11-18 |
Xuebin Qin |
Methods and compositions for the treatment of proliferative and pathogenic diseases
|
RU2491094C2
(ru)
|
2007-03-30 |
2013-08-27 |
Медиммун, Ллк |
Препарат антитела
|
KR101515243B1
(ko)
|
2007-04-02 |
2015-04-24 |
필로겐 에스.피.에이. |
종양 전이암의 신생혈관과 관련된 피브리노겐의 ed―a 항원
|
ATE501280T1
(de)
*
|
2007-04-04 |
2011-03-15 |
Chimera Biotec Gmbh |
Verfahren zum nachweis eines analyten in einer biologischen matrix
|
WO2008124176A2
(en)
|
2007-04-10 |
2008-10-16 |
The Administrators Of The Tulane Educational Fund |
Soluble and membrane-anchored forms of lassa virus subunit proteins
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
SI2644205T1
(sl)
|
2007-04-12 |
2018-11-30 |
The Brigham And Women's Hospital, Inc. |
Ciljanje ABCB5 za zdravljenje raka
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
RU2523894C2
(ru)
*
|
2007-04-18 |
2014-07-27 |
Янссен Альцгеймер Иммунотерапи |
Предупреждение и лечение церебральной амилоидной ангиопатии
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
ES2619647T3
(es)
*
|
2007-04-20 |
2017-06-26 |
Bioventures Llc |
Compuestos de hapteno y composiciones y usos de los mismos
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
CN101293924A
(zh)
|
2007-04-24 |
2008-10-29 |
上海国健生物技术研究院 |
骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
|
CN101293916A
(zh)
|
2007-04-24 |
2008-10-29 |
上海国健生物技术研究院 |
骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
|
US20080267977A1
(en)
*
|
2007-04-26 |
2008-10-30 |
Friedrich-Alexander University Of Erlangen-Nuremberg |
Combined immunological agent and sensitizing agent for the treatment of cancer
|
US20100143336A1
(en)
|
2007-04-26 |
2010-06-10 |
Opsona Therapeutics Limited |
Toll-like receptor binding epitope and compositions for binding thereto
|
US20100322949A1
(en)
|
2007-04-26 |
2010-12-23 |
Ludwig Institute For Cancer Research Ltd. |
Methods for diagnosing and treating astrocytomas
|
EP2152301A4
(en)
*
|
2007-04-28 |
2010-07-28 |
Fraunhofer Usa Inc |
TRYPANOSOME ANTIGENS, VACCINE COMPOSITIONS AND RELATED METHODS
|
EP2145185A4
(en)
|
2007-04-30 |
2010-06-02 |
Nanogen Inc |
DOSAGE OF SEVERAL ANALYTES
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
DK2155789T3
(da)
*
|
2007-05-01 |
2013-10-21 |
Res Dev Foundation |
Immunoglobulin-Fc-biblioteker
|
CA2688548A1
(en)
*
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
CA2685213C
(en)
|
2007-05-04 |
2017-02-21 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
JP5575636B2
(ja)
|
2007-05-07 |
2014-08-20 |
メディミューン,エルエルシー |
抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
|
EP2155894A4
(en)
|
2007-05-09 |
2010-08-18 |
Burnham Inst Medical Research |
HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES
|
EP3456733A1
(en)
|
2007-05-11 |
2019-03-20 |
Genzyme Corporation |
Methods of producing a secreted protein
|
US20110091377A1
(en)
|
2007-05-11 |
2011-04-21 |
The Johns Hopkins University |
Biomarkers for melanoma
|
WO2009101479A2
(en)
|
2007-05-14 |
2009-08-20 |
Novimmune Sa |
Fc receptor-binding polypeptides with modified effector functions
|
EP2650018A3
(en)
|
2007-05-14 |
2014-09-03 |
The University of Chicago |
Antibody-LIGHT fusion products for cancer therapeutics
|
JP2010527356A
(ja)
|
2007-05-14 |
2010-08-12 |
メディミューン,エルエルシー |
好酸球レベルを低下させる方法
|
JP2010530359A
(ja)
*
|
2007-05-17 |
2010-09-09 |
ジェネンテック, インコーポレイテッド |
ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造
|
AU2008254582A1
(en)
*
|
2007-05-21 |
2008-11-27 |
Genentech, Inc. |
Methods and compositions for identifying and treating lupus
|
PL2164514T3
(pl)
|
2007-05-21 |
2017-08-31 |
Alderbio Holdings Llc |
Przeciwciała przeciwko IL-6 i ich zastosowanie
|
CN101688194B
(zh)
|
2007-05-23 |
2013-09-11 |
Uab研究基金会 |
去毒的肺炎球菌神经氨酸酶及其用途
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
EP2164992B1
(en)
|
2007-05-30 |
2016-05-04 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
KR20150029002A
(ko)
|
2007-06-07 |
2015-03-17 |
제넨테크, 인크. |
보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
EP2164862B1
(en)
|
2007-06-08 |
2015-07-22 |
Australian Poultry CRC Pty Ltd |
Clostridial toxin netb
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
PT2170956E
(pt)
|
2007-06-15 |
2015-02-05 |
Medigene Ag |
Tratamento de tumores utilizando um anticorpo anti-l1 específico
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
EP2716656B1
(en)
|
2007-06-15 |
2016-10-12 |
Xiamen University |
Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof
|
AU2008266951B2
(en)
|
2007-06-18 |
2013-12-12 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor PD-1
|
US20080317768A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Boeing Company |
Bioconjugated nanoparticles
|
CN101821288A
(zh)
|
2007-06-21 |
2010-09-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
ES2466916T3
(es)
|
2007-06-27 |
2014-06-11 |
Admune Therapeutics Llc |
Complejos de IL-15 e IL-15R alfa y usos de los mismos
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
JPWO2009005040A1
(ja)
*
|
2007-06-29 |
2010-08-26 |
明治製菓株式会社 |
緑膿菌の外膜タンパク質pa4710
|
US8158757B2
(en)
|
2007-07-02 |
2012-04-17 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
LT3597659T
(lt)
|
2007-07-09 |
2023-05-10 |
Genentech, Inc. |
Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
|
CA2692933C
(en)
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
US10219780B2
(en)
|
2007-07-12 |
2019-03-05 |
Volcano Corporation |
OCT-IVUS catheter for concurrent luminal imaging
|
EP2014681A1
(en)
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
US8492329B2
(en)
|
2007-07-12 |
2013-07-23 |
Compugen Ltd. |
Bioactive peptides and methods of using same
|
US9596993B2
(en)
|
2007-07-12 |
2017-03-21 |
Volcano Corporation |
Automatic calibration systems and methods of use
|
EP2175884B8
(en)
*
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
JP5524835B2
(ja)
|
2007-07-12 |
2014-06-18 |
ヴォルカノ コーポレイション |
生体内撮像用カテーテル
|
US7919313B2
(en)
|
2007-07-12 |
2011-04-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
|
CA2696833A1
(en)
|
2007-07-15 |
2009-01-22 |
Yitzchak Hillman |
Disease treatment via antimicrobial peptides or their inhibitors
|
IL184627A0
(en)
|
2007-07-15 |
2008-12-29 |
Technion Res & Dev Foundation |
Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
|
ES2381788T3
(es)
|
2007-07-16 |
2012-05-31 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
EP2215474A4
(en)
|
2007-07-16 |
2012-07-18 |
Avaxia Biologics Inc |
ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
ES2398536T3
(es)
|
2007-07-25 |
2013-03-20 |
Philogen S.P.A. |
El antígeno ED-A de fibronectina está asociado con la neovasculatura de la metástasis tumoral
|
AU2008280057A1
(en)
|
2007-07-25 |
2009-01-29 |
Japan As Represented By Director-General Of National Institute Of Infectious Diseases |
Antibody having inhibitory activity on infection with hepatitis C virus (HCV), and use thereof
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
WO2009018386A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
EP2023144A1
(en)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
HUE025283T2
(en)
*
|
2007-08-02 |
2016-03-29 |
Gilead Biologics Inc |
LOX and LOX2 inhibitors and their use
|
MX2010001381A
(es)
|
2007-08-03 |
2010-09-14 |
Spirogene Pty Ltd |
Genes y proteinas de brachyspira hyodysenteriae y usos de los mismos.
|
JP5576275B2
(ja)
|
2007-08-03 |
2014-08-20 |
オプソナ セラピューティクス リミテッド |
再灌流障害および組織損傷を処置するためのtlr−2拮抗薬の使用
|
EP2185688A4
(en)
|
2007-08-06 |
2010-08-25 |
Burnham Inst Medical Research |
ZNF206: NEW REGULATOR FOR AUTOMATIC RENEWAL AND PLURIPOTENCE OF EMBRYONIC STEM CELLS
|
US20090038182A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Lans Maris J |
Footwear with built-in scale
|
AU2008287427B2
(en)
|
2007-08-13 |
2014-10-09 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to EphB4
|
ES2609915T3
(es)
*
|
2007-08-14 |
2017-04-25 |
Ludwig Institute For Cancer Research Ltd. |
Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
|
KR20100071972A
(ko)
|
2007-08-15 |
2010-06-29 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Mmp-9의 조절인자 및 그의 용도
|
US7897139B2
(en)
|
2007-08-17 |
2011-03-01 |
Biochrom Pharma, Inc. |
PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
|
US8501929B2
(en)
|
2007-08-17 |
2013-08-06 |
Biochrom Pharma Inc. |
PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
|
US20110059130A1
(en)
*
|
2007-08-20 |
2011-03-10 |
Fraunhofer Usa, Inc. |
Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
|
EA201591355A1
(ru)
|
2007-08-21 |
2016-04-29 |
Амген Инк. |
АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
|
CN101802182A
(zh)
|
2007-08-21 |
2010-08-11 |
诺达利蒂公司 |
用于诊断、预后和治疗方法的方法
|
WO2009026496A1
(en)
*
|
2007-08-22 |
2009-02-26 |
University Of Southern California |
Grp78 and tumor angiogenesis
|
JP6035009B2
(ja)
|
2007-08-22 |
2016-11-30 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
|
EP2190478B1
(en)
|
2007-08-24 |
2016-03-23 |
Oncotherapy Science, Inc. |
Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
|
WO2009029550A2
(en)
*
|
2007-08-24 |
2009-03-05 |
Singulex, Inc. |
Highly sensitive system and methods for analysis of prostate specific antigen (psa)
|
RU2010111120A
(ru)
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
|
TW200920405A
(en)
|
2007-08-24 |
2009-05-16 |
Oncotherapy Science Inc |
PKIB and NAALADL2 for target genes of prostate cancer therapy and diagnosis
|
EP2190985A4
(en)
|
2007-08-24 |
2010-12-15 |
Oncotherapy Science Inc |
GENES RELATED TO CANCER, CDCA5, EPHA7, STK31 AND WDHD1
|
AU2008296478B9
(en)
*
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
EP2570431A3
(en)
*
|
2007-08-30 |
2013-05-01 |
CureDM Group Holdings, LLC |
Compositions and methods of using proislet peptides and analogs thereof
|
PL2769729T3
(pl)
|
2007-09-04 |
2019-09-30 |
Compugen Ltd. |
Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
KR101621837B1
(ko)
|
2007-09-12 |
2016-05-17 |
노파르티스 아게 |
Gas57 돌연변이 항원 및 gas57 항체
|
CA2697193C
(en)
|
2007-09-14 |
2017-06-06 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
JP5963341B2
(ja)
*
|
2007-09-14 |
2016-08-10 |
アムジエン・インコーポレーテツド |
均質な抗体集団
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
US7951785B2
(en)
*
|
2007-09-21 |
2011-05-31 |
California Institute Of Technology |
NFIA in glial fate determination, glioma therapy and astrocytoma treatment
|
EP2205625B1
(en)
|
2007-09-24 |
2012-09-12 |
Cornell University |
Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
|
DE102007045701B3
(de)
*
|
2007-09-24 |
2009-05-14 |
Uhde Gmbh |
Gewinnung von Milchsäure durch Fermentation und Extraktion mit Aminen
|
US7695963B2
(en)
*
|
2007-09-24 |
2010-04-13 |
Cythera, Inc. |
Methods for increasing definitive endoderm production
|
EP2535349A1
(en)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
MX369784B
(es)
|
2007-09-26 |
2019-11-21 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
GB0718843D0
(en)
|
2007-09-26 |
2007-11-07 |
Cancer Rec Tech Ltd |
Materials and methods relating to modifying the binding of antibodies
|
PH12018501459A1
(en)
|
2007-09-26 |
2019-11-11 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
US8431352B2
(en)
|
2007-09-27 |
2013-04-30 |
Virus Ikagaku Kenkyusho Inc. |
Diagnosis of mood disorders by detecting latent infection with human herpesvirus-6
|
EP2196541B1
(en)
|
2007-09-28 |
2012-11-07 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican-3 antibody having improved kinetics in plasma
|
PT2915564T
(pt)
|
2007-09-28 |
2021-02-09 |
Alexion Pharma Inc |
Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
|
US8426149B2
(en)
|
2007-10-01 |
2013-04-23 |
The University Of British Columbia |
Granzyme A and granzyme B diagnostics
|
KR101601986B1
(ko)
|
2007-10-02 |
2016-03-17 |
추가이 세이야쿠 가부시키가이샤 |
인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
|
EP2725035A1
(en)
|
2007-10-02 |
2014-04-30 |
Avaxia Biologics, Inc. |
Antibody therapy for use in the digestive tract
|
NZ584963A
(en)
|
2007-10-02 |
2012-11-30 |
Theranos Inc |
Modular Point-of-care devices as addressible assay units with tips of assay units having interior to immobilize reagents by capillary action
|
US8691222B2
(en)
|
2007-10-02 |
2014-04-08 |
Genentech, Inc. |
NLRR-1 antagonists and uses thereof
|
US8470560B2
(en)
|
2007-10-03 |
2013-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
|
GB0719231D0
(en)
|
2007-10-03 |
2007-11-14 |
Oxford Genome Sciences Uk Ltd |
Protein
|
US9464135B2
(en)
|
2007-10-08 |
2016-10-11 |
The Regents Of The University Of California |
Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR)
|
CN101980603A
(zh)
*
|
2007-10-11 |
2011-02-23 |
比奥根艾迪克Ma公司 |
LINGO-1和TrkB拮抗剂的用途
|
AR068767A1
(es)
*
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
AU2008312406B2
(en)
|
2007-10-16 |
2014-03-06 |
Ares Trading S.A. |
Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0720250D0
(en)
|
2007-10-17 |
2007-11-28 |
Univ Edinburgh |
Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
|
EP3741851A1
(en)
|
2007-10-18 |
2020-11-25 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
US8216571B2
(en)
*
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
JP2011501760A
(ja)
|
2007-10-23 |
2011-01-13 |
ノバルティス アーゲー |
呼吸器疾患の処置のためのtrkb抗体の使用
|
US8143224B2
(en)
|
2007-10-23 |
2012-03-27 |
The Cleveland Clinic Foundation |
Oxidant resistant apolipoprotein A-1 and mimetic peptides
|
FI20070808A0
(fi)
|
2007-10-25 |
2007-10-25 |
Mart Saarma |
GDNF:n silmukointivariantit ja niiden käytöt
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
EP2214708A4
(en)
|
2007-10-26 |
2011-01-12 |
Centocor Ortho Biotech Inc |
VECTORS, HOST CELLS, METHODS OF PRODUCTION AND USES
|
ES2807753T3
(es)
|
2007-10-30 |
2021-02-24 |
Philogen Spa |
Un antígeno asociado con artritis reumatoide
|
SG175597A1
(en)
|
2007-10-30 |
2011-11-28 |
Genentech Inc |
Antibody purification by cation exchange chromatography
|
EP2664344B1
(en)
|
2007-10-31 |
2019-02-27 |
Idexx Laboratories, Inc. |
Ehrlichia canis diva (differentiate infection from vaccinated animals)
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
MY149546A
(en)
|
2007-11-02 |
2013-09-13 |
Novartis Ag |
Improved nogo-a binding molecules and pharmaceutical use tereof
|
EA201000718A1
(ru)
|
2007-11-02 |
2011-06-30 |
Новартис Аг |
Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
WO2009061818A1
(en)
|
2007-11-05 |
2009-05-14 |
Medimmune, Llc |
Methods of treating scleroderma
|
CA2704499C
(en)
|
2007-11-07 |
2020-03-10 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
|
WO2009062102A2
(en)
|
2007-11-07 |
2009-05-14 |
Genentech, Inc. |
Compositions and methods for treatment of microbial disorders
|
EP2217697B1
(en)
*
|
2007-11-08 |
2015-06-10 |
Biogen MA Inc. |
Use of lingo-4 antagonists in the treatment of conditions involving demyelination
|
WO2009064805A1
(en)
|
2007-11-12 |
2009-05-22 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of influenza
|
ES2556214T3
(es)
|
2007-11-12 |
2016-01-14 |
U3 Pharma Gmbh |
Anticuerpos para AXL
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
US8637435B2
(en)
*
|
2007-11-16 |
2014-01-28 |
Merck Sharp & Dohme Corp. |
Eukaryotic cell display systems
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
EP2227556B1
(en)
|
2007-11-19 |
2014-08-27 |
Celera Corporation |
Lung cancer markers and uses thereof
|
CN101932712B
(zh)
|
2007-11-20 |
2014-05-14 |
先锋国际良种公司 |
用于改善植物应激耐性的玉米乙烯信号转导基因及其调节
|
US8541543B2
(en)
*
|
2007-11-20 |
2013-09-24 |
Academia Sinica |
Peptides specific for hepatocellular carcinoma cells and applications thereof
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
WO2009070642A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
AU2008334095A1
(en)
|
2007-11-29 |
2009-06-11 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
CN101932728B
(zh)
*
|
2007-11-30 |
2013-06-19 |
西门子医疗保健诊断公司 |
脂连蛋白受体片段和使用方法
|
RS51987B
(en)
|
2007-11-30 |
2012-02-29 |
Genentech Inc. |
VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIC THERAPY
|
NZ602498A
(en)
|
2007-11-30 |
2014-08-29 |
Abbvie Inc |
Protein formulations and methods of making same
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
WO2010070380A2
(en)
*
|
2007-12-03 |
2010-06-24 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
Doc1 compositions and methods for treating cancer
|
EP2236604B1
(en)
|
2007-12-05 |
2016-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
EP2229410A4
(en)
|
2007-12-05 |
2012-07-04 |
Massachusetts Inst Technology |
AGLYCOSYLATED IMMUNOGLOBULIN MUTANTS
|
GB0723797D0
(en)
*
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
US20110038935A1
(en)
|
2007-12-06 |
2011-02-17 |
Marasco Wayne A |
Antibodies against influenza virus and methods of use thereof
|
GB0724051D0
(en)
*
|
2007-12-08 |
2008-01-16 |
Medical Res Council |
Mutant proteins and methods for producing them
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
ES2483942T5
(es)
|
2007-12-14 |
2017-02-06 |
Novo Nordisk A/S |
Anticuerpos contra NKG2D humano y usos de los mismos
|
JP5737944B2
(ja)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドPfizer Limited |
間質性膀胱炎の治療
|
RU2528738C2
(ru)
|
2007-12-18 |
2014-09-20 |
Биоэллаенс К.В. |
Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
|
ES2626634T3
(es)
|
2007-12-19 |
2017-07-25 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
|
SI2391650T1
(sl)
|
2007-12-20 |
2015-03-31 |
Xoma (Us) Llc |
Postopki za zdravljenje protina
|
GB0724860D0
(en)
|
2007-12-20 |
2008-01-30 |
Heptares Therapeutics Ltd |
Screening
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
EP2604628A3
(en)
|
2007-12-21 |
2013-08-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4R) - 173
|
CA2709354C
(en)
|
2007-12-21 |
2014-06-17 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
AU2008342152B2
(en)
|
2007-12-25 |
2013-06-27 |
Meiji Seika Pharma Co., Ltd. |
Component protein PA1698 for type-III secretion system of Pseudomonas aeruginosa
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
NZ586544A
(en)
*
|
2007-12-26 |
2012-07-27 |
Vaccinex Inc |
Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
|
KR101603076B1
(ko)
|
2007-12-28 |
2016-03-14 |
프로테나 바이오사이언시즈 리미티드 |
아밀로이드증의 치료 및 예방
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
*
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
BRPI0906492A2
(pt)
|
2008-01-11 |
2015-12-01 |
Synovex Corp |
antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
|
JP2011509650A
(ja)
|
2008-01-11 |
2011-03-31 |
株式会社ジーンテクノサイエンス |
ヒト化抗−α9インテグリン抗体及びその使用
|
DK3043181T3
(da)
|
2008-01-15 |
2020-05-04 |
Univ Leland Stanford Junior |
Markører af akutte myeloid-leukæmi-stamceller
|
EP2085095B1
(en)
|
2008-01-17 |
2012-03-07 |
Philogen S.p.A. |
Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
|
ES2613963T3
(es)
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
US8133488B2
(en)
|
2008-01-18 |
2012-03-13 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
US8575107B2
(en)
*
|
2008-01-22 |
2013-11-05 |
Compugen Ltd. |
Clusterin derived peptide
|
BRPI0908508A2
(pt)
|
2008-01-24 |
2016-03-22 |
Novo Nordisk As |
anticorpo monoclonal nkg2a anti-humano humanizado
|
CN102037007A
(zh)
|
2008-01-25 |
2011-04-27 |
奥尔胡斯大学 |
选择性外部位点抑制papp-a对igfbp-4的活性
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
JP2011510653A
(ja)
|
2008-01-29 |
2011-04-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
CD161hiおよび/またはIL18Rahiであり、迅速な薬剤流出能力を有するCD8+T細胞の同定
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
WO2009095478A1
(en)
|
2008-01-31 |
2009-08-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
IL287292B
(en)
|
2008-01-31 |
2022-09-01 |
Genentech Inc |
and fusion antibody-drug-cd79b engineered antibodies cysteine-
|
EP2245055A2
(en)
*
|
2008-01-31 |
2010-11-03 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
EP2641612A1
(en)
|
2008-02-05 |
2013-09-25 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
SI2250279T1
(sl)
|
2008-02-08 |
2016-10-28 |
Medimmune, Llc |
Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda
|
GB0802474D0
(en)
*
|
2008-02-11 |
2008-03-19 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for selecting them
|
JP2011511647A
(ja)
*
|
2008-02-13 |
2011-04-14 |
ダイアックス コーポレイション |
特異的結合対を作製するための改善された方法
|
US8461310B2
(en)
|
2008-02-14 |
2013-06-11 |
Gene Techno Science Co., Ltd. |
Anti-ADAM-15 antibodies and utilization of the same
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
DK2250498T3
(da)
|
2008-02-25 |
2013-02-04 |
Nestec Sa |
Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays
|
EP2363407A1
(en)
|
2008-02-28 |
2011-09-07 |
Murdoch University |
Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
WO2009107129A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Ramot At Tel Aviv University Ltd. |
Immunoglobulin compositions and methods of producing same
|
EP2263089B1
(en)
|
2008-03-03 |
2015-01-28 |
GlycoFi, Inc. |
Surface display of recombinant proteins in lower eukaryotes
|
MX2010009722A
(es)
|
2008-03-04 |
2010-09-30 |
Pfizer Ltd |
Procedimiento de tratamiento del dolor cronico.
|
WO2008068534A2
(en)
*
|
2008-03-05 |
2008-06-12 |
Heptares Therapeutics Limited |
Crystal structure of a betal -adremergi c receptor and uses thereof
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
TW200942552A
(en)
*
|
2008-03-06 |
2009-10-16 |
Genentech Inc |
Combination therapy with c-Met and HER antagonists
|
US7982012B2
(en)
*
|
2008-03-10 |
2011-07-19 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
CA2715921A1
(en)
|
2008-03-12 |
2009-09-17 |
Otago Innovation Limited |
Biomarkers
|
DK2265641T3
(en)
*
|
2008-03-12 |
2018-04-23 |
Otago Innovation Ltd |
Biomarkers
|
EP2257634A1
(en)
*
|
2008-03-12 |
2010-12-08 |
Wyeth LLC |
Method for identifying cells suitable for large-scale production of recombinant proteins
|
ES2524312T3
(es)
|
2008-03-14 |
2014-12-05 |
Allergan, Inc. |
Ensayos de actividad de serotipo A de toxina botulínica de base inmunológica
|
PL2842575T3
(pl)
|
2008-03-18 |
2018-02-28 |
Seattle Genetics, Inc. |
Koniugaty aurystatyny lek łącznik
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
EP2105742A1
(en)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Use of cathepsin C
|
CA2719553A1
(en)
|
2008-03-27 |
2009-10-01 |
Spirogene Pty Ltd |
Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
|
EP2260863A1
(en)
|
2008-03-27 |
2010-12-15 |
Takara Bio, Inc. |
Prophylactic/therapeutic agent for infectious disease
|
PL2274008T3
(pl)
|
2008-03-27 |
2014-07-31 |
Zymogenetics Inc |
Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
|
NZ588853A
(en)
*
|
2008-03-31 |
2013-07-26 |
Genentech Inc |
Compositions and methods for treating and diagnosing asthma
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
EP3498307A1
(en)
|
2008-04-02 |
2019-06-19 |
Georgia State University Research Foundation, Inc. |
Contrast agents, methods for preparing contrast agents, and methods of imaging
|
US8835147B2
(en)
|
2008-04-04 |
2014-09-16 |
Massachusetts Institute Of Technology |
Cellular production of glucaric acid through recombinant expression of uronate dehydrogenase and myo-inositol oxygenase
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
EP2279412B1
(en)
|
2008-04-09 |
2017-07-26 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
AU2009234389B2
(en)
|
2008-04-10 |
2014-08-21 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR mutations in cancer
|
CN102144163A
(zh)
|
2008-04-10 |
2011-08-03 |
麻省理工学院 |
关于鉴定和使用靶向癌症干细胞的试剂的方法
|
CN102057054B
(zh)
|
2008-04-11 |
2015-06-10 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
NZ603059A
(en)
*
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
DK2708559T3
(en)
|
2008-04-11 |
2018-06-14 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
|
EP2285449A2
(en)
*
|
2008-04-14 |
2011-02-23 |
Abraxis BioScience, LLC |
Sparc anti-inflammatory activity and uses thereof
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
CA2721506C
(en)
|
2008-04-16 |
2019-09-17 |
Jun Luo |
Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
|
GB0807018D0
(en)
*
|
2008-04-17 |
2008-05-21 |
Fusion Antibodies Ltd |
Antibodies and treatment
|
EP3329931B1
(en)
|
2008-04-18 |
2022-06-08 |
The General Hospital Corporation |
Immunotherapies employing self-assembling vaccines
|
GB0807161D0
(en)
*
|
2008-04-18 |
2008-05-21 |
Danisco |
Process
|
AU2009239558B2
(en)
|
2008-04-21 |
2013-05-02 |
Bio-Rad Laboratories, Inc. |
Recombinant deamidated gliadin antigen
|
CA2721716C
(en)
|
2008-04-24 |
2019-09-24 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
CA2722137C
(en)
|
2008-04-28 |
2019-03-19 |
Kalobios Pharmaceuticals, Inc. |
Antibodies to granulocyte-macrophage colony-stimulating factor
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2280995A2
(en)
*
|
2008-04-29 |
2011-02-09 |
Wyeth LLC |
Methods for treating inflammation
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
EP2281034B1
(en)
|
2008-04-30 |
2015-10-21 |
DuPont Nutrition Biosciences ApS |
Process using Pseudoglucanobacter saccharoketogenes alcohol dehydrogenase
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
US20110229460A1
(en)
*
|
2008-05-01 |
2011-09-22 |
Gtc Biotherapeutics, Inc. |
anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
KR101690590B1
(ko)
|
2008-05-06 |
2016-12-28 |
제넨테크, 인크. |
친화력-성숙 CRIg 변이체
|
EP2116261A1
(en)
|
2008-05-07 |
2009-11-11 |
Institut Pasteur |
Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
|
ES2354661B1
(es)
|
2008-05-08 |
2012-02-01 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos.
|
EP2116555A1
(en)
|
2008-05-08 |
2009-11-11 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
|
US8680025B2
(en)
*
|
2008-05-09 |
2014-03-25 |
Akonni Biosystems, Inc. |
Microarray system
|
BRPI0911758A8
(pt)
|
2008-05-09 |
2017-10-10 |
Abbott Lab |
Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos
|
EP2281057B1
(en)
|
2008-05-09 |
2013-12-25 |
Akonni Biosystems |
Microarray system
|
ES2532896T5
(es)
|
2008-05-14 |
2018-03-20 |
Immatics Biotechnologies Gmbh |
Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
|
US20110111417A1
(en)
|
2008-05-14 |
2011-05-12 |
Millennium Pharmaceuticals, Inc. |
Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
|
EP2291536A4
(en)
|
2008-05-15 |
2013-02-27 |
Selexys Pharmaceuticals Corp |
ANTI-PSGL-1 ANTIBODIES AND METHODS OF IDENTIFICATION AND USE THEREOF
|
PL2279004T3
(pl)
*
|
2008-05-16 |
2015-06-30 |
Hoffmann La Roche |
Zastosowanie biomarkerów do oceny leczenia zaburzeń zapalnych przewodu pokarmowego antagonistami integryny beta7
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
EP2853269B1
(en)
|
2008-05-19 |
2019-05-01 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
WO2009148964A2
(en)
|
2008-05-29 |
2009-12-10 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression and assembly of human group c rotavirus-like particles and uses thereof
|
EP2297208A4
(en)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
NZ589434A
(en)
*
|
2008-06-03 |
2012-11-30 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
WO2010033279A2
(en)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
CA2893175C
(en)
|
2008-06-10 |
2016-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
US8999702B2
(en)
*
|
2008-06-11 |
2015-04-07 |
Emd Millipore Corporation |
Stirred tank bioreactor
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
ES2595362T3
(es)
|
2008-06-16 |
2016-12-29 |
Patrys Limited |
Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
|
WO2009154770A2
(en)
|
2008-06-18 |
2009-12-23 |
The Texas A & M University System |
Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
|
KR20110031343A
(ko)
|
2008-06-20 |
2011-03-25 |
와이어쓰 엘엘씨 |
베타-용혈성 스트렙토코커스 균주로부터 유래된 orf1358을 사용하는 조성물 및 방법
|
US20110123542A1
(en)
*
|
2008-06-24 |
2011-05-26 |
Hadasit Medical Research Services And Development Ltd. |
Ccl20-specific antibodies for cancer therapy
|
DK2732823T3
(da)
|
2008-06-25 |
2019-09-16 |
H Lundbeck As |
Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
|
EP2307571A4
(en)
*
|
2008-06-26 |
2012-03-07 |
Univ South Florida |
PROOF AND SENSITIZATION PROCEDURE FOR THE PLATINUM RESISTANCE OF CANCER DISORDERS
|
EP2138511A1
(en)
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
KR20110025215A
(ko)
|
2008-06-30 |
2011-03-09 |
온코세라피 사이언스 가부시키가이샤 |
방사성 동위원소 표지로 표지된 항―cdh3 항체 및 이의 용도
|
EP2310414B1
(en)
*
|
2008-06-30 |
2016-06-22 |
Dako Denmark A/S |
Pax 5 monoclonal antibody
|
US20110111977A1
(en)
*
|
2008-07-03 |
2011-05-12 |
Pfenex, Inc. |
High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein
|
CA2729949A1
(en)
*
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
WO2010006059A1
(en)
|
2008-07-08 |
2010-01-14 |
Abbott Laboratories |
Prostaglandin e2 binding proteins and uses thereof
|
PL2307459T3
(pl)
|
2008-07-08 |
2015-05-29 |
Oncomed Pharm Inc |
Czynniki wiążące receptor Notch1 i sposoby ich stosowania
|
FR2933702A1
(fr)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
EP2878680B1
(en)
|
2008-07-09 |
2016-06-08 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
|
EP2315779A2
(en)
*
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
US7981627B2
(en)
*
|
2008-07-17 |
2011-07-19 |
Ramot At Tel-Aviv University Ltd. |
Methods for diagnosing and monitoring liver diseases
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
CA2737146A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
CA2732715C
(en)
|
2008-08-01 |
2015-04-07 |
Kusuki Nishioka |
Treatment agent or preventative agent for osteoarthritis
|
EP2815766B1
(en)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Compositions and methods for antibodies targeting complement protein C5
|
WO2010016067A2
(en)
|
2008-08-07 |
2010-02-11 |
Yeda Research And Development Co. Ltd. |
Affinity purification by cohesin-dockerin interaction
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
US20110144311A1
(en)
*
|
2008-08-14 |
2011-06-16 |
Rebecca Chmielowski |
Methods for purifying antibodies using protein a affinity chromatography
|
ES2527943T5
(es)
|
2008-08-14 |
2019-03-07 |
Genentech Inc |
Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas
|
WO2010019120A1
(en)
|
2008-08-15 |
2010-02-18 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
|
EP3121597A1
(en)
|
2008-08-18 |
2017-01-25 |
Mesoblast, Inc. |
Monoclonal antibody stro-4
|
KR101759586B1
(ko)
|
2008-08-22 |
2017-07-19 |
상가모 테라퓨틱스, 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
US20120128684A1
(en)
|
2008-08-25 |
2012-05-24 |
Burnham Institute For Medical Research |
Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
|
EP2318435B1
(en)
|
2008-08-28 |
2015-12-23 |
Taiga Biotechnologies, Inc. |
Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
AU2009288167B2
(en)
*
|
2008-09-03 |
2015-10-22 |
Genentech, Inc. |
Multispecific antibodies
|
AU2008361352B2
(en)
|
2008-09-07 |
2013-05-09 |
Glyconex Inc. |
Anti-extended Type I glycosphingolipid antibody, derivatives thereof and use
|
MX2011002372A
(es)
|
2008-09-10 |
2011-04-04 |
Genentech Inc |
Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
|
US20100129375A1
(en)
|
2008-09-10 |
2010-05-27 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
WO2010029434A1
(en)
*
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
US8927697B2
(en)
*
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
DK2334703T3
(en)
|
2008-09-17 |
2015-10-05 |
Innate Pharma |
Configurations and methods for detection of tlr3
|
SI2331090T1
(en)
|
2008-09-19 |
2018-04-30 |
Pfizer Inc. |
Stable liquid antibody formulation
|
US8658350B2
(en)
|
2008-09-22 |
2014-02-25 |
Oregon Health & Science University |
Methods for detecting Mycobacterium tuberculosis disease
|
WO2010034015A2
(en)
|
2008-09-22 |
2010-03-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Modulating the alternative complement pathway
|
EP2344180A2
(en)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Methods for predicting production of activating signals by cross-linked binding proteins
|
CA2738605A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Luke Anthony O'neill |
Composition and method for treatment of preterm labor
|
DK2342226T3
(en)
|
2008-09-26 |
2016-09-26 |
Dana Farber Cancer Inst Inc |
HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
GB0817891D0
(en)
|
2008-09-30 |
2008-11-05 |
Medical Res Council |
Antibodies against il-25
|
JP5730018B2
(ja)
|
2008-09-30 |
2015-06-03 |
オリエンタル酵母工業株式会社 |
新しい軟骨細胞増殖及び分化誘導剤
|
SI2172211T1
(sl)
|
2008-10-01 |
2015-03-31 |
Immatics Biotechnologies Gmbh |
Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
US8715654B2
(en)
|
2008-10-02 |
2014-05-06 |
Celtaxsys, Inc. |
Methods of modulating the negative chemotaxis of immune cells
|
WO2010042562A2
(en)
|
2008-10-06 |
2010-04-15 |
Minerva Biotechnologies Corporation |
Muc1* antibodies
|
EP2346532B1
(en)
*
|
2008-10-07 |
2020-10-07 |
Bracco Suisse SA |
Targeting construct comprising anti-polymer antibody and microvesicles binding to the same
|
EP2355847A1
(en)
|
2008-10-07 |
2011-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
|
EP4201421A1
(en)
|
2008-10-09 |
2023-06-28 |
Minerva Biotechnologies Corporation |
Method for inducing pluripotency in cells
|
TR201802130T4
(tr)
|
2008-10-10 |
2018-03-21 |
Beth Israel Deaconess Medical Ct Inc |
Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı.
|
WO2010042933A2
(en)
|
2008-10-10 |
2010-04-15 |
Northwestern University |
Inhibition and treatment of prostate cancer metastasis
|
EP2358749B1
(en)
|
2008-10-10 |
2018-07-18 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
PE20110707A1
(es)
|
2008-10-14 |
2011-10-11 |
Genentech Inc |
Variantes de inmunoglobulinas
|
JP5808249B2
(ja)
|
2008-10-20 |
2015-11-10 |
アッヴィ・インコーポレイテッド |
プロテインaアフィニティークロマトグラフィーを用いる抗体の単離および精製
|
SG195557A1
(en)
|
2008-10-22 |
2013-12-30 |
Genentech Inc |
Modulation of axon degeneration
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
EP2349335B1
(en)
|
2008-10-24 |
2013-08-07 |
ARK Diagnostics, Inc. |
Levetiracetam immunoassays
|
EP3351628B1
(en)
|
2008-10-24 |
2023-07-26 |
The Government of The United States of America as represented by The Secretary, Department of Health and Human Services |
Human ebola virus species and compositions and methods thereof
|
EP2346904B1
(en)
|
2008-10-29 |
2017-04-12 |
China Synthetic Rubber Corporation |
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
|
US9393304B2
(en)
|
2008-10-29 |
2016-07-19 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
WO2010096126A1
(en)
|
2008-10-29 |
2010-08-26 |
Bg Medicine, Inc. |
Galectin-3 immunoassay
|
MX2011004558A
(es)
|
2008-10-29 |
2011-06-01 |
Wyeth Llc |
Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US8409567B2
(en)
|
2008-10-31 |
2013-04-02 |
Janssen Biotech, Inc. |
Toll-like receptor 3 antagonists
|
US8574582B2
(en)
*
|
2008-10-31 |
2013-11-05 |
Janssen Biotech, Inc. |
Methods for mediating fibrotic response
|
AU2009313615B2
(en)
|
2008-11-05 |
2012-11-29 |
Regents Of The University Of Minnesota |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
|
EP2346903A1
(en)
*
|
2008-11-06 |
2011-07-27 |
Glenmark Pharmaceuticals S.A. |
Treatment with anti-alpha2 integrin antibodies
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
PT2894165T
(pt)
|
2008-11-10 |
2023-03-17 |
Alexion Pharma Inc |
Métodos e composições para o tratamento de distúrbios associados ao complemento
|
CN102272599B
(zh)
|
2008-11-11 |
2015-01-14 |
密执安大学评议会 |
抗cxcr1组合物和方法
|
US8329188B2
(en)
*
|
2008-11-12 |
2012-12-11 |
Theraclone Sciences, Inc. |
Human M2e peptide immunogens
|
CA2743469C
(en)
|
2008-11-12 |
2019-01-15 |
Medimmune, Llc |
Antibody formulation
|
US8309306B2
(en)
*
|
2008-11-12 |
2012-11-13 |
Nodality, Inc. |
Detection composition
|
CA2742871C
(en)
|
2008-11-13 |
2018-10-23 |
Herb Lin |
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
|
KR20110083730A
(ko)
*
|
2008-11-13 |
2011-07-20 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
Cd37 면역치료제 병용 요법 및 이의 용도
|
WO2010056966A2
(en)
|
2008-11-14 |
2010-05-20 |
Smith Stephen M |
Novel hiv-2 isolate
|
US20110287036A1
(en)
|
2008-11-17 |
2011-11-24 |
Riken |
Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
|
WO2010055525A1
(en)
|
2008-11-17 |
2010-05-20 |
Technion Research & Development Foundation Ltd. |
Method for predicting a patient's responsiveness to anti-folate therapy
|
JP5677972B2
(ja)
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
WO2010058396A1
(en)
|
2008-11-19 |
2010-05-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
A cd44vra antibody and diagnostic and therapeutic methods using same
|
AR074369A1
(es)
*
|
2008-11-20 |
2011-01-12 |
Genentech Inc |
Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
|
DK2189539T4
(en)
*
|
2008-11-21 |
2018-09-17 |
Chimera Biotec Gmbh |
Conjugate complexes for analyte detection
|
DK2361085T4
(en)
|
2008-11-22 |
2018-10-08 |
Hoffmann La Roche |
USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
|
NZ602166A
(en)
|
2008-11-25 |
2014-02-28 |
Alder Biopharmaceuticals Inc |
Antibodies to il-6 and use thereof
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
BRPI0920962A2
(pt)
|
2008-11-26 |
2016-07-12 |
Amgen Inc |
variantes de polipeptídeos receptores de activina iib e usos dos mesmos
|
US20100183620A1
(en)
|
2008-11-26 |
2010-07-22 |
Kaumudi Bhawe |
Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
|
US8211434B2
(en)
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
WO2010061393A1
(en)
|
2008-11-30 |
2010-06-03 |
Compugen Ltd. |
He4 variant nucleotide and amino acid sequences, and methods of use thereof
|
US20120070443A1
(en)
|
2008-12-02 |
2012-03-22 |
University Of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
AR074439A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
US8545839B2
(en)
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
EP2374813A1
(en)
|
2008-12-03 |
2011-10-12 |
Proyecto de Biomedicina Cima, S.L. |
Use of phenol-soluble modulins for vaccine development
|
US20110287088A1
(en)
|
2008-12-03 |
2011-11-24 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
CA2743707A1
(en)
|
2008-12-04 |
2010-06-10 |
Pioneer Hi-Bred International, Inc. |
Methods and compositions for enhanced yield by targeted expression of knotted1
|
SG171812A1
(en)
*
|
2008-12-04 |
2011-07-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
KR101413480B1
(ko)
|
2008-12-05 |
2014-07-10 |
아브락시스 바이오사이언스, 엘엘씨 |
Sparc 결합 펩티드와 이들의 용도
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US20110044990A1
(en)
*
|
2008-12-05 |
2011-02-24 |
Sabbadini Roger A |
Antibody design using anti-lipid antibody crystal structures
|
US20120009123A1
(en)
|
2008-12-05 |
2012-01-12 |
Abraxis Bioscience, Llc |
Albumin binding peptide-mediated disease targeting
|
EP2865689A1
(en)
|
2008-12-08 |
2015-04-29 |
Compugen Ltd. |
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
CN108997498A
(zh)
|
2008-12-09 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
WO2010074702A1
(en)
|
2008-12-16 |
2010-07-01 |
Millipore Corporation |
Purification of proteins
|
DK2370561T3
(da)
|
2008-12-16 |
2019-10-21 |
Emd Millipore Corp |
Omrøringstankreaktor og fremgangsmåde
|
US20100151457A1
(en)
|
2008-12-17 |
2010-06-17 |
National Tsing Hua University |
Detection of Unhealthy Cell and Uses Thereof
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
US20100159485A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Centre For Dna Fingerprinting And Diagnostics |
Detection of mycobacterium tuberculosis
|
GB0823309D0
(en)
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
US8703125B2
(en)
|
2008-12-19 |
2014-04-22 |
H. Lundbeck A/S |
Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
|
WO2010078916A1
(en)
|
2008-12-19 |
2010-07-15 |
Philogen S.P.A. |
Immunocytokines for tumour therapy with chemotherapeutic agents
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
EP2379710A1
(en)
|
2008-12-19 |
2011-10-26 |
Schering Corporation |
Feed supplement for mammalian cell culture and methods of use
|
RU2535032C2
(ru)
|
2008-12-22 |
2014-12-10 |
Милленниум Фармасьютикалз, Инк. |
Сочетание ингибиторов аврора киназы и анти-cd 20 антител
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
EP3318573A1
(en)
|
2008-12-23 |
2018-05-09 |
F. Hoffmann-La Roche AG |
Mmunoglobulin variants with altered binding to protein a
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
SG172355A1
(en)
|
2008-12-23 |
2011-07-28 |
Genentech Inc |
Methods and compositions for diagnostic use in cancer patients
|
WO2010075540A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
EP2376526A4
(en)
|
2008-12-24 |
2013-02-27 |
Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M |
MODIFIED STREPTOCOCCUS PNEUMONIAE PNEUMOLYSIN (PLY) POLYPEPTIDE
|
EP2376653A2
(en)
|
2008-12-29 |
2011-10-19 |
Yissum Research Development Company of The Hebrew University of Jerusalem |
Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
|
WO2010078376A2
(en)
|
2008-12-30 |
2010-07-08 |
Ventana Medical Systems, Inc. |
Fc-specific polymer-conjugated antibodies and their diagnostic use
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
WO2010080769A2
(en)
|
2009-01-06 |
2010-07-15 |
Arresto Biosciences, Inc. |
Chemotherapeutic methods and compositions
|
WO2010078950A2
(en)
|
2009-01-07 |
2010-07-15 |
Philogen S.P.A. |
Antigens associated with endometriosis, psoriatic arthritis and psoriasis
|
US20110318302A1
(en)
|
2009-01-07 |
2011-12-29 |
Kathrin Schwager |
Cancer Treatment
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
AU2010204139A1
(en)
|
2009-01-12 |
2011-08-11 |
Novartis Ag |
Cna_B domain antigens in vaccines against gram positive bacteria
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
JP2012515158A
(ja)
|
2009-01-12 |
2012-07-05 |
武田薬品工業株式会社 |
癌の予防・治療剤
|
ES2568509T3
(es)
|
2009-01-15 |
2016-04-29 |
Adaptive Biotechnologies Corporation |
Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
|
KR20110114664A
(ko)
*
|
2009-01-16 |
2011-10-19 |
메사추세츠 인스티튜트 오브 테크놀로지 |
자폐 스펙트럼 장애의 진단 및 치료
|
US8492133B2
(en)
|
2009-01-20 |
2013-07-23 |
Ramot At Tel Aviv University, Ltd. |
MIR-21 promoter driven targeted cancer therapy
|
EP2389195B1
(en)
|
2009-01-20 |
2015-05-20 |
Homayoun H. Zadeh |
Antibody mediated osseous regeneration
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
WO2010085345A1
(en)
|
2009-01-22 |
2010-07-29 |
Ludwig Institute For Cancer Research Ltd. |
Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies
|
DK2389587T3
(en)
|
2009-01-26 |
2014-03-03 |
Electrophoretics Ltd |
Diagnostic and prognostic methods related Alzheimer's Disease
|
RU2011135768A
(ru)
*
|
2009-01-29 |
2013-03-10 |
Эбботт Лэборетриз |
Белки, связывающие il-1
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
CA2746128C
(en)
|
2009-01-30 |
2020-07-28 |
Pronota N.V. |
Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
|
EP2219029A1
(en)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Test systems, methods and uses involving AS160 protein
|
WO2010088522A2
(en)
|
2009-01-30 |
2010-08-05 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and uses therefor
|
EP2391714B2
(en)
|
2009-01-30 |
2019-07-24 |
Whitehead Institute for Biomedical Research |
Methods for ligation and uses thereof
|
WO2010086382A1
(en)
|
2009-01-30 |
2010-08-05 |
Pronota N.V. |
Target for treatment of acute heart failure
|
WO2010086386A1
(en)
|
2009-01-30 |
2010-08-05 |
Pronota N.V. |
Protein quantification methods and use thereof for candidate biomarker validation
|
WO2010086384A1
(en)
|
2009-01-30 |
2010-08-05 |
Pronota N.V. |
Target for treatment of acute heart failure
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US8309530B2
(en)
*
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
WO2010091182A2
(en)
|
2009-02-04 |
2010-08-12 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
EP2393515A1
(en)
|
2009-02-04 |
2011-12-14 |
Kalobios Pharmaceuticals, Inc. |
Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
|
US9079942B2
(en)
*
|
2009-02-09 |
2015-07-14 |
Epitomics, Inc. |
CDR-anchored amplification method
|
EP2393787B1
(en)
|
2009-02-09 |
2018-01-24 |
Georgetown University |
Cadherin-11 inhibitors and methods of use thereof
|
US20100233733A1
(en)
*
|
2009-02-10 |
2010-09-16 |
Nodality, Inc., A Delaware Corporation |
Multiple mechanisms for modulation of the pi3 kinase pathway
|
EP3722810A3
(en)
|
2009-02-11 |
2021-01-13 |
Caris MPI, Inc. |
Molecular profiling of tumors
|
WO2010093450A2
(en)
|
2009-02-11 |
2010-08-19 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
NO2396652T3
(xx)
|
2009-02-11 |
2018-05-12 |
|
|
WO2010093814A1
(en)
|
2009-02-11 |
2010-08-19 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating dementia using a gm-csf antagonist
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
ES2637174T3
(es)
|
2009-02-12 |
2017-10-11 |
Cell Signaling Technology, Inc. |
Expresión de ROS mutante en el cáncer de hígado humano
|
RU2532222C2
(ru)
|
2009-02-16 |
2014-10-27 |
Серенис Терапьютикс Холдинг С.А, |
Миметики аполипопротеина а-i
|
US20110306069A1
(en)
|
2009-02-19 |
2011-12-15 |
Qingyu Wu |
Corin As A Marker For Heart Failure
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
RU2011138951A
(ru)
|
2009-02-23 |
2013-03-27 |
Сайтомкс Терапьютикс, Инк. |
Пропротеины и способы их применения
|
EP2399937B1
(en)
|
2009-02-23 |
2016-04-27 |
Gene Techno Science Co., Ltd. |
Anti-human alpha9 integrin antibody and use thereof
|
WO2010098166A1
(ja)
|
2009-02-24 |
2010-09-02 |
国立大学法人宮崎大学 |
細胞接着阻害剤およびその用途
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
US20120003695A1
(en)
|
2009-02-25 |
2012-01-05 |
Davidson Robert C |
Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
|
GB0903151D0
(en)
|
2009-02-25 |
2009-04-08 |
Bioinvent Int Ab |
Antibody uses and methods
|
GB0903168D0
(en)
|
2009-02-25 |
2009-04-08 |
Fusion Antibodies Ltd |
Diagnostic method and kit
|
US20100292443A1
(en)
*
|
2009-02-26 |
2010-11-18 |
Sabbadini Roger A |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
CA2752884A1
(en)
|
2009-02-27 |
2010-09-02 |
Genentech, Inc. |
Methods and compositions for protein labelling
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
US8648176B2
(en)
|
2009-02-27 |
2014-02-11 |
Massachusetts Institute Of Technology |
Engineered proteins with high affinity for DOTA chelates
|
WO2010100056A2
(en)
|
2009-03-02 |
2010-09-10 |
Stichting Top Institute Pharma |
Antibodies against a proliferating inducing ligand (april)
|
WO2010101818A1
(en)
|
2009-03-02 |
2010-09-10 |
Pioneer Hi-Bred International, Inc. |
Nac transcriptional activators involved in abiotic stress tolerance
|
US20100227335A1
(en)
|
2009-03-05 |
2010-09-09 |
Becton, Dickinson And Company |
Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
EP2403531A4
(en)
|
2009-03-05 |
2013-02-27 |
Abbott Lab |
IL-17 BINDING PROTEINS
|
EA028336B1
(ru)
|
2009-03-05 |
2017-11-30 |
МЕДАРЕКС Л.Л.Си. |
Полностью человеческие антитела, специфические в отношении cadm1
|
US8568732B2
(en)
|
2009-03-06 |
2013-10-29 |
Novartis Ag |
Chlamydia antigens
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
US9599591B2
(en)
|
2009-03-06 |
2017-03-21 |
California Institute Of Technology |
Low cost, portable sensor for molecular assays
|
CA2753713A1
(en)
|
2009-03-06 |
2010-09-10 |
Tripath Imaging, Inc |
Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
WO2010102244A1
(en)
|
2009-03-06 |
2010-09-10 |
Kalobios Pharmaceuticals, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
CA2753282C
(en)
|
2009-03-10 |
2017-11-28 |
Med Discovery Sa |
Use of serine protease inhibitors in the treatment of neutropenia
|
EP2406285B1
(en)
|
2009-03-10 |
2016-03-09 |
Gene Techno Science Co., Ltd. |
Generation, expression and characterization of the humanized k33n monoclonal antibody
|
JP2010213694A
(ja)
|
2009-03-12 |
2010-09-30 |
Wyeth Llc |
PKN3/RhoC高分子複合体およびその使用方法
|
SG174353A1
(en)
|
2009-03-13 |
2011-11-28 |
Allergan Inc |
Immuno-based retargeted endopeptidase activity assays
|
GB0904355D0
(en)
|
2009-03-13 |
2009-04-29 |
Imp Innovations Ltd |
Biological materials and uses thereof
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP2409155A1
(en)
|
2009-03-15 |
2012-01-25 |
Technion Research and Development Foundation, Ltd. |
Soluble hla complexes for use in disease diagnosis
|
EP2230515B1
(en)
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivation of surfaces after ligand coupling
|
EP2408818A1
(en)
|
2009-03-17 |
2012-01-25 |
Université de la Méditerranée |
Btla antibodies and uses thereof
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
US20100286762A1
(en)
*
|
2009-03-18 |
2010-11-11 |
Musc Foundation For Research Development |
Compositions and Methods for Ameliorating Clinical Electrical Disturbances
|
EP2408468B1
(en)
|
2009-03-19 |
2014-04-30 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
USE OF NKp46 FOR PREVENTING TYPE 1 DIABETES
|
TWI461211B
(zh)
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
MX338969B
(es)
|
2009-03-20 |
2016-05-06 |
Amgen Inc |
Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
|
MX347291B
(es)
|
2009-03-20 |
2017-04-17 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
CN201397956Y
(zh)
*
|
2009-03-23 |
2010-02-03 |
富士康(昆山)电脑接插件有限公司 |
电连接器组件
|
WO2010111198A1
(en)
|
2009-03-23 |
2010-09-30 |
Quark Pharmaceuticals, Inc. |
Compounds compositions and methods of treating cancer and fibrotic diseases
|
US8242248B2
(en)
*
|
2009-03-23 |
2012-08-14 |
Nodality, Inc. |
Kits for multiparametric phospho analysis
|
WO2010108926A1
(en)
|
2009-03-24 |
2010-09-30 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method for diagnosing or predicting a non syndromic autosomal recessive optic atrophy, or a risk of a non syndromic autosomal recessive optic atrophy.
|
AU2010228990A1
(en)
|
2009-03-24 |
2011-10-27 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against LIGHT and uses thereof
|
JP6159528B2
(ja)
|
2009-03-24 |
2017-07-05 |
ワイス・エルエルシー |
高濃縮のタンパク質治療薬を生成するための膜蒸発
|
US8124740B2
(en)
|
2009-03-25 |
2012-02-28 |
Genentech, Inc. |
Anti- α5 β1 antibodies and uses thereof
|
HUE061117T2
(hu)
|
2009-03-25 |
2023-05-28 |
Genentech Inc |
Anti-FGFR3 antitestek és eljárások alkalmazásukra
|
EP2411050A4
(en)
|
2009-03-25 |
2013-07-17 |
Vet Therapeutics Inc |
ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
|
JP2012522017A
(ja)
|
2009-03-26 |
2012-09-20 |
クアンタム イミュノロジクス, インコーポレイテッド |
診断適用および臨床適用のための癌胎児抗原/未熟ラミニン受容体抗体
|
CN102510756A
(zh)
*
|
2009-03-26 |
2012-06-20 |
昆腾免疫有限公司 |
用于癌症治疗的致敏树突状细胞的癌胚胎抗原/未成熟层粘连蛋白受体肽
|
ES2607935T3
(es)
|
2009-03-30 |
2017-04-04 |
Portola Pharmaceuticals, Inc. |
Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
|
WO2010113096A1
(en)
|
2009-03-30 |
2010-10-07 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Methods of predicting clinical course and treating multiple sclerosis
|
CA2757114C
(en)
|
2009-03-30 |
2019-05-21 |
Universite De Lausanne |
Preparation of isolated agonist anti-edar monoclonal antibodies
|
WO2010112033A2
(en)
|
2009-03-31 |
2010-10-07 |
Østjysk Innovation A/S |
Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
EP2413967A1
(en)
|
2009-04-01 |
2012-02-08 |
F. Hoffmann-La Roche AG |
Treatment of insulin-resistant disorders
|
EP2344179A1
(en)
|
2009-04-01 |
2011-07-20 |
The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center |
A method of regulating proliferation and differentiation of keratinocyes
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
GB0905972D0
(en)
|
2009-04-06 |
2009-05-20 |
Medical Res Council |
Antibodies against IL-17BR
|
CA2762187C
(en)
|
2009-04-08 |
2017-08-01 |
Olle Hernell |
New methods for treatment of inflammatory diseases
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
WO2010116375A1
(en)
|
2009-04-08 |
2010-10-14 |
Yeda Research And Development Co. Ltd. |
Isolated peptides for regulating apoptosis
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
US20120121706A1
(en)
|
2009-04-10 |
2012-05-17 |
Tufts Medical Center, Inc. |
PAR-1 Activation by Metalloproteinase-1 (MMP-1)
|
PL2510947T3
(pl)
|
2009-04-14 |
2016-09-30 |
|
Kompozycje do immunizacji przeciwko Staphylococcus aureus
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
CA2758964A1
(en)
|
2009-04-16 |
2010-10-21 |
Abbott Biotherapeutics Corp. |
Anti-tnf-.alpha. antibodies and their uses
|
MX2011010971A
(es)
*
|
2009-04-17 |
2012-01-19 |
Biogen Idec Inc |
Composiciones y metodos para tratar leucemia mielogena aguda.
|
JP5822822B2
(ja)
|
2009-04-17 |
2015-11-24 |
ニューヨーク ユニバーシティ |
Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用
|
WO2010121093A2
(en)
*
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
JP5836929B2
(ja)
|
2009-04-18 |
2015-12-24 |
ジェネンテック, インコーポレイテッド |
抗cd40抗体を用いる治療に対するb細胞性リンパ腫の応答性を評価するための方法
|
CA2759538C
(en)
|
2009-04-20 |
2018-07-24 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
FI20090161A0
(fi)
|
2009-04-22 |
2009-04-22 |
Faron Pharmaceuticals Oy |
Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
|
ES2693165T3
(es)
|
2009-04-23 |
2018-12-07 |
Siemens Healthcare Diagnostics Inc. |
Formas monoméricas y diméricas de fragmentos de receptores de adiponectina y métodos de uso
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
WO2010124163A2
(en)
*
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
EP2421559B1
(en)
|
2009-04-24 |
2016-07-20 |
Vanderbilt University |
Anti-tgf-beta induction of bone growth
|
GB0908770D0
(en)
|
2009-04-24 |
2009-07-01 |
Danisco |
Method
|
EP2424567B1
(en)
*
|
2009-04-27 |
2018-11-21 |
OncoMed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
US8741581B2
(en)
|
2009-04-27 |
2014-06-03 |
Technion Research And Development Foundation Ltd. |
Markers for cancer detection
|
EP2949673A1
(en)
|
2009-04-27 |
2015-12-02 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-il-3ra antibody for use in treatment of blood tumor
|
MA33279B1
(fr)
|
2009-04-27 |
2012-05-02 |
Novartis Ag |
Compositions et procédés pour l'augmentation de la croissance des muscles
|
WO2010126590A1
(en)
|
2009-04-27 |
2010-11-04 |
Cold Spring Harbor Laboratory |
Ptp1b inhibitors
|
EA201101572A1
(ru)
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
JP5727463B2
(ja)
|
2009-04-29 |
2015-06-03 |
ヤンセン バイオテツク,インコーポレーテツド |
Toll様受容体3アンタゴニスト
|
US8367350B2
(en)
|
2009-04-29 |
2013-02-05 |
Morehouse School Of Medicine |
Compositions and methods for diagnosis, prognosis and management of malaria
|
EP2424891B1
(en)
|
2009-04-29 |
2014-06-11 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Erg monoclonal antibodies
|
US9018358B2
(en)
|
2009-04-30 |
2015-04-28 |
University Of Rochester |
DC-STAMP antibodies
|
PT2424896E
(pt)
|
2009-04-30 |
2015-11-30 |
Univ Ramot |
Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
|
CA2760687A1
(en)
|
2009-05-01 |
2010-11-04 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
PL2448970T3
(pl)
|
2009-05-04 |
2014-12-31 |
Abbvie Res B V |
Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
DK3248610T3
(da)
*
|
2009-05-05 |
2024-01-15 |
Amgen Inc |
Fgf21-mutanter og anvendelser deraf
|
CN104974250A
(zh)
|
2009-05-05 |
2015-10-14 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
US9023767B2
(en)
*
|
2009-05-07 |
2015-05-05 |
Memorial Sloan-Kettering Cancer Center |
γ-Secretase substrates and methods of use
|
WO2010129609A2
(en)
|
2009-05-07 |
2010-11-11 |
The Regents Of The University Of California |
Antibodies and methods of use thereof
|
US8187885B2
(en)
*
|
2009-05-07 |
2012-05-29 |
Nodality, Inc. |
Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
|
US9187568B2
(en)
|
2009-05-07 |
2015-11-17 |
Stallergenes S.A. |
Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
|
EP2270053A1
(en)
|
2009-05-11 |
2011-01-05 |
U3 Pharma GmbH |
Humanized AXL antibodies
|
CA2939492C
(en)
|
2009-05-13 |
2019-03-19 |
Genzyme Corporation |
Anti-human cd52 immunoglobulins
|
CN102482345A
(zh)
|
2009-05-13 |
2012-05-30 |
航道生物技术有限责任公司 |
针对流感病毒的中和分子
|
AR076875A1
(es)
|
2009-05-15 |
2011-07-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo contra receptor de la tirosina quinasa (anti-axl)
|
US20100291706A1
(en)
|
2009-05-15 |
2010-11-18 |
Millipore Corporation |
Dye conjugates and methods of use
|
GB0908425D0
(en)
|
2009-05-15 |
2009-06-24 |
Medical Res Council |
Medical use
|
MX2011012313A
(es)
|
2009-05-19 |
2011-12-12 |
Danisco |
Uso.
|
US8921281B2
(en)
*
|
2009-05-20 |
2014-12-30 |
Novimmune S.A. |
Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
|
CA2682429A1
(en)
*
|
2009-05-20 |
2010-11-20 |
Gary Levy |
An assay for measuring plasma fgl-2 and methods and uses thereof
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
WO2010136168A2
(en)
|
2009-05-25 |
2010-12-02 |
Merck Patent Gmbh |
Continuous administration of integrin ligands for treating cancer
|
EP2435476A4
(en)
|
2009-05-27 |
2013-04-17 |
Synageva Biopharma Corp |
ANTIBODIES OBTAINED FROM BIRDS
|
US9989533B2
(en)
|
2009-05-28 |
2018-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Anti-TNF induced apoptosis (ATIA) diagnostic markers and therapies
|
ES2533343T3
(es)
*
|
2009-05-28 |
2015-04-09 |
Abraxis Bioscience, Llc |
Uso de 2 anticuerpos anti-SPARC para predecir la respuesta a quimioterapia
|
US20120070449A1
(en)
|
2009-05-28 |
2012-03-22 |
Yeda Research And Development Co. Ltd. |
Methods of treating inflammation
|
EP2435071A1
(en)
|
2009-05-29 |
2012-04-04 |
F. Hoffmann-La Roche AG |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US8680055B2
(en)
|
2009-06-03 |
2014-03-25 |
University Of Southern California |
Methods for decreasing steroidogenesis in prostate cancer cells
|
CN106390107B
(zh)
|
2009-06-10 |
2019-12-31 |
纽约大学 |
病理tau蛋白的免疫靶向
|
US20100317539A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Guo-Liang Yu |
Library of Engineered-Antibody Producing Cells
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
UA104626C2
(ru)
|
2009-06-17 |
2014-02-25 |
Эббви Биотерапеутикс Инк. |
Анти-vegf антитело и его применение
|
WO2010148117A1
(en)
|
2009-06-17 |
2010-12-23 |
Scantibodies Laboratory, Inc. |
Therapeutic and diagnostic affinity purified specific polyclonal antibodies
|
EP2443145A1
(en)
*
|
2009-06-17 |
2012-04-25 |
Amgen, Inc |
Chimeric fgf19 polypeptides and uses thereof
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
US20120087926A1
(en)
|
2009-06-18 |
2012-04-12 |
Basf Coatings Gmbh |
Chicken-derived anti-lox-1 antibody
|
US9090690B2
(en)
|
2009-06-18 |
2015-07-28 |
Pfizer Inc. |
Anti Notch-1 antibodies
|
GB0910620D0
(en)
|
2009-06-19 |
2009-08-05 |
Immunovia Ab |
Agents and uses thereof
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
GB0910725D0
(en)
|
2009-06-22 |
2009-08-05 |
Heptares Therapeutics Ltd |
Mutant proteins and methods for producing them
|
JP2012531423A
(ja)
|
2009-06-24 |
2012-12-10 |
エルパス, インコーポレーテッド |
リゾホスファチジン酸に対する抗体を用いたニューロン分化の増加法
|
AU2010265964B2
(en)
|
2009-06-25 |
2014-09-18 |
Horizon Therapeutics Usa, Inc. |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
|
CA2766009A1
(en)
|
2009-06-25 |
2010-12-29 |
Danisco A/S |
Variant lipolytic enzymes with improved expression, functionality and/or activity
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
WO2010151664A2
(en)
|
2009-06-26 |
2010-12-29 |
Massachusetts Institute Of Technology |
Compositions and methods for treating cancer and modulating stress granule formation
|
US8435961B2
(en)
*
|
2009-06-26 |
2013-05-07 |
Massachusetts Institute Of Technology |
Methods and compositions for increasing the activity of inhibitory RNA
|
US8268550B2
(en)
*
|
2009-06-26 |
2012-09-18 |
Massachusetts Institute Of Technology |
Compositions and methods for identification of PARP function, inhibitors, and activators
|
WO2011000384A1
(ru)
|
2009-06-30 |
2011-01-06 |
Общество С Ограниченной Ответсвенностью "Онкомакс" |
Способ подавления роста опухоли путем блокирования рецептора фактора роста фибробластов, способ диагностики злокачественных новообразований
|
EP2272979A1
(en)
|
2009-06-30 |
2011-01-12 |
Centre National de la Recherche Scientifique (CNRS) |
Method for testing a subject thought to be predisposed to having cancer
|
CA2766065C
(en)
*
|
2009-06-30 |
2020-07-21 |
Research Development Foundation |
Immunoglobulin fc polypeptides
|
WO2011001276A1
(en)
|
2009-06-30 |
2011-01-06 |
Philogen S.P.A. |
Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
|
EP2448961A2
(en)
|
2009-06-30 |
2012-05-09 |
Université de Liège |
Targets for retrovirus associated diseases
|
WO2011003100A2
(en)
|
2009-07-02 |
2011-01-06 |
Massachusetts Institute Of Technology |
Compositions and methods for diagnosing and/or treating influenza infection
|
EP2453906A4
(en)
|
2009-07-02 |
2014-01-15 |
Musc Found For Res Dev |
METHOD FOR STIMULATING THE LIVER REGENERATION
|
EP2448966B1
(en)
|
2009-07-03 |
2018-11-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
CN102471381A
(zh)
|
2009-07-07 |
2012-05-23 |
霍夫曼-拉罗奇有限公司 |
自身免疫性脱髓鞘疾病的诊断和治疗
|
CA2766861A1
(en)
|
2009-07-09 |
2011-01-13 |
F. Hoffmann-La Roche Ag |
In vivo tumor vasculature imaging
|
WO2011006001A1
(en)
|
2009-07-09 |
2011-01-13 |
Genentech, Inc. |
Animal model for the evaluation of adjuvant therapies of cancer
|
RU2562865C2
(ru)
|
2009-07-10 |
2015-09-10 |
Иннэйт Фарма |
Tlr3 связывающие агенты
|
WO2011004379A1
(en)
|
2009-07-10 |
2011-01-13 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Compositions and methods for treating cancer
|
AU2010273585B2
(en)
|
2009-07-13 |
2015-04-23 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
EP2454373B1
(en)
*
|
2009-07-15 |
2014-11-19 |
AbbVie Inc. |
Enhancement of cellular production through mechanotransduction
|
EP2454598B1
(en)
|
2009-07-15 |
2017-03-22 |
DiaTech Holdings, Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
WO2011008885A1
(en)
|
2009-07-15 |
2011-01-20 |
Portola Pharmaceuticals, Inc. |
Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
|
US20110033486A1
(en)
|
2009-07-20 |
2011-02-10 |
Abbas Alexander R |
Gene expression markers for crohn's disease
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
US8765431B2
(en)
*
|
2009-07-23 |
2014-07-01 |
The Regents Of The University Of Michigan |
Method for enzymatic production of decarboxylated polyketides and fatty acids
|
WO2011011062A2
(en)
|
2009-07-24 |
2011-01-27 |
Akonni Biosystems |
Flow cell device
|
CA2767914C
(en)
|
2009-07-24 |
2020-02-25 |
Geadic Biotec, Aie. |
Markers for endometrial cancer
|
BR112012001463A2
(pt)
|
2009-07-24 |
2016-03-15 |
Univ California |
métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP2459184A1
(en)
|
2009-07-31 |
2012-06-06 |
The Brigham and Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
NZ597531A
(en)
|
2009-07-31 |
2014-05-30 |
Genentech Inc |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
US20120231013A1
(en)
|
2009-07-31 |
2012-09-13 |
Black Roy A |
Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
MY161541A
(en)
|
2009-07-31 |
2017-04-28 |
Shin Maeda |
Cancer metastasis inhibitor
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
EP2459594A1
(en)
|
2009-07-31 |
2012-06-06 |
N.V. Organon |
Fully human antibodies to btla
|
BR112012002460A2
(pt)
|
2009-08-04 |
2016-11-08 |
Hoffmann La Roche |
anticorpo marcador de célula beta
|
WO2011017492A2
(en)
|
2009-08-05 |
2011-02-10 |
Pioneer Hi-Bred International, Inc. |
Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
|
ES2712997T3
(es)
|
2009-08-05 |
2019-05-17 |
Philogen Spa |
Selección como diana de neovasculatura de médula ósea
|
KR20190018041A
(ko)
|
2009-08-06 |
2019-02-20 |
제넨테크, 인크. |
단백질 정제 시의 바이러스 제거의 개선방법
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
IN2012DN00338A
(xx)
*
|
2009-08-07 |
2015-05-22 |
Millipore Corp |
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
SG178358A1
(en)
|
2009-08-11 |
2012-03-29 |
Genentech Inc |
Production of proteins in glutamine-free cell culture media
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
WO2011020079A1
(en)
*
|
2009-08-13 |
2011-02-17 |
Calmune Corporation |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
EP3381937A3
(en)
|
2009-08-13 |
2018-10-31 |
The Johns Hopkins University |
Methods of modulating immune function
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
MX2012001716A
(es)
|
2009-08-14 |
2012-04-02 |
Genentech Inc |
Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
|
WO2011020107A2
(en)
|
2009-08-14 |
2011-02-17 |
Georgetown University |
Compositions and methods for detection and treatment of breast cancer
|
AR077848A1
(es)
|
2009-08-15 |
2011-09-28 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
EP2467156B1
(en)
|
2009-08-17 |
2017-11-01 |
Tracon Pharmaceuticals, Inc. |
Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
|
GB0914446D0
(en)
|
2009-08-18 |
2009-09-30 |
King S College London |
Bioconjugates and their uses in imaging
|
US9163086B2
(en)
|
2009-08-18 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods and compositions for the treatment of proliferative and pathogenic diseases
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
GB2472856B
(en)
|
2009-08-21 |
2012-07-11 |
Cantargia Ab |
IL1-RAP modulators and uses thereof
|
RU2012110587A
(ru)
*
|
2009-08-21 |
2013-09-27 |
Джилид Байолоджикс, Инк. |
Терапевтические способы и композиции
|
AU2010284000A1
(en)
*
|
2009-08-21 |
2012-03-22 |
Gilead Biologics, Inc. |
In vitro screening assays
|
WO2011022667A2
(en)
|
2009-08-21 |
2011-02-24 |
Arresto Biosciences, Inc |
Catalytic domains from lysyl oxidase and loxl2
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
AU2010284039A1
(en)
*
|
2009-08-21 |
2012-03-22 |
Gilead Biologics, Inc. |
In vivo screening assays
|
WO2011022670A1
(en)
*
|
2009-08-21 |
2011-02-24 |
Arresto Biosciences, Inc |
In vivo screening assays
|
RU2016133412A
(ru)
|
2009-08-24 |
2018-12-10 |
Фидженикс, Инк. |
Целенаправленное воздействие на pax2 для лечения рака молочной железы
|
BR112012007877A2
(pt)
|
2009-08-26 |
2019-09-24 |
Medizinische Hochschule Hannover |
meios e métodos para produção de polissacarídeos capsulares artificiais de neisseria meningitidis
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
EP3165236B1
(en)
|
2009-08-28 |
2022-03-16 |
Teva Pharmaceuticals International GmbH |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
CN102002104A
(zh)
|
2009-08-28 |
2011-04-06 |
江苏先声药物研究有限公司 |
一种抗vegf的单克隆抗体及含有该抗体的药物组合物
|
MX2012002605A
(es)
*
|
2009-08-29 |
2012-04-02 |
Abbott Lab |
Proteinas terapeutico de union a dll4.
|
AU2010288469A1
(en)
|
2009-08-31 |
2012-03-01 |
Roche Glycart Ag |
Affinity-matured humanized anti CEA monoclonal antibodies
|
EP2293072A1
(en)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Use of cathepsin H
|
AU2010286351A1
(en)
|
2009-08-31 |
2012-03-15 |
Amplimmune, Inc. |
B7-H4 fusion proteins and methods of use thereof
|
US20120283115A1
(en)
|
2009-08-31 |
2012-11-08 |
Ludwig Institute For Cancer Research Ltd. |
Seromic analysis of ovarian cancer
|
BR112012004710A2
(pt)
*
|
2009-09-01 |
2016-08-16 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e uso das mesmas
|
MX2012002565A
(es)
|
2009-09-01 |
2012-05-29 |
Genentech Inc |
Purificacion de proteina mejorada a traves de una elucion de proteina a modificada.
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US8178307B2
(en)
|
2009-09-02 |
2012-05-15 |
National Tsing Hua University |
Methods and compositions for detection of lethal cell and uses thereof
|
MX2012002766A
(es)
|
2009-09-03 |
2012-04-02 |
Genentech Inc |
Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
US20120171213A1
(en)
|
2009-09-10 |
2012-07-05 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Method of treating tumors
|
EP2475388B1
(en)
|
2009-09-10 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Use of il-33 antagonists to treat fibrotic disease
|
CN102655882B
(zh)
|
2009-09-11 |
2014-11-19 |
美国政府健康及人类服务部 |
具有降低的免疫原性的改进的假单胞菌外毒素a
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
US8293483B2
(en)
*
|
2009-09-11 |
2012-10-23 |
Epitomics, Inc. |
Method for identifying lineage-related antibodies
|
CA2773662A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
PL2477656T3
(pl)
|
2009-09-15 |
2017-09-29 |
Csl Limited |
Leczenie stanów neurologicznych
|
NZ598962A
(en)
|
2009-09-16 |
2014-12-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
WO2011033006A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
AU2010295324B2
(en)
|
2009-09-18 |
2015-04-30 |
Abraxis Bioscience, Llc |
Use of the SPARC microenvironment signature in the treatment of cancer
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
US20120178910A1
(en)
|
2009-09-23 |
2012-07-12 |
Medarex, Inc. |
Cation exchange chromatography (methods)
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8926976B2
(en)
*
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2480892A1
(en)
|
2009-09-25 |
2012-08-01 |
Origene Technologies, Inc. |
Protein arrays and uses thereof
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
GB0917054D0
(en)
|
2009-09-29 |
2009-11-11 |
Cytoguide As |
Agents, uses and methods
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
EP2484694B1
(en)
|
2009-09-30 |
2014-12-17 |
Ishihara Sangyo Kaisha, Ltd. |
Monoclonal antibody against human hig-1 polypeptide
|
WO2011041336A2
(en)
|
2009-09-30 |
2011-04-07 |
Genentech, Inc. |
Methods of treating cancer using notch antagonists
|
WO2011038894A1
(en)
|
2009-10-01 |
2011-04-07 |
F. Hoffmann-La Roche Ag |
Protein a chromatography
|
CA2776037A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
EP2483424B1
(en)
|
2009-10-02 |
2013-12-04 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method for the diagnosis/prognosis of age-related macular degeneration
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
JP2013507365A
(ja)
|
2009-10-07 |
2013-03-04 |
サンフォード−バーナム メディカル リサーチ インスティテュート |
血餅結合脂質化合物に関する方法および組成物
|
RU2016131167A
(ru)
|
2009-10-07 |
2018-12-07 |
Дженентек, Инк. |
Способы лечения, диагностики и мониторинга волчанки
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
WO2011045704A1
(en)
|
2009-10-12 |
2011-04-21 |
Pfizer Inc. |
Cancer treatment
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
PT2488554T
(pt)
|
2009-10-14 |
2019-09-13 |
Humanigen Inc |
Anticorpos para epha3
|
JP2013508287A
(ja)
|
2009-10-14 |
2013-03-07 |
ヤンセン バイオテツク,インコーポレーテツド |
抗体を親和性成熟する方法
|
WO2011046515A1
(en)
|
2009-10-14 |
2011-04-21 |
Nanyang Technological University |
Antiproliferative agent
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
CN102656266B
(zh)
*
|
2009-10-15 |
2016-08-03 |
霍夫曼-拉罗奇有限公司 |
具有改变的受体特异性的嵌合成纤维细胞生长因子
|
KR20120098664A
(ko)
|
2009-10-15 |
2012-09-05 |
아바시아 바이오로직스, 인크. |
소화 기관에서 국소 활성을 가진 항체 치료법
|
MX2012004415A
(es)
|
2009-10-15 |
2012-05-08 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
HUE029661T2
(en)
|
2009-10-16 |
2017-03-28 |
Oncomed Pharm Inc |
A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
WO2011047340A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
CN106390117A
(zh)
*
|
2009-10-16 |
2017-02-15 |
奥默罗斯公司 |
通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
|
CN102596999B
(zh)
|
2009-10-16 |
2014-12-24 |
国立大学法人京都大学 |
识别淀粉样蛋白β的转角结构的抗体
|
HUE026447T2
(en)
|
2009-10-16 |
2016-05-30 |
Novartis Ag |
Pharmacodynamic tumor response biomarkers
|
PT2488551T
(pt)
|
2009-10-16 |
2018-10-31 |
Inst Nat Sante Rech Med |
Anticorpos monoclonais contra a progastrina e suas utilizações
|
US20110206704A1
(en)
*
|
2009-10-19 |
2011-08-25 |
Genentech, Inc. |
Methods and compositions for modulating hepatocyte growth factor activator
|
AR078667A1
(es)
|
2009-10-19 |
2011-11-23 |
Genentech Inc |
Moduladores de activador del factor de crecimiento de hepatocitos (hgfa)
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2777934A1
(en)
|
2009-10-20 |
2011-04-28 |
Prometheus Laboratories Inc. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
AU2010310748C1
(en)
|
2009-10-20 |
2015-11-26 |
Abbvie Inc. |
Isolation and purification of anti-IL-13 antibodies using Protein A affinity chromatography
|
CA2778401C
(en)
|
2009-10-21 |
2019-08-13 |
Hiroshima University |
Integrin alpha 8-beta 1-specific monoclonal antibody
|
JP5810089B2
(ja)
|
2009-10-21 |
2015-11-11 |
マイカーティス エヌ.ヴェ.MyCartis NV |
体液ホメオスタシスのバイオマーカーとしてのmcam
|
MX2012004638A
(es)
|
2009-10-22 |
2012-07-04 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
EP2491059B1
(en)
|
2009-10-22 |
2015-02-25 |
F.Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods using same
|
WO2011048598A1
(en)
|
2009-10-22 |
2011-04-28 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating aspergillosis
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
US8785600B2
(en)
|
2009-10-23 |
2014-07-22 |
Millennium Pharmaceuticals, Inc. |
Anti-GCC antibody molecules and related compositions and methods
|
MX344935B
(es)
*
|
2009-10-26 |
2017-01-11 |
Genentech Inc |
Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
WO2011056688A2
(en)
|
2009-10-27 |
2011-05-12 |
Caris Life Sciences, Inc. |
Molecular profiling for personalized medicine
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
US8771693B2
(en)
|
2009-10-27 |
2014-07-08 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the generation and use of conformation-specific antibodies
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
JP6095368B2
(ja)
|
2009-10-27 |
2017-03-15 |
ユセベ ファルマ ソシエテ アノニム |
機能改変するNav1.7抗体
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP2494062B1
(en)
|
2009-10-28 |
2016-12-28 |
Janssen Biotech, Inc. |
Anti-glp-1r antibodies and their uses
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
AU2010313395A1
(en)
|
2009-10-30 |
2012-05-10 |
Abbvie Inc. |
sORF constructs and multiple gene expression
|
CN102596996B
(zh)
|
2009-10-30 |
2014-06-18 |
东丽株式会社 |
对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
BR112012010251A2
(pt)
|
2009-10-30 |
2018-03-20 |
The Board Of Trustes Of The Leland Stanford Junior Univ |
mutações de gna11 em melanoma
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
EP2322149A1
(en)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of ischemia
|
CA2780221A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
NZ599761A
(en)
|
2009-11-04 |
2014-04-30 |
Merck Sharp & Dohme |
Engineered anti-tslp antibody
|
KR101968766B1
(ko)
|
2009-11-05 |
2019-04-12 |
제넨테크, 인크. |
이종 폴리펩티드의 분비를 위한 방법 및 조성물
|
US9588121B2
(en)
|
2009-11-06 |
2017-03-07 |
Go Therapeutics, Inc. |
Method for early detection of cancer
|
RU2012124090A
(ru)
|
2009-11-09 |
2013-12-20 |
Алексион Фармасьютикалз, Инк. |
Реагенты и способы для определения клеток ii типа при pnh
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
US9556272B2
(en)
|
2009-11-11 |
2017-01-31 |
The Trustees Of The University Of Pennsylvania |
Anti-TEM1 antibodies and uses thereof
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
MX2012005464A
(es)
|
2009-11-12 |
2012-06-08 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas.
|
TWI630916B
(zh)
|
2009-11-13 |
2018-08-01 |
第一三共歐洲公司 |
供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
EP3431608A3
(en)
|
2009-11-17 |
2019-02-20 |
E. R. Squibb & Sons, L.L.C. |
Method for enhanced protein production
|
GB0920089D0
(en)
|
2009-11-17 |
2009-12-30 |
Danisco |
Method
|
EP3037435B1
(en)
|
2009-11-17 |
2019-08-07 |
MUSC Foundation for Research Development |
Human monoclonal antibodies to human nucleolin
|
GB0920258D0
(en)
|
2009-11-19 |
2010-01-06 |
Alligator Bioscience Ab |
New medical agents and use thereof
|
CA2781532A1
(en)
|
2009-11-20 |
2011-05-26 |
Amgen Inc. |
Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
|
US20130183326A9
(en)
|
2009-11-20 |
2013-07-18 |
St. Jude Children's Research Hospital |
Methods and compositions for modulating the activity of the interleukin-35 receptor complex
|
US8961989B2
(en)
|
2009-11-20 |
2015-02-24 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
RU2012126312A
(ru)
|
2009-11-26 |
2014-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Маркерный белок для диабета типа 2
|
MX2012006072A
(es)
|
2009-11-30 |
2012-07-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
WO2011068870A2
(en)
|
2009-12-01 |
2011-06-09 |
President And Fellows Of Harvard College |
Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
AU2010326024A1
(en)
*
|
2009-12-02 |
2012-07-05 |
Amgen Inc. |
Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
US8324352B2
(en)
|
2009-12-07 |
2012-12-04 |
Decimmune Therapeutics, Inc. |
Anti-inflammatory antibodies and uses therefor
|
EP2509997B1
(en)
|
2009-12-07 |
2017-08-30 |
i2 Pharmaceuticals, Inc. |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
BR112012013734A2
(pt)
|
2009-12-08 |
2017-01-10 |
Abbott Gmbh & Co Kg |
anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
WO2011069528A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Lyophilization of nucleic acids in lactate-containing solutions
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
EP2336171A1
(en)
|
2009-12-11 |
2011-06-22 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel targets for the treatment of proliferative diseases
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
WO2011075524A1
(en)
*
|
2009-12-15 |
2011-06-23 |
Abbott Biotechnology Ltd |
Improved firing button for automatic injection device
|
US20110150891A1
(en)
|
2009-12-16 |
2011-06-23 |
Philip Bosch |
Methods of Treating Interstitial Cystitis
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
CA2784145A1
(en)
|
2009-12-18 |
2011-06-23 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
WO2011084750A1
(en)
|
2009-12-21 |
2011-07-14 |
Genentech, Inc. |
Antibody formulation
|
GB0922377D0
(en)
|
2009-12-22 |
2010-02-03 |
Arab Gulf University The |
Mutant LDL receptor
|
PL2516465T3
(pl)
|
2009-12-23 |
2016-11-30 |
|
Przeciwciała anty-bv8 i ich zastosowania
|
DK2516468T3
(en)
|
2009-12-23 |
2016-05-23 |
Synimmune Gmbh |
ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
|
AU2010334809C1
(en)
|
2009-12-23 |
2015-02-26 |
Agenus Inc. |
Binding members for human cytomegalovirus
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
TW201125583A
(en)
*
|
2009-12-23 |
2011-08-01 |
Bioalliance Cv |
Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
|
WO2011075786A1
(en)
|
2009-12-23 |
2011-06-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
EP2338492A1
(en)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of alzheimer
|
DK2519542T3
(en)
|
2009-12-28 |
2019-01-14 |
Onco Therapy Science Inc |
ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
US9267948B2
(en)
*
|
2009-12-30 |
2016-02-23 |
Brigham Young University |
Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
|
WO2011080322A1
(en)
|
2009-12-30 |
2011-07-07 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
|
US9005579B2
(en)
|
2010-01-05 |
2015-04-14 |
Contrafect Corporation |
Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
|
ES2561102T3
(es)
|
2010-01-13 |
2016-02-24 |
Oncomed Pharmaceuticals, Inc. |
Agentes de unión a Notch1 y procedimientos de uso de los mismos
|
US20110177107A1
(en)
|
2010-01-14 |
2011-07-21 |
Haplomics, Inc. |
Predicting and reducing alloimmunogenicity of protein therapeutics
|
WO2011085811A1
(en)
|
2010-01-14 |
2011-07-21 |
Universite Catholique De Louvain |
Method for evaluating the response of rheumatoid arthritis patients to therapy and for diagnosing disease severity
|
WO2011088385A2
(en)
|
2010-01-15 |
2011-07-21 |
The Regents Of The University Of California |
Compositions and methods for detecting cancer
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
CA2787755A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
CA2787783A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
AU2011207210A1
(en)
|
2010-01-22 |
2012-08-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
|
PL2529033T3
(pl)
|
2010-01-26 |
2017-10-31 |
Nat Jewish Health |
Sposoby do przewidywania ryzyka, diagnozowania i prognozowania zaburzeń płucnych
|
AU2011210362B2
(en)
|
2010-01-27 |
2015-09-10 |
Yeda Research And Development Co. Ltd. |
Antibodies that inhibit metalloproteins
|
JP6101489B2
(ja)
|
2010-01-28 |
2017-03-22 |
アブ バイオサイエンシズ インコーポレイテッド |
親和性が低下した抗体およびそれを作製する方法
|
JPWO2011093083A1
(ja)
|
2010-01-29 |
2013-05-30 |
Axis株式会社 |
変形性関節症治療又は予防用医薬組成物及びその製造方法
|
KR101684246B1
(ko)
|
2010-01-29 |
2016-12-08 |
가부시키가이샤 아크시스 |
변형성 관절증 치료제를 포함하는 주사제
|
JP2012246222A
(ja)
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
US20130137584A1
(en)
|
2010-02-01 |
2013-05-30 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
FR2955773B1
(fr)
|
2010-02-01 |
2017-05-26 |
Commissariat A L'energie Atomique |
Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
|
JP2013518590A
(ja)
|
2010-02-02 |
2013-05-23 |
アボツト・バイオテクノロジー・リミテツド |
TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
|
AU2011212830B2
(en)
|
2010-02-04 |
2014-05-22 |
Gilead Biologics, Inc. |
Antibodies that bind to lysyl oxidase-like 2 (LOXL2) and methods of use therefor
|
TWI518325B
(zh)
|
2010-02-04 |
2016-01-21 |
自治醫科大學 |
對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
|
PT2531527E
(pt)
|
2010-02-04 |
2014-05-16 |
Hoffmann La Roche |
Anticorpo monoclonal contra cd44 para ser utilizado no tratamento de carcinoma de células escamosas da cabeça e do pescoço
|
EP2354159A1
(en)
|
2010-02-05 |
2011-08-10 |
RWTH Aachen |
CCL17 inhibitors for use in T helper cell-driven diseases
|
EP2533804B1
(en)
|
2010-02-08 |
2018-04-11 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
WO2011098449A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
EP4219560A3
(en)
*
|
2010-02-18 |
2023-08-23 |
The Regents of The University of California |
Integrin alpha v beta 8 neutralizing antibody
|
EP2536748B1
(en)
|
2010-02-18 |
2014-08-20 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
WO2011103426A2
(en)
|
2010-02-19 |
2011-08-25 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
CN102844050B
(zh)
|
2010-02-19 |
2019-02-05 |
康奈尔大学 |
自身免疫性脱髓鞘疾病及其它自身免疫疾病或炎性疾病的治疗方法
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
WO2011103471A1
(en)
|
2010-02-22 |
2011-08-25 |
Duke University |
Compositions and methods for the treatment of neurologic and psychiatric conditions
|
US10369189B2
(en)
|
2010-02-22 |
2019-08-06 |
Duke University |
Compositions and methods for uncoupling TrkB receptor from PLC gamma 1 for the treatment of epilepsy and anxiety-like disorder
|
AU2011221229B2
(en)
|
2010-02-23 |
2015-06-18 |
F. Hoffmann-La Roche Ag |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2790866C
(en)
|
2010-02-23 |
2019-02-12 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
MX2012009802A
(es)
|
2010-02-24 |
2012-09-12 |
Merck Sharp & Dohme |
Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris.
|
KR20220017432A
(ko)
|
2010-02-24 |
2022-02-11 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
TWI552760B
(zh)
|
2010-02-24 |
2016-10-11 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
EP2539357B1
(en)
|
2010-02-26 |
2017-06-14 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP3708190A1
(en)
|
2010-02-26 |
2020-09-16 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
WO2011107939A1
(en)
|
2010-03-01 |
2011-09-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
|
CA3101298A1
(en)
|
2010-03-01 |
2011-09-09 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
JP2013520970A
(ja)
|
2010-03-02 |
2013-06-10 |
エフ.ホフマン−ラ ロシュ アーゲー |
発現ベクター
|
EP3056510B1
(en)
|
2010-03-03 |
2018-10-03 |
The University Of British Columbia |
Oligomer-specific amyloid beta epitope and antibodies
|
JP2013520999A
(ja)
|
2010-03-04 |
2013-06-10 |
ベット・セラピューティクス・インコーポレイテッド |
Cd52に対するモノクローナル抗体
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
GB201003630D0
(en)
|
2010-03-04 |
2010-04-21 |
Novartis Ag |
Avian rotavirus
|
EP2542262A4
(en)
|
2010-03-04 |
2014-02-26 |
Vet Therapeutics Inc |
MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20
|
US20110236386A1
(en)
*
|
2010-03-04 |
2011-09-29 |
Zimering Mark B |
Novel method for prediction of cardiovascular disease risk in type 2 diabetes
|
CN102869381A
(zh)
|
2010-03-04 |
2013-01-09 |
大日本住友制药株式会社 |
用于炎性肠病的药物
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
NZ602161A
(en)
|
2010-03-04 |
2014-12-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
DK2542590T4
(da)
|
2010-03-05 |
2020-07-13 |
Univ Johns Hopkins |
Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
US20130045181A1
(en)
|
2010-03-09 |
2013-02-21 |
Guangming Zhong |
Methods and Compositions for Chlamydial Antigens for Diagnosis and Treatment of Chlamydial Infection and Disease
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
SA111320266B1
(ar)
|
2010-03-11 |
2015-06-21 |
رينات نيوروساينس كوربوريشن |
أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
|
EP2630963A1
(en)
|
2010-03-11 |
2013-08-28 |
Abraxis BioScience, LLC |
SPARC angiogenic domain and methods of use
|
LT2544719T
(lt)
|
2010-03-12 |
2019-10-25 |
Debiopharm Int Sa |
Cd37 surišančios molekulės, ir jų imunokonjugatai
|
EP2368428A1
(en)
|
2010-03-16 |
2011-09-28 |
Institut National De La Recherche Agronomique |
Obtention of a rex animal by molecular methods based on the alteration of the LIPH function
|
JP2013522313A
(ja)
|
2010-03-17 |
2013-06-13 |
アボツト・リサーチ・ベー・フエー |
抗神経成長因子(ngf)抗体組成物
|
WO2011114251A1
(en)
|
2010-03-18 |
2011-09-22 |
Danisco A/S |
Foodstuff
|
WO2011113118A1
(en)
|
2010-03-19 |
2011-09-22 |
Katholieke Universiteit Leuven |
Drug tolerance/persistence of fungal biofilms
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
EP2550285B1
(en)
|
2010-03-22 |
2017-07-19 |
President and Fellows of Harvard College |
Trioxacarcins and uses thereof
|
SI2550018T1
(sl)
|
2010-03-22 |
2019-05-31 |
F. Hoffmann-La Roche Ag |
Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
|
WO2013040142A2
(en)
|
2011-09-16 |
2013-03-21 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
WO2011119484A1
(en)
|
2010-03-23 |
2011-09-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
BR112012022044A2
(pt)
|
2010-03-24 |
2020-08-25 |
Genentech Inc |
''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
|
TR201903279T4
(tr)
|
2010-03-25 |
2019-03-21 |
Ucb Biopharma Sprl |
Disülfür stabilize edilmiş DVD-IG molekülleri.
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
ES2621874T3
(es)
|
2010-03-26 |
2017-07-05 |
Memorial Sloan-Kettering Cancer Center |
Anticuerpos para MUC16 y métodos de uso de los mismos
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
AU2011231537B2
(en)
|
2010-03-26 |
2016-05-12 |
Mycartis Nv |
LTBP2 as a biomarker for renal dysfunction, glomerular filtration rate, dyspnea, acute heart failure, left ventricular hypertrophy, cardiac fibrosis, preeclampsia, pregnancy-associated proteinuria
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
EP2552957A4
(en)
|
2010-03-29 |
2013-11-20 |
Zymeworks Inc |
ANTIBODIES HAVING ENHANCED OR DELETED EFFECTIVE FUNCTION
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
SG184195A1
(en)
|
2010-03-30 |
2012-11-29 |
Janssen Biotech Inc |
Humanized il-25 antibodies
|
KR101760242B1
(ko)
|
2010-03-31 |
2017-07-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
항-cd40 항체
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
CA2793778A1
(en)
|
2010-04-05 |
2011-11-13 |
Wyeth Llc |
Biomarkers for p13k-driven cancer
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
US9441032B2
(en)
|
2010-04-07 |
2016-09-13 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
ES2566602T3
(es)
|
2010-04-09 |
2016-04-14 |
Aveo Pharmaceuticals, Inc. |
Anticuerpos anti-ErbB3
|
RU2625014C2
(ru)
|
2010-04-09 |
2017-07-11 |
Критикал Кэа Дайэгностикс, Инк. |
Антитела против растворимого st-2 человека и способы анализа
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
WO2011128357A2
(en)
|
2010-04-13 |
2011-10-20 |
Pronota N.V. |
Biomarkers for hypertensive disorders of pregnancy
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
EP2558497A2
(en)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
BR112012026213B1
(pt)
|
2010-04-15 |
2021-12-28 |
Medimmune Limited |
Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
|
AU2011239512B2
(en)
|
2010-04-16 |
2016-01-21 |
Biogen Ma Inc. |
Anti-VLA-4 antibodies
|
EP2561356B1
(en)
|
2010-04-18 |
2016-08-03 |
Yeda Research and Development Co. Ltd. |
MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
CA2796601C
(en)
|
2010-04-19 |
2019-03-26 |
Research Development Foundation |
Rtef-1 variants and uses thereof
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
RU2695703C2
(ru)
|
2010-04-21 |
2019-07-25 |
Эббви Байотекнолоджи Лтд. |
Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов
|
GB201006768D0
(en)
|
2010-04-22 |
2010-06-09 |
Cancer Rec Tech Ltd |
Method for obtaining dendritic cells
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
BR112012027531A2
(pt)
|
2010-04-29 |
2017-08-08 |
Hadasit Medical Res Service And Development Co Ltd |
método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica
|
US9011852B2
(en)
|
2010-04-30 |
2015-04-21 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies
|
EP2563394B1
(en)
|
2010-04-30 |
2018-03-21 |
Beth Israel Deaconess Medical Center |
Methods and compositions for treating celiac disease
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
EP3150631B1
(en)
|
2010-05-03 |
2023-08-30 |
University Of Rochester |
Anti-glucosaminidase passive immunization for staphylococcus aureus infections
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
SG185366A1
(en)
|
2010-05-04 |
2012-12-28 |
Merrimack Pharmaceuticals Inc |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
TR201900368T4
(tr)
|
2010-05-04 |
2019-02-21 |
Five Prime Therapeutics Inc |
Csf1r'ye bağlanan antikorlar.
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
ES2949159T3
(es)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
|
JP5947289B2
(ja)
|
2010-05-10 |
2016-07-06 |
アカデミア シニカAcademia Sinica |
抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
|
CA2798331C
(en)
|
2010-05-14 |
2022-03-15 |
Baxter International Inc. |
Ospa chimeras and use thereof in vaccines
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
KR101539684B1
(ko)
|
2010-05-14 |
2015-07-27 |
애브비 인코포레이티드 |
Il-1 결합 단백질
|
EP2569335B1
(en)
|
2010-05-14 |
2018-08-22 |
Orega Biotech |
Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
|
EP3597671B1
(en)
|
2010-05-17 |
2022-09-21 |
EMD Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2572204B1
(en)
|
2010-05-20 |
2017-12-27 |
Roche Diagnostics GmbH |
Release reagent for vitamin d compounds
|
GB201008541D0
(en)
|
2010-05-21 |
2010-07-07 |
Univ Geneve |
Diagnostic methods
|
WO2011145085A2
(en)
|
2010-05-21 |
2011-11-24 |
Procognia (Israel) Ltd |
Novel antibodies and methods of use for the treatment and diagnosis of cancer
|
NZ603648A
(en)
|
2010-05-25 |
2014-12-24 |
Genentech Inc |
Methods of purifying polypeptides
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
WO2011149461A1
(en)
|
2010-05-27 |
2011-12-01 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
EA023541B1
(ru)
|
2010-05-27 |
2016-06-30 |
Янссен Байотек, Инк. |
Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1
|
WO2011150241A2
(en)
|
2010-05-28 |
2011-12-01 |
Genentech, Inc. |
Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
|
US20130136733A1
(en)
|
2010-05-28 |
2013-05-30 |
Novo Nordisk A/S |
Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
DK2578231T3
(da)
|
2010-05-28 |
2022-12-12 |
Chugai Pharmaceutical Co Ltd |
Antitumor-t-celle-reaktionsforstærker
|
WO2011150454A1
(en)
|
2010-06-01 |
2011-12-08 |
Monash University |
ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
|
US8858944B2
(en)
|
2010-06-02 |
2014-10-14 |
Sumitomo Dainippon Pharma Co., Ltd. |
Treatment drug for autoimmune diseases and allergic diseases
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
AU2011261396B2
(en)
|
2010-06-02 |
2015-11-05 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
LT2575884T
(lt)
|
2010-06-03 |
2018-09-25 |
Abbvie Biotechnology Ltd |
Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui
|
WO2011151833A1
(en)
|
2010-06-03 |
2011-12-08 |
Ramot At Tel-Aviv University Ltd. |
Methods of treating diabetes and compositions capable of same
|
CN103119442A
(zh)
|
2010-06-03 |
2013-05-22 |
霍夫曼-拉罗奇有限公司 |
抗体和免疫偶联物的免疫peg成像及其用途
|
CA3067107C
(en)
|
2010-06-03 |
2022-07-12 |
Idexx Laboratories, Inc. |
Markers for renal disease
|
CA2801190A1
(en)
|
2010-06-03 |
2011-12-08 |
Abraxis Bioscience, Llc |
Use of the sparc microenvironment signature in the treatment of cancer
|
GB201009455D0
(en)
|
2010-06-04 |
2010-07-21 |
King S College London |
Nanoparticles and their uses in molecular imaging
|
WO2011151076A2
(en)
|
2010-06-04 |
2011-12-08 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
|
CA2799540A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JP2013534914A
(ja)
|
2010-06-09 |
2013-09-09 |
クイーン マリー アンド ウエストフィールド カレッジ、ユニバーシティ オブ ロンドン |
アネキシン1抗体
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
EP2580239A1
(en)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
RU2013101779A
(ru)
|
2010-06-16 |
2014-07-27 |
Эббви Инк. |
Сравнение образцов белков
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
TW201204388A
(en)
|
2010-06-18 |
2012-02-01 |
Genentech Inc |
Anti-Axl antibodies and methods of use
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
EP3327035A1
(en)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
AU2011270959A1
(en)
|
2010-06-22 |
2013-01-10 |
Musc Foundation For Research Development |
Antibodies to the C3d fragment of complement component 3
|
CA2803029A1
(en)
|
2010-06-23 |
2011-12-29 |
Monash University |
Constrained immunogenic compositions and uses therefor
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
ES2880802T3
(es)
|
2010-06-24 |
2021-11-25 |
Hoffmann La Roche |
Composiciones y procedimientos para estabilizar formulaciones que contienen proteínas
|
ES2706913T3
(es)
|
2010-06-25 |
2019-04-01 |
Univ Aston |
Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
|
EP2588631A4
(en)
|
2010-07-01 |
2013-11-20 |
Univ California |
GENETIC MUTATION OF CK2 PROTEIN KINASE, AMPLIFICATIONS AND POLYMORPHISMS IN HUMAN CANCER, AND METHODS OF USE
|
WO2012003472A1
(en)
|
2010-07-02 |
2012-01-05 |
Aveo Pharmaceuticals, Inc. |
Anti-notch1 antibodies
|
WO2012004565A1
(en)
|
2010-07-06 |
2012-01-12 |
Robert White |
Cancer biomarker brf1
|
US8603478B2
(en)
|
2010-07-06 |
2013-12-10 |
Aveo Pharmaceuticals, Inc. |
Anti-RON antibodies
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
AU2011275753A1
(en)
|
2010-07-08 |
2013-01-10 |
Pronota N.V. |
Quiescin Q6 as biomarker for hypertensive disorders of pregnancy
|
US9485812B2
(en)
|
2010-07-08 |
2016-11-01 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
GB201011513D0
(en)
|
2010-07-08 |
2010-08-25 |
Danisco |
Method
|
WO2012004367A1
(en)
|
2010-07-09 |
2012-01-12 |
N.V. Organon |
Agonistic antibody to cd27
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
MX2013000083A
(es)
|
2010-07-09 |
2013-02-26 |
Genentech Inc |
Anticuerpos de anti-neuropilina y metodos de uso.
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CA3062786C
(en)
|
2010-07-09 |
2022-04-19 |
Janssen Vaccines & Prevention B.V. |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
GB201011771D0
(en)
|
2010-07-13 |
2010-08-25 |
Bioinvent Int Ab |
Biological material and particular uses thereof
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
KR101695056B1
(ko)
|
2010-07-15 |
2017-01-10 |
애드헤론 쎄라퓨틱스, 인코포레이티드 |
카드헤린-11의 ec1 도메인을 표적으로 하는 인간화 항체 및 관련 조성물 및 방법
|
EP2593551B1
(en)
|
2010-07-15 |
2016-09-14 |
Technion Research & Development Foundation Ltd. |
Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
|
WO2012007950A2
(en)
|
2010-07-15 |
2012-01-19 |
Technion Research & Development Foundation Ltd. |
Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
|
TW201201840A
(en)
|
2010-07-15 |
2012-01-16 |
Hoffmann La Roche |
Antibodies specifically binding to human TSLPR and methods of use
|
EP2593476A2
(en)
|
2010-07-16 |
2013-05-22 |
Ablynx N.V. |
Modified single domain antigen binding molecules and uses thereof
|
CN103153328A
(zh)
|
2010-07-16 |
2013-06-12 |
默克专利股份有限公司 |
肽在乳腺癌和/或骨转移灶的治疗中的用途
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
KR20130055647A
(ko)
|
2010-07-19 |
2013-05-28 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
EP2596010B1
(en)
|
2010-07-19 |
2017-04-12 |
Otago Innovation Limited |
Signal biomarkers
|
CA2805653A1
(en)
|
2010-07-20 |
2012-01-26 |
Cephalon Australia Pty Ltd |
Anti-il-23 heterodimer specific antibodies
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9624469B2
(en)
|
2010-07-22 |
2017-04-18 |
Cellect Biotherapeutics Ltd. |
Regulatory immune cells with enhanced targeted cell death effect
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
US20130177500A1
(en)
|
2010-07-23 |
2013-07-11 |
Trustee Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
EP2412724A1
(en)
|
2010-07-29 |
2012-02-01 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
|
CA2806314C
(en)
|
2010-07-30 |
2019-09-24 |
Medimmune, Llc |
Method for purifying active polypeptides or immunoconjugates
|
JP2013533286A
(ja)
|
2010-07-30 |
2013-08-22 |
セントルイス ユニバーシティ |
疼痛を治療する方法
|
JP5964300B2
(ja)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
AU2011285852B2
(en)
|
2010-08-03 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CN103153341B
(zh)
|
2010-08-03 |
2015-05-27 |
霍夫曼-拉罗奇有限公司 |
慢性淋巴细胞性白血病(cll)生物标志物
|
EP2600885A2
(en)
|
2010-08-04 |
2013-06-12 |
Ramot at Tel Aviv University, Ltd. |
Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2012018404A2
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
US9465039B2
(en)
|
2010-08-06 |
2016-10-11 |
Mycartis Nv |
Perlecan as a biomarker for renal dysfunction
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
WO2012021648A1
(en)
|
2010-08-10 |
2012-02-16 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
EP2603606B1
(en)
|
2010-08-12 |
2014-06-04 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and kits for of identifying a premature infant at risk of having or developing bronchopulmonary dysplasia
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
JP2013537539A
(ja)
|
2010-08-13 |
2013-10-03 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのIL−1β及びIL−18に対する抗体
|
TW201209063A
(en)
|
2010-08-13 |
2012-03-01 |
Roche Glycart Ag |
Anti-tenascin-C A2 antibodies and methods of use
|
SI2603530T1
(en)
|
2010-08-13 |
2018-02-28 |
Roche Glycart Ag |
Anti-FAP antibodies and methods of use
|
CN105348387B
(zh)
|
2010-08-14 |
2020-08-25 |
Abbvie 公司 |
β淀粉样蛋白结合蛋白
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
JP2013537425A
(ja)
|
2010-08-16 |
2013-10-03 |
アムジエン・インコーポレーテツド |
ミオスタチンに結合するポリペプチド、組成物および方法
|
US20130212721A1
(en)
|
2010-08-16 |
2013-08-15 |
Kyushu University, National University Corporation |
Reagent for tumor testing and pharmaceutical composition for tumor prevention
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
CN103068852B
(zh)
|
2010-08-17 |
2016-04-20 |
弗·哈夫曼-拉罗切有限公司 |
抗人IgG1抗体
|
KR101234807B1
(ko)
|
2010-08-18 |
2013-02-19 |
한국원자력의학원 |
혈관신생 촉진용 약학 조성물 및 혈관신생 촉진용 활성물질을 스크리닝하는 방법
|
LT3333188T
(lt)
|
2010-08-19 |
2022-06-10 |
Zoetis Belgium S.A. |
Anti-ngf antikūnai ir jų panaudojimas
|
WO2012022774A1
(en)
|
2010-08-19 |
2012-02-23 |
Roche Diagnostics Gmbh |
An assay for measurement of antibodies binding to a therapeutic monoclonal antibody
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
JP2013535981A
(ja)
|
2010-08-20 |
2013-09-19 |
ワイス・エルエルシー |
成長因子不含適合細胞の細胞培養
|
PT2609118T
(pt)
|
2010-08-23 |
2017-03-22 |
Univ Texas |
Anticorpos anti-ox40 e métodos de utilização dos mesmos
|
ES2850973T3
(es)
|
2010-08-23 |
2021-09-01 |
Wyeth Llc |
Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
|
JP5978212B2
(ja)
|
2010-08-24 |
2016-08-24 |
アボット・ラボラトリーズAbbott Laboratories |
Hivコアタンパク質に特異的な抗体及びその使用
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
WO2012027555A2
(en)
|
2010-08-25 |
2012-03-01 |
President And Fellows Of Harvard College |
Glycated cd59 peptides, their preparation, and uses thereof
|
WO2012025536A1
(en)
|
2010-08-25 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Antibodies against il-18r1 and uses thereof
|
PE20140229A1
(es)
|
2010-08-26 |
2014-03-27 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
JP5878538B2
(ja)
|
2010-08-27 |
2016-03-08 |
ギリアド バイオロジクス, インク.Gilead Biologics, Inc. |
マトリクスメタロプロティナーゼ9に対する抗体
|
EP2608807A1
(en)
|
2010-08-27 |
2013-07-03 |
Stem Centrx, Inc. |
Notum protein modulators and methods of use
|
SG10201408229WA
(en)
|
2010-08-31 |
2015-02-27 |
Genentech Inc |
Biomarkers and methods of treatment
|
EP2611465A4
(en)
|
2010-08-31 |
2014-06-04 |
Theraclone Sciences Inc |
NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
|
ES2715177T3
(es)
|
2010-09-01 |
2019-06-03 |
Genzyme Corp |
Tratamiento de infarto de miocardio usando antagonistas de tgf-beta
|
EP2689787A1
(en)
|
2010-09-03 |
2014-01-29 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
EP2426213A1
(en)
|
2010-09-03 |
2012-03-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Marker for sunitnib resistance formation
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
SG10201506959SA
(en)
|
2010-09-03 |
2015-10-29 |
Stemcentrx Inc |
Novel modulators and methods of use
|
CN103502466A
(zh)
|
2010-09-07 |
2014-01-08 |
斯隆-凯特林纪念癌症中心 |
用于γ-分泌酶测定的方法和组合物
|
WO2012032043A1
(en)
|
2010-09-07 |
2012-03-15 |
Areva Med Llc |
212 pb imaging
|
SG188471A1
(en)
|
2010-09-08 |
2013-04-30 |
Yeda Res & Dev |
An immunosuppressive drug combination for a stable and long term engraftment
|
RU2710717C2
(ru)
|
2010-09-09 |
2020-01-10 |
Пфайзер Инк. |
Молекулы, связывающиеся с 4-1ВВ
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
WO2012032143A1
(en)
|
2010-09-10 |
2012-03-15 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Phosphorylated twist1 and metastasis
|
CN103221823A
(zh)
|
2010-09-13 |
2013-07-24 |
Abbvie公司 |
高度灵敏的单克隆抗体残留物检测测定法
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
RU2608499C2
(ru)
|
2010-09-20 |
2017-01-18 |
Эббви Инк. |
Очистка антител с помощью хроматографии с псевдодвижущимся слоем
|
EP2640405A4
(en)
|
2010-09-21 |
2015-04-15 |
Massachusetts Inst Technology |
TREATMENT AND / OR CHARACTERIZATION OF INFLUENZA; POLYPEPTIDES HA ADAPTED TO MAN
|
EA201370076A1
(ru)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
Иммуноглобулины-переносчики и их применение
|
JP6126991B2
(ja)
|
2010-09-27 |
2017-05-10 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒトii型コラーゲンに結合する抗体
|
MX2013003561A
(es)
|
2010-09-27 |
2013-09-02 |
Zestagen S A |
Composiciones y métodos para tratar la neoplasia.
|
TW202344270A
(zh)
|
2010-09-29 |
2023-11-16 |
美商艾澤西公司 |
與191p4d12蛋白結合之抗體藥物共軛物(adc)
|
KR101857310B1
(ko)
|
2010-09-29 |
2018-05-11 |
가부시키가이샤 에누비 켄코우겡큐쇼 |
인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
|
US8530427B2
(en)
|
2010-09-30 |
2013-09-10 |
Mayo Foundation For Medical Education And Research |
Methods for modulating resistance to apoptosis using KLK6
|
WO2012043747A1
(ja)
|
2010-09-30 |
2012-04-05 |
独立行政法人理化学研究所 |
グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
CN104531812A
(zh)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
设计核酸及其使用方法
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
US10226527B2
(en)
|
2010-10-04 |
2019-03-12 |
Massachusetts Institute Of Technology |
Hemagglutinin polypeptides, and reagents and methods relating thereto
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
FR2965810B1
(fr)
|
2010-10-06 |
2012-12-28 |
Commissariat Energie Atomique |
Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
|
WO2012049229A1
(en)
|
2010-10-15 |
2012-04-19 |
Université Libre de Bruxelles |
Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof
|
AU2011317743B2
(en)
|
2010-10-18 |
2015-05-21 |
Mediapharma S.R.L. |
ErbB3 binding antibody
|
CN103429260B
(zh)
|
2010-10-19 |
2016-08-10 |
梅奥医学教育和研究基金会 |
用于治疗神经疾病的人抗体及其诊断和治疗用途
|
EP2630154A1
(en)
|
2010-10-20 |
2013-08-28 |
F.Hoffmann-La Roche Ag |
Methods and compositions for modulating the wnt pathway
|
US9272052B2
(en)
|
2010-10-22 |
2016-03-01 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
EP2633317A1
(en)
|
2010-10-25 |
2013-09-04 |
Genentech, Inc. |
Treatment of gastrointestinal inflammation and psoriasis a
|
BR112013010136A2
(pt)
|
2010-10-25 |
2019-09-24 |
Univ Minnesota |
vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
|
SG10202100921YA
(en)
|
2010-10-27 |
2021-03-30 |
Univ New York State Res Found |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
EP2632956B1
(en)
|
2010-10-28 |
2018-06-20 |
Yeda Research and Development Co. Ltd. |
Methods of generating antibodies to metalloenzymes
|
KR20130130732A
(ko)
|
2010-11-01 |
2013-12-02 |
제넨테크, 인크. |
다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
JP6126532B2
(ja)
|
2010-11-04 |
2017-05-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗il−23抗体
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
SG10201407036YA
(en)
|
2010-11-05 |
2014-12-30 |
Transbio Ltd |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
WO2012064743A2
(en)
|
2010-11-08 |
2012-05-18 |
The Johns Hopkins University |
Methods for improving heart function
|
CN103476793A
(zh)
|
2010-11-08 |
2013-12-25 |
基因技术公司 |
皮下施用的抗-il-6受体抗体
|
CN103228674B
(zh)
|
2010-11-10 |
2019-07-05 |
霍夫曼-拉罗奇有限公司 |
用于神经疾病免疫疗法的方法和组合物
|
SG190793A1
(en)
|
2010-11-11 |
2013-07-31 |
Agency Science Tech & Res |
Targeting metabolic enzymes in human cancer
|
GB201019118D0
(en)
|
2010-11-11 |
2010-12-29 |
King S College |
Conjugates and their uses in molecular imaging
|
JP2014502262A
(ja)
|
2010-11-12 |
2014-01-30 |
ザ ロックフェラー ユニバーシティ |
Hiv治療用の融合タンパク質
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
JP5889912B2
(ja)
|
2010-11-17 |
2016-03-22 |
ジェネンテック, インコーポレイテッド |
アラニニルメイタンシノール抗体コンジュゲート
|
WO2012099566A1
(en)
|
2010-11-17 |
2012-07-26 |
Sea Lane Biotechnologies, Llc |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
EP2640425A2
(en)
|
2010-11-18 |
2013-09-25 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
US20130244907A1
(en)
|
2010-11-18 |
2013-09-19 |
National University Corporation Okayama University |
Method for preparing b cell which produces human-type antibody
|
EP2640744A4
(en)
|
2010-11-19 |
2014-05-28 |
Eisai R&D Man Co Ltd |
NEUTRALIZATION OF ANTIBODIES TO CCL20
|
PT2643352T
(pt)
|
2010-11-23 |
2018-08-01 |
Glaxo Group Ltd |
Proteínas de ligação a antigénio para a oncostatina m (osm)
|
MY164281A
(en)
|
2010-11-23 |
2017-11-30 |
Pantheryx Inc |
Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
|
AU2011332817A1
(en)
|
2010-11-23 |
2013-06-13 |
Alder Biopharmaceuticals, Inc. |
Anti-IL-6 antibodies for the treatment of anemia
|
RU2013123793A
(ru)
|
2010-11-24 |
2014-12-27 |
Лексикон Фармасьютикалз, Инк. |
Антитела, связывающиеся с notum пектинацетилэстеразой
|
WO2012071513A2
(en)
|
2010-11-24 |
2012-05-31 |
Hong Gao |
Expanding hematopoietic stem cells
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
TWI689314B
(zh)
|
2010-11-30 |
2020-04-01 |
建南德克公司 |
低親和力血腦障壁受體抗體及其用途
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
WO2012075340A2
(en)
|
2010-12-01 |
2012-06-07 |
Alderbio Holdings Llc |
Anti-ngf compositions and use thereof
|
US20120148559A1
(en)
|
2010-12-01 |
2012-06-14 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012075333A2
(en)
|
2010-12-02 |
2012-06-07 |
Prometheus Laboratories Inc. |
Her2delta16 peptides
|
EP2649454B1
(en)
|
2010-12-06 |
2018-06-20 |
Mycartis N.V. |
Biomarkers and parameters for hypertensive disorders of pregnancy
|
AU2011360938B2
(en)
|
2010-12-08 |
2016-07-28 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
US10202615B2
(en)
|
2010-12-10 |
2019-02-12 |
Vanderbilt University |
Mammalian genes involved in toxicity and infection
|
SI2651975T1
(en)
|
2010-12-14 |
2018-03-30 |
National University Of Singapore |
Human monoclonal antibody with specificity for the E protein of denga serotype 1 and its use
|
US9127060B2
(en)
|
2010-12-15 |
2015-09-08 |
Wyeth Llc |
Anti-Notch1 antibodies
|
WO2012080769A1
(en)
|
2010-12-15 |
2012-06-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd277 antibodies and uses thereof
|
EP3447491A3
(en)
|
2010-12-16 |
2019-06-05 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to th2 inhibition
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
UY33807A
(es)
|
2010-12-17 |
2012-07-31 |
Sanofi Sa |
miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
CA2824278C
(en)
|
2010-12-20 |
2022-09-20 |
The Rockefeller University |
Modulating agonistic tnfr antibodies
|
EP2655418B1
(en)
|
2010-12-20 |
2017-10-04 |
F. Hoffmann-La Roche AG |
Anti-mesothelin antibodies and immunoconjugates
|
MX2013007067A
(es)
|
2010-12-20 |
2013-11-01 |
Medimmune Ltd |
Anticuerpos anti-il-18 y sus usos.
|
CA2821976A1
(en)
|
2010-12-21 |
2012-09-13 |
Abbvie Inc. |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
CA2822610C
(en)
|
2010-12-21 |
2019-09-03 |
Selexys Pharmaceuticals Corporation |
Use of anti-p-selectin antibodies
|
US9631002B2
(en)
|
2010-12-21 |
2017-04-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin K-dependent proteins
|
WO2012088094A2
(en)
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
WO2012085132A1
(en)
|
2010-12-22 |
2012-06-28 |
Orega Biotech |
Antibodies against human cd39 and use thereof
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
US11141063B2
(en)
|
2010-12-23 |
2021-10-12 |
Philips Image Guided Therapy Corporation |
Integrated system architectures and methods of use
|
KR20140002711A
(ko)
|
2010-12-23 |
2014-01-08 |
네스텍 소시에테아노님 |
항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법
|
US9085772B2
(en)
|
2010-12-27 |
2015-07-21 |
National University Corporation Nagoya University |
Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
|
CN103582651A
(zh)
|
2010-12-27 |
2014-02-12 |
公益财团法人日本健康科学振兴财团 |
识别人类乳突病毒(hpv)l2蛋白质的单克隆抗体及使用其的测定hpv中和抗体的效价的方法
|
US20140038842A1
(en)
|
2010-12-28 |
2014-02-06 |
Xoma Technology |
Cell surface display using pdz domains
|
EP2471554A1
(en)
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
US11040140B2
(en)
|
2010-12-31 |
2021-06-22 |
Philips Image Guided Therapy Corporation |
Deep vein thrombosis therapeutic methods
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012092376A2
(en)
*
|
2010-12-31 |
2012-07-05 |
Short Jay M |
Comprehensive monoclonal antibody generation
|
ES2609439T3
(es)
|
2010-12-31 |
2017-04-20 |
Bioatla Llc |
Humanización rápida de anticuerpos
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
WO2012093068A1
(en)
|
2011-01-03 |
2012-07-12 |
F. Hoffmann-La Roche Ag |
A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
|
EP2664680A1
(en)
|
2011-01-07 |
2013-11-20 |
Bioscience Slovakia |
Antibody-based methods of diagnosing infections with lymphocytic choriomeningitis virus (LCMV)
|
US20140080153A1
(en)
|
2011-01-07 |
2014-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
RU2013131825A
(ru)
|
2011-01-10 |
2015-02-20 |
Зе Реджентс Оф Зе Юниверсити Оф Мичиган |
Ингибитор фактора стволовых клеток
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
RU2606852C2
(ru)
|
2011-01-11 |
2017-01-10 |
Дзе Гавернинг Каунсил Оф Дзе Юниверсити Оф Торонто |
Способ детекции белков
|
CA2824313A1
(en)
|
2011-01-12 |
2012-07-19 |
Innate Pharma |
Tlr3 binding agents
|
CA2824805A1
(en)
|
2011-01-14 |
2012-07-19 |
Five Prime Therapeutics, Inc. |
Il-27 antagonists for treating inflammatory diseases
|
DK3216878T3
(da)
|
2011-01-17 |
2019-06-11 |
Life Technologies Corp |
Arbejdsprocedure til påvisning af ligander ved anvendelse af nukleinsyrer
|
CN103492575A
(zh)
|
2011-01-18 |
2014-01-01 |
安姆根有限公司 |
NaV1.7敲除小鼠及其用途
|
DK3020730T3
(en)
|
2011-01-19 |
2019-04-15 |
Cantargia Ab |
ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATMENT OF SOLID TUMORS
|
TW202208825A
(zh)
|
2011-01-21 |
2022-03-01 |
美商拉布拉多診斷有限責任公司 |
樣本使用最大化之系統及方法
|
WO2012101125A1
(en)
|
2011-01-24 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific antibodies against human cxcl4 and uses thereof
|
BR112013018905B1
(pt)
|
2011-01-24 |
2021-07-13 |
Abbvie Biotechnology Ltd |
Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
|
EP2668210B1
(en)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
WO2012103520A1
(en)
|
2011-01-28 |
2012-08-02 |
Board Of Regents Of The University Of Nebraska |
Methods and compositions for modulating cyclophilin d
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
AU2012259470B2
(en)
|
2011-02-02 |
2017-01-12 |
Emory University |
Antagonism of the VIP signaling pathway
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
WO2012106615A1
(en)
|
2011-02-03 |
2012-08-09 |
Xoma Technology Ltd. |
Methods and materials for enhancing functional protein expression in bacteria
|
EP2670776B1
(en)
|
2011-02-04 |
2018-11-21 |
F. Hoffmann-La Roche AG |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
EP2670436B1
(en)
|
2011-02-04 |
2017-07-12 |
John Wayne Cancer Institute |
Foxc1 antibodies and methods of their use
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
CA2826467C
(en)
|
2011-02-07 |
2019-11-12 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
EP2487242A1
(en)
|
2011-02-09 |
2012-08-15 |
Ruprecht-Karls-Universität Heidelberg |
B-type plexin antagonists and uses thereof
|
MX2013009151A
(es)
|
2011-02-10 |
2013-08-29 |
Roche Glycart Ag |
Inmunoterapia mejorada.
|
BR112013020402A2
(pt)
|
2011-02-11 |
2018-09-25 |
Irm Llc |
antagonistas pcsk9
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012112842A2
(en)
|
2011-02-17 |
2012-08-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating poliovirus
|
WO2012110824A1
(en)
|
2011-02-18 |
2012-08-23 |
Astrazeneca Ab |
Binding agents with specificity for a nucleic acid modification
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
WO2012113718A1
(en)
|
2011-02-21 |
2012-08-30 |
Roche Diagnostics Gmbh |
A diagnostic method for type ii diabetes
|
WO2012114339A1
(en)
|
2011-02-23 |
2012-08-30 |
Rappaport Family Institute For Research In The Medical Sciences |
High affinity molecules capable of binding a type a plexin receptor and uses of same
|
FR2972006B1
(fr)
|
2011-02-24 |
2016-03-25 |
Centre Nat Rech Scient |
Nouveaux fragments d'il-33 superactifs et leurs utilisations
|
EP2678682A4
(en)
|
2011-02-24 |
2014-10-01 |
Vermillion Inc |
BIOLOGICAL MARKERS PANEL, DIAGNOSTIC METHODS AND TESTING NEEDS FOR OVARIAN CANCER
|
BR112013021526B1
(pt)
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
|
WO2012118693A1
(en)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Methods of diagnosing clostridium difficile infection
|
CA2827859A1
(en)
|
2011-02-28 |
2012-09-07 |
Genentech, Inc. |
Biological markers and methods for predicting response to b-cell antagonists
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
CA2828405A1
(en)
|
2011-02-28 |
2012-09-07 |
Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale |
Apoptosis-inducing molecules and uses therefor
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
CN103501859B
(zh)
|
2011-03-02 |
2017-08-25 |
博格有限责任公司 |
基于细胞的探询式分析及其应用
|
SI2681244T1
(en)
|
2011-03-02 |
2018-03-30 |
Roche Glycart Ag |
PROTITELESA CEA
|
JP6000287B2
(ja)
|
2011-03-03 |
2016-09-28 |
クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. |
肺疾患および損傷を治療するための組成物および方法
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
WO2012120004A1
(en)
|
2011-03-07 |
2012-09-13 |
F. Hoffmann-La Roche Ag |
In vivo selection of therapeutically active antibodies
|
EP2683290B1
(en)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Methods for in vivo testing of therapeutic antibodies
|
US9061006B2
(en)
|
2011-03-08 |
2015-06-23 |
Ramot At Tel-Aviv University Ltd. |
Compositions and methods for diagnosing and treating phenylketonuria (PKU)
|
HUE037095T2
(hu)
|
2011-03-09 |
2018-08-28 |
Cell Signaling Technology Inc |
Eljárások és reagensek monoklonális ellenanyagok elõállítására
|
EP2684045B2
(en)
|
2011-03-09 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods to characterize patients suffering from hemolysis
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
WO2012125569A2
(en)
|
2011-03-11 |
2012-09-20 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
EP2686016B1
(en)
|
2011-03-14 |
2019-05-01 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
WO2012125735A1
(en)
|
2011-03-15 |
2012-09-20 |
Abott Laboratories |
An integrated approach to the isolation and purification of antibodies
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
EP3235508B1
(en)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Compositions comprising a dual v region antibody-like protein
|
EP2686348B1
(en)
|
2011-03-17 |
2015-12-30 |
Ramot at Tel-Aviv University Ltd. |
Bi- and monospecific, asymmetric antibodies and methods of generating the same
|
TW201239355A
(en)
|
2011-03-23 |
2012-10-01 |
Abbott Lab |
Methods and systems for the analysis of protein samples
|
EP2688585B1
(en)
|
2011-03-23 |
2018-09-05 |
The Regents of The University of California |
Methods and compositions for improving antiangiogenic therapy with anti-integrins
|
WO2012129520A1
(en)
|
2011-03-24 |
2012-09-27 |
Texas Tech University System |
Tcr mimic antibodies as vascular targeting tools
|
US9051619B2
(en)
|
2011-03-25 |
2015-06-09 |
Florida Agricultural and Mechanical University (FAMU) |
Methods and compositions for prostate cancer metastasis
|
KR20140022845A
(ko)
|
2011-03-25 |
2014-02-25 |
제넨테크, 인크. |
신규 단백질 정제 방법
|
MX354359B
(es)
|
2011-03-29 |
2018-02-28 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
WO2012131053A1
(en)
|
2011-03-30 |
2012-10-04 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against tnf-alpha
|
US20140030276A1
(en)
|
2011-03-31 |
2014-01-30 |
Oriental Yeast Co., Ltd. |
Cancer immunopotentiating agent containing rankl antagonist
|
BR112013023787A2
(pt)
|
2011-03-31 |
2017-06-13 |
Genentech Inc |
método de tratamento de um distúrbio inflamatório gastrointestinal em um paciente, artigo de manufatura e método para induzir a remissão prolongada em um paciente sofrendo de colite ulcerativa
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
JP6220774B2
(ja)
|
2011-03-31 |
2017-10-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Icosに対する抗体及びその使用
|
AU2012240231B2
(en)
|
2011-04-04 |
2017-05-25 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
EP2694095B1
(en)
|
2011-04-05 |
2018-03-07 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
CN103596983B
(zh)
|
2011-04-07 |
2016-10-26 |
霍夫曼-拉罗奇有限公司 |
抗fgfr4抗体及使用方法
|
EP2952210A3
(en)
|
2011-04-07 |
2016-03-16 |
Emory University |
Compositions comprising saccharide binding moieties and methods for targeted therapy
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
EP2694108B1
(en)
|
2011-04-08 |
2018-06-06 |
University Of Leicester |
Methods for treating conditions associated with masp-2 dependent complement activation
|
US20140186340A1
(en)
|
2011-04-08 |
2014-07-03 |
Gilead Biologics, Inc. |
Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
|
US20140031272A1
(en)
|
2011-04-08 |
2014-01-30 |
Danisco Us Inc. |
Compositions
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
AU2012239961A1
(en)
|
2011-04-08 |
2013-10-24 |
Biogen Ma Inc. |
Biomarkers predictive of therapeutic responsiveness to IFNbeta and uses thereof
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
EP2511293A1
(en)
|
2011-04-13 |
2012-10-17 |
LEK Pharmaceuticals d.d. |
A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
|
US20140157443A1
(en)
|
2011-04-14 |
2014-06-05 |
St. Jude Children's Research Hospital |
Methods and compositions for detecting and modulating a novel mtor complex
|
CN105601741A
(zh)
|
2011-04-15 |
2016-05-25 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
EP2514831A1
(en)
|
2011-04-19 |
2012-10-24 |
Pronota NV |
New biomarker for measuring beta cell activity
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
EP3699286A1
(en)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-emapii 항체 및 이의 용도
|
EP3020428A1
(en)
|
2011-04-21 |
2016-05-18 |
AbbVie Inc. |
Wearable automatic injection device for controlled administration of therapeutic agents
|
AU2012245073B2
(en)
|
2011-04-21 |
2016-02-11 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
US20140127240A1
(en)
|
2011-04-21 |
2014-05-08 |
Bayer Pharma Aktiengesellschaft |
Novel Binder-Drug Conjugates (ADCs) and Use of Same
|
JP6152090B2
(ja)
|
2011-04-21 |
2017-06-21 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
視神経脊髄炎を処置するための組成物および方法
|
CN107189997A
(zh)
|
2011-04-21 |
2017-09-22 |
洛克菲勒大学 |
用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
|
KR102007444B1
(ko)
|
2011-04-25 |
2019-08-06 |
어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 |
절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
|
EP2518157A1
(en)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Test Systems and methods for identifying a compound altering cellular DDR activity
|
US10487114B2
(en)
|
2011-04-27 |
2019-11-26 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
|
GB2490655A
(en)
|
2011-04-28 |
2012-11-14 |
Univ Aston |
Modulators of tissue transglutaminase
|
WO2012149246A1
(en)
|
2011-04-29 |
2012-11-01 |
Novartis Ag |
Methods of treating squamous cell carcinoma related applications
|
US20140065164A1
(en)
|
2011-04-29 |
2014-03-06 |
Bristol-Myers Squibb Company |
Ip-10 antibody dosage escalation regimens
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
UY34054A
(es)
|
2011-05-02 |
2012-11-30 |
Millennium Pharm Inc |
FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
US20140178398A1
(en)
|
2011-05-03 |
2014-06-26 |
Genentech, Inc |
Vascular disruption agents and uses thereof
|
WO2012151465A1
(en)
|
2011-05-04 |
2012-11-08 |
Pop Test, Llc |
Diagnostic device
|
KR102024016B1
(ko)
|
2011-05-04 |
2019-11-04 |
오메로스 코포레이션 |
Masp-2 의존적 보체 활성화를 억제하는 조성물
|
WO2015067913A1
(en)
|
2013-11-07 |
2015-05-14 |
Diagnodus Limited |
Biomarkers
|
GB201107467D0
(en)
|
2011-05-05 |
2011-06-15 |
Univ Leuven Kath |
Novel treatment of pain
|
RU2600067C2
(ru)
|
2011-05-06 |
2016-10-20 |
Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретари Оф Дзе Депармент Оф Хелс Энд Хьюман Сёрвисез |
Рекомбинантный иммунотоксин, нацеленный на мезотелин
|
EP2707031B1
(en)
|
2011-05-08 |
2019-06-26 |
LegoChem Biosciences, Inc. |
Protein-active agent conjugates and method for preparing the same
|
US20140086827A1
(en)
|
2011-05-09 |
2014-03-27 |
The Cleveland Clinic Foundation |
Serum S100B And Uses Thereof
|
CN103534272B
(zh)
|
2011-05-09 |
2016-05-11 |
株式会社英仙蛋白质科学 |
能够特异性识别转铁蛋白受体的抗体
|
JP2014518624A
(ja)
|
2011-05-12 |
2014-08-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
ニューログラニン診断キットのためのアッセイ試薬
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
CN103596980B
(zh)
|
2011-05-16 |
2017-08-08 |
霍夫曼-拉罗奇有限公司 |
Fgfr1激动剂及使用方法
|
CA2836468C
(en)
|
2011-05-17 |
2021-05-04 |
The Rockefeller University |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
|
EP2524699A1
(en)
|
2011-05-17 |
2012-11-21 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
ES2703780T3
(es)
|
2011-05-17 |
2019-03-12 |
Trion Res Gmbh |
Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno
|
WO2012156447A1
(en)
|
2011-05-18 |
2012-11-22 |
Pronota N.V. |
New biomarker for the classification of ovarian tumours
|
WO2012159079A1
(en)
|
2011-05-18 |
2012-11-22 |
The Parkinson's Institute |
Assay to determine lrrk2 activity in parkinson's disease
|
AU2012255143A1
(en)
|
2011-05-19 |
2014-02-20 |
The Regents Of The University Of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
CN103890010B
(zh)
|
2011-05-19 |
2017-04-19 |
法国国家健康医学研究院 |
抗‑人‑her3抗体及其用途
|
NZ732875A
(en)
|
2011-05-20 |
2022-08-26 |
H Lundbeck As |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
KR101965461B1
(ko)
|
2011-05-20 |
2019-04-04 |
앨더바이오 홀딩스 엘엘씨 |
필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
|
LT3495392T
(lt)
|
2011-05-20 |
2021-09-27 |
H. Lundbeck A/S |
Anti-cgrp kompozicijos ir jų panaudojimas
|
KR20190105112A
(ko)
|
2011-05-21 |
2019-09-11 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
KR102046666B1
(ko)
|
2011-05-25 |
2019-11-19 |
이나뜨 파르마 |
염증성 장애의 치료를 위한 항-kir 항체
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
ES2953190T3
(es)
|
2011-05-27 |
2023-11-08 |
Glaxo Group Ltd |
Proteínas de unión a BCMA (CD269/TNFRSF17)
|
JP2014516551A
(ja)
|
2011-06-02 |
2014-07-17 |
マサチューセッツ インスティテュート オブ テクノロジー |
メタカリオート(metakaryotic)幹細胞のdsRNA/DNAハイブリッドゲノム複製中間体
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
BR112013030958B1
(pt)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
EP2718327A1
(en)
|
2011-06-06 |
2014-04-16 |
Neotope Biosciences Limited |
Mcam antagonists and methods of treatment
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
EP2717913A4
(en)
|
2011-06-08 |
2014-11-26 |
Univ Indiana Res & Tech Corp |
MONOCLONAL ANTIBODIES AND ANTIGENS FOR DIAGNOSING AND TREATING PULMONARY DISEASE AND INJURY
|
WO2012168399A1
(en)
|
2011-06-08 |
2012-12-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting, treating and modelling hormone resistance
|
AU2012268013B2
(en)
|
2011-06-09 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
|
BE1021759B1
(fr)
|
2011-06-10 |
2016-01-15 |
Universite Libre De Bruxelles |
Marqueurs pour la consolidation alteree des fractures osseuses
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
KR102111171B1
(ko)
|
2011-06-10 |
2020-05-14 |
메디뮨 엘엘씨 |
항슈도모나스 psl 결합 분자 및 그의 용도
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
WO2012168484A1
(en)
|
2011-06-10 |
2012-12-13 |
Université Libre de Bruxelles |
Targets and agents for the treatment of impaired bone fracture healing
|
AU2012267484B2
(en)
|
2011-06-10 |
2017-03-23 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
JP6187777B2
(ja)
|
2011-06-13 |
2017-08-30 |
シーエスエル、リミテッド |
G−csfrに対する抗体およびその使用
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2720720B1
(en)
|
2011-06-14 |
2018-02-28 |
Yeda Research and Development Co. Ltd. |
Combination therapy to prevent dcis formation and progression to breast cancer
|
MX2013014008A
(es)
|
2011-06-15 |
2014-03-12 |
Hoffmann La Roche |
Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
MX2013014847A
(es)
|
2011-06-17 |
2015-01-12 |
Amgen Inc |
Metodo para tratar o aminorar trastornos metabolicos udando clec-2.
|
EP2723362A1
(en)
|
2011-06-21 |
2014-04-30 |
Innate Pharma |
NKp46-MEDIATED NK CELL TUNING
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
CA2839508A1
(en)
|
2011-06-22 |
2012-12-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-axl antibodies and uses thereof
|
BR112013032899A2
(pt)
|
2011-06-22 |
2017-01-24 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
anticorpos anti-axl e utilizações dos mesmos
|
CN103649125A
(zh)
|
2011-06-22 |
2014-03-19 |
霍夫曼-拉罗奇有限公司 |
利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
|
WO2013003555A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
PT2726508T
(pt)
|
2011-06-28 |
2017-09-26 |
Oxford Biotherapeutics Ltd |
Anticorpos para adp-ribosil ciclase 2
|
PL2726094T3
(pl)
|
2011-06-28 |
2017-06-30 |
Oxford Biotherapeutics Ltd |
Cel terapeutyczny i diagnostyczny
|
MX2013014687A
(es)
|
2011-06-30 |
2014-02-17 |
Genentech Inc |
Formulaciones de anticuerpo anti-c-met.
|
HUE040455T2
(hu)
|
2011-06-30 |
2019-03-28 |
Genzyme Corp |
T-sejt aktiválás inhibitorai
|
CN103619874A
(zh)
|
2011-06-30 |
2014-03-05 |
株式会社免疫生物研究所 |
可溶性整联蛋白α4突变体
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CN102268089A
(zh)
|
2011-07-05 |
2011-12-07 |
上海交通大学 |
Agr2阻断抗体及其用途
|
EP2543679A1
(en)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the treatment and prevention of thrombosis
|
EP2543677A1
(en)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the treatment and prevention of thrombosis
|
EP2732021B1
(en)
|
2011-07-08 |
2020-05-27 |
EMD Millipore Corporation |
Improved depth filters for disposable biotechnological processes
|
EP2543678A1
(en)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the treatment and prevention of thrombosis
|
AU2012282116B2
(en)
|
2011-07-11 |
2016-07-07 |
Ichnos Sciences SA |
Antibodies that bind to OX40 and their uses
|
WO2013009767A2
(en)
|
2011-07-12 |
2013-01-17 |
Epitomics, Inc. |
Facs-based method for obtaining an antibody sequence
|
CN103857411A
(zh)
|
2011-07-13 |
2014-06-11 |
阿布维公司 |
使用抗il-13抗体治疗哮喘的方法和组合物
|
US9835621B2
(en)
|
2011-07-14 |
2017-12-05 |
University Of Kentucky Research Foundation |
Process for detection of alzheimer's disease from a serum sample
|
GB201112091D0
(en)
|
2011-07-14 |
2011-08-31 |
Gt Biolog Ltd |
Bacterial strains isolated from pigs
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
US9156911B2
(en)
|
2011-07-18 |
2015-10-13 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
EP2548891A1
(en)
|
2011-07-18 |
2013-01-23 |
Universiteit Maastricht |
Human monoclonal antibody against the gamma subunit of the acetylcholine receptor for use in the treatment of rhabdomyosarcoma.
|
WO2013012894A1
(en)
|
2011-07-18 |
2013-01-24 |
The Ohio State University |
Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
|
WO2013011072A1
(en)
|
2011-07-20 |
2013-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Carbapenemase and antibacterial treatment
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013014538A2
(en)
|
2011-07-25 |
2013-01-31 |
American University In Cairo |
Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
|
WO2013015367A1
(ja)
|
2011-07-26 |
2013-01-31 |
独立行政法人産業技術総合研究所 |
上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法
|
JP5849254B2
(ja)
|
2011-07-26 |
2016-01-27 |
国立研究開発法人産業技術総合研究所 |
上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法
|
ES2872964T3
(es)
|
2011-07-27 |
2021-11-03 |
Philogen Spa |
Inmunoconjugado de IL-12
|
EP2737083A1
(en)
|
2011-07-27 |
2014-06-04 |
INSERM (Institut National de la Santé et de la Recherche Scientifique) |
Methods for diagnosing and treating myhre syndrome
|
KR20140050689A
(ko)
|
2011-07-28 |
2014-04-29 |
제넨테크, 인크. |
Pik3ca h1047r 녹-인 비인간 동물 유방암 모델
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
TW201840336A
(zh)
|
2011-08-01 |
2018-11-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
CN103975241B
(zh)
|
2011-08-03 |
2016-01-20 |
奎德尔公司 |
用于提高a型链球菌免疫测定法的特异性的n-乙酰基-d-葡糖胺
|
WO2013017691A1
(en)
|
2011-08-04 |
2013-02-07 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
EP2739310B1
(en)
|
2011-08-05 |
2018-04-18 |
Research Development Foundation |
Improved methods and compositions for modulation of olfml3 mediated angiogenesis
|
WO2013021228A1
(en)
|
2011-08-10 |
2013-02-14 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Early childhood membranous nephropathy due to cationic bovine serum albumin
|
EP3939613A1
(en)
|
2011-08-11 |
2022-01-19 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
JP5925783B2
(ja)
|
2011-08-12 |
2016-05-25 |
国立感染症研究所長 |
アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
|
WO2013023994A1
(en)
|
2011-08-12 |
2013-02-21 |
Pronota N.V. |
New biomarker for the classification of ovarian tumours
|
EP2741777B1
(en)
|
2011-08-12 |
2017-01-18 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
US9605083B2
(en)
|
2011-08-16 |
2017-03-28 |
Emory University |
JAML specific binding agents, antibodies, and uses related thereto
|
EP2744823B1
(en)
|
2011-08-17 |
2017-08-02 |
The Regents of the University of California |
Antibodies that bind integrin alpha-v beta-8
|
JP2014526891A
(ja)
|
2011-08-17 |
2014-10-09 |
ジェネンテック, インコーポレイテッド |
ニューレグリン抗体とその使用
|
KR20140068877A
(ko)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
불응성 종양에서의 혈관신생의 억제
|
WO2013025936A1
(en)
|
2011-08-18 |
2013-02-21 |
Cornell University |
Detection and treatment of metastatic disease
|
CN103890246A
(zh)
|
2011-08-18 |
2014-06-25 |
亲和生物科学公司 |
可溶性多肽
|
WO2013028330A2
(en)
|
2011-08-19 |
2013-02-28 |
Emd Millipore Corporation |
Methods of reducing level of one of more impurities in a sample during protein purification
|
BR112014004162A2
(pt)
|
2011-08-22 |
2018-04-24 |
Cangene Corp |
anticorpos contra clostridium difficile
|
KR101723273B1
(ko)
|
2011-08-23 |
2017-04-04 |
로슈 글리카트 아게 |
2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
AU2012298884B2
(en)
|
2011-08-23 |
2017-11-16 |
Foundation Medicine, Inc. |
Novel KIF5B-RET fusion molecules and uses thereof
|
RU2014109038A
(ru)
|
2011-08-23 |
2015-09-27 |
Рош Гликарт Аг |
Антитела к хондроитинсульфат протеогликану меланомы
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9360630B2
(en)
|
2011-08-31 |
2016-06-07 |
Volcano Corporation |
Optical-electrical rotary joint and methods of use
|
MX346560B
(es)
|
2011-09-01 |
2017-03-24 |
Eisai R&D Man Co Ltd |
Anticuerpos anti-xcr1 humano.
|
KR101851425B1
(ko)
|
2011-09-02 |
2018-04-23 |
네스텍 소시에테아노님 |
치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
CA2846667A1
(en)
|
2011-09-06 |
2013-03-14 |
Guy L. Reed |
Serpinf2-binding molecules and methods of use
|
WO2013035824A1
(ja)
|
2011-09-07 |
2013-03-14 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞の分離
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
AU2012305807B2
(en)
|
2011-09-09 |
2015-08-20 |
Department of Medical Sciences (DMSc) |
Dengue-virus serotype neutralizing antibodies
|
US10040853B2
(en)
|
2011-09-09 |
2018-08-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving NKG2D inhibitors and cancer
|
US20140378537A1
(en)
|
2011-09-09 |
2014-12-25 |
Genentech, Inc. |
Treatment of th17 mediated inflammatory diseases
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EA201490623A1
(ru)
|
2011-09-12 |
2016-01-29 |
Янссен Байотек Инк. |
Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
US8840838B2
(en)
|
2011-09-25 |
2014-09-23 |
Theranos, Inc. |
Centrifuge configurations
|
US9619627B2
(en)
|
2011-09-25 |
2017-04-11 |
Theranos, Inc. |
Systems and methods for collecting and transmitting assay results
|
US8435738B2
(en)
|
2011-09-25 |
2013-05-07 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
US10093705B2
(en)
|
2011-09-13 |
2018-10-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
US9268915B2
(en)
|
2011-09-25 |
2016-02-23 |
Theranos, Inc. |
Systems and methods for diagnosis or treatment
|
US9632102B2
(en)
|
2011-09-25 |
2017-04-25 |
Theranos, Inc. |
Systems and methods for multi-purpose analysis
|
US8475739B2
(en)
|
2011-09-25 |
2013-07-02 |
Theranos, Inc. |
Systems and methods for fluid handling
|
US20140170735A1
(en)
|
2011-09-25 |
2014-06-19 |
Elizabeth A. Holmes |
Systems and methods for multi-analysis
|
US9664702B2
(en)
|
2011-09-25 |
2017-05-30 |
Theranos, Inc. |
Fluid handling apparatus and configurations
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
EP2756307B1
(en)
|
2011-09-15 |
2020-10-21 |
Vaxil Bio Therapeutics Ltd. |
Antibodies directed against signal peptides, methods and uses thereof
|
US9206240B2
(en)
|
2011-09-16 |
2015-12-08 |
The United States of America, as represented by the Secretary, Department of Helath and Human Services |
Pseudomonas exotoxin A with less immunogenic B cell epitopes
|
CN103930111A
(zh)
|
2011-09-19 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
包含c-met拮抗剂和b-raf拮抗剂的组合治疗
|
US9127040B2
(en)
|
2011-09-20 |
2015-09-08 |
The University Of North Carolina At Chapel Hill |
Regulation of sodium channels by PLUNC proteins
|
US9599608B2
(en)
|
2011-09-21 |
2017-03-21 |
Fujirebio Inc. |
Antibody against affinity complex
|
CA2846432A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
ES2707580T3
(es)
|
2011-09-23 |
2019-04-04 |
Oncomed Pharm Inc |
Agentes de unión a VEGF/DLL4 y usos de los mismos
|
CA2845147A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
SG10201504605RA
(en)
|
2011-09-23 |
2015-07-30 |
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa |
Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
|
US10012664B2
(en)
|
2011-09-25 |
2018-07-03 |
Theranos Ip Company, Llc |
Systems and methods for fluid and component handling
|
US9250229B2
(en)
|
2011-09-25 |
2016-02-02 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
US9810704B2
(en)
|
2013-02-18 |
2017-11-07 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
WO2013045125A1
(en)
|
2011-09-26 |
2013-04-04 |
Philogen S.P.A. |
Immunocytokine combination therapy
|
US20140234307A1
(en)
|
2011-09-27 |
2014-08-21 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
GB2495113A
(en)
|
2011-09-29 |
2013-04-03 |
Bioinvent Int Ab |
Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
|
WO2013049666A1
(en)
|
2011-09-30 |
2013-04-04 |
Sarcotein Diagnostics, Llc |
Bin1 expression as a marker of cancer
|
CN103958543B
(zh)
|
2011-09-30 |
2016-12-14 |
达纳-法伯癌症研究所股份有限公司 |
治疗肽
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
EA035018B1
(ru)
|
2011-09-30 |
2020-04-17 |
Тева Фармасьютикал Австралия Пти Лтд. |
АНТИТЕЛА К TL1a И ИХ ПРИМЕНЕНИЕ
|
RU2707251C2
(ru)
|
2011-10-03 |
2019-11-25 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
AR088048A1
(es)
|
2011-10-04 |
2014-05-07 |
Univ Columbia |
Señuelos notch1 humanos
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
WO2013052155A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
ES2683035T3
(es)
|
2011-10-05 |
2018-09-24 |
The Rockefeller University |
Lisinas de bacteriófago diméricas
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
CN103906767A
(zh)
|
2011-10-10 |
2014-07-02 |
米迪缪尼有限公司 |
对类风湿关节炎的治疗
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
CN104093744A
(zh)
|
2011-10-11 |
2014-10-08 |
弗·哈夫曼-拉罗切有限公司 |
双特异性抗体的改进的组装
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
WO2013055908A1
(en)
|
2011-10-12 |
2013-04-18 |
The Scripps Research Institute |
An hiv-1 gp120 mini v3 loop and uses thereof
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
CN104039351A
(zh)
|
2011-10-13 |
2014-09-10 |
阿尔皮奥治疗学股份有限公司 |
用于治疗血管渗漏综合征和癌症的方法
|
AU2012323849B2
(en)
|
2011-10-13 |
2017-04-20 |
EyePoint Pharmaceuticals, Inc. |
Treatment of ocular disease
|
EP2581388A1
(en)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Anti-sPLA2-V antibodies and uses thereof
|
EP2766028B1
(en)
|
2011-10-14 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Peptide inhibitors of bace1
|
DK2766040T3
(da)
|
2011-10-14 |
2019-07-22 |
Hoffmann La Roche |
Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
|
KR101877598B1
(ko)
|
2011-10-14 |
2018-07-11 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
EP2766033B1
(en)
|
2011-10-14 |
2019-11-20 |
Novartis AG |
Antibodies and methods for wnt pathway-related diseases
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
CN103917556B
(zh)
|
2011-10-14 |
2018-02-06 |
霍夫曼-拉罗奇有限公司 |
抗HtrA1抗体及使用方法
|
AU2012322891A1
(en)
|
2011-10-14 |
2014-05-15 |
Mycartis Nv |
Procathepsin L and cathepsin L as biomarkers for ischemia
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
AU2012326137B2
(en)
|
2011-10-17 |
2018-11-29 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
EP2768971A1
(en)
|
2011-10-20 |
2014-08-27 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods for the detection and the treatment of cardiac remodeling
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
US20140322758A1
(en)
|
2011-10-21 |
2014-10-30 |
Pfizer Inc. |
Addition of iron to improve cell culture
|
CN104203978A
(zh)
|
2011-10-24 |
2014-12-10 |
艾伯维股份有限公司 |
针对硬化蛋白的免疫结合剂
|
WO2013063186A2
(en)
|
2011-10-26 |
2013-05-02 |
Novartis Animal Health Us, Inc. |
Monoclonal antibodies and methods of use
|
RU2014120577A
(ru)
|
2011-10-26 |
2015-12-10 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Моноклональное антитело cd44 для лечения b-клеточной хронической лимфоцитарной лейкемии и других гематологических злокачественных заболеваний
|
WO2013061328A2
(en)
|
2011-10-27 |
2013-05-02 |
Yeda Research And Development Co. Ltd. |
Method of treating cancer
|
US20140302511A1
(en)
|
2011-10-28 |
2014-10-09 |
Pharmalogicals Research Pte. Ltd. |
Cancer stem cell-specific molecule
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
KR102232811B1
(ko)
|
2011-10-28 |
2021-03-29 |
프레닥스 에이비 |
치료제 및 이의 용도
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
CA2853822A1
(en)
|
2011-10-28 |
2013-05-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
LT3091029T
(lt)
|
2011-10-31 |
2023-02-27 |
F. Hoffmann-La Roche Ag |
Anti-il13 antikūno kompozicijos
|
CA2853230C
(en)
|
2011-10-31 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
CA2854330A1
(en)
|
2011-11-02 |
2013-05-10 |
Genentech, Inc. |
Overload and elute chromatography
|
JP5837215B2
(ja)
|
2011-11-02 |
2015-12-24 |
ユニバーシティー オブ ロチェスター |
黄色ブドウ球菌(Staphylococcusaureus)感染症に対する抗グルコサミニダーゼ受動免疫処置
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
PT2773671T
(pt)
|
2011-11-04 |
2021-12-14 |
Zymeworks Inc |
Geração de anticorpo heterodimérico estável com mutações no domínio fc
|
KR102184343B1
(ko)
|
2011-11-07 |
2020-11-30 |
메디뮨 엘엘씨 |
항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법
|
CA2854372A1
(en)
|
2011-11-07 |
2013-05-16 |
Universite Laval |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
EP2592103A1
(en)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymer aldehyde derivatives
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
WO2013071233A1
(en)
|
2011-11-10 |
2013-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for detecting infectious agents and a novel virus detected thereby
|
EP2776586B1
(en)
|
2011-11-11 |
2018-03-07 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
SG11201401649VA
(en)
|
2011-11-11 |
2014-07-30 |
Ucb Pharma Sa |
Albumin binding antibodies and binding fragments thereof
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
CA2855356A1
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
DK2780373T3
(da)
|
2011-11-16 |
2019-11-04 |
Boehringer Ingelheim Int |
Anti-IL-36R-antistoffer
|
US8828401B2
(en)
|
2011-11-17 |
2014-09-09 |
Pfizer Inc. |
Cytotoxic peptides and antibody drug conjugates thereof
|
MX2014005642A
(es)
|
2011-11-18 |
2014-07-11 |
Hoffmann La Roche |
Reactivo de liberacion para compuesto de vitamida d.
|
CN104066748A
(zh)
|
2011-11-21 |
2014-09-24 |
霍夫曼-拉罗奇有限公司 |
抗c-met抗体的纯化
|
CA2854244A1
(en)
|
2011-11-22 |
2013-05-30 |
Cnrs (Centre National De La Recherche Scientifique) |
Methods and pharmaceutical compositions for reducing airway hyperresponse
|
US20140322723A1
(en)
|
2011-11-22 |
2014-10-30 |
President and Dellows of Harvard College |
Diabetes diagnosis through the detection of glycated proteins in urine
|
RU2620068C2
(ru)
|
2011-11-23 |
2017-05-22 |
МЕДИММЬЮН, ЭлЭлСи |
Связывающие молекулы, специфичные по отношению к her3, и их применения
|
RU2014124530A
(ru)
|
2011-11-23 |
2015-12-27 |
Идженика, Инк. |
Антитела к cd98 и способы их применения
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-pd-l1 항체 및 그의 용도
|
JP6082402B2
(ja)
|
2011-11-28 |
2017-02-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
加齢に伴う機能障害の処置に使用するための薬学的組成物
|
AR089028A1
(es)
|
2011-11-29 |
2014-07-23 |
Genentech Inc |
Composiciones y metodos para el analisis de cancer de prostata
|
EP2599496A1
(en)
|
2011-11-30 |
2013-06-05 |
Kenta Biotech AG |
Novel targets of Acinetobacter baumannii
|
US20150147274A1
(en)
|
2011-12-02 |
2015-05-28 |
Cancer Research Technology Limited |
Antibodies against hgf - receptor and uses
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
JP6483442B2
(ja)
|
2011-12-05 |
2019-03-13 |
エックス−ボディ インコーポレイテッド |
Pdgf受容体ベータ結合ポリペプチド
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
EP2602265A1
(en)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antibodies anti-sPLA2-X and uses thereof
|
WO2013083781A2
(en)
|
2011-12-08 |
2013-06-13 |
Pronota N.V. |
Biomarkers and test panels useful in systemic inflammatory conditions
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
SG11201402375VA
(en)
|
2011-12-08 |
2014-10-30 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
CA2858455A1
(en)
|
2011-12-09 |
2013-06-13 |
Pronota N.V. |
Ltbp2 as a biomarker for lung injury
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
WO2013088136A1
(en)
|
2011-12-12 |
2013-06-20 |
Ahrens Susan |
Ligand for dngr-1 receptor
|
WO2013090635A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
GB201121564D0
(en)
|
2011-12-14 |
2012-01-25 |
Queen Mary & Westfield College |
Use of antibody
|
MX2014007121A
(es)
|
2011-12-14 |
2014-09-04 |
Seattle Genetics Inc |
Nuevos conjugados de principio activo-ligante (adc) y su uso.
|
WO2013090633A2
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CA2858876A1
(en)
|
2011-12-15 |
2013-06-20 |
The University Of Chicago |
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
WO2013087887A2
(en)
|
2011-12-15 |
2013-06-20 |
Pronota N.V. |
Biomarkers and parameters for hypertensive disorders of pregnancy
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
EP2793925B1
(en)
|
2011-12-19 |
2019-03-20 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
AU2012359039B2
(en)
|
2011-12-20 |
2017-08-24 |
Janssen Biotech, Inc. |
Anti-PHF-tau antibodies and their uses
|
GB201121891D0
(en)
|
2011-12-20 |
2012-02-01 |
Bakhiet Abdelmoiz |
Applications of an immune system-released activating agent (ISRAA)
|
AU2012356170B2
(en)
|
2011-12-21 |
2016-06-16 |
Novartis Ag |
Compositions and methods for antibodies targeting Factor P
|
EP3354660A1
(en)
|
2011-12-22 |
2018-08-01 |
F. Hoffmann-La Roche AG |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
SG10201601882PA
(en)
|
2011-12-22 |
2016-04-28 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
ES2710916T3
(es)
|
2011-12-22 |
2019-04-29 |
I2 Pharmaceuticals Inc |
Proteínas de unión sustitutas
|
BR112014014824A2
(pt)
|
2011-12-22 |
2019-09-24 |
Rinat Neuroscience Corp |
anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos
|
AU2012355356B2
(en)
|
2011-12-22 |
2017-10-12 |
Genentech, Inc. |
Ion exchange membrane chromatography
|
BR112014013035A2
(pt)
|
2011-12-22 |
2018-10-09 |
Hoffmann La Roche |
métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
GB201122325D0
(en)
|
2011-12-23 |
2012-02-01 |
Cytoguide As |
Novel formulations
|
US9717803B2
(en)
|
2011-12-23 |
2017-08-01 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
EP3539982A3
(en)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
US9823246B2
(en)
|
2011-12-28 |
2017-11-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon
|
AU2012362326A1
(en)
|
2011-12-30 |
2014-07-24 |
Abbvie Inc. |
Dual variable domain immunoglobulins against IL-13 and/or IL-17
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CA2858336A1
(en)
|
2012-01-01 |
2013-07-04 |
Qbi Enterprises Ltd. |
Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
RU2645252C2
(ru)
|
2012-01-05 |
2018-02-19 |
Глюкос Финланд Ой |
Клетка нитчатых грибов с дефицитом протеаз и способы ее применения
|
CA2862830A1
(en)
|
2012-01-06 |
2013-07-11 |
Bg Medicine, Inc. |
Use of galectin-3 for risk assessment and detection of preeclampsia and related conditions
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
NZ626620A
(en)
|
2012-01-10 |
2016-07-29 |
Biogen Ma Inc |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
CN102571433B
(zh)
|
2012-01-11 |
2014-07-30 |
华为技术有限公司 |
呈现网络路径的方法和装置
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
US9512212B2
(en)
|
2012-01-11 |
2016-12-06 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
WO2013104798A1
(en)
|
2012-01-12 |
2013-07-18 |
Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences |
Modulators of immune responses
|
CA2862835A1
(en)
|
2012-01-13 |
2013-07-18 |
Genentech, Inc. |
Biological markers for identifying patients for treatment with vegf antagonists
|
RU2014133547A
(ru)
|
2012-01-18 |
2016-03-10 |
Дженентек, Инк. |
Способы применения модуляторов fgf19
|
TW201335187A
(zh)
|
2012-01-18 |
2013-09-01 |
Genentech Inc |
抗lrp5抗體及使用方法
|
ES2698606T3
(es)
|
2012-01-20 |
2019-02-05 |
Genzyme Corp |
Anticuerpos anti-CXCR3
|
KR102081567B1
(ko)
|
2012-01-25 |
2020-02-26 |
디엔에이트릭스, 인코포레이티드 |
바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법
|
GB201201314D0
(en)
|
2012-01-26 |
2012-03-07 |
Isis Innovation |
Composition
|
IL297229A
(en)
|
2012-01-27 |
2022-12-01 |
Abbvie Inc |
The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
|
WO2013113755A1
(en)
|
2012-01-30 |
2013-08-08 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
CN104185681A
(zh)
|
2012-02-01 |
2014-12-03 |
卡姆普根有限公司 |
C1orf32抗体及其用于治疗癌症的用途
|
US9896695B2
(en)
|
2012-02-02 |
2018-02-20 |
Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) |
HAHB11 provides improved plant yield and tolerance to abiotic stress
|
PT2812443T
(pt)
|
2012-02-06 |
2019-09-05 |
Inhibrx Inc |
Anticorpos cd47 e métodos de utilização dos mesmos
|
MX363819B
(es)
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
US9546219B2
(en)
|
2012-02-08 |
2017-01-17 |
North Carolina State University |
Treatment of allergic diseases with recombinant antibodies
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
EP2812702B1
(en)
|
2012-02-10 |
2019-04-17 |
Seattle Genetics, Inc. |
Diagnosis and management of CD30-expressing cancers
|
JP6545959B2
(ja)
|
2012-02-11 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
Rスポンジン転位およびその使用方法
|
SG11201404608WA
(en)
|
2012-02-13 |
2014-09-26 |
Gamida Cell Ltd |
Mesenchymal stem cells conditioned medium and methods of generating and using the same
|
TR201808458T4
(tr)
|
2012-02-15 |
2018-07-23 |
Hoffmann La Roche |
FC-reseptör bazlı afinite kromatografisi.
|
LT2814844T
(lt)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
RS57827B1
(sr)
|
2012-02-15 |
2018-12-31 |
Novo Nordisk As |
Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
CA2864702A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
RU2014138474A
(ru)
|
2012-02-24 |
2016-04-10 |
СтемСентРкс, Инк. |
Новые модуляторы и способы применения
|
BR112014021477A2
(pt)
|
2012-02-29 |
2018-06-12 |
Gilead Sciences Inc |
anticorpos para metaloproteinase de matriz 9
|
US9732156B2
(en)
|
2012-02-29 |
2017-08-15 |
Gilead Biologics, Inc. |
Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Streptococcuspneumoniae抗原の増強された製剤
|
US9631028B2
(en)
|
2012-03-07 |
2017-04-25 |
Yeda Research And Development Co. Ltd. |
Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same
|
KR101666289B1
(ko)
|
2012-03-08 |
2016-10-13 |
에프. 호프만-라 로슈 아게 |
아밀로이드-베타 펩타이드 항체 제형
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
CN104411327A
(zh)
|
2012-03-12 |
2015-03-11 |
阿德瓦希斯公司 |
李斯特菌疫苗治疗以后的抑制细胞功能抑制
|
US20150098988A1
(en)
|
2012-03-13 |
2015-04-09 |
Hoffmann-La Roche Inc. |
Combination therapy for the treatment of ovarian cancer
|
EP3626254A1
(en)
|
2012-03-16 |
2020-03-25 |
University Health Network |
Soluble toso protein and its use in treating autoimmune disorders
|
ES2661516T3
(es)
|
2012-03-20 |
2018-04-02 |
Otago Innovation Limited |
Biomarcadores
|
EP3211002B1
(en)
|
2012-03-21 |
2020-05-13 |
Ben-Gurion University of The Negev |
Peptides derived from the ectodomain of nkp46
|
WO2013139956A1
(en)
|
2012-03-22 |
2013-09-26 |
Thrombogenics Nv |
Antibodies abrogating cell binding to lactadherin
|
EP2828280B1
(en)
|
2012-03-22 |
2018-05-02 |
Ramot at Tel-Aviv University Ltd. |
Plif multimeric peptides and uses thereof
|
EP2641916A1
(en)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Novel antibodies anti-sPLA2-IIA and uses thereof
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
JP6404208B2
(ja)
|
2012-03-27 |
2018-10-10 |
ジェネンテック, インコーポレイテッド |
特発性肺線維症の予後予測、診断および処置の方法
|
SI2831261T1
(en)
|
2012-03-27 |
2018-01-31 |
F.Hoffmann-La Roche |
A process for the production of low-level recombinant proteins DHNA (1,4-dihydroxy-2-naphthoate)
|
JP5733546B2
(ja)
|
2012-03-28 |
2015-06-10 |
国立大学法人広島大学 |
インテグリンα8β1の機能を阻害する事による線維化の抑制
|
MY184037A
(en)
|
2012-03-28 |
2021-03-17 |
Sanofi Sa |
Antibodies to bradykinin b1 receptor ligands
|
US9139659B2
(en)
|
2012-03-28 |
2015-09-22 |
Genentech, Inc. |
Idiotypic antibodies and uses thereof
|
HUE037613T2
(hu)
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
EP2831112A1
(en)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
CN104411332B
(zh)
|
2012-03-30 |
2018-11-23 |
索伦托治疗有限公司 |
与vegfr2结合的全人抗体
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
SG11201406184XA
(en)
|
2012-03-30 |
2014-10-30 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
EP2833892A4
(en)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
|
EA038600B1
(ru)
|
2012-04-02 |
2021-09-21 |
Берг Ллк |
Основанные на клетках перекрестные анализы и их применение
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
WO2013152011A1
(en)
|
2012-04-02 |
2013-10-10 |
Ab Biosciences, Inc. |
Novel human control antibodies and uses therefor
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
RU2018114903A
(ru)
|
2012-04-06 |
2019-03-04 |
Омерос Корпорейшн |
Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии
|
US9566329B2
(en)
|
2012-04-06 |
2017-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Live, attenuated rubella vector to express vaccine antigens
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
US20150106960A1
(en)
|
2012-04-11 |
2015-04-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method for diagnosing a skeletal ciliopathy
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
JP6162219B2
(ja)
|
2012-04-17 |
2017-07-12 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列
|
CN104245937B
(zh)
|
2012-04-17 |
2021-09-21 |
弗·哈夫曼-拉罗切有限公司 |
使用修饰的核酸表达多肽的方法
|
RU2014145830A
(ru)
|
2012-04-17 |
2016-06-10 |
Арсанис Байосайенсиз Гмбх |
Перекрестно-реактивные антитела против staphylococcus aureus
|
US10114023B2
(en)
|
2012-04-18 |
2018-10-30 |
Massachusetts Institute Of Technology |
Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV
|
PL2838998T3
(pl)
|
2012-04-18 |
2018-04-30 |
Cell Signaling Technology, Inc. |
EGFR i ROS1 w nowotworze
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
ES2743399T3
(es)
|
2012-04-20 |
2020-02-19 |
Merus Nv |
Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
CN104379741B
(zh)
|
2012-04-23 |
2021-07-20 |
基因先端领域株式会社 |
抗人cd69抗体及其用于医疗目的的用途
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
EP2841454A1
(en)
|
2012-04-24 |
2015-03-04 |
ThromboGenics N.V. |
Anti-pdgf-c antibodies
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
RU2727476C2
(ru)
|
2012-04-26 |
2020-07-21 |
Новартис Аг |
Антигены и антигенные композиции
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
PT2841456T
(pt)
|
2012-04-27 |
2018-10-19 |
Novo Nordisk As |
Proteinas de ligação ao antigénio do ligando de cd30 humano
|
WO2013162748A1
(en)
|
2012-04-27 |
2013-10-31 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
|
EP2844300B1
(en)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
CN104428000A
(zh)
|
2012-05-02 |
2015-03-18 |
纽约大学 |
治疗和预防金黄色葡萄球菌感染和相关病状的方法
|
MX368653B
(es)
|
2012-05-03 |
2019-10-10 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23p19.
|
EP2844291B1
(en)
|
2012-05-03 |
2019-02-13 |
Fibrogen, Inc. |
Methods for treating idiopathic pulmonary fibrosis
|
US9441045B2
(en)
|
2012-05-04 |
2016-09-13 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
EP2847589A1
(en)
|
2012-05-09 |
2015-03-18 |
Advanced Animal Diagnostics, Inc. |
Rapid detection of analytes in liquid samples
|
WO2013167681A1
(en)
|
2012-05-10 |
2013-11-14 |
Georg-August-Universität Göttingen |
CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
|
EP3492101A3
(en)
|
2012-05-10 |
2019-10-23 |
Massachusetts Institute Of Technology |
Agents for influenza neutralization
|
LT2847228T
(lt)
|
2012-05-10 |
2018-11-12 |
Bayer Pharma Aktiengesellschaft |
Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas
|
JP2013235003A
(ja)
|
2012-05-10 |
2013-11-21 |
Fujita Gakuen |
細胞におけるdna損傷の検出方法及びdna鎖切断応答性細胞表面抗原に対する抗体
|
US9416189B2
(en)
|
2012-05-11 |
2016-08-16 |
Microbial Chemistry Research Foundation |
Anti-CXADR antibody
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
CA2871445C
(en)
|
2012-05-11 |
2020-07-07 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
CN104470541A
(zh)
|
2012-05-14 |
2015-03-25 |
比奥根艾迪克Ma公司 |
用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
|
CN104271600B
(zh)
|
2012-05-14 |
2018-09-14 |
诺和诺德股份有限公司 |
稳定化的蛋白溶液
|
JP6423340B2
(ja)
|
2012-05-15 |
2018-11-14 |
シアトル ジェネティクス,インコーポレイティド |
自己安定化リンカー結合体
|
EP2849786B1
(en)
|
2012-05-15 |
2019-11-06 |
Eisai Inc. |
Methods for treatment of gastric cancer
|
US20150133381A1
(en)
|
2012-05-16 |
2015-05-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the diagnosis and the treatment of familial thoracic aortic aneurysms caused by tgfb2 loss of function mutations
|
US9399672B2
(en)
|
2012-05-17 |
2016-07-26 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Hepatitis C virus neutralizing antibody
|
WO2013173266A1
(en)
|
2012-05-17 |
2013-11-21 |
The Johns Hopkins University |
Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy
|
CA3062003C
(en)
|
2012-05-17 |
2022-01-11 |
Extend Biosciences, Inc. |
Vitamin d as a targeting group for therapeutic peptides
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
SG10201709555SA
(en)
|
2012-05-18 |
2017-12-28 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
WO2013177118A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
TW201400132A
(zh)
|
2012-05-21 |
2014-01-01 |
Genentech Inc |
改善血腦屏障運送之安全性之方法
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
JP2015520373A
(ja)
|
2012-05-22 |
2015-07-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
巣状分節性糸球体硬化症を診断及び処置するための方法
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
JP6294311B2
(ja)
|
2012-05-23 |
2018-03-14 |
ジェネンテック, インコーポレイテッド |
治療薬の選択方法
|
US9695454B2
(en)
|
2012-05-23 |
2017-07-04 |
Glykos Finland Oy |
Production of fucosylated glycoproteins
|
MX369626B
(es)
|
2012-05-24 |
2019-11-13 |
Mountgate Group Ltd |
Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
US10502737B2
(en)
|
2012-05-25 |
2019-12-10 |
The University Of Vermont And State Agriculture College |
Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
|
ES2695151T3
(es)
|
2012-05-31 |
2019-01-02 |
Innate Pharma |
Agentes de ligación a TLR3
|
EP2855528B1
(en)
|
2012-05-31 |
2019-06-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
SI2854841T1
(sl)
|
2012-06-04 |
2017-06-30 |
Diamedica Inc. |
Glikozilacijske izooblike humanega tkivnega kalikreina-1
|
CN104364264B
(zh)
|
2012-06-06 |
2018-07-24 |
硕腾服务有限责任公司 |
犬源化抗ngf抗体和其方法
|
WO2013184900A2
(en)
|
2012-06-06 |
2013-12-12 |
Sanofi Pasteur Biologics, Llc |
Immunogenic compositions and related methods
|
WO2013184912A2
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
JP2015521589A
(ja)
|
2012-06-08 |
2015-07-30 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
プロコアグラント化合物
|
CA2875451A1
(en)
|
2012-06-08 |
2013-12-12 |
Kinki University |
Antibody against transporter and use thereof
|
JP2015520182A
(ja)
|
2012-06-08 |
2015-07-16 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
アミノ酸置換を有するヒト化抗TrkA抗体
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
キメラ性凝固因子
|
ES2843675T3
(es)
|
2012-06-11 |
2021-07-20 |
Univ Xiamen |
Polipéptidos y anticuerpos para el tratamiento de la infección por VHB y enfermedades relacionadas
|
MX2014015195A
(es)
|
2012-06-11 |
2015-02-17 |
Amgen Inc |
Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos.
|
US20130330761A1
(en)
|
2012-06-12 |
2013-12-12 |
Celcuity, LLC |
Whole cell assays and methods
|
US10155987B2
(en)
|
2012-06-12 |
2018-12-18 |
Dana-Farber Cancer Institute, Inc. |
Methods of predicting resistance to JAK inhibitor therapy
|
CN104619350A
(zh)
|
2012-06-14 |
2015-05-13 |
Ambrx公司 |
结合到核受体配体多肽的抗psma抗体
|
CA2915412A1
(en)
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
US10301389B2
(en)
|
2012-06-15 |
2019-05-28 |
Imaginab, Inc. |
Antigen binding constructs to CD3
|
KR20220100997A
(ko)
|
2012-06-18 |
2022-07-18 |
오메로스 코포레이션 |
다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
|
CA2877363A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
EP2864352B1
(en)
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
EP2864345B1
(en)
|
2012-06-25 |
2019-12-11 |
Emory University |
Particle-nucleic acid conjugates and therapeutic uses related thereto
|
US9676847B2
(en)
|
2012-06-25 |
2017-06-13 |
Orega Biotech |
IL-17 antagonist antibodies
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
WO2014001326A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
US9457071B2
(en)
|
2012-06-28 |
2016-10-04 |
Hiroshima University |
Histamine releaser contained in human sweat
|
WO2014004103A1
(en)
|
2012-06-29 |
2014-01-03 |
Emd Millipore Corporation |
Methods for inactivating viruses during a protein purification process
|
EP2682168A1
(en)
|
2012-07-02 |
2014-01-08 |
Millipore Corporation |
Purification of biological molecules
|
US20150218238A1
(en)
|
2012-06-29 |
2015-08-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Treating diseases by modulating a specific isoform of mkl1
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
EP2866829B1
(en)
|
2012-07-02 |
2017-12-06 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Paramyxovirus and methods of use
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
EP3339328A1
(en)
|
2012-07-04 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
EP2869848B1
(en)
|
2012-07-04 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Covalently linked antigen-antibody conjugates
|
EP2870238A4
(en)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
|
MX356162B
(es)
|
2012-07-05 |
2018-05-16 |
Genentech Inc |
Sistema de expresion y secrecion.
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
CA2873889A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Anti-cd22 antibodies and immunoconjugates
|
ES2661572T3
(es)
|
2012-07-09 |
2018-04-02 |
Genentech, Inc. |
Inmunoconjugados que comprenden anticuerpos anti-CD79b
|
EP2684896A1
(en)
|
2012-07-09 |
2014-01-15 |
International-Drug-Development-Biotech |
Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
|
CN104428007B
(zh)
|
2012-07-09 |
2018-03-16 |
基因泰克公司 |
包含抗cd22抗体的免疫缀合物
|
MX2015000359A
(es)
|
2012-07-09 |
2015-04-14 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b.
|
WO2014011908A1
(en)
|
2012-07-11 |
2014-01-16 |
Esperion Therapeutics, Inc. |
Apolipoprotein mixtures
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
HUE056217T2
(hu)
|
2012-07-13 |
2022-02-28 |
Roche Glycart Ag |
Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
EP2872526B1
(en)
|
2012-07-13 |
2020-04-01 |
The Trustees of the University of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
US20150184155A1
(en)
|
2012-07-18 |
2015-07-02 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for preventing and treating chronic kidney disease (ckd)
|
US20140024015A1
(en)
|
2012-07-18 |
2014-01-23 |
Idexx Laboratories, Inc. |
Boone Cardiovirus
|
MX2015000789A
(es)
|
2012-07-19 |
2015-05-07 |
Zoetis Llc |
Composiciones de virus de la gripe bovina.
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US20150175979A1
(en)
|
2012-07-23 |
2015-06-25 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
KR20200068756A
(ko)
|
2012-07-27 |
2020-06-15 |
박스알타 인코퍼레이티드 |
키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법
|
AU2013295770A1
(en)
|
2012-07-27 |
2015-01-29 |
Zoetis Services Llc |
Tick toxin compositions
|
WO2014021339A1
(ja)
|
2012-07-30 |
2014-02-06 |
国立大学法人名古屋大学 |
ヒトミッドカインに対するモノクローナル抗体
|
WO2014020293A1
(en)
|
2012-07-31 |
2014-02-06 |
Imperial Innovations Limited |
Assay
|
PL2880053T3
(pl)
|
2012-08-01 |
2021-01-11 |
Ikaika Therapeutics, Llc |
Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2880170B1
(en)
|
2012-08-02 |
2016-08-24 |
F. Hoffmann-La Roche AG |
METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
|
WO2014022759A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
SG11201500903XA
(en)
|
2012-08-07 |
2015-03-30 |
Genentech Inc |
Combination therapy for the treatment of glioblastoma
|
AU2013301582B2
(en)
|
2012-08-07 |
2018-09-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
WO2014027959A1
(en)
|
2012-08-14 |
2014-02-20 |
Nanyang Technological University |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
BR112015003326A2
(pt)
|
2012-08-16 |
2017-07-04 |
Ipierian Inc |
métodos de tratamento de uma tauopatia
|
WO2014027626A1
(ja)
|
2012-08-17 |
2014-02-20 |
国立大学法人広島大学 |
汗アレルギー抗原蛋白質に結合するモノクローナルIgE抗体
|
WO2014028939A2
(en)
|
2012-08-17 |
2014-02-20 |
California Institute Of Technology |
Targeting phosphofructokinase and its glycosylation form for cancer
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US20140056901A1
(en)
|
2012-08-21 |
2014-02-27 |
The Institute For Molecular Medicine |
Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
EP3597747B1
(en)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse fcgammarii-specific fc antibody
|
CA2882272C
(en)
|
2012-08-24 |
2023-08-29 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc region variant
|
US10501525B2
(en)
|
2012-08-28 |
2019-12-10 |
Novartis Ag |
Methods for purification of antibodies using aliphatic alcohols
|
PT2890712T
(pt)
|
2012-08-29 |
2019-06-28 |
Hoffmann La Roche |
Transportador para a barreira hematoencefálica
|
EP2891715A4
(en)
|
2012-08-30 |
2016-04-20 |
Univ Hiroshima |
CELLULAR PROLIFERATION REGULATION COMPOSITION CONTAINING PEPTIDE COMPRISING A PARTIAL SEQUENCE OF AMINO ACIDS FOR BBF2H7 (HUMAN HOMOLOGIDE OF BBF2 ON CHROMOSOME 7) OR ANTIBODY SUITABLE FOR BINDING PEPTIDE
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
PL2890717T3
(pl)
|
2012-08-31 |
2020-08-10 |
Immunogen, Inc. |
Testy i zestawy diagnostyczne do wykrywania receptora folianu
|
US9561266B2
(en)
|
2012-08-31 |
2017-02-07 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
EP2892928B1
(en)
|
2012-09-03 |
2018-05-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies directed against icos for treating graft-versus-host disease
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
EP2892544A4
(en)
|
2012-09-05 |
2016-11-02 |
Univ Virginia Patent Found |
TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS
|
PT2892560T
(pt)
|
2012-09-06 |
2019-10-18 |
Adelaide Research&Innovation Pty Ltd |
Métodos e produtos para prevenção e/ou tratamento do cancro metastático
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
FR2995214B1
(fr)
|
2012-09-10 |
2014-11-21 |
Adocia |
Solution a viscosite reduite de proteine a concentration elevee
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
ES2807173T3
(es)
|
2012-09-10 |
2021-02-22 |
Int Aids Vaccine Initiative |
Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
|
US10543278B2
(en)
|
2012-09-12 |
2020-01-28 |
Ramot At Tel-Aviv University Ltd. |
Immunoparticles and methods of generating and using same
|
WO2014042251A1
(ja)
|
2012-09-13 |
2014-03-20 |
中外製薬株式会社 |
遺伝子ノックイン非ヒト動物
|
ES2752190T3
(es)
|
2012-09-14 |
2020-04-03 |
Us Health |
Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
|
US9303071B2
(en)
|
2012-09-17 |
2016-04-05 |
Novartis Tiergesundheit Ag |
Salmonid alphavirus and uses thereof
|
CA2885230C
(en)
|
2012-09-19 |
2021-08-03 |
Anthony Letai |
Dynamic bh3 profiling
|
CN104603620B
(zh)
|
2012-09-24 |
2018-02-23 |
文塔纳医疗系统公司 |
使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法
|
EA031631B1
(ru)
|
2012-09-27 |
2019-01-31 |
Чугаи Сеияку Кабушики Каиша |
Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
|
EP3470431A1
(en)
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
CN111621507A
(zh)
|
2012-09-28 |
2020-09-04 |
北卡罗来纳-查佩尔山大学 |
靶向少突胶质细胞的aav载体
|
EP2904106A4
(en)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
|
NO2760138T3
(xx)
|
2012-10-01 |
2018-08-04 |
|
|
JP6486826B2
(ja)
|
2012-10-01 |
2019-03-20 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
|
US20140094383A1
(en)
|
2012-10-02 |
2014-04-03 |
Ohio State Innovation Foundation |
Tethered Lipoplex nanoparticle Biochips And Methods Of Use
|
JP6158933B2
(ja)
|
2012-10-03 |
2017-07-05 |
フィロゲン エスピーエー |
炎症性腸疾患に関連する抗原
|
JP6581505B2
(ja)
|
2012-10-03 |
2019-09-25 |
ザイムワークス,インコーポレイテッド |
重鎖および軽鎖ポリペプチドの対を定量化する方法
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
US9292918B2
(en)
|
2012-10-05 |
2016-03-22 |
Volcano Corporation |
Methods and systems for transforming luminal images
|
PL2903691T3
(pl)
|
2012-10-05 |
2019-10-31 |
Hoffmann La Roche |
Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
|
US9858668B2
(en)
|
2012-10-05 |
2018-01-02 |
Volcano Corporation |
Guidewire artifact removal in images
|
US10568586B2
(en)
|
2012-10-05 |
2020-02-25 |
Volcano Corporation |
Systems for indicating parameters in an imaging data set and methods of use
|
US11272845B2
(en)
|
2012-10-05 |
2022-03-15 |
Philips Image Guided Therapy Corporation |
System and method for instant and automatic border detection
|
US9307926B2
(en)
|
2012-10-05 |
2016-04-12 |
Volcano Corporation |
Automatic stent detection
|
US9367965B2
(en)
|
2012-10-05 |
2016-06-14 |
Volcano Corporation |
Systems and methods for generating images of tissue
|
US9324141B2
(en)
|
2012-10-05 |
2016-04-26 |
Volcano Corporation |
Removal of A-scan streaking artifact
|
WO2014055880A2
(en)
|
2012-10-05 |
2014-04-10 |
David Welford |
Systems and methods for amplifying light
|
US10070827B2
(en)
|
2012-10-05 |
2018-09-11 |
Volcano Corporation |
Automatic image playback
|
US9286673B2
(en)
|
2012-10-05 |
2016-03-15 |
Volcano Corporation |
Systems for correcting distortions in a medical image and methods of use thereof
|
AU2013329372B2
(en)
|
2012-10-08 |
2018-07-12 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
US9877981B2
(en)
|
2012-10-09 |
2018-01-30 |
President And Fellows Of Harvard College |
NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
EP3750560A3
(en)
|
2012-10-09 |
2021-03-24 |
Biogen MA Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
EP2906954B1
(en)
|
2012-10-09 |
2018-04-11 |
Ramot at Tel-Aviv University Ltd. |
Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
|
US20150231240A1
(en)
|
2012-10-09 |
2015-08-20 |
Igenica Biotherapeutics, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
ES2660029T3
(es)
|
2012-10-12 |
2018-03-20 |
Medimmune Limited |
Conjugados de anticuerpo-pirrolobenzodiazepinas
|
HUE035694T2
(en)
|
2012-10-12 |
2018-05-28 |
Adc Therapeutics Sa |
Pirrolobenzodiazepine anti-CD22 antibody conjugates
|
TR201902494T4
(tr)
|
2012-10-12 |
2019-03-21 |
Medimmune Ltd |
Pirrolobenzodiazepinler ve onların konjugatları.
|
ES2703151T3
(es)
|
2012-10-12 |
2019-03-07 |
Adc Therapeutics Sa |
Conjugados de anticuerpos de pirrolobenzodiazepinas
|
NZ707486A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
SI2906296T1
(en)
|
2012-10-12 |
2018-06-29 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
EP2906241B1
(en)
|
2012-10-12 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Enhancement of the immune response
|
PT2839860T
(pt)
|
2012-10-12 |
2019-07-29 |
Medimmune Ltd |
Pirrolobenzodiazepinas e conjugados das mesmas
|
CA2885305C
(en)
|
2012-10-12 |
2019-11-12 |
Spirogen Sarl |
Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
|
US9834598B2
(en)
|
2012-10-15 |
2017-12-05 |
Medimmune Limited |
Antibodies to amyloid beta
|
EA035012B1
(ru)
|
2012-10-18 |
2020-04-17 |
Рокфеллер Юниверсити (Дзе) |
Нейтрализующие анти-вич-антитела широкого спектра действия
|
EP2909230B1
(en)
|
2012-10-19 |
2019-05-22 |
Danisco US Inc. |
Stabilization of biomimetic membranes
|
US9395369B2
(en)
|
2012-10-19 |
2016-07-19 |
Regents Of The University Of Minnesota |
Guinea pig cytomegalovirus (CIDMTR strain)
|
US9840734B2
(en)
|
2012-10-22 |
2017-12-12 |
Raindance Technologies, Inc. |
Methods for analyzing DNA
|
WO2014066328A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
EP2912062A1
(en)
|
2012-10-24 |
2015-09-02 |
Yeda Research and Development Co. Ltd. |
Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
|
DK2912064T3
(da)
|
2012-10-24 |
2019-07-22 |
Res Found Dev |
Jam-c-antistoffer og fremgangsmåder til behandling af cancer
|
CA2889170C
(en)
|
2012-10-25 |
2021-09-07 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
WO2014066733A2
(en)
|
2012-10-25 |
2014-05-01 |
Life Technologies Corporation |
Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
|
EP2911681A1
(en)
|
2012-10-26 |
2015-09-02 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
JP6348115B2
(ja)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
がん療法のためのエンドサイトーシス阻害剤および抗体の使用
|
US10206911B2
(en)
|
2012-10-26 |
2019-02-19 |
Memorial Sloan-Kettering Cancer Center |
Androgen receptor variants and methods for making and using
|
WO2014065822A1
(en)
|
2012-10-26 |
2014-05-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hepatitis c virus neutralizing epitopes, antibodies, and methods
|
EP2912060B1
(en)
|
2012-10-29 |
2019-12-25 |
The University of North Carolina at Chapel Hill |
Compositions and methods for inhibiting pathogen infection
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
US9833410B2
(en)
|
2012-10-31 |
2017-12-05 |
Takeda Gmbh |
Lyophilized formulation comprising GM-CSF neutralizing compound
|
AR093297A1
(es)
|
2012-10-31 |
2015-05-27 |
Amgen Res (Munich) Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
EP2914628A1
(en)
|
2012-11-01 |
2015-09-09 |
Max-Delbrück-Centrum für Molekulare Medizin |
An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
RS63212B1
(sr)
|
2012-11-02 |
2022-06-30 |
Bioverativ Usa Inc |
Antikomplementna c1s antitela i njihove primene
|
US9809863B2
(en)
|
2012-11-02 |
2017-11-07 |
Elanco Tiergesundheit Ag |
Flavivirus associated with Theiler's disease
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
JP6355641B2
(ja)
|
2012-11-05 |
2018-07-11 |
ファイザー・インク |
スプライソスタチン類似体
|
MX2015005722A
(es)
|
2012-11-05 |
2016-01-12 |
Genzyme Corp |
Composiciones y metodos para el tratamiento de proteinopatias.
|
TW201726746A
(zh)
|
2012-11-07 |
2017-08-01 |
輝瑞股份有限公司 |
抗切口3(anti-notch3)抗體及抗體-藥物共軛體
|
EP2917347B1
(en)
|
2012-11-08 |
2019-01-02 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of bone metastases
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
ES2689782T3
(es)
|
2012-11-08 |
2018-11-15 |
University Of Miyazaki |
Anticuerpo capaz de reconocer específicamente un receptor de transferrina
|
EP3489258A1
(en)
|
2012-11-08 |
2019-05-29 |
Eleven Biotherapeutics, Inc. |
Il-6 antagonists and uses thereof
|
EP2918678B1
(en)
|
2012-11-09 |
2019-01-30 |
GeneFrontier Corporation |
Anti-adam28 antibody for treating cancer
|
JP2015536339A
(ja)
|
2012-11-09 |
2015-12-21 |
ファイザー・インク |
血小板由来増殖因子b特異的抗体ならびにこれらの組成物および使用
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
EP2916835A4
(en)
|
2012-11-12 |
2016-07-27 |
Redwood Bioscience Inc |
COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
|
TWI657095B
(zh)
|
2012-11-13 |
2019-04-21 |
美商建南德克公司 |
抗血球凝集素抗體及使用方法
|
CA2890979A1
(en)
|
2012-11-15 |
2014-05-22 |
Genentech, Inc. |
Ionic strength-mediated ph gradient ion exchange chromatography
|
EP2733153A1
(en)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the preparation of immunoconjugates and uses thereof
|
SI3660033T1
(sl)
|
2012-11-15 |
2021-09-30 |
Apellis Pharmaceuticals, Inc. |
Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
CA2890906A1
(en)
|
2012-11-16 |
2014-05-22 |
The Regents Of The University Of California |
Pictet-spengler ligation for protein chemical modification
|
CA2889962C
(en)
|
2012-11-20 |
2023-10-24 |
Sanofi |
Anti-ceacam5 antibodies and uses thereof
|
GB201220924D0
(en)
|
2012-11-21 |
2013-01-02 |
Cancer Res Inst Royal |
Materials and methods for determining susceptibility or predisposition to cancer
|
EP2735874A1
(en)
|
2012-11-21 |
2014-05-28 |
Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro |
Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
WO2014082065A1
(en)
|
2012-11-26 |
2014-05-30 |
President And Fellows Of Harvard College |
Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
|
FR2998579B1
(fr)
|
2012-11-27 |
2015-06-19 |
Commissariat Energie Atomique |
Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
BR112015002626A2
(pt)
|
2012-11-29 |
2017-09-26 |
Yeda Res & Dev |
métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa
|
EP2925779A1
(en)
|
2012-11-30 |
2015-10-07 |
Institut Pasteur |
Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US10407503B2
(en)
|
2012-11-30 |
2019-09-10 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-Met
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
EP2925782B1
(en)
|
2012-12-03 |
2020-01-22 |
NovImmune SA |
Anti-cd47 antibodies and methods of use thereof
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
PT2928921T
(pt)
|
2012-12-05 |
2021-04-06 |
Novartis Ag |
Composições e métodos para anticorpos que visam epo
|
ES2664095T3
(es)
|
2012-12-07 |
2018-04-18 |
Pfizer Inc. |
Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética
|
WO2014088940A1
(en)
|
2012-12-07 |
2014-06-12 |
Danisco Us Inc. |
Compositions and methods of use
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
US9383357B2
(en)
|
2012-12-07 |
2016-07-05 |
Northwestern University |
Biomarker for replicative senescence
|
ES2614039T3
(es)
|
2012-12-07 |
2017-05-29 |
Danisco Us Inc. |
Composiciones y métodos de uso
|
US20150329639A1
(en)
|
2012-12-12 |
2015-11-19 |
University Of Virginia Patent Foundation |
Compositions and methods for regulating erythropoiesis
|
MX2015007234A
(es)
|
2012-12-12 |
2015-10-29 |
Danisco Us Inc |
Variantes de celobiohidrolasas.
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
JP6322210B2
(ja)
|
2012-12-13 |
2018-05-09 |
ボルケーノ コーポレイション |
標的化された挿管のためのデバイス、システム、および方法
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
CA2884313C
(en)
|
2012-12-13 |
2023-01-03 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
AU2013359001A1
(en)
|
2012-12-13 |
2015-07-23 |
The Board Of Regents Of The University Of Oklahoma |
Target peptides for ovarian cancer therapy and diagnostics
|
EP3514175A1
(fr)
|
2012-12-17 |
2019-07-24 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
EP2935589A1
(en)
|
2012-12-18 |
2015-10-28 |
Novartis AG |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
US9790276B2
(en)
|
2012-12-18 |
2017-10-17 |
The Rockefeller University |
Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
|
SG11201504764SA
(en)
|
2012-12-19 |
2015-07-30 |
Amplimmune Inc |
Anti-human b7-h4 antibodies and their uses
|
PL2935330T3
(pl)
|
2012-12-19 |
2019-11-29 |
Aveo Pharmaceuticals Inc |
Przeciwciała przeciw notch3
|
EP2934602B1
(en)
|
2012-12-19 |
2019-02-27 |
Genentech, Inc. |
Methods and compositions for radiohalogen protein labeling
|
WO2014100602A1
(en)
|
2012-12-20 |
2014-06-26 |
Hospital For Special Surgery |
Treatment of egf-receptor dependent pathologies
|
JP2016504589A
(ja)
|
2012-12-20 |
2016-02-12 |
ナサニエル ジェイ. ケンプ, |
異なる撮像モード間で再構成可能な光コヒーレンストモグラフィシステム
|
CN105007937B
(zh)
|
2012-12-20 |
2019-11-19 |
米迪缪尼有限公司 |
生产免疫偶联物的方法
|
US11406498B2
(en)
|
2012-12-20 |
2022-08-09 |
Philips Image Guided Therapy Corporation |
Implant delivery system and implants
|
US10939826B2
(en)
|
2012-12-20 |
2021-03-09 |
Philips Image Guided Therapy Corporation |
Aspirating and removing biological material
|
US9730613B2
(en)
|
2012-12-20 |
2017-08-15 |
Volcano Corporation |
Locating intravascular images
|
US10942022B2
(en)
|
2012-12-20 |
2021-03-09 |
Philips Image Guided Therapy Corporation |
Manual calibration of imaging system
|
JP6785554B2
(ja)
|
2012-12-20 |
2020-11-18 |
ボルケーノ コーポレイション |
平滑遷移カテーテル
|
WO2014099672A1
(en)
|
2012-12-21 |
2014-06-26 |
Andrew Hancock |
System and method for multipath processing of image signals
|
EP2936426B1
(en)
|
2012-12-21 |
2021-10-13 |
Jason Spencer |
System and method for graphical processing of medical data
|
AR094271A1
(es)
|
2012-12-21 |
2015-07-22 |
Aveo Pharmaceuticals Inc |
Anticuerpos anti-gdf15
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
WO2014100530A1
(en)
|
2012-12-21 |
2014-06-26 |
Whiseant Chester |
System and method for catheter steering and operation
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
US9486143B2
(en)
|
2012-12-21 |
2016-11-08 |
Volcano Corporation |
Intravascular forward imaging device
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
US9612105B2
(en)
|
2012-12-21 |
2017-04-04 |
Volcano Corporation |
Polarization sensitive optical coherence tomography system
|
SG11201504887TA
(en)
|
2012-12-21 |
2015-07-30 |
Bioalliance Cv |
Hydrophilic self-immolative linkers and conjugates thereof
|
US10058284B2
(en)
|
2012-12-21 |
2018-08-28 |
Volcano Corporation |
Simultaneous imaging, monitoring, and therapy
|
WO2014099760A1
(en)
|
2012-12-21 |
2014-06-26 |
Mai Jerome |
Ultrasound imaging with variable line density
|
US10191220B2
(en)
|
2012-12-21 |
2019-01-29 |
Volcano Corporation |
Power-efficient optical circuit
|
EP2935332B1
(en)
|
2012-12-21 |
2021-11-10 |
MedImmune, LLC |
Anti-h7cr antibodies
|
JP2016507892A
(ja)
|
2012-12-21 |
2016-03-10 |
デイビッド ウェルフォード, |
光の波長放出を狭幅化するためのシステムおよび方法
|
EP2934653B1
(en)
|
2012-12-21 |
2018-09-19 |
Douglas Meyer |
Rotational ultrasound imaging catheter with extended catheter body telescope
|
CN104884474A
(zh)
|
2012-12-21 |
2015-09-02 |
弗·哈夫曼-拉罗切有限公司 |
包含i类mhc的二硫键连接多价多功能蛋白质
|
EA031585B1
(ru)
|
2012-12-21 |
2019-01-31 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
EA201690004A1
(ru)
|
2012-12-27 |
2016-07-29 |
Санофи |
Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
US9938344B2
(en)
|
2012-12-28 |
2018-04-10 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
ES2639559T3
(es)
|
2012-12-28 |
2017-10-27 |
Ventana Medical Systems, Inc. |
Análisis de imágenes para el pronóstico de cáncer de mama
|
CN105102067B
(zh)
|
2013-01-02 |
2020-03-03 |
艾科诺斯科技股份有限公司 |
结合tl1a的抗体及其用途
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
GB201300346D0
(en)
|
2013-01-09 |
2013-02-20 |
Biolnvent Internat Ab |
BiologIcal materials and uses thereof
|
WO2014108854A1
(en)
|
2013-01-09 |
2014-07-17 |
Fusimab Ltd. |
Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
|
WO2014111516A1
(en)
|
2013-01-17 |
2014-07-24 |
Arsanis Biosciences Gmbh |
Mdr e. coli specific antibody
|
US9970929B2
(en)
|
2013-01-18 |
2018-05-15 |
Ark Diagnostics, Inc. |
Voriconazole immunoassays
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
WO2014118705A1
(en)
|
2013-01-31 |
2014-08-07 |
Novartis Ag |
Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
EP2951589A1
(en)
|
2013-02-01 |
2015-12-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for predicting and preventing metastasis in triple negative breast cancers
|
SG11201505960VA
(en)
|
2013-02-01 |
2015-08-28 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
ES2762622T3
(es)
|
2013-02-01 |
2020-05-25 |
Kira Biotech Pty Ltd |
Anticuerpos anti-CD83 y uso de los mismos
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP4137518A1
(en)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
JP2016513098A
(ja)
|
2013-02-07 |
2016-05-12 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の2−ピロリノドキソルビシン(p2pdox)
|
AU2014214530B2
(en)
|
2013-02-07 |
2014-10-16 |
Csl Limited |
IL-11R binding proteins and uses thereof
|
SG11201505744XA
(en)
|
2013-02-07 |
2015-08-28 |
Massachusetts Inst Technology |
Human adaptation of h5 influenza
|
PT2953634T
(pt)
|
2013-02-07 |
2021-09-02 |
Massachusetts Gen Hospital |
Métodos de expansão ou depleção das células t reguladoras
|
JP6357113B2
(ja)
|
2013-02-08 |
2018-07-11 |
株式会社医学生物学研究所 |
ヒトnrg1タンパク質に対する抗体
|
US10126301B2
(en)
|
2013-02-08 |
2018-11-13 |
Institute For Myeloma & Bone Cancer Research |
Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
|
UY35315A
(es)
|
2013-02-08 |
2014-09-30 |
Novartis Ag |
Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
|
JP2016514091A
(ja)
|
2013-02-08 |
2016-05-19 |
ミスフォールディング ダイアグノスティクス, インコーポレイテッド |
トランスサイレチン抗体およびその使用
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2956480B1
(en)
|
2013-02-13 |
2019-09-04 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Highly galactosylated anti-tnf-alpha antibodies and uses thereof
|
ES2674704T3
(es)
|
2013-02-13 |
2018-07-03 |
Ark Diagnostics, Inc. |
Inmunoensayos de posaconazol
|
EP2956003A2
(en)
|
2013-02-13 |
2015-12-23 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Proteins with modified glycosylation and methods of production thereof
|
EP3255062B1
(en)
|
2013-02-14 |
2019-07-03 |
Innate Pharma |
Anti-nkp46 antibody for diganosis of a non-cutaneous peripheral t-cell lymphoma (ptcl)
|
EP2958941B1
(en)
|
2013-02-20 |
2019-04-10 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
EP3626741A1
(en)
|
2013-02-20 |
2020-03-25 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
DK2958588T3
(da)
|
2013-02-22 |
2017-11-20 |
Curevac Ag |
Kombination af vaccination og hæmning af PD-1-reaktionsvejen
|
US9968687B2
(en)
|
2013-02-22 |
2018-05-15 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibody drug conjugates
|
DK3292873T3
(da)
|
2013-02-22 |
2019-06-03 |
Curevac Ag |
Kombination af vaccination og hæmning af PD-1-vejen
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
CA2901126C
(en)
|
2013-02-25 |
2022-01-25 |
Genentech, Inc. |
Methods and compositions for detecting and treating drug resistant akt mutant
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
US9429584B2
(en)
|
2013-02-28 |
2016-08-30 |
National Cancer Center |
Antibody against insoluble fibrin
|
US10398661B2
(en)
|
2013-02-28 |
2019-09-03 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
CN105246511A
(zh)
|
2013-03-06 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
治疗和预防癌症药物抗性的方法
|
CN113705586A
(zh)
|
2013-03-07 |
2021-11-26 |
飞利浦影像引导治疗公司 |
血管内图像中的多模态分割
|
US10226597B2
(en)
|
2013-03-07 |
2019-03-12 |
Volcano Corporation |
Guidewire with centering mechanism
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
WO2014164472A1
(en)
|
2013-03-10 |
2014-10-09 |
The Board Of Regents Of The University Of Texas System |
Biomarkers for chagas disease related cardiomyopathy
|
EP2778176A1
(en)
|
2013-03-12 |
2014-09-17 |
Sanofi |
Compositions and methods for analyzing histidine phosphorylation
|
US11154313B2
(en)
|
2013-03-12 |
2021-10-26 |
The Volcano Corporation |
Vibrating guidewire torquer and methods of use
|
CN105473154A
(zh)
|
2013-03-12 |
2016-04-06 |
通用医疗公司 |
修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途
|
US10638939B2
(en)
|
2013-03-12 |
2020-05-05 |
Philips Image Guided Therapy Corporation |
Systems and methods for diagnosing coronary microvascular disease
|
JP6371758B2
(ja)
|
2013-03-12 |
2018-08-08 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
CN113045660B
(zh)
|
2013-03-13 |
2023-09-01 |
伊麦吉纳博公司 |
与cd8的抗原结合构建体
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
BR112015022484A2
(pt)
|
2013-03-13 |
2017-07-18 |
Genentech Inc |
formulações com oxidação reduzida
|
KR20210043006A
(ko)
|
2013-03-13 |
2021-04-20 |
사노피 |
항-cd38 항체 및 카르필조밉을 포함하는 조성물
|
US9301687B2
(en)
|
2013-03-13 |
2016-04-05 |
Volcano Corporation |
System and method for OCT depth calibration
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
KR102127085B1
(ko)
|
2013-03-13 |
2020-06-26 |
제넨테크, 인크. |
항체 제제
|
US9023353B2
(en)
|
2013-03-13 |
2015-05-05 |
The Board Of Trustees Of The University Of Arkansas |
Anti-(+)—methamphetamine monoclonal antibodies
|
US11026591B2
(en)
|
2013-03-13 |
2021-06-08 |
Philips Image Guided Therapy Corporation |
Intravascular pressure sensor calibration
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
CN105142674B
(zh)
|
2013-03-13 |
2018-11-13 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓和其结合物
|
US10550201B2
(en)
|
2013-03-13 |
2020-02-04 |
Bioventures, Llc |
Antibody-nanoparticle conjugates for the treatment of drug abuse
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
NZ710745A
(en)
|
2013-03-13 |
2019-03-29 |
Genentech Inc |
Pyrrolobenzodiazepines and conjugates thereof
|
US10758207B2
(en)
|
2013-03-13 |
2020-09-01 |
Philips Image Guided Therapy Corporation |
Systems and methods for producing an image from a rotational intravascular ultrasound device
|
CA3135558A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Prevention of protein oxidation in a composition
|
BR112015023355A8
(pt)
|
2013-03-14 |
2018-01-30 |
Abbott Lab |
antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
|
US10219887B2
(en)
|
2013-03-14 |
2019-03-05 |
Volcano Corporation |
Filters with echogenic characteristics
|
BR112015023098A2
(pt)
|
2013-03-14 |
2017-07-18 |
Univ Jefferson |
agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
|
US10292677B2
(en)
|
2013-03-14 |
2019-05-21 |
Volcano Corporation |
Endoluminal filter having enhanced echogenic properties
|
EP2968550B1
(en)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Compositions and methods for treating angiogenesis-related disorders
|
CA2899449A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
EP2970474B1
(en)
|
2013-03-14 |
2017-12-20 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
AU2014239264A1
(en)
|
2013-03-14 |
2015-08-27 |
Shire Human Genetic Therapies, Inc. |
Quantitative assessment for cap efficiency of messenger RNA
|
CN105246508A
(zh)
|
2013-03-14 |
2016-01-13 |
基因泰克公司 |
Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
BR112015017307A2
(pt)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
composições de espécies com baixa acidez e métodos para produção e uso das mesmas
|
EP2968526A4
(en)
|
2013-03-14 |
2016-11-09 |
Abbott Lab |
ANTIGEN-ANTIBODY COMBINATION ASSAY OF HEPATITIS C VIRUS AND METHODS AND COMPOSITIONS FOR USE THEREWITH
|
US10132816B2
(en)
|
2013-03-14 |
2018-11-20 |
Beth Israel Deaconess Medical Center, Inc. |
Measurement of FGF21 as a biomarker of fructose metabolism
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
MX2015012709A
(es)
|
2013-03-14 |
2016-05-31 |
Macrogenics Inc |
Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
AU2014236309A1
(en)
|
2013-03-14 |
2015-10-29 |
Ren Liu |
Cancer treatment using antibodies that bing cell surface GRP78
|
EP3916103A1
(en)
|
2013-03-14 |
2021-12-01 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
WO2014152365A2
(en)
|
2013-03-14 |
2014-09-25 |
Volcano Corporation |
Filters with echogenic characteristics
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
LT2970449T
(lt)
|
2013-03-15 |
2019-11-25 |
Amgen Res Munich Gmbh |
Viengrandės surišančios molekulės, apimančios n galo abp
|
JP2016520528A
(ja)
|
2013-03-15 |
2016-07-14 |
ジェネンテック, インコーポレイテッド |
癌の治療及び抗癌剤耐性の防止方法
|
ES2779398T3
(es)
|
2013-03-15 |
2020-08-17 |
Dana-Farber Cancer Institute Inc |
Péptidos terapéuticos
|
JP6431038B2
(ja)
|
2013-03-15 |
2018-11-28 |
ザイムワークス インコーポレイティド |
細胞毒性及び抗有糸分裂性化合物とその使用方法
|
KR20150131177A
(ko)
|
2013-03-15 |
2015-11-24 |
제넨테크, 인크. |
항-CRTh2 항체 및 그의 용도
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
JP2016522793A
(ja)
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
US9688747B2
(en)
|
2013-03-15 |
2017-06-27 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the generation and use of conformation-specific antibodies
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
RU2718986C2
(ru)
|
2013-03-15 |
2020-04-15 |
Дженентек, Инк. |
Композиции клеточных культур с антиоксидантами и способы получения полипептидов
|
JP2016515515A
(ja)
|
2013-03-15 |
2016-05-30 |
バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC |
抗プロラクチン受容体抗体製剤
|
KR102202476B1
(ko)
|
2013-03-15 |
2021-01-12 |
제넨테크, 인크. |
세포 배양 배지 및 항체 생산 방법
|
KR20150130387A
(ko)
|
2013-03-15 |
2015-11-23 |
테라노스, 인코포레이티드 |
시료 준비용 기기, 시스템 및 방법
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
JP6568514B2
(ja)
|
2013-03-15 |
2019-08-28 |
エーシー イミューン エス.エー. |
抗タウ抗体及び使用方法
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
CN105377892A
(zh)
|
2013-03-15 |
2016-03-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
WO2014144632A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Human pac1 antibodies
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
AU2014236815B2
(en)
|
2013-03-15 |
2019-04-04 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
EP2968508B1
(en)
|
2013-03-15 |
2022-04-27 |
Sanofi Pasteur Biologics, LLC |
Antibodies against clostridium difficile toxins and methods of using the same
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
EP4292657A3
(en)
|
2013-03-15 |
2024-03-20 |
Dana Farber Cancer Institute, Inc. |
Flavivirus neutralizing antibodies and methods of use thereof
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
TR201809571T4
(tr)
|
2013-03-15 |
2018-07-23 |
Hoffmann La Roche |
Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
JP6462599B2
(ja)
|
2013-03-15 |
2019-01-30 |
シャアメン ユニバーシティ |
Rsv融合タンパク質のエピトープ及びそのエピトープを認識する抗体
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
CA2905798C
(en)
|
2013-03-15 |
2023-01-24 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
KR102218494B1
(ko)
|
2013-03-15 |
2021-02-19 |
인트린식 라이프사이언시스, 엘엘씨 |
항-헵시딘 항체 및 그의 용도
|
EP2968469A4
(en)
|
2013-03-15 |
2016-08-31 |
Longevity Biotech Inc |
PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
|
WO2014144600A2
(en)
|
2013-03-15 |
2014-09-18 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
MD20150098A2
(ro)
|
2013-03-15 |
2016-02-29 |
Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center |
Compoziţii şi procedee de tratare a agenţilor patogeni fungici şi bacterieni
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
JP6574754B2
(ja)
|
2013-03-19 |
2019-09-11 |
ベイジン シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体関連疾患を処置するための抗体及び方法
|
IL225380A
(en)
|
2013-03-21 |
2014-04-30 |
Savyon Diagnostics Ltd |
Bacterial training test and kit
|
US9447193B2
(en)
|
2013-03-24 |
2016-09-20 |
Development Center For Biotechnology |
Methods for suppressing cancer by inhibition of TMCC3
|
JP6615745B2
(ja)
|
2013-03-27 |
2019-12-04 |
ジェネンテック, インコーポレイテッド |
ベータ7インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
|
EP2981554B1
(en)
|
2013-04-01 |
2020-07-29 |
The Regents of The University of California |
Methods and compositions for treating and preventing disease associated with avb8 integrin
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
WO2014161483A1
(zh)
|
2013-04-02 |
2014-10-09 |
厦门大学 |
识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
|
WO2014165422A1
(en)
|
2013-04-02 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
WO2014169076A1
(en)
|
2013-04-09 |
2014-10-16 |
Annexon,,Inc. |
Methods of treatment for neuromyelitis optica
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
US10544461B2
(en)
|
2013-04-16 |
2020-01-28 |
The Johns Hopkins University |
Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (PWSS)
|
JP2016518126A
(ja)
|
2013-04-19 |
2016-06-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ローンスターウイルス
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
MY172430A
(en)
|
2013-04-29 |
2019-11-25 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
EP2992010B1
(en)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
US10501802B2
(en)
|
2013-04-30 |
2019-12-10 |
Universite De Montreal |
Biomarkers for acute myeloid leukemia
|
RS61778B1
(sr)
|
2013-05-06 |
2021-06-30 |
Scholar Rock Inc |
Kompozicije i postupci za modulaciju faktora rasta
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
GB201308259D0
(en)
|
2013-05-08 |
2013-06-12 |
Iles Raymond K |
Cancer diagnosis and monitoring
|
WO2014182972A2
(en)
|
2013-05-10 |
2014-11-13 |
The Regents Of The University Of California |
Diagnostic and monitoring system for huntington's disease
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
CA2912526C
(en)
|
2013-05-16 |
2021-09-14 |
Kyoto University |
Method for determining prognosis of cancer
|
US10005839B2
(en)
|
2013-05-17 |
2018-06-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antagonist of the BTLA/HVEM interaction for use in therapy
|
JP6416224B2
(ja)
|
2013-05-17 |
2018-10-31 |
セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク(シーエヌアールエス) |
抗cxcl1抗体、抗cxcl7抗体および抗cxcl8抗体ならびにそれらの用途
|
TWI573805B
(zh)
|
2013-05-20 |
2017-03-11 |
建南德克公司 |
抗轉鐵蛋白受體抗體及其使用方法
|
WO2014187746A2
(en)
|
2013-05-21 |
2014-11-27 |
Arsanis Biosciences Gmbh |
Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
|
WO2014188423A1
(en)
|
2013-05-21 |
2014-11-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Treatment of mast cell related pathologies
|
EP2999484B1
(en)
|
2013-05-23 |
2019-09-11 |
Shire Human Genetic Therapies, Inc. |
Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
|
EP3004892B1
(en)
|
2013-05-24 |
2018-10-10 |
Nestec S.A. |
Method for diagnosing irritable bowel syndrome
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
RU2655439C2
(ru)
|
2013-05-31 |
2018-05-28 |
Займворкс Инк. |
Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
|
WO2014197723A2
(en)
|
2013-06-05 |
2014-12-11 |
Massachusetts Institute Of Technology |
Human adaptation of h7 ha
|
EP3293275B1
(en)
|
2013-06-06 |
2021-08-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
|
US10781259B2
(en)
|
2013-06-06 |
2020-09-22 |
Magenta Therapeutics, Inc. |
Modified antibodies and related compounds, compositions, and methods of use
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
EA039554B1
(ru)
|
2013-06-10 |
2022-02-09 |
АйПИЕРИАН, ИНК. |
Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
|
WO2014201118A2
(en)
|
2013-06-11 |
2014-12-18 |
Sanford-Burnham Medical Research Institute |
Compositions and methods for targeted endometriosis treatment
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
US9587032B2
(en)
|
2013-06-12 |
2017-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
IgE antibodies for the inhibition of tumor metastasis
|
WO2014197937A1
(en)
|
2013-06-13 |
2014-12-18 |
University Of South Australia |
Methods for detecting prostate cancer
|
US9428748B2
(en)
|
2013-06-17 |
2016-08-30 |
Hong Gao |
Method of expanding hematopoietic stem cells
|
JP6652916B2
(ja)
|
2013-06-20 |
2020-02-26 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
膵臓がんを診断するための方法
|
WO2014202773A1
(en)
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
US9890369B2
(en)
|
2013-06-20 |
2018-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
WO2014202775A1
(en)
|
2013-06-21 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
US10221239B2
(en)
|
2013-06-28 |
2019-03-05 |
Singapore Health Services Pte Ltd |
TRPM4 channel inhibitors for stroke treatment
|
EP2818484A1
(en)
|
2013-06-28 |
2014-12-31 |
Universitat Autònoma de Barcelona |
Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
|
CA2916594C
(en)
|
2013-07-04 |
2020-03-10 |
Novartis Ag |
O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
FI3019240T3
(fi)
|
2013-07-09 |
2024-05-30 |
Annexon Inc |
Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
CA2916899C
(en)
|
2013-07-10 |
2020-03-10 |
Novartis Ag |
Production of glycoproteins having increased n-glycosylation site occupancy
|
WO2015005961A1
(en)
|
2013-07-12 |
2015-01-15 |
Emd Millipore Corporation |
A method of determining virus removal from a sample containing a target protein using activated carbon
|
CA2918052A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
MY183503A
(en)
|
2013-07-16 |
2021-02-23 |
Genentech Inc |
Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
WO2015010100A2
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
US10005838B2
(en)
|
2013-07-19 |
2018-06-26 |
The Regents Of The University Of California |
Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EA201690269A1
(ru)
|
2013-07-23 |
2016-05-31 |
Сентро Де Инмунологиа Молекулар |
Способы контроля уровней фукозилирования в белках
|
WO2015015489A1
(en)
|
2013-07-30 |
2015-02-05 |
Biolinerx Ltd. |
Antibody for treating diabetes and autoimmune diseases
|
WO2015015448A2
(en)
|
2013-07-31 |
2015-02-05 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates
|
JP2015030666A
(ja)
|
2013-07-31 |
2015-02-16 |
学校法人順天堂 |
抗ヒトcd26モノクローナル抗体又はその抗原結合性断片
|
EP3027225B1
(en)
|
2013-07-31 |
2021-03-24 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using transforming growth factor alpha
|
SI3027651T1
(sl)
|
2013-08-01 |
2019-05-31 |
Five Prime Therapeutics, Inc. |
Afukozilirana protitelesa proti fgfr2iiib
|
SG11201600587VA
(en)
|
2013-08-01 |
2016-02-26 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
EP3027650B1
(en)
|
2013-08-01 |
2021-01-13 |
Université catholique de Louvain |
Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1
|
US9770461B2
(en)
|
2013-08-02 |
2017-09-26 |
California Institute Of Technology |
Tailored glycopolymers as anticoagulant heparin mimetics
|
JP2016531907A
(ja)
|
2013-08-02 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
免疫刺激のためのcd27アゴニストと免疫チェックポイント阻害との組み合わせ
|
SG11201600171SA
(en)
|
2013-08-02 |
2016-02-26 |
Pfizer |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
US10227370B2
(en)
|
2013-08-02 |
2019-03-12 |
California Institute Of Technology |
Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
|
TWI777198B
(zh)
|
2013-08-05 |
2022-09-11 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(七)
|
WO2015018421A1
(en)
|
2013-08-07 |
2015-02-12 |
Rigshospitalet Copenhagen University Hospital |
Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
|
EP3030902B1
(en)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
EP3030268B1
(en)
|
2013-08-09 |
2022-07-27 |
The Trustees Of The University Of Pennsylvania |
Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
|
JP2016528252A
(ja)
|
2013-08-12 |
2016-09-15 |
トーカイ ファーマシューティカルズ, インコーポレイテッド |
アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
|
AU2014307080B2
(en)
|
2013-08-12 |
2018-06-07 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
CN107318267B
(zh)
|
2013-08-12 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
用于治疗补体相关的病症的组合物和方法
|
CN112142845A
(zh)
|
2013-08-13 |
2020-12-29 |
赛诺菲 |
纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
EP3033356B1
(en)
|
2013-08-14 |
2020-01-15 |
Sachdev Sidhu |
Antibodies against frizzled proteins and methods of use thereof
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
ES2827679T3
(es)
|
2013-08-20 |
2021-05-24 |
Merck Sharp & Dohme |
Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
|
CN114621346A
(zh)
|
2013-08-21 |
2022-06-14 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
US9993566B2
(en)
|
2013-08-28 |
2018-06-12 |
Abbvie Stemcentrx Llc |
SEZ6 modulators and methods of use
|
KR20160044042A
(ko)
|
2013-08-28 |
2016-04-22 |
스템센트알엑스 인코포레이티드 |
부위-특이적 항체 접합 방법 및 조성물
|
CA2922698C
(en)
|
2013-08-29 |
2023-01-03 |
City Of Hope |
Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
|
WO2015028657A1
(en)
|
2013-08-30 |
2015-03-05 |
Takeda Gmbh |
Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
WO2015031815A2
(en)
|
2013-08-30 |
2015-03-05 |
Immunogen, Inc. |
Antibodies and assays for detection of folate receptor 1
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US20160251410A1
(en)
|
2013-09-03 |
2016-09-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compositions and methods for expressing recombinant polypeptides
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
EP3041868A2
(en)
|
2013-09-05 |
2016-07-13 |
Aduro Biotech Holdings, Europe B.V. |
Cd70-binding peptides and method, process and use relating thereto
|
CA2922832A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Method for chromatography reuse
|
AU2014332458B2
(en)
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
MX2018005873A
(es)
|
2013-09-06 |
2022-11-17 |
Labrador Diagnostics Llc |
Sistemas y metodos para detectar enfermedades infecciosas.
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
KR102298172B1
(ko)
|
2013-09-06 |
2021-09-06 |
아카데미아 시니카 |
변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EP3043775B1
(en)
|
2013-09-11 |
2020-11-04 |
Eagle Biologics, Inc. |
Liquid protein formulations containing viscosity-lowering agents
|
EP3044236A2
(en)
|
2013-09-12 |
2016-07-20 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP3683232A1
(en)
|
2013-09-13 |
2020-07-22 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
KR102332302B1
(ko)
|
2013-09-13 |
2021-12-01 |
제넨테크, 인크. |
세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
|
WO2015037009A1
(en)
|
2013-09-16 |
2015-03-19 |
Plexicure Ltd. |
Isolated proteins capable of binding plexin-a4 and methods of producing and using same
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
KR20160055275A
(ko)
|
2013-09-17 |
2016-05-17 |
유니버시티 헬스 네트워크 |
시스 rgma/네오제닌 상호작용 또는 지질 래프트에 대해 지시되는 제제 및 치료 방법에서의 이의 용도
|
EP3047276B1
(en)
|
2013-09-19 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
JP6615100B2
(ja)
|
2013-09-24 |
2019-12-04 |
ザ ファインスタイン インスティチュート フォー メディカル リサーチ |
低温誘導性rna結合タンパク質活性を阻害するペプチド
|
ES2894333T3
(es)
|
2013-09-26 |
2022-02-14 |
Beth Israel Deaconess Medical Ct Inc |
Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
GB201317207D0
(en)
|
2013-09-27 |
2013-11-13 |
Univ Glasgow |
Materials and methods for modulating disc1 turnover
|
RU2758952C1
(ru)
|
2013-09-27 |
2021-11-03 |
Чугаи Сейяку Кабусики Кайся |
Способ получения полипептидного гетеромультимера
|
SG11201602283UA
(en)
|
2013-09-27 |
2016-04-28 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
EP3049437A1
(en)
|
2013-09-27 |
2016-08-03 |
F. Hoffmann-La Roche AG |
Thermus thermophilus slyd fkbp domain specific antibodies
|
WO2015048819A1
(en)
|
2013-09-30 |
2015-04-02 |
The Regents Of The University Of California |
Anti-alphavbeta1 integrin compounds and methods
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
EP3470081A1
(en)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
AU2014329609B2
(en)
|
2013-10-02 |
2019-09-12 |
Humabs Biomed Sa |
Neutralizing anti-influenza A antibodies and uses thereof
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
US9388222B2
(en)
|
2013-10-06 |
2016-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified Pseudomonas exotoxin A
|
SG11201602361UA
(en)
|
2013-10-08 |
2016-04-28 |
Immunogen Inc |
Anti-folr1 immunoconjugate dosing regimens
|
JP2016539350A
(ja)
|
2013-10-09 |
2016-12-15 |
ユニバーシティー オブ ロチェスター |
マルチプレックスな肺炎連鎖球菌血清学のためのチップ、検出システム、及び方法
|
AU2014331938A1
(en)
|
2013-10-09 |
2016-04-28 |
University Of Miami |
Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation
|
EP3054973B1
(en)
|
2013-10-10 |
2020-12-02 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
KR20160068855A
(ko)
|
2013-10-11 |
2016-06-15 |
제넨테크, 인크. |
Nsp4 억제제 및 사용 방법
|
PE20160561A1
(es)
|
2013-10-11 |
2016-06-03 |
Oxford Biotherapeutics Ltd |
Anticuerpos conjugados contra ly75 para el tratamiento de cancer
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
EP2860243A1
(en)
|
2013-10-14 |
2015-04-15 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Reprogramming bone endothelial cells for bone angiogenesis and osteogenesis
|
CA2921707C
(en)
|
2013-10-15 |
2023-03-28 |
Seattle Genetics, Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
AU2014335251B2
(en)
|
2013-10-15 |
2020-04-30 |
Genefrontier Corporation |
Human antibody against aggrecanase-type ADAMTS species for therapeutics of aggrecanase-related diseases
|
US10188738B2
(en)
|
2013-10-16 |
2019-01-29 |
Université Libre de Bruxelles |
Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
|
JP2016539919A
(ja)
|
2013-10-17 |
2016-12-22 |
オメロス コーポレーション |
Masp−2依存性補体活性化に関連した状態を治療するための方法
|
BR112016008275A2
(pt)
|
2013-10-17 |
2017-10-03 |
Arsanis Biosciences Gmbh |
Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
|
RU2016114074A
(ru)
|
2013-10-18 |
2017-11-23 |
Дженентек, Инк. |
Анти-rspo антитела и способы применения
|
EP3060685B1
(en)
|
2013-10-23 |
2019-05-01 |
F. Hoffmann-La Roche AG |
Method of predicting the response of an asthma patient to therapy
|
JP2016536018A
(ja)
|
2013-10-28 |
2016-11-24 |
ドッツ テクノロジー コーポレイションDOTS Technology Corp. |
アレルゲン検出
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
EP3070167A4
(en)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Antibody having broad neutralizing activity in group 1 influenza a virus
|
EP2871189A1
(en)
|
2013-11-07 |
2015-05-13 |
Institut Pasteur |
High-affinity monoclonal anti-strep-tag antibody
|
WO2015067986A1
(en)
|
2013-11-07 |
2015-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neuregulin allosteric anti-her3 antibody
|
US20160272674A1
(en)
|
2013-11-07 |
2016-09-22 |
Abbvie Inc. |
Isolation and purification of antibodies
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
WO2015070009A2
(en)
|
2013-11-08 |
2015-05-14 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
US10357554B2
(en)
|
2013-11-11 |
2019-07-23 |
The United States Of America, As Represented By The Secretary Of The Army |
AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
|
CA2929044A1
(en)
|
2013-11-11 |
2015-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
US10273303B2
(en)
|
2013-11-13 |
2019-04-30 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
SG10201810298VA
(en)
|
2013-11-13 |
2018-12-28 |
Pfizer |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
GB201320061D0
(en)
|
2013-11-13 |
2013-12-25 |
Electrophoretics Ltd |
Materials nad methods for diagnosis and prognosis of liver cancer
|
KR102238133B1
(ko)
|
2013-11-15 |
2021-04-09 |
제넨테크, 인크. |
환경-친화적 세제를 사용한 바이러스 불활성화 방법
|
WO2015071701A1
(en)
|
2013-11-15 |
2015-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pancreatic cancers
|
CN105940115B
(zh)
|
2013-11-15 |
2021-07-06 |
巴斯德研究所 |
恶性疟原虫青蒿素耐药性的分子标记物
|
EP2873740A1
(en)
|
2013-11-19 |
2015-05-20 |
Oncodiag |
Methods for the surveillance, diagnosis and screening of bladder cancer
|
BR112016011025B1
(pt)
|
2013-11-19 |
2024-01-23 |
Fredax Ab |
Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico
|
NZ717673A
(en)
|
2013-11-21 |
2020-02-28 |
Hoffmann La Roche |
Anti-alpha-synuclein antibodies and methods of use
|
JP6879739B2
(ja)
|
2013-11-25 |
2021-06-02 |
フェイムウェイヴ リミテッド |
癌治療のための抗ceacam1および抗pd抗体を含む組成物
|
JP6620094B2
(ja)
|
2013-11-26 |
2019-12-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答を調節するための組成物および方法
|
WO2015081282A1
(en)
|
2013-11-27 |
2015-06-04 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
BR112016010454A2
(pt)
|
2013-11-27 |
2017-12-05 |
Ipierian Inc |
métodos para tratar uma taupatia
|
CA2931356A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
EP3074038B1
(en)
|
2013-11-28 |
2019-01-02 |
CSL Limited |
Method of treating diabetic nephropathy
|
JP6667437B2
(ja)
|
2013-12-02 |
2020-03-18 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定
|
MX371298B
(es)
|
2013-12-03 |
2020-01-23 |
Harvard College |
Métodos y reactivos para la evaluación de diabetes gestacional.
|
US9321834B2
(en)
|
2013-12-05 |
2016-04-26 |
Leidos, Inc. |
Anti-malarial compositions
|
JP6705746B2
(ja)
|
2013-12-06 |
2020-06-03 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
治療用ペプチド
|
US10335494B2
(en)
|
2013-12-06 |
2019-07-02 |
Millennium Pharmaceuticals, Inc. |
Combination of aurora kinase inhibitors and anti-CD30 antibodies
|
EP3077417A1
(en)
|
2013-12-08 |
2016-10-12 |
Peptcell Limited |
Hiv antigens and antibodies and compositions, methods and uses thereof
|
EP3611191A1
(en)
|
2013-12-09 |
2020-02-19 |
Allakos Inc. |
Anti-siglec-8 antibodies and methods of use thereof
|
US9644023B2
(en)
|
2013-12-09 |
2017-05-09 |
New York University |
Compositions and methods for phagocyte delivery of anti-staphylococcal agents
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
AU2014362307A1
(en)
|
2013-12-11 |
2016-06-30 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
EP3079475B1
(en)
|
2013-12-11 |
2020-10-07 |
Sloan-kettering Institute For Cancer Research |
Glucocorticoid inhibitors for treatment of prostate cancer
|
WO2015089380A2
(en)
|
2013-12-12 |
2015-06-18 |
Celcuity Llc |
Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
EP3080611B1
(en)
|
2013-12-13 |
2018-11-14 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
BR112016013514B1
(pt)
|
2013-12-13 |
2022-04-19 |
Stora Enso Oyj (Fi) |
Papelão de múltiplas camadas
|
WO2015088346A1
(en)
|
2013-12-13 |
2015-06-18 |
Rijksuniversiteit Groningen |
Antibodies against staphylococcus aureus and uses thereof.
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
CA2929565A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
JP6895254B2
(ja)
|
2013-12-16 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
ペプチド模倣化合物及びその抗体−薬物コンジュゲート
|
CN106029874B
(zh)
|
2013-12-16 |
2020-09-15 |
北卡罗来纳-查佩尔山大学 |
浆细胞样树突状细胞的耗竭
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
EP3083670A2
(en)
|
2013-12-17 |
2016-10-26 |
Westfälische Wilhelms-Universität Münster |
Means and methods for treating a pruritus-like skin-disease
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
HUE047699T2
(hu)
|
2013-12-17 |
2020-05-28 |
Hoffmann La Roche |
Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
|
EP3084003A4
(en)
|
2013-12-17 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
CN110156893B
(zh)
|
2013-12-17 |
2023-03-03 |
基因泰克公司 |
抗cd3抗体及使用方法
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
KR20160096194A
(ko)
|
2013-12-18 |
2016-08-12 |
씨에스엘 리미티드 |
상처 치료 방법
|
TWI777502B
(zh)
|
2013-12-19 |
2022-09-11 |
美商西雅圖遺傳學公司 |
與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
|
EP3083936B1
(en)
|
2013-12-19 |
2018-07-04 |
Danisco US Inc. |
Use of hydrophobins to increase gas transfer in aerobic fermentation processes
|
CN105899533B
(zh)
|
2013-12-20 |
2019-10-11 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
CA2932515C
(en)
|
2013-12-20 |
2023-08-01 |
Intervet International B.V. |
Caninized antibodies
|
WO2015095539A1
(en)
|
2013-12-20 |
2015-06-25 |
Genentech, Inc. |
Dual specific antibodies
|
EP3082847A1
(en)
|
2013-12-20 |
2016-10-26 |
Indiana University Research and Technology Corporation |
Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
|
PT3086814T
(pt)
|
2013-12-23 |
2020-09-04 |
Bayer Pharma AG |
Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
|
EP2960252A1
(en)
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase for treatment of immunosuppression
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
EP3088890B1
(en)
|
2013-12-24 |
2020-09-23 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring soluble gpc3 protein
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
BR112016013347B1
(pt)
|
2013-12-26 |
2023-12-12 |
Mitsubishi Tanabe Pharma Corporation |
Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
KR102384740B1
(ko)
|
2013-12-27 |
2022-04-07 |
자임워크스 인코포레이티드 |
약물 접합체를 위한 설폰아마이드-함유 연결 시스템
|
EP3088001B1
(en)
|
2013-12-27 |
2020-02-12 |
National University Corporation Kochi University |
Anti-lipolysis stimulated liporotein receptor antibodies for treatment of ovarian cancer
|
TW201609093A
(zh)
|
2013-12-27 |
2016-03-16 |
Chugai Pharmaceutical Co Ltd |
Fgfr門控蛋白變異基因及以其爲標的之醫藥
|
WO2015102341A1
(ko)
|
2013-12-30 |
2015-07-09 |
재단법인 의약바이오컨버젼스연구단 |
항 krs 모노클로날 항체 및 이의 용도
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
BR112016012666A2
(pt)
|
2014-01-03 |
2017-09-26 |
Hoffmann La Roche |
conjugado, anticorpos, formulação farmacêutica e usos de conjugado
|
WO2015103026A2
(en)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
RU2694659C2
(ru)
|
2014-01-06 |
2019-07-16 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные модули-переносчики через гематоэнцефалический барьер
|
ES2902835T3
(es)
|
2014-01-09 |
2022-03-30 |
Hadasit Med Res Service |
Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
|
KR20160101196A
(ko)
|
2014-01-14 |
2016-08-24 |
더 메디컬 컬리지 오브 위스콘신, 인크. |
암의 치료 및 예방을 위한 clptm1l 표적화
|
EP3094736A4
(en)
|
2014-01-14 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
EP3835318A1
(en)
|
2014-01-15 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP2896400A1
(en)
|
2014-01-17 |
2015-07-22 |
Université Catholique De Louvain |
Method for increasing the bioavailability of inhaled compounds
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
RU2701434C2
(ru)
|
2014-01-24 |
2019-09-26 |
Нгм Биофармасьютикалс, Инк. |
Связывающие белки и способы их применения
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3096797A1
(en)
|
2014-01-24 |
2016-11-30 |
F. Hoffmann-La Roche AG |
Methods of using anti-steap1 antibodies and immunoconjugates
|
CN106459055B
(zh)
|
2014-01-27 |
2019-11-01 |
辉瑞大药厂 |
双功能细胞毒类药剂
|
CN106133523B
(zh)
|
2014-01-28 |
2019-06-28 |
奎斯特诊断投资股份有限公司 |
用于在癌症中检测腺瘤-腺癌过渡的方法和组合物
|
MX2016009954A
(es)
|
2014-01-29 |
2017-02-23 |
Dana Farber Cancer Inst Inc |
Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
JP6511459B2
(ja)
|
2014-01-31 |
2019-05-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規な抗baff抗体
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN111068053A
(zh)
|
2014-02-03 |
2020-04-28 |
耶路撒冷希伯来大学的益生研究开发有限公司 |
使用酪蛋白激酶i抑制剂以消耗干细胞的用途
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
WO2015120097A2
(en)
|
2014-02-04 |
2015-08-13 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
ES2710211T3
(es)
|
2014-02-04 |
2019-04-23 |
Pfizer |
Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
|
AU2015214404B2
(en)
|
2014-02-04 |
2020-10-01 |
Incyte Corporation |
Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer
|
ES2696348T3
(es)
|
2014-02-06 |
2019-01-15 |
Yeda Res & Dev |
Anticuerpos anti CD84, composiciones que comprenden los mismos y usos de los mismos
|
AU2015213741B2
(en)
|
2014-02-08 |
2020-10-08 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
CN106163548A
(zh)
|
2014-02-08 |
2016-11-23 |
健泰科生物技术公司 |
治疗阿尔茨海默氏病的方法
|
DK3105250T3
(da)
|
2014-02-10 |
2020-09-28 |
Igm Biosciences Inc |
Multispecifikke iga-bindingsmolekyler
|
EP4190809A1
(en)
|
2014-02-11 |
2023-06-07 |
Seagen Inc. |
Selective reduction of proteins
|
EP4047015A1
(en)
|
2014-02-11 |
2022-08-24 |
Visterra, Inc. |
Antibody molecules to dengue virus and uses thereof
|
TW201902515A
(zh)
|
2014-02-12 |
2019-01-16 |
美商建南德克公司 |
抗jagged1抗體及使用方法
|
US10106623B2
(en)
|
2014-02-12 |
2018-10-23 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
WO2015123687A1
(en)
|
2014-02-14 |
2015-08-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
SG10202001468UA
(en)
|
2014-02-17 |
2020-04-29 |
Seattle Genetics Inc |
Hydrophilic antibody-drug conjugates
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
WO2015124588A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
|
WO2015127140A2
(en)
|
2014-02-19 |
2015-08-27 |
Jody Berry |
Marburg monoclonal antibodies
|
SG11201606842RA
(en)
|
2014-02-20 |
2016-09-29 |
Allergan Inc |
Complement component c5 antibodies
|
KR20160124165A
(ko)
|
2014-02-21 |
2016-10-26 |
제넨테크, 인크. |
항-il-13/il-17 이중특이적 항체 및 그의 용도
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
GB201403115D0
(en)
|
2014-02-21 |
2014-04-09 |
Qbd Qs Ip Ltd |
Red blood cell detection
|
WO2015130805A1
(en)
|
2014-02-26 |
2015-09-03 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna gridiron compositions and methods
|
EP3110845A1
(en)
|
2014-02-27 |
2017-01-04 |
Allergan, Inc. |
Complement factor bb antibodies
|
EA201691414A1
(ru)
|
2014-02-27 |
2017-03-31 |
Джилид Сайэнс, Инк. |
Антитела к матриксной металлопротеиназе 9 и способы их применения
|
WO2015127685A1
(en)
|
2014-02-28 |
2015-09-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
EP3110446B1
(en)
|
2014-02-28 |
2021-12-01 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
WO2015130172A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibodies that bind egfr and erbb3
|
US11279770B2
(en)
|
2014-02-28 |
2022-03-22 |
Merus N.V. |
Antibody that binds ErbB-2 and ErbB-3
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
GB201403815D0
(en)
|
2014-03-04 |
2014-04-16 |
Mologic Ltd |
Assay
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
AU2015225867B2
(en)
|
2014-03-07 |
2020-02-06 |
University Health Network |
Methods and compositions for modifying the immune response
|
WO2015135558A1
(en)
|
2014-03-12 |
2015-09-17 |
Curevac Gmbh |
Combination of vaccination and ox40 agonists
|
US10435694B2
(en)
|
2014-03-14 |
2019-10-08 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
EP3116909B1
(en)
|
2014-03-14 |
2019-11-13 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
EP3116903A2
(en)
|
2014-03-14 |
2017-01-18 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
ES2857226T3
(es)
|
2014-03-15 |
2021-09-28 |
Novartis Ag |
Receptor de antígeno quimérico regulable
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
WO2015140708A1
(en)
|
2014-03-19 |
2015-09-24 |
Pfizer Inc. |
Method of cell culture
|
EP3119804A2
(en)
|
2014-03-19 |
2017-01-25 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
WO2015143335A1
(en)
|
2014-03-20 |
2015-09-24 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for chimeric coronavirus spike proteins
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
JP6568099B2
(ja)
|
2014-03-21 |
2019-08-28 |
テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH |
カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
|
EP3119812B1
(en)
|
2014-03-21 |
2020-04-29 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
ES2778680T3
(es)
|
2014-03-25 |
2020-08-11 |
Hoffmann La Roche |
Procedimientos de preparación de un poloxámero para su uso en medio de cultivo celular
|
DK3123151T3
(en)
|
2014-03-26 |
2019-03-18 |
Siemens Healthcare Diagnostics Inc |
LUMINESCENT OXYGEN CHANNELING IMMUNOASSAY USING THREE ANTIBODIES AND METHODS FOR PRODUCING AND USING THEREOF
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
SG11201607938UA
(en)
|
2014-03-27 |
2016-10-28 |
Genentech Inc |
Methods for diagnosing and treating inflammatory bowel disease
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
SG11201607772WA
(en)
|
2014-03-31 |
2016-10-28 |
Debiopharm Int Sa |
Fgfr fusions
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
CR20160500A
(es)
|
2014-03-31 |
2016-12-14 |
Genentech Inc |
Anticuerpos anti-ox40 y métodos de uso
|
US9995746B2
(en)
|
2014-04-02 |
2018-06-12 |
The United States Of America, As Represented By The Secretary Of The Army |
Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
|
SG11201608054YA
(en)
|
2014-04-02 |
2016-10-28 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
PL3126383T3
(pl)
|
2014-04-03 |
2019-08-30 |
Igm Biosciences, Inc. |
Zmodyfikowany łańcuch J
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
HUE054588T2
(hu)
|
2014-04-07 |
2021-09-28 |
Novartis Ag |
Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
|
CA2948275C
(en)
|
2014-04-08 |
2023-10-17 |
Boston Pharmaceuticals Inc. |
Binding molecules specific for il-21 and uses thereof
|
BR112016020009A2
(pt)
|
2014-04-10 |
2017-10-17 |
Obi Pharma Inc |
anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
|
WO2015157592A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Bispecific her2 antibodies
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
WO2015158851A1
(en)
|
2014-04-16 |
2015-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the prevention or the treatment of bleeding episodes
|
RU2689145C2
(ru)
|
2014-04-16 |
2019-05-24 |
Биокон Лтд. |
Стабильные белковые препараты, содержащие молярный избыток сорбитола
|
EP2933640A1
(en)
|
2014-04-17 |
2015-10-21 |
eXcorLab GmbH |
Diagnosis of chronic kidney disease by quantitative analysis of post-translational modifications of plasma proteins
|
WO2015158898A2
(en)
|
2014-04-17 |
2015-10-22 |
Medizinische Hochschule Hannover |
Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
|
JP6649895B2
(ja)
|
2014-04-18 |
2020-02-19 |
アクセルロン ファーマ, インコーポレイテッド |
赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
|
EP3134439B1
(en)
|
2014-04-21 |
2018-12-26 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk antibody molecules and use of same for syk-targeted therapy
|
GB201407132D0
(en)
|
2014-04-23 |
2014-06-04 |
Velgene Biotechnology |
Marker for neurodegenerative disorders
|
EP3134546A4
(en)
|
2014-04-24 |
2017-12-06 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
US10131704B2
(en)
|
2014-04-25 |
2018-11-20 |
Dana-Farber Cancer Institute, Inc. |
Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
CN106456798B
(zh)
|
2014-04-25 |
2021-02-12 |
瑞纳神经科学公司 |
具有高药物负载的抗体-药物缀合物
|
JP6789117B2
(ja)
|
2014-04-25 |
2020-11-25 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫媒介性疾患を有する対象を処置するための組成物および方法
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
KR102452349B1
(ko)
|
2014-04-27 |
2022-10-11 |
페임웨이브 리미티드 |
Ceacam1에 대한 인간화 항체
|
US10087259B1
(en)
|
2014-04-28 |
2018-10-02 |
Memorial Sloan Kettering Cancer Center |
Depleting tumor-specific tregs
|
US9753036B2
(en)
|
2014-04-29 |
2017-09-05 |
Edp Biotech Corporation |
Methods and compositions for screening and detecting biomarkers
|
CN106659801B
(zh)
|
2014-04-30 |
2019-12-10 |
辉瑞大药厂 |
抗-ptk7抗体-药物缀合物
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
EA201692109A1
(ru)
|
2014-05-01 |
2017-03-31 |
Дженентек, Инк. |
Варианты антител к фактору d и их применение
|
WO2015166105A2
(en)
|
2014-05-02 |
2015-11-05 |
Medimmune Limited |
Ion channel modulators and uses thereof
|
JP6533797B2
(ja)
|
2014-05-02 |
2019-06-19 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
抗lystによる免疫調整のための組成物及び方法
|
EP2942627A1
(en)
|
2014-05-05 |
2015-11-11 |
MicroBPlex, Inc. |
Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
|
BR112016024462B1
(pt)
|
2014-05-06 |
2022-12-27 |
Genentech, Inc |
Métodos para a preparação de um anticorpo
|
US10258639B2
(en)
|
2014-05-06 |
2019-04-16 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
|
US11173208B2
(en)
|
2014-05-07 |
2021-11-16 |
Takeda Gmbh |
Liquid formulation comprising GM-CSF neutralizing compound
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
AU2015259516B2
(en)
|
2014-05-13 |
2020-05-28 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
|
FR3020947B1
(fr)
|
2014-05-14 |
2018-08-31 |
Adocia |
Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
|
WO2015176010A1
(en)
|
2014-05-15 |
2015-11-19 |
The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services |
Treatment or prevention of an intestinal disease or disorder
|
JP6671298B2
(ja)
|
2014-05-16 |
2020-03-25 |
アムジェン インコーポレイテッド |
Th1及びth2細胞集団を検出するためのアッセイ
|
US9903868B2
(en)
|
2014-05-16 |
2018-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for the detection and quantitation of biomarkers
|
EP3888690A3
(en)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
EP3146081B1
(en)
|
2014-05-19 |
2020-10-28 |
The Johns Hopkins University |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
|
EP3145934B1
(en)
|
2014-05-19 |
2020-11-11 |
Pfizer Inc |
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
|
JP2017517506A
(ja)
|
2014-05-21 |
2017-06-29 |
ファイザー・インコーポレイテッド |
癌を処置するための抗ccr4抗体および4−1bbアゴニストの併用
|
CA2945822A1
(en)
|
2014-05-21 |
2015-11-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer with anti bip or anti mica antibodies
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
CN107074945B
(zh)
|
2014-05-27 |
2021-08-24 |
中央研究院 |
增进抗体功效的通用糖型的组合物及方法
|
WO2015184002A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
EP4198059A1
(en)
|
2014-05-27 |
2023-06-21 |
The University of Queensland |
Modulation of cellular stress
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR102433464B1
(ko)
|
2014-05-28 |
2022-08-17 |
아게누스 인코포레이티드 |
항-gitr 항체 및 이의 사용 방법
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
TWI707872B
(zh)
|
2014-05-29 |
2020-10-21 |
美商宏觀基因股份有限公司 |
特異性結合多種癌症抗原的三特異性結合分子和其使用方法
|
JP6691872B2
(ja)
|
2014-05-30 |
2020-05-13 |
ヘンリクス バイオテック カンパニー リミテッド |
抗上皮増殖因子受容体(egfr)抗体
|
US20170253881A1
(en)
|
2014-06-02 |
2017-09-07 |
Technion Research & Development Foundation Limited |
Compositions and methods of selectively inhibiting irp1 and treating inflammation
|
WO2015187499A1
(en)
|
2014-06-03 |
2015-12-10 |
Gilead Sciences, Inc. |
Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
KR102486180B1
(ko)
|
2014-06-06 |
2023-01-11 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|
WO2015191615A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
|
US11034757B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
US11033620B2
(en)
|
2014-06-09 |
2021-06-15 |
Biomed Valley Discoveries, Inc. |
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
|
WO2015191583A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
|
WO2015191617A2
(en)
|
2014-06-09 |
2015-12-17 |
Biomed Valley Discoveries, Inc. |
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
|
SI3151859T1
(sl)
|
2014-06-09 |
2021-06-30 |
Ultragenyx Pharmaceutical Inc. |
Uspešen in učinkovit nadzor serumskega fosfata za optimalno tvorbo kosti
|
US10434174B2
(en)
|
2014-06-09 |
2019-10-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
|
US10758526B2
(en)
|
2014-06-09 |
2020-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health |
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
MX2016016233A
(es)
|
2014-06-11 |
2017-03-31 |
Genentech Inc |
Anticuerpos anti-lgr5 y sus usos.
|
JP6353082B2
(ja)
|
2014-06-11 |
2018-07-04 |
ギリアード サイエンシーズ, インコーポレイテッド |
心血管疾患を処置するための方法
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
US20170137824A1
(en)
|
2014-06-13 |
2017-05-18 |
Indranil BANERJEE |
New treatment against influenza virus
|
TN2016000553A1
(en)
|
2014-06-13 |
2018-04-04 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
JP2017522289A
(ja)
|
2014-06-17 |
2017-08-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
改善されたα−Vβ−8抗体
|
ES2694296T3
(es)
|
2014-06-17 |
2018-12-19 |
Centre National De La Recherche Scientifique (Cnrs) |
Anticuerpos monoclonales anti-pVHL y usos de los mismos
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
MX2016016490A
(es)
|
2014-06-20 |
2017-07-28 |
Bioalliance Cv |
Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos.
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
EA201790051A1
(ru)
|
2014-06-20 |
2017-04-28 |
Авео Фармасьютикалз, Инк. |
Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
|
WO2015196142A1
(en)
|
2014-06-20 |
2015-12-23 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
SG11201610672YA
(en)
|
2014-06-23 |
2017-01-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
WO2015198320A1
(en)
|
2014-06-24 |
2015-12-30 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
WO2015199976A1
(en)
|
2014-06-24 |
2015-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Target activated microdissection
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
TW201628647A
(zh)
|
2014-06-27 |
2016-08-16 |
賽諾菲公司 |
抗-il4-il13雙特異性抗體
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
AU2015283704A1
(en)
|
2014-07-01 |
2016-12-15 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
US10398765B2
(en)
|
2014-07-03 |
2019-09-03 |
Yale University |
Dickkopf2 (Dkk2) inhibition suppresses tumor formation
|
EP3164492B1
(en)
|
2014-07-03 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Polypeptide expression systems
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
US20160000791A1
(en)
|
2014-07-07 |
2016-01-07 |
Mayo Foundation For Medical Education And Research |
Par1 modulation to alter myelination
|
JP6630717B2
(ja)
*
|
2014-07-07 |
2020-01-15 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
組織試料における切断snap25の検出方法
|
MX2017000231A
(es)
|
2014-07-09 |
2017-06-27 |
Genentech Inc |
Ajuste del ph para mejorar la recuperacion por descongelamiento de bancos de celulas.
|
WO2016005545A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
WO2016007235A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
US10166304B2
(en)
|
2014-07-11 |
2019-01-01 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
CN106573060A
(zh)
|
2014-07-15 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
|
ES2799404T3
(es)
|
2014-07-15 |
2020-12-17 |
Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd |
Polipéptidos de CD44 aislados y usos de los mismos
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
US20170227541A1
(en)
|
2014-07-17 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Methods for using exosomes to monitor transplanted organ status
|
MX2017000484A
(es)
|
2014-07-17 |
2017-05-01 |
Novo Nordisk As |
Mutagenesis dirigida al sitio anticuerpos receptor desencadenante expresado en las celulas mieloides de tipo 1 (trem-1) para reducir la viscosidad.
|
KR20170052569A
(ko)
|
2014-07-18 |
2017-05-12 |
어드박시스, 인크. |
전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
CN112481283A
(zh)
|
2014-07-21 |
2021-03-12 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3172233B1
(en)
|
2014-07-22 |
2019-09-11 |
Sutro Biopharma, Inc. |
Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
|
WO2016014839A2
(en)
|
2014-07-23 |
2016-01-28 |
Ohio State Innovation Foundation |
Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
US10507241B2
(en)
|
2014-07-24 |
2019-12-17 |
Boehringer Ingelheim International Gmbh |
Biomarkers useful in the treatment of IL-23A related diseases
|
EP3511413B1
(en)
|
2014-07-25 |
2022-09-07 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
WO2016019126A1
(en)
|
2014-07-30 |
2016-02-04 |
The Research Foundation For The State University Of New York |
System and method for delivering genetic material or protein to cells
|
WO2016016415A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
BR112017001860A2
(pt)
|
2014-07-31 |
2018-02-27 |
Uab Research Foundation |
peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
EP3174987B1
(en)
|
2014-08-01 |
2023-10-11 |
The Johns Hopkins University |
Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
|
US10426735B2
(en)
|
2014-08-01 |
2019-10-01 |
Massachusetts Institute Of Technology |
Modified alginates for anti-fibrotic materials and applications
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
US10072097B2
(en)
|
2014-08-04 |
2018-09-11 |
Academia Sinica |
Compositions and methods for detection of protein S-nitrosylation and oxidation
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
JP6629321B2
(ja)
|
2014-08-05 |
2020-01-15 |
マブクエスト エスエーMabQuest SA |
免疫学的試薬
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
US10392444B2
(en)
|
2014-08-08 |
2019-08-27 |
Oncoquest, Inc. |
Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
|
MX2017001531A
(es)
|
2014-08-08 |
2017-05-15 |
Alector Llc |
Anticuerpos anti-trem2 y metodos de uso de los mismos.
|
SG11201610052TA
(en)
|
2014-08-08 |
2017-02-27 |
Us Health |
Photo-controlled removal of targets in vitro and in vivo
|
EP3180024B1
(en)
|
2014-08-11 |
2022-05-18 |
University of Massachusetts |
Anti-ospa antibodies and methods of use
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
GFRα−4キメラ抗原受容体を用いる癌の治療
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
UA122395C2
(uk)
|
2014-08-19 |
2020-11-10 |
Мерк Шарп Енд Доум Корп. |
Антитіло проти tigit
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
JP6858559B2
(ja)
*
|
2014-08-20 |
2021-04-14 |
中外製薬株式会社 |
蛋白質溶液の粘度測定方法
|
WO2016029079A2
(en)
|
2014-08-21 |
2016-02-25 |
Walter Reed Army Institute Of Research Department Of The Army |
Monoclonal antibodies for treatment of microbial infections
|
WO2016026143A1
(en)
|
2014-08-22 |
2016-02-25 |
Huiru Wang |
Saccharide-based biomarkers and therapeutics
|
WO2016026978A1
(en)
|
2014-08-22 |
2016-02-25 |
Universite Nice Sophia Antipolis |
Methods and pharmaceutical compositions for treating drug addiction
|
JP2017530950A
(ja)
|
2014-08-25 |
2017-10-19 |
ファイザー・インコーポレイテッド |
癌を処置するためのpd−1アンタゴニストおよびalk阻害剤の併用
|
WO2016033114A1
(en)
|
2014-08-25 |
2016-03-03 |
The Johns Hopkins University |
Methods and compositions related to prostate cancer therapeutics
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
WO2016030791A1
(en)
|
2014-08-28 |
2016-03-03 |
Pfizer Inc. |
Stability-modulating linkers for use with antibody drug conjugates
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
EP3186284B1
(en)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
DK3189132T3
(da)
|
2014-09-04 |
2020-08-10 |
Stemcell Tech Inc |
Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
CA2959716A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Anti-her3 antibodies and uses of same
|
AU2015313811A1
(en)
|
2014-09-08 |
2017-04-06 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
EP3191520B1
(en)
|
2014-09-12 |
2020-01-01 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
SG10201809668TA
(en)
|
2014-09-12 |
2018-11-29 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
EP3191134B1
(en)
|
2014-09-12 |
2019-11-20 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
IL234638A0
(en)
|
2014-09-14 |
2014-12-02 |
Yeda Res & Dev |
NMDA receptor antagonists for the treatment of Gaucher disease
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
WO2016043577A1
(en)
|
2014-09-16 |
2016-03-24 |
Academisch Medisch Centrum |
Ig-like molecules binding to bmp4
|
EP3110447B1
(en)
|
2014-09-16 |
2020-04-29 |
Synermore Biologics Co., Ltd. |
Anti-egfr antibody and uses of same
|
CN107124870A
(zh)
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
HUE057768T2
(hu)
|
2014-09-17 |
2022-06-28 |
Zymeworks Inc |
Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
|
MA40575A
(fr)
|
2014-09-17 |
2016-03-24 |
Genentech Inc |
Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
WO2016044588A1
(en)
|
2014-09-19 |
2016-03-24 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
WO2016044697A1
(en)
|
2014-09-19 |
2016-03-24 |
The Johns Hopkins University |
Biomarkers of cognitive dysfunction
|
EP3197915A4
(en)
|
2014-09-22 |
2018-12-19 |
Intrinsic Lifesciences LLC |
Humanized anti-hepcidin antibodies and uses thereof
|
EP3689910A3
(en)
|
2014-09-23 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
US20170306008A1
(en)
|
2014-09-25 |
2017-10-26 |
Aveo Pharmaceuticals, Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
CR20170109A
(es)
|
2014-09-26 |
2017-07-26 |
Macrogenics Inc |
Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
|
EP3201227A4
(en)
|
2014-09-29 |
2018-04-18 |
Duke University |
Bispecific molecules comprising an hiv-1 envelope targeting arm
|
EP3201330A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta mannanase and methods of use
|
EP3201333A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta-mannanase and methods of use
|
EP3201331A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta mannanase and methods of use
|
WO2016054194A1
(en)
|
2014-09-30 |
2016-04-07 |
1/1Danisco Us Inc |
Compositions comprising beta-mannanase and methods of use
|
EP3201332A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta-mannanase and methods of use
|
CN107108741B
(zh)
|
2014-09-30 |
2021-07-16 |
德国公共权益癌症研究中心基金会 |
与l1cam(cd171)结合的结合分子,特别是抗体
|
KR102497368B1
(ko)
|
2014-10-01 |
2023-02-10 |
이글 바이올로직스 인코포레이티드 |
점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
|
WO2016054354A1
(en)
|
2014-10-02 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating malignancies
|
CA2963281A1
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
CN107250159A
(zh)
|
2014-10-03 |
2017-10-13 |
达纳-法伯癌症研究所公司 |
糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其使用方法
|
CN107250160B
(zh)
|
2014-10-06 |
2022-01-11 |
达纳-法伯癌症研究所公司 |
人源化cc趋化因子受体4 (ccr4)抗体及其使用方法
|
EP3204516B1
(en)
|
2014-10-06 |
2023-04-26 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
US9921230B2
(en)
|
2014-10-08 |
2018-03-20 |
Rhode Island Hospital |
Methods for diagnosis and treatment of concussion or brain injury
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP3204119B1
(en)
|
2014-10-09 |
2021-06-09 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable il-2 dose regimen for treating immune disorders
|
JP6708635B2
(ja)
|
2014-10-09 |
2020-06-10 |
エンクマフ エスアーエールエル |
CD3εおよびROR1に対する二特異性抗体
|
EP3736294A3
(en)
|
2014-10-10 |
2021-02-17 |
Innate Pharma |
Cd73 blockade
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
ES2900331T3
(es)
|
2014-10-15 |
2022-03-16 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
|
EP3207057A2
(en)
|
2014-10-16 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Anti-alpha-synuclein antibodies and methods of use
|
WO2016059512A1
(en)
|
2014-10-18 |
2016-04-21 |
Pfizer Inc. |
Anti-il-7r antibody compositions
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
EP3220961B1
(en)
|
2014-10-22 |
2023-07-05 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
US10870704B2
(en)
|
2014-10-23 |
2020-12-22 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
CA2965423A1
(en)
|
2014-10-24 |
2016-04-28 |
Dupont Nutrition Biosciences Aps |
Proline tolerant tripeptidyl peptidases and uses thereof
|
WO2016065329A1
(en)
|
2014-10-24 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
CN107075534A
(zh)
|
2014-10-24 |
2017-08-18 |
丹尼斯科美国公司 |
使用三肽基肽酶制备醇的方法
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
TWI711463B
(zh)
|
2014-10-29 |
2020-12-01 |
美商戊瑞治療有限公司 |
用於癌症之組合療法
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
CN107106609A
(zh)
|
2014-10-31 |
2017-08-29 |
宾夕法尼亚大学董事会 |
刺激和扩展t细胞的组合物和方法
|
EP3015475A1
(en)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Mammalian cells expressing cytomegalovirus antigens
|
ES2832711T3
(es)
|
2014-10-31 |
2021-06-11 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-CS1 y conjugados anticuerpo fármaco
|
JP6827415B2
(ja)
|
2014-10-31 |
2021-02-10 |
メレオ バイオファーマ 5 インコーポレイテッド |
疾患の処置のための併用療法
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
US10738078B2
(en)
|
2014-11-03 |
2020-08-11 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
US10302644B2
(en)
|
2014-11-04 |
2019-05-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
US20160146799A1
(en)
|
2014-11-05 |
2016-05-26 |
Nirmidas Biotech, Inc. |
Metal composites for enhanced imaging
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
KR102544705B1
(ko)
|
2014-11-05 |
2023-06-15 |
제넨테크, 인크. |
박테리아 내 2쇄 단백질을 생산하는 방법
|
KR20170075793A
(ko)
|
2014-11-05 |
2017-07-03 |
제넨테크, 인크. |
박테리아 내 2쇄 단백질을 생산하는 방법
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
WO2016071376A2
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
WO2016073282A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
SG11201703574VA
(en)
|
2014-11-07 |
2017-05-30 |
Eleven Biotherapeutics Inc |
Improved il-6 antibodies
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
RS62003B1
(sr)
|
2014-11-10 |
2021-07-30 |
Medimmune Ltd |
Vezujući molekuli specifični za cd73 i njihove upotrebe
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
WO2016075612A1
(en)
|
2014-11-12 |
2016-05-19 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
JP6951973B2
(ja)
|
2014-11-12 |
2021-10-20 |
シージェン インコーポレイテッド |
グリカン相互作用化合物及び使用方法
|
WO2016079736A2
(en)
|
2014-11-17 |
2016-05-26 |
Yeda Research And Development Co. Ltd. |
Methods of treating diseases related to mitochondrial function
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US9982057B2
(en)
|
2014-11-17 |
2018-05-29 |
Pelican Therapeutics, Inc. |
Human TNFRSF25 antibody
|
EA201791093A1
(ru)
|
2014-11-18 |
2018-04-30 |
Янссен Фармацевтика Нв |
Антитела к cd47, способы и применение
|
WO2016079597A1
(en)
|
2014-11-19 |
2016-05-26 |
Axon Neuroscience Se |
Humanized tau antibodies in alzheimer's disease
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
JP2018501202A
(ja)
|
2014-11-19 |
2018-01-18 |
ネステク ソシエテ アノニム |
セロトニン、トリプトファン、及びキヌレニンの代謝産物に対する抗体及びその使用
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
CN107250158B
(zh)
|
2014-11-19 |
2022-03-25 |
基因泰克公司 |
抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
WO2016081808A1
(en)
|
2014-11-20 |
2016-05-26 |
The Regents Of The University Of California |
Compositions and methods related to hematologic recovery
|
RU2727015C2
(ru)
|
2014-11-21 |
2020-07-17 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Векторы aav, нацеленные на центральную нервную систему
|
US10927185B2
(en)
|
2014-11-21 |
2021-02-23 |
Astellas Pharma Inc. |
Bispecific antibody format
|
NZ731633A
(en)
|
2014-11-21 |
2022-01-28 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
GB201420852D0
(en)
|
2014-11-24 |
2015-01-07 |
Genevillage Kft |
Method
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
BR112017010414A2
(pt)
|
2014-11-25 |
2018-05-15 |
Bristol-Myers Squibb Company |
métodos e composições para radiomarcação com 18f de substâncias biológicas
|
WO2016084062A1
(en)
|
2014-11-25 |
2016-06-02 |
Rappaport Family Institute For Research In The Medical Sciences |
Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection
|
US20170327584A1
(en)
|
2014-11-26 |
2017-11-16 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab for the Treatment of Fistulizing Crohn's Disease
|
JP6872482B2
(ja)
|
2014-11-27 |
2021-05-19 |
ザイムワークス,インコーポレイテッド |
Her2を標的とする二重特異性抗原結合性構築物の使用方法
|
KR101760467B1
(ko)
|
2014-12-01 |
2017-07-24 |
중앙대학교 산학협력단 |
수태능력 관련 단백질 마커를 이용한 동물의 산자수 예측 방법과 클로르테트라사이클린 염색법을 이용한 동물의 정액 품질 및 산자수의 예측 방법
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
WO2016087889A1
(en)
|
2014-12-03 |
2016-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
WO2016090050A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
EP3227336B1
(en)
|
2014-12-05 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Anti-cd79b antibodies and methods of use
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
US10982008B2
(en)
|
2014-12-05 |
2021-04-20 |
Merck Patent Gmbh |
Domain-exchanged antibody
|
EP3229837A4
(en)
|
2014-12-08 |
2018-05-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
|
EP3031822A1
(en)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Cytomegalovirus antigens
|
SG10202012249YA
(en)
|
2014-12-08 |
2021-01-28 |
Berg Llc |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
AU2015360736A1
(en)
|
2014-12-09 |
2017-06-01 |
Merck Sharp & Dohme Corp. |
System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
|
KR20170093943A
(ko)
|
2014-12-09 |
2017-08-16 |
애브비 인코포레이티드 |
낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
|
CN107249643A
(zh)
|
2014-12-09 |
2017-10-13 |
艾伯维公司 |
具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
CA2967224C
(en)
|
2014-12-11 |
2023-08-22 |
Inbiomotion S.L. |
Binding members for human c-maf
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
CN114230664A
(zh)
|
2014-12-11 |
2022-03-25 |
皮埃尔法布雷医药公司 |
抗c10orf54抗体及其用途
|
KR102439094B1
(ko)
|
2014-12-12 |
2022-08-31 |
셀퀴티 인크. |
환자를 진단 및 치료하기 위한 신호전달 경로 활성의 측정 방법
|
JP6743015B2
(ja)
|
2014-12-15 |
2020-08-19 |
バイエル ファーマ アクチエンゲゼルシャフト |
Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類)
|
EP3633371A1
(en)
|
2014-12-18 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Assay and method for determining cdc eliciting antibodies
|
US20170362621A1
(en)
|
2014-12-18 |
2017-12-21 |
Danisco Us Inc. |
Engineered multifunctional enzymes and methods of use
|
US10357563B2
(en)
|
2014-12-18 |
2019-07-23 |
The University Of Chicago |
Methods and composition for neutralization of influenza
|
US20180002683A1
(en)
|
2014-12-18 |
2018-01-04 |
Danisco Us Inc. |
Engineered multifunctional enzymes and methods of use
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
ES2786322T3
(es)
|
2014-12-19 |
2020-10-09 |
Inst Nat Sante Rech Med |
Métodos de predicción de alteraciones de injerto
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
LT3233921T
(lt)
|
2014-12-19 |
2021-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antikūnai ir panaudojimo būdai
|
EP3233916A4
(en)
|
2014-12-19 |
2018-06-06 |
Alder Biopharmaceuticals, Inc. |
Humanized anti-acth antibodies and use thereof
|
AU2015369854B2
(en)
|
2014-12-22 |
2021-07-01 |
Five Prime Therapeutics, Inc. |
Anti-CSF1R antibodies for treating PVNS
|
AR103172A1
(es)
|
2014-12-22 |
2017-04-19 |
Novartis Ag |
Reducción selectiva de residuos de cisteina en anticuerpos il-17
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
EP3400953A1
(en)
|
2014-12-23 |
2018-11-14 |
4D Pharma Research Limited |
Pirin polypeptide and immune modulation
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
WO2016103093A1
(en)
|
2014-12-23 |
2016-06-30 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
KR102523805B1
(ko)
|
2014-12-23 |
2023-04-20 |
4디 파마 리서치 리미티드 |
면역 조정
|
WO2016105572A1
(en)
|
2014-12-24 |
2016-06-30 |
Millennium Pharmaceuticals, Inc. |
PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
|
PT3240801T
(pt)
|
2014-12-31 |
2021-02-18 |
Checkmate Pharmaceuticals Inc |
Imunoterapia antitumoral combinada
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
EP3244911B1
(en)
|
2015-01-12 |
2019-10-23 |
Rigshospitalet, Copenhagen University Hospital |
A method for determining a likely effect of a treatment to improve male infertility
|
US10689423B2
(en)
|
2015-01-13 |
2020-06-23 |
City Of Hope |
CTLA4-binding protein peptide-linker masks
|
AU2016206682B2
(en)
|
2015-01-14 |
2021-11-11 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer with anti-LAP monoclonal antibodies
|
CN107405410B
(zh)
|
2015-01-15 |
2021-08-10 |
OncoQuest制药有限公司 |
增加抗癌剂向靶递送的方法
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3244910B1
(en)
|
2015-01-16 |
2020-09-16 |
City of Hope |
Cell penetrating antibodies
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3048114A1
(en)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Cytomegalovirus antigens and uses thereof
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
EP3047856A1
(en)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Cmv antigens and uses thereof
|
UA126269C2
(uk)
|
2015-01-23 |
2022-09-14 |
Санофі |
АНТИТІЛОПОДІБНИЙ ЗВ’ЯЗУВАЛЬНИЙ БІЛОК, ЯКИЙ СПЕЦИФІЧНО ЗВ’ЯЗУЄТЬСЯ З ПОЗАКЛІТИННИМ ДОМЕНОМ CD3<font face="Symbol">e</font> ЛЮДИНИ І З CD123<font face="Symbol">e</font>
|
WO2016118947A1
(en)
|
2015-01-23 |
2016-07-28 |
The University Of North Carolina At Chapel Hill |
Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
JP6602875B2
(ja)
|
2015-01-26 |
2019-11-06 |
マクロジェニクス,インコーポレーテッド |
Dr5結合ドメインを含む多価分子
|
EP3250184A1
(en)
|
2015-01-27 |
2017-12-06 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
CN107206080B
(zh)
|
2015-01-28 |
2022-07-08 |
辉瑞公司 |
稳定的水性抗血管内皮细胞生长因子(vegf)抗体制剂
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
EP3250595B1
(en)
|
2015-01-29 |
2024-04-24 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
|
US10539572B2
(en)
|
2015-01-30 |
2020-01-21 |
Salk Institute For Biological Studies |
Compositions and methods for treating age-related diabetes and related disorders
|
CN114702581A
(zh)
|
2015-01-30 |
2022-07-05 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
WO2016122738A1
(en)
|
2015-01-31 |
2016-08-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
CN104593416A
(zh)
*
|
2015-02-02 |
2015-05-06 |
上海交通大学 |
pHAb-FAST人源抗体表达载体系统及其使用方法
|
DK3254110T3
(da)
|
2015-02-03 |
2020-05-18 |
Ventana Med Syst Inc |
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
|
EP3253796A1
(en)
|
2015-02-03 |
2017-12-13 |
Université Catholique de Louvain |
Anti-garp protein and uses thereof
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
IL307578A
(en)
|
2015-02-04 |
2023-12-01 |
Boehringer Ingelheim Int |
Methods for treating inflammatory diseases
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
CA2976236A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
US10266584B2
(en)
|
2015-02-09 |
2019-04-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
|
CN105461809B
(zh)
|
2015-02-11 |
2018-10-12 |
康融东方(广东)医药有限公司 |
Pcsk9抗体、其药物组合物及其用途
|
US20180031579A1
(en)
|
2015-02-12 |
2018-02-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
CA2973134A1
(en)
|
2015-02-17 |
2016-08-25 |
Arsanis Biosciences Gmbh |
Antibodies targeting a galactan-based o-antigen of k. pneumoniae
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
US10202444B2
(en)
|
2015-02-24 |
2019-02-12 |
Rpeptide, Llc |
Anti-tau antibodies
|
US10479825B2
(en)
|
2015-02-25 |
2019-11-19 |
Vanderbilt University |
Antibody-mediated neutralization of Marburg virus
|
JP2018507868A
(ja)
|
2015-02-26 |
2018-03-22 |
ジェネンテック, インコーポレイテッド |
インテグリンベータ7アンタゴニスト及びクローン病の治療方法
|
RU2714233C2
(ru)
|
2015-02-26 |
2020-02-13 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
CA2977607A1
(en)
|
2015-02-26 |
2016-09-01 |
Jacob Schneiderman |
Methods and compositions relating to leptin antagonists
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
EP3265811B1
(en)
|
2015-03-02 |
2022-10-26 |
Sarcotein Diagnostics LLC |
13+/17+ bin1 expression as a marker of cardiac disorders
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
EP3265074B1
(en)
|
2015-03-03 |
2020-08-12 |
ARK Diagnostics, Inc. |
Pregabalin immunoassays
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
HUE054642T2
(hu)
|
2015-03-04 |
2021-09-28 |
Igm Biosciences Inc |
CD20 kötõ molekulák és ezek felhasználása
|
SG11201706872SA
(en)
|
2015-03-04 |
2017-09-28 |
Merck Sharp & Dohme |
Combination of a pd-1 antagonist and eribulin for treating cancer
|
EP3265474A1
(en)
|
2015-03-05 |
2018-01-10 |
Sirenas LLC |
Cyclic peptide analogs and conjugates thereof
|
EP4223786A3
(en)
|
2015-03-06 |
2023-08-16 |
Public University Corporation Yokohama City University |
Novel anti-pad4 antibodies
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
AR103852A1
(es)
|
2015-03-06 |
2017-06-07 |
Genentech Inc |
DsbA Y DsbC ULTRAPURIFICADOS Y SUS MÉTODOS DE PREPARACIÓN Y USO
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
SG11201706659WA
(en)
|
2015-03-06 |
2017-09-28 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
GB201503967D0
(en)
|
2015-03-09 |
2015-04-22 |
Univ Glasgow |
Biocompatible implants for use in tendon therapy
|
MY178919A
(en)
|
2015-03-09 |
2020-10-23 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
JP2018515424A
(ja)
|
2015-03-10 |
2018-06-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抗アルファvベータ1インテグリン阻害剤及び使用方法
|
WO2016142385A1
(en)
|
2015-03-11 |
2016-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing ocular anterior chamber dysgenesis
|
JP6807859B2
(ja)
|
2015-03-13 |
2021-01-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
クロマトグラフィーにおける不純物を取り除くためのアルカリ洗浄の使用
|
EP3067062A1
(en)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
|
MX2017011486A
(es)
|
2015-03-16 |
2018-06-15 |
Genentech Inc |
Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
SG11201706786UA
(en)
|
2015-03-18 |
2017-09-28 |
Seattle Genetics Inc |
Cd48 antibodies and conjugates thereof
|
WO2016145536A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
IL237852A0
(en)
|
2015-03-19 |
2016-03-24 |
Yeda Res & Dev |
Antibodies against amphigoline, medical preparations containing them and their use
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
WO2016151432A1
(en)
|
2015-03-20 |
2016-09-29 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the cti pharmacophore
|
US20180105555A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
US20180105554A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran sulfate to enhance protein a affinity chromatography
|
US10023635B2
(en)
|
2015-03-23 |
2018-07-17 |
Jounce Therapeutics, Inc. |
Antibodies to ICOS
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
EP3274724A1
(en)
|
2015-03-25 |
2018-01-31 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
WO2016151557A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c5 convertase of the alternative complement pathway
|
WO2016157175A1
(en)
|
2015-03-27 |
2016-10-06 |
Yeda Research And Development Co. Ltd. |
Methods of treating motor neuron diseases
|
JP6976854B2
(ja)
|
2015-03-30 |
2021-12-08 |
シティ・オブ・ホープCity of Hope |
機械的にかみ合った複合体
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
EP3277306B1
(en)
|
2015-04-01 |
2023-02-22 |
Hadasit Medical Research Services and Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for use in a treatment of liver disorders
|
CN113861294B
(zh)
|
2015-04-02 |
2024-03-08 |
英特维特国际股份有限公司 |
针对犬白介素-4受体α的抗体
|
CA2981304C
(en)
|
2015-04-02 |
2024-01-02 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/hvem proteins and methods of use thereof
|
US20180208658A1
(en)
|
2015-04-03 |
2018-07-26 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
US10167334B2
(en)
|
2015-04-03 |
2019-01-01 |
Xoma Technology Ltd. |
Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
BR112017021510A2
(pt)
|
2015-04-06 |
2018-07-03 |
Acceleron Pharma Inc |
heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
BR112017021536A2
(pt)
|
2015-04-06 |
2018-07-03 |
Harvard College |
composições e métodos para o condicionamento não mieloablativo
|
EP4212175A1
(en)
|
2015-04-06 |
2023-07-19 |
Bioverativ USA Inc. |
Humanized anti-c1s antibodies and methods of use thereof
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
EP3280455A1
(en)
|
2015-04-07 |
2018-02-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Non-invasive imaging of tumor pd-l1 expression
|
US10849992B1
(en)
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
PT3280441T
(pt)
|
2015-04-07 |
2021-11-30 |
Alector Llc |
Anticorpos anti-sortilina e métodos para a sua utilização
|
US10968185B2
(en)
|
2015-04-07 |
2021-04-06 |
Ela Pharma Ltd. |
Substituted thiazoles for preventing and/or treating cell or tissue necrosis
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
AU2016246065B2
(en)
|
2015-04-08 |
2021-06-03 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
JP2018517892A
(ja)
|
2015-04-10 |
2018-07-05 |
アプライド プロテオミクス,インク. |
結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
CN114681608A
(zh)
|
2015-04-13 |
2022-07-01 |
戊瑞治疗有限公司 |
癌症组合疗法
|
IL290488B1
(en)
|
2015-04-13 |
2024-03-01 |
Pfizer |
Therapeutic antibodies and their uses
|
CN114149511A
(zh)
|
2015-04-13 |
2022-03-08 |
辉瑞公司 |
靶向b细胞成熟抗原的嵌合抗原受体
|
MX2017013156A
(es)
|
2015-04-14 |
2018-02-21 |
Boehringer Ingelheim Int |
Metodos para tratar enfermedades.
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
WO2016166223A1
(en)
|
2015-04-17 |
2016-10-20 |
Arsanis Biosciences Gmbh |
Anti-staphylococcus aureus antibody combination preparation
|
EP4276116A3
(en)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
WO2016169807A1
(en)
|
2015-04-22 |
2016-10-27 |
Nestec S.A. |
Biomarkers for predicting degree of weight loss in female subjects
|
WO2016168133A1
(en)
|
2015-04-17 |
2016-10-20 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
JP6803339B2
(ja)
|
2015-04-21 |
2020-12-23 |
エンリヴェックス セラピューティクス リミテッド |
治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
|
WO2016170022A1
(en)
|
2015-04-21 |
2016-10-27 |
Institut Gustave Roussy |
Therapeutic methods, products and compositions inhibiting znf555
|
EP3286565A1
(en)
|
2015-04-21 |
2018-02-28 |
Genentech, Inc. |
Compositions and methods for prostate cancer analysis
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
WO2016170027A1
(en)
|
2015-04-22 |
2016-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
|
CN107533067A
(zh)
|
2015-04-22 |
2018-01-02 |
雀巢产品技术援助有限公司 |
用于预测雄性受试者体重减轻程度的生物标志物
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
AU2016253957C1
(en)
|
2015-04-27 |
2021-04-01 |
Dana-Farber Cancer Institute, Inc. |
High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
|
EP3288976B1
(en)
|
2015-04-29 |
2020-04-08 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
US10556956B2
(en)
|
2015-05-01 |
2020-02-11 |
Dana-Farber Cancer Institute, Inc. |
Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibody
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
MA42043A
(fr)
|
2015-05-07 |
2018-03-14 |
Agenus Inc |
Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
|
CN116196414A
(zh)
|
2015-05-11 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
WO2016181393A1
(en)
|
2015-05-11 |
2016-11-17 |
Yeda Research And Development Co. Ltd. |
Citrin inhibitors for the treatment of cancer
|
US20160333087A1
(en)
|
2015-05-12 |
2016-11-17 |
Bioven 3 Limited |
Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
|
HRP20201900T4
(hr)
|
2015-05-12 |
2024-06-07 |
F. Hoffmann - La Roche Ag |
Terapeutski i dijagnostički postupci kod raka
|
MA48852A
(fr)
|
2015-05-13 |
2020-04-01 |
Univ Pennsylvania |
Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
|
PT3294764T
(pt)
|
2015-05-15 |
2021-02-15 |
Hope City |
Composições de recetores de antigénios quiméricos
|
AU2016263198C1
(en)
|
2015-05-15 |
2023-10-05 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
EP3298033B2
(en)
|
2015-05-18 |
2023-07-12 |
TCR2 Therapeutics Inc. |
Compositions and medical uses for tcr reprogramming using fusion proteins
|
ES2739749T3
(es)
|
2015-05-18 |
2020-02-03 |
Tolero Pharmaceuticals Inc |
Profármacos de alvocidib que tienen biodisponibilidad aumentada
|
WO2016185457A1
(en)
|
2015-05-19 |
2016-11-24 |
Yeda Research And Development Co. Ltd. |
Methods of promoting lymphangiogenesis
|
WO2016185481A2
(en)
|
2015-05-20 |
2016-11-24 |
Yeda Research And Development Co. Ltd. |
Method of targeting senescent cells
|
KR101997241B1
(ko)
|
2015-05-21 |
2019-07-09 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
WO2016191397A1
(en)
|
2015-05-22 |
2016-12-01 |
Td2 Inc. |
Benzamide and active compound compositions and methods of use
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
CN107646038B
(zh)
|
2015-05-28 |
2021-08-20 |
基因泰克公司 |
用于检测抗cd3同二聚体的基于细胞的测定
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
PE20180926A1
(es)
|
2015-05-29 |
2018-06-08 |
Bristol Myers Squibb Co |
Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
|
DK3303395T3
(da)
|
2015-05-29 |
2020-01-27 |
Abbvie Inc |
Anti-cd40-antistoffer og anvendelser deraf
|
AR105618A1
(es)
|
2015-05-29 |
2017-10-25 |
Genentech Inc |
Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
JP2018080114A
(ja)
|
2015-05-29 |
2018-05-24 |
株式会社アールテック・ウエノ |
抗ヒトvap−1モノクローナル抗体
|
BR112017025562A2
(pt)
|
2015-05-29 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
WO2016196605A1
(en)
|
2015-06-01 |
2016-12-08 |
The University Of Chicago |
Treatment of cancer by manipulation of commensal microflora
|
DK3303384T3
(da)
|
2015-06-01 |
2021-10-18 |
Medimmune Llc |
Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック, インコーポレイテッド |
抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法
|
WO2016191811A1
(en)
|
2015-06-03 |
2016-12-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
JP6793134B2
(ja)
|
2015-06-05 |
2020-12-02 |
ジェネンテック, インコーポレイテッド |
抗tau抗体及び使用方法
|
BR112017021484A2
(pt)
|
2015-06-05 |
2018-07-03 |
Novartis Ag |
anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
EP3307772B1
(en)
|
2015-06-12 |
2020-09-09 |
Ludwig Institute For Cancer Research Limited |
Tgf-beta 3 specific antibodies and methods and uses thereof
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201709929A
(zh)
|
2015-06-12 |
2017-03-16 |
宏觀基因股份有限公司 |
治療癌症的聯合療法
|
US11136390B2
(en)
|
2015-06-12 |
2021-10-05 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
TW201709932A
(zh)
|
2015-06-12 |
2017-03-16 |
西雅圖遺傳學公司 |
Cd123抗體及其共軛物
|
MA41060B1
(fr)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
PT3307288T
(pt)
|
2015-06-15 |
2019-10-17 |
4D Pharma Res Ltd |
Composições compreendendo estirpes bacterianas
|
PT3240554T
(pt)
|
2015-06-15 |
2019-11-04 |
4D Pharma Res Ltd |
Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
DK3206700T3
(da)
|
2015-06-15 |
2019-08-05 |
4D Pharma Res Ltd |
Sammensætninger omfattende bakteriestammer
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
MA41010B1
(fr)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
CA2989586A1
(en)
|
2015-06-16 |
2016-12-22 |
Pfizer, Inc. |
Pd-l1 antagonist combination treatments
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
AR105026A1
(es)
|
2015-06-16 |
2017-08-30 |
Genentech Inc |
ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
KR20180018538A
(ko)
|
2015-06-17 |
2018-02-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
EP3310385A4
(en)
|
2015-06-17 |
2018-12-19 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
ES2909486T3
(es)
|
2015-06-19 |
2022-05-06 |
Centurion Biopharma Corp |
Sistemas de administración para liberación controlada de fármaco
|
SG10201908685QA
(en)
|
2015-06-22 |
2019-10-30 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
|
CN107921145A
(zh)
|
2015-06-23 |
2018-04-17 |
拜耳医药股份有限公司 |
Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物(adc)
|
CN108025086A
(zh)
|
2015-06-23 |
2018-05-11 |
拜耳制药股份公司 |
Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc)
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
LT3313879T
(lt)
|
2015-06-24 |
2022-03-25 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš transferino receptorių su pritaikytu giminingumu
|
WO2016207245A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
GB201511196D0
(en)
|
2015-06-25 |
2015-08-12 |
Cytosystems Ltd |
Monoclonal antibodies
|
WO2016210395A1
(en)
|
2015-06-26 |
2016-12-29 |
Dupont Nutrition Biosciences Aps |
Aminopeptidases for protein hydrlyzates
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
JP2018520153A
(ja)
|
2015-06-29 |
2018-07-26 |
ジェネンテック, インコーポレイテッド |
臓器移植における使用のためのii型抗cd20抗体
|
WO2017004026A1
(en)
|
2015-06-29 |
2017-01-05 |
Immunogen, Inc. |
Anti-cd 123 antibodies and conjugates and derivatives thereof
|
EP3313186A4
(en)
|
2015-06-29 |
2019-04-03 |
Biomed Valley Discoveries, Inc. |
COMBINATION OF LPT-723 INHIBITORS AND IMMUNE CONTROL POINT AND METHODS OF TREATMENT
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
AU2016288461B2
(en)
|
2015-06-29 |
2021-10-07 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
EP3919507A3
(en)
|
2015-07-01 |
2022-01-12 |
Immatics Biotechnologies GmbH |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
MX2017015908A
(es)
|
2015-07-06 |
2018-03-15 |
Ucb Biopharma Sprl |
Anticuerpos de union a tau.
|
MA51531A
(fr)
|
2015-07-06 |
2020-11-11 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
|
UA124616C2
(uk)
|
2015-07-06 |
2021-10-20 |
Юсб Біофарма Срл |
Зв'язуюче тау-білок антитіло
|
US20180201687A1
(en)
|
2015-07-07 |
2018-07-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to myosin 18a and uses thereof
|
DK3115376T3
(en)
|
2015-07-10 |
2018-11-26 |
Merus Nv |
HUMANT CD3 BINDING ANTIBODY
|
WO2017011275A1
(en)
|
2015-07-10 |
2017-01-19 |
Nersissian Aram M |
Factor viii protein compositions and methods of treating hemophilia a
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
WO2017009842A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
US10877045B2
(en)
|
2015-07-21 |
2020-12-29 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
DK3124976T3
(en)
|
2015-07-28 |
2018-12-10 |
Hoffmann La Roche |
IMPROVED BACTERIAL ENDOTOXIN TEST FOR THE DETERMINATION OF ENDOTOXINES
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
IL297090A
(en)
|
2015-07-30 |
2022-12-01 |
Macrogenics Inc |
Molecules that bind pd-1 and methods of using them
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
AU2016303688B2
(en)
|
2015-07-31 |
2023-06-15 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
BR112018001955B1
(pt)
|
2015-08-03 |
2021-05-11 |
Engmab Sárl |
anticorpo monoclonal que se liga às células b humanas (bcma), composição farmacêutica e seu uso
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
WO2017023861A1
(en)
|
2015-08-03 |
2017-02-09 |
The Regents Of The University Of California |
Compositions and methods for modulating abhd2 activity
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
CA2994413A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma, Inc. |
Methods for treating myeloproliferative disorders
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
MX2018001465A
(es)
|
2015-08-05 |
2019-01-31 |
Acticor Biotech |
Nuevos anticuerpos anti-gpvi humana y sus usos.
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
CN108135958B
(zh)
|
2015-08-06 |
2022-03-04 |
希望之城 |
细胞穿透蛋白-抗体缀合物及其使用方法
|
AU2016304588A1
(en)
|
2015-08-06 |
2018-02-15 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
WO2017025458A1
(en)
|
2015-08-07 |
2017-02-16 |
Gamamabs Pharma |
Antibodies, antibody drug conjugates and methods of use
|
AU2016306907A1
(en)
|
2015-08-07 |
2018-03-29 |
Merck Patent Gmbh |
A transglutamine tag for efficient site-specific bioconjugation
|
AU2016304764C1
(en)
|
2015-08-07 |
2023-06-01 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
CN108135989B
(zh)
|
2015-08-14 |
2022-08-09 |
硕腾服务有限责任公司 |
牛支原体组合物
|
JP6720293B2
(ja)
|
2015-08-19 |
2020-07-08 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
安定な抗ifnar1製剤
|
US11384138B2
(en)
|
2015-08-19 |
2022-07-12 |
Rutgers, The State University Of New Jersey |
Methods of generating antibodies
|
CN107923911A
(zh)
|
2015-08-20 |
2018-04-17 |
豪夫迈·罗氏有限公司 |
使用聚乙二醇化分析物特异性结合剂的基于颗粒的免疫测定法
|
GB201514928D0
(en)
|
2015-08-21 |
2015-10-07 |
King S College London |
PDD compounds
|
EP4218777A3
(en)
|
2015-08-28 |
2023-08-23 |
The Trustees of the University of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
KR20180054639A
(ko)
|
2015-08-28 |
2018-05-24 |
알렉터 엘엘씨 |
항-siglec-7 항체 및 이의 사용 방법
|
US11890301B2
(en)
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
US20170058038A1
(en)
|
2015-09-01 |
2017-03-02 |
Boehringer Ingelheim International Gmbh |
Use of anti-cd40 antibodies for treatment of lupus nephritis
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
EP3798234A1
(en)
|
2015-09-02 |
2021-03-31 |
Immutep S.A.S. |
Anti-lag-3 agonistic antibodies
|
EP3344658B1
(en)
|
2015-09-02 |
2022-05-11 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
|
CA2997179A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The Unversity Of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
AU2016315873B2
(en)
|
2015-09-04 |
2022-08-18 |
Primatope Therapeutics Inc. |
Humanized anti-CD40 antibodies and uses thereof
|
EP3347377B1
(en)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
WO2017042278A1
(en)
|
2015-09-09 |
2017-03-16 |
Medizinische Hochschule Hannover |
Diagnosing and treating peripartum cardiomyopathy through the level of plasminogen activator inhibitor
|
WO2017042814A1
(en)
|
2015-09-10 |
2017-03-16 |
Yeda Research And Development Co. Ltd. |
Use of perforin positive immature dendritic cells in disease treatment
|
EP3922645A1
(en)
|
2015-09-15 |
2021-12-15 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
PL3349776T3
(pl)
|
2015-09-17 |
2021-08-02 |
Histide Ag |
Związek farmaceutyczny agonisty receptora czynnika wzrostu i inhibitora białka adhezyjnego do przekształcania komórki nowotworowej w komórkę nienowotworową i jego zastosowanie
|
US20190330290A1
(en)
|
2015-09-17 |
2019-10-31 |
Histide Ag |
Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
|
WO2017049149A1
(en)
|
2015-09-17 |
2017-03-23 |
Immunogen, Inc. |
Therapeutic combinations comprising anti-folr1 immunoconjugates
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
CA2999083A1
(en)
|
2015-09-18 |
2017-03-23 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
TWI751300B
(zh)
|
2015-09-18 |
2022-01-01 |
日商中外製藥股份有限公司 |
Il-8 結合抗體及其用途
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
US10647752B2
(en)
|
2015-09-22 |
2020-05-12 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
|
KR102645625B1
(ko)
|
2015-09-22 |
2024-03-07 |
제넨테크, 인크. |
Fc-함유 단백질의 발현
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
EP3353204B1
(en)
|
2015-09-23 |
2023-10-18 |
Mereo BioPharma 5, Inc. |
Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
|
SG10201911226QA
(en)
|
2015-09-23 |
2020-01-30 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
CA2999224C
(en)
|
2015-09-23 |
2023-10-24 |
Pfizer Inc. |
Cells and method of cell culture
|
AU2016326738B2
(en)
|
2015-09-24 |
2023-08-31 |
Abvitro Llc |
HIV antibody compositions and methods of use
|
KR102625783B1
(ko)
|
2015-09-25 |
2024-01-15 |
퀴아젠 사이언시스, 엘엘씨 |
라임병을 진단하기 위한 및 치료 후 라임병 스피로헤타 제거를 예측하기 위한 조성물 및 방법
|
JP6764474B2
(ja)
|
2015-09-25 |
2020-09-30 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及び使用方法
|
RU2638457C2
(ru)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
|
US10947598B2
(en)
|
2015-09-29 |
2021-03-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for determining the metabolic status of lymphomas
|
WO2017059132A1
(en)
|
2015-09-29 |
2017-04-06 |
The General Hospital Corporation |
Methods of treating and diagnosing disease using biomarkers for bcg therapy
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
CN108463472A
(zh)
|
2015-09-30 |
2018-08-28 |
Igm生物科学有限公司 |
具有修饰的j-链的结合分子
|
JP2018529719A
(ja)
|
2015-09-30 |
2018-10-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ
|
WO2017059380A1
(en)
|
2015-09-30 |
2017-04-06 |
Igm Biosciences, Inc. |
Binding molecules with modified j-chain
|
EP3355908A1
(en)
|
2015-10-01 |
2018-08-08 |
Amgen Inc. |
Treatment of bile acid disorders
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
EP3356404B1
(en)
|
2015-10-02 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-pd1 antibodies and methods of use
|
US10800826B2
(en)
|
2015-10-05 |
2020-10-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
CN117069841A
(zh)
|
2015-10-06 |
2023-11-17 |
艾利妥 |
抗trem2抗体及其使用方法
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
RU2770099C2
(ru)
|
2015-10-07 |
2022-04-14 |
Апеллис Фармасьютикалс, Инк. |
Схемы введения
|
CN108472362B
(zh)
|
2015-10-07 |
2022-03-29 |
台湾浩鼎生技股份有限公司 |
新颖糖类抗体、医药组成物及其用途
|
CN116396393A
(zh)
|
2015-10-08 |
2023-07-07 |
酵活英属哥伦比亚省公司 |
包含κ和λ轻链的抗原结合多肽构建体及其用途
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
CA3001590A1
(en)
|
2015-10-10 |
2017-04-13 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
EP3362475B1
(en)
|
2015-10-12 |
2023-08-30 |
Innate Pharma |
Cd73 blocking agents
|
WO2017064716A1
(en)
|
2015-10-13 |
2017-04-20 |
Rappaport Family Institute For Research |
Heparanase-neutralizing monoclonal antibodies
|
EP3365027B1
(en)
|
2015-10-14 |
2022-03-30 |
Research Institute at Nationwide Children's Hospital |
Hu specific antibodies and their use in inhibiting biofilm
|
US20180298084A1
(en)
|
2015-10-16 |
2018-10-18 |
Arsanis Biosciences Gmbh |
Bactericidal monoclonal antibody targeting klebsiella pneumoniae
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017064302A1
(en)
|
2015-10-16 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
MX2018004986A
(es)
|
2015-10-21 |
2019-01-14 |
Redcoat Solutions Inc |
Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
|
GB201518675D0
(en)
|
2015-10-21 |
2015-12-02 |
Cellcap Technologies Ltd |
Detection of structural forms of proteins
|
LT3370515T
(lt)
|
2015-10-21 |
2022-05-10 |
Redcoat Solutions, Inc. |
Patalinių blakių aptikimo įrenginys
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
WO2017070460A1
(en)
|
2015-10-22 |
2017-04-27 |
Massachusetts Institute Of Technology |
Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
|
CA2998208A1
(en)
|
2015-10-22 |
2017-04-27 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3365369A1
(en)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2 antibodies and compositions and uses thereof
|
SG10201913245UA
(en)
|
2015-10-23 |
2020-02-27 |
Eureka Therapeutics Inc |
Antibody/t-cell receptor chimeric constructs and uses thereof
|
CN108602888B
(zh)
|
2015-10-23 |
2022-10-04 |
美勒斯公司 |
抑制癌症生长的结合分子
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
EP3365376A1
(en)
|
2015-10-25 |
2018-08-29 |
Yeda Research and Development Co., Ltd. |
Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
|
RU2018119317A
(ru)
|
2015-10-28 |
2019-12-04 |
Йейл Юниверсити |
Гуманизированное антитело к dkk2 и его применение
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
AU2016343978A1
(en)
|
2015-10-29 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
|
SG11201803567XA
(en)
|
2015-10-29 |
2018-05-30 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
KR20180069065A
(ko)
|
2015-10-29 |
2018-06-22 |
에프. 호프만-라 로슈 아게 |
항-변이체 fc-부위 항체 및 사용 방법
|
US20170137535A1
(en)
|
2015-10-30 |
2017-05-18 |
Genentech, Inc. |
Anti-factor d antibody formulations
|
CN115925962A
(zh)
|
2015-10-30 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
铰链修饰的抗体片段和其制备方法
|
EP3368578B1
(en)
|
2015-10-30 |
2021-03-17 |
H. Hoffnabb-La Roche Ag |
Anti-htra1 antibodies and methods of use thereof
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
DK3368085T3
(da)
|
2015-11-01 |
2024-04-02 |
Massachusetts Inst Technology |
Modificerede alginater til anti-fibrotiske materialer og anvendelser
|
PL3371206T3
(pl)
|
2015-11-02 |
2021-09-27 |
F. Hoffmann-La Roche Ag |
Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
|
EP3165532B1
(en)
|
2015-11-03 |
2018-12-19 |
Industrial Technology Research Institute |
Auristatin derivatives, linker-drugs and ligand-drug conjugates
|
WO2017079215A1
(en)
|
2015-11-03 |
2017-05-11 |
Glycomimetics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
WO2017079419A1
(en)
|
2015-11-05 |
2017-05-11 |
The Regents Of The University Of California |
Cells labelled with lipid conjugates and methods of use thereof
|
EP3371217A1
(en)
|
2015-11-08 |
2018-09-12 |
H. Hoffnabb-La Roche Ag |
Methods of screening for multispecific antibodies
|
WO2017083296A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
GEP20247583B
(en)
|
2015-11-09 |
2024-01-10 |
Univ Leicester |
Methods for treating condi tions associated with masp-2 dependent complement activation
|
HUE050312T2
(hu)
|
2015-11-10 |
2020-11-30 |
Medimmune Llc |
ASCT2-RE specifikus kötõmolekulák és alkalmazásaik
|
WO2017083515A2
(en)
|
2015-11-10 |
2017-05-18 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
WO2017083582A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2017087901A2
(en)
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
KR101914245B1
(ko)
|
2015-11-20 |
2018-11-02 |
4디 파마 리서치 리미티드 |
박테리아성 균주를 함유한 조성물
|
GB201520597D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520579D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520557D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520564D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
CN108697793B
(zh)
|
2015-11-23 |
2023-08-01 |
阿塞勒隆制药公司 |
治疗眼睛疾病的方法
|
GB201604468D0
(en)
|
2016-03-16 |
2016-04-27 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520546D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520541D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607535D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520539D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520565D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520544D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520592D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520542D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520558D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520595D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520631D0
(en)
|
2015-11-23 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
GB201520548D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520638D0
(en)
|
2015-11-23 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520575D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520566D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520562D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520563D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520583D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520559D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607534D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
RU2021107536A
(ru)
|
2015-11-23 |
2021-07-02 |
Файв Прайм Терапьютикс, Инк. |
Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
|
GB201520536D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520567D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520603D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520543D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520589D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
WO2017089786A1
(en)
|
2015-11-23 |
2017-06-01 |
Immunocore Limited |
Peptides
|
GB201520570D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520545D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
MY197345A
(en)
|
2015-11-25 |
2023-06-14 |
Visterra Inc |
Antibody molecules to april and uses thereof
|
CN107847606A
(zh)
|
2015-11-25 |
2018-03-27 |
乐高化学生物科学股份有限公司 |
包含自降解基团的缀合物及其相关方法
|
EP3383903A1
(en)
|
2015-11-30 |
2018-10-10 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
AU2016365117A1
(en)
|
2015-11-30 |
2018-05-31 |
Abbvie Biotherapeutics Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
WO2017095805A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
CN109415437B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特库伯株式会社 |
与btn1a1免疫特异性结合的抗体和分子及其治疗用途
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
EP3176183A1
(en)
|
2015-12-02 |
2017-06-07 |
Yeda Research and Development Co. Ltd |
Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
|
US10144768B2
(en)
|
2015-12-04 |
2018-12-04 |
Novartis Ag |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
AU2016363013B2
(en)
|
2015-12-04 |
2022-03-10 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
WO2017093985A1
(en)
|
2015-12-05 |
2017-06-08 |
Centre Hospitalier Universitaire Vaudois |
Hiv binding agents
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
EP3386549A4
(en)
|
2015-12-10 |
2019-08-07 |
City of Hope |
ANTIBODIES COUPLED WITH CYANINE WITH CELL PENETRATION
|
TWI758267B
(zh)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
IL296354B1
(en)
|
2015-12-15 |
2024-03-01 |
Oncoc4 Inc |
Chimeric and humanized monoclonal antibodies against CTLA-4 and their uses
|
RU2018123481A
(ru)
|
2015-12-16 |
2020-01-20 |
Мерк Шарп И Доум Корп. |
Анти-lag3 антитела и антигенсвязывающие фрагменты
|
CA3008392C
(en)
|
2015-12-17 |
2021-11-09 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
WO2017106566A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
TWI747936B
(zh)
|
2015-12-18 |
2021-12-01 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
CN109152811A
(zh)
|
2015-12-18 |
2019-01-04 |
阿吉尔瓦克斯公司 |
与xCT肽相关的组合物和方法
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
NZ743474A
(en)
|
2015-12-23 |
2023-03-31 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
EA201891509A1
(ru)
|
2015-12-24 |
2019-01-31 |
Корвус Фармасьютикалз, Инк. |
Способы лечения рака
|
US10561706B2
(en)
|
2015-12-28 |
2020-02-18 |
B. G. Negev Technologies And Applications |
Isolated polypeptide and compositions comprising same
|
AU2016381694A1
(en)
|
2015-12-30 |
2018-07-05 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
CN108712911A
(zh)
|
2015-12-30 |
2018-10-26 |
科达制药股份有限公司 |
抗体及其缀合物
|
KR20180098625A
(ko)
|
2015-12-30 |
2018-09-04 |
제넨테크, 인크. |
분해가 감소된 폴리소르베이트를 갖는 제형
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
EP3401336A4
(en)
|
2016-01-05 |
2020-01-22 |
Jiangsu Hengrui Medicine Co., Ltd. |
PCSK9 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USES THEREOF
|
IL294411A
(en)
|
2016-01-05 |
2022-08-01 |
Omeros Corp |
masp-2 suppressors for use in suppressing fibrosis
|
JP2019505511A
(ja)
|
2016-01-06 |
2019-02-28 |
イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. |
悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法
|
WO2017120479A1
(en)
|
2016-01-07 |
2017-07-13 |
The Schepens Eye Research Institute, Inc. |
Therapeutics for ocular immunoinflammatory diseases
|
US11103589B2
(en)
|
2016-01-08 |
2021-08-31 |
Apg Therapeutics, Inc. |
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
WO2017120523A2
(en)
|
2016-01-08 |
2017-07-13 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
US20170198290A1
(en)
|
2016-01-08 |
2017-07-13 |
Northwestern University |
Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
|
TWI753875B
(zh)
|
2016-01-08 |
2022-02-01 |
美商美國全心醫藥生技股份有限公司 |
四價抗psgl-1抗體及其用途
|
JP6974348B2
(ja)
|
2016-01-09 |
2021-12-01 |
アーベル リミテッドArbele Limited |
がん処置のためのカドヘリン−17特異的抗体及び細胞傷害性細胞
|
CA3010678A1
(en)
|
2016-01-10 |
2017-07-20 |
Neotx Therapeutics Ltd. |
Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
|
US20190178888A1
(en)
|
2016-01-11 |
2019-06-13 |
Technion Research & Development Foundation Limited |
Methods of determining prognosis of sepsis and treating same
|
ES2898329T3
(es)
|
2016-01-12 |
2022-03-07 |
Oncotracker Inc |
Métodos mejorados para supervisar el estado inmunitario de un sujeto
|
WO2017121880A1
(en)
|
2016-01-15 |
2017-07-20 |
Philogen S.P.A |
Intestinal antigens for pharmacodelivery applications
|
CN108602883A
(zh)
|
2016-01-20 |
2018-09-28 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
EP3405490B1
(en)
|
2016-01-21 |
2021-10-20 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
ES2942362T3
(es)
|
2016-01-21 |
2023-05-31 |
Pfizer |
Receptores quiméricos para el antígeno que se dirigen a la variante III del receptor del factor de crecimiento epidérmico
|
AU2017208819B2
(en)
|
2016-01-22 |
2023-10-19 |
MabQuest SA |
PD1 specific antibodies
|
JOP20170013B1
(ar)
|
2016-01-22 |
2021-08-17 |
Merck Sharp & Dohme |
أجسام xi مضادة لعامل مضاد للتجلط
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
EP3408294A1
(en)
|
2016-01-25 |
2018-12-05 |
Pfizer Inc. |
Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
|
CN109073635A
(zh)
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
US11028410B2
(en)
|
2016-01-27 |
2021-06-08 |
Just-Evotec Biologics, Inc. |
Hybrid promoter and uses thereof
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
US10918737B2
(en)
|
2016-01-28 |
2021-02-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
US10118963B2
(en)
|
2016-01-29 |
2018-11-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
WO2017132103A2
(en)
|
2016-01-29 |
2017-08-03 |
Merck Sharp & Dohme Corp. |
Phosphonate linkers and their use to facilitate cellular retention of compounds
|
WO2017134547A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
JP7134870B2
(ja)
|
2016-02-01 |
2022-09-12 |
プレベンシオ, インコーポレイテッド |
心臓血管疾患及び事象のための診断及び予後方法
|
PL3411404T3
(pl)
|
2016-02-03 |
2023-02-13 |
Amgen Research (Munich) Gmbh |
Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
|
US10301391B2
(en)
|
2016-02-03 |
2019-05-28 |
Amgen Research (Munich) Gmbh |
BCMA and CD3 bispecific T cell engaging antibody constructs
|
US20190038720A1
(en)
|
2016-02-03 |
2019-02-07 |
President And Fellows Of Harvard College |
Methods of treating inflammatory bowel disease and parasite infection
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3202788A1
(en)
|
2016-02-05 |
2017-08-09 |
MediaPharma S.r.l. |
Endosialin-binding antibody
|
EP3410849B1
(en)
|
2016-02-05 |
2023-07-05 |
Institut Pasteur |
Use of inhibitors of adam12 as adjuvants in tumor therapies
|
AU2017214541B2
(en)
|
2016-02-05 |
2024-03-21 |
NanoView Biosciences, Inc. |
Detection of exosomes having surface markers
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
BR112018014998A2
(pt)
|
2016-02-10 |
2018-12-18 |
Pfizer |
nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso das mesmas
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
CN115969970A
(zh)
|
2016-02-10 |
2023-04-18 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan的组合
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
WO2017138008A2
(en)
|
2016-02-14 |
2017-08-17 |
Yeda Research And Development Co. Ltd. |
Methods of modulating protein exocytosis and uses of same in therapy
|
US11484577B2
(en)
|
2016-02-15 |
2022-11-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
|
US20190054110A1
(en)
|
2016-02-16 |
2019-02-21 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Modulators of ccr9 for treating tumor resistance to immune responses
|
US20200164068A1
(en)
|
2016-02-16 |
2020-05-28 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Modulators of tumor immune resistance for the treatment of cancer
|
EP3207937A1
(en)
|
2016-02-17 |
2017-08-23 |
Royal College of Surgeons in Ireland |
A method of treating or preventing sepsis
|
IL260732B1
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
WO2017139975A1
(en)
|
2016-02-19 |
2017-08-24 |
Huiru Wang |
Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
|
GB201603002D0
(en)
|
2016-02-22 |
2016-04-06 |
Univ Manchester |
Inflammation biomarker
|
CA3013383A1
(en)
|
2016-02-25 |
2017-08-31 |
Dupont Nutrition Biosciences Aps |
Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
|
CN116672445A
(zh)
|
2016-02-26 |
2023-09-01 |
德克萨斯大学体系董事会 |
连接蛋白(Cx)43半通道结合抗体及其用途
|
US20230183346A1
(en)
|
2016-02-26 |
2023-06-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
US10941447B2
(en)
|
2016-02-29 |
2021-03-09 |
Rhode Island Hospital |
Diagnostics for pulmonary arterial hypertension and sudden cardiac death
|
US11725247B2
(en)
|
2016-02-29 |
2023-08-15 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
KR20180119632A
(ko)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
CA3015619A1
(en)
|
2016-03-01 |
2017-09-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human poliovirus receptor (pvr)
|
IL302705A
(en)
|
2016-03-01 |
2023-07-01 |
Immatics Biotechnologies Gmbh |
Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
|
CN114191428A
(zh)
|
2016-03-02 |
2022-03-18 |
卫材研究发展管理有限公司 |
基于艾日布林的抗体-药物偶联物和使用方法
|
TWI822655B
(zh)
|
2016-03-02 |
2023-11-21 |
美商英代斯實驗公司 |
用於檢測及診斷腎臟疾病及牙周病之方法及組合物
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
MX2018010672A
(es)
|
2016-03-04 |
2019-05-27 |
Univ Rockefeller |
Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
|
MA42560B1
(fr)
|
2016-03-04 |
2019-07-31 |
4D Pharma Plc |
Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
US20190216891A1
(en)
|
2016-03-06 |
2019-07-18 |
Yeda Research And Development Co., Ltd. |
Method for modulating myelination
|
US10443054B2
(en)
|
2016-03-06 |
2019-10-15 |
Massachusetts Institute Of Technology |
Methods for identifying and treating invasive/metastatic breast cancers
|
EP3426691A4
(en)
|
2016-03-07 |
2019-09-25 |
Charlestonpharma, LLC |
ANTI-NUCLEOLIN ANTIBODIES
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
US11078274B2
(en)
|
2016-03-08 |
2021-08-03 |
Innate Pharma |
Siglec neutralizing antibodies
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
US11014088B2
(en)
|
2016-03-09 |
2021-05-25 |
The Board Of Regents Of The University Of Texas System |
Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
|
AU2017230091B2
(en)
|
2016-03-10 |
2022-04-07 |
Acceleron Pharma Inc. |
Activin type 2 receptor binding proteins and uses thereof
|
CA3017356A1
(en)
|
2016-03-10 |
2017-09-14 |
Aperisys, Inc. |
Antigen-binding fusion proteins with modified hsp70 domains
|
CA3055555A1
(en)
|
2016-03-11 |
2017-09-14 |
Scholar Rock, Inc. |
Tgf.beta.1-binding immunoglobulins and use thereof
|
JP7155008B2
(ja)
|
2016-03-14 |
2022-10-18 |
ウニヴァーシテテット イ オスロ |
変化されたFcRnを有する改変された免疫グロブリン
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
EP4112641A1
(en)
|
2016-03-15 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
JP6903680B2
(ja)
|
2016-03-15 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
KR102413037B1
(ko)
|
2016-03-15 |
2022-06-23 |
메르사나 테라퓨틱스, 인코포레이티드 |
Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
KR20170108203A
(ko)
|
2016-03-16 |
2017-09-27 |
주식회사 피플바이오 |
응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
RS61412B1
(sr)
|
2016-03-17 |
2021-03-31 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
DK3219726T3
(da)
|
2016-03-17 |
2020-12-07 |
Tillotts Pharma Ag |
Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
|
US10787508B2
(en)
|
2016-03-17 |
2020-09-29 |
Numab Innovation Ag |
Anti-TNFα-antibodies and functional fragments thereof
|
US10759852B2
(en)
|
2016-03-17 |
2020-09-01 |
Numab Innovation Ag |
Anti-TNF-alpha-antibodies and functional fragments thereof
|
SG11201808041UA
(en)
|
2016-03-17 |
2018-10-30 |
Numab Innovation Ag |
ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
WO2017158436A1
(en)
|
2016-03-17 |
2017-09-21 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
WO2017162604A1
(en)
|
2016-03-21 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and treatment of solar lentigo
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
JP2019509322A
(ja)
|
2016-03-22 |
2019-04-04 |
バイオノミクス リミテッド |
抗lgr5モノクローナル抗体の投与
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
WO2017161976A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
EP3433279A1
(en)
|
2016-03-23 |
2019-01-30 |
Prothix BV |
Monoclonal antibodies against the active site of factor xi and uses thereof
|
JP7251981B2
(ja)
|
2016-03-24 |
2023-04-04 |
バイエル ファーマ アクチエンゲゼルシャフト |
酵素開裂基を有する細胞毒性活性剤のプロドラッグ
|
WO2017165736A1
(en)
|
2016-03-25 |
2017-09-28 |
Visterra, Inc. |
Formulation of antibody molecules to dengue virus
|
JP6943872B2
(ja)
|
2016-03-25 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
多重全抗体及び抗体複合体化薬物定量化アッセイ
|
SG11201807827VA
(en)
|
2016-03-25 |
2018-10-30 |
Seattle Genetics Inc |
Process for the preparation of pegylated drug-linkers and intermediates thereof
|
EP3943508B1
(en)
|
2016-03-29 |
2024-01-10 |
Board Of Regents, The University Of Texas System |
Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
|
US10765724B2
(en)
|
2016-03-29 |
2020-09-08 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
|
EP3436475A1
(en)
|
2016-03-29 |
2019-02-06 |
STCube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
EP3225997A1
(en)
|
2016-03-29 |
2017-10-04 |
Universitätsklinikum Hamburg-Eppendorf |
Thsd7a as a novel target for cancer therapy and diagnosis
|
CA3019373A1
(en)
|
2016-03-29 |
2017-10-05 |
Geltor, Inc. |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436480A4
(en)
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
CA3018774C
(en)
|
2016-03-31 |
2023-02-28 |
Omeros Corporation |
Methods for inhibiting angiogenesis in a subject in need thereof
|
US10836720B2
(en)
|
2016-04-01 |
2020-11-17 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 5 beta 1 and methods of use
|
CR20180529A
(es)
|
2016-04-04 |
2019-03-21 |
Bioverativ Usa Inc |
Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
|
MX2018012129A
(es)
|
2016-04-05 |
2018-12-17 |
Pfizer |
Proceso de cultivo celular.
|
BR112018070452A2
(pt)
|
2016-04-05 |
2019-02-05 |
Baliopharm Ag |
um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
|
EP3439659A1
(en)
|
2016-04-06 |
2019-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
CA3016107A1
(en)
|
2016-04-06 |
2017-10-12 |
Nestec S.A. |
Biomarkers for predicting degree of weight loss
|
CN109071605A
(zh)
|
2016-04-06 |
2018-12-21 |
伊玛提克斯生物技术有限公司 |
用于aml和其他癌症免疫治疗的新型肽和肽组合物
|
CA3020339C
(en)
|
2016-04-07 |
2022-05-03 |
The Johns Hopkins University |
Compositions and methods for treating pancreatitis and pain with death receptor agonists
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3440113A1
(en)
|
2016-04-08 |
2019-02-13 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
CN109414489B
(zh)
|
2016-04-08 |
2022-08-16 |
埃缇健康公司D/B/A泽尔拜尔 |
网蛋白-1结合抗体及其用途
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CN109311977B
(zh)
|
2016-04-15 |
2022-06-14 |
H.伦德贝克公司 |
人源化的抗pacap抗体及其用途
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
BR112018071096A2
(pt)
|
2016-04-15 |
2019-02-26 |
Novartis Ag |
composições e métodos para a expressão da proteína seletiva
|
AU2017250296A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
KR20230162730A
(ko)
|
2016-04-15 |
2023-11-28 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
AU2017250583A1
(en)
|
2016-04-15 |
2018-08-16 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
US20170298119A1
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
CA3019588A1
(en)
|
2016-04-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Cmv neutralizing antigen binding proteins
|
ES2910365T3
(es)
|
2016-04-22 |
2022-05-12 |
Alligator Bioscience Ab |
Nuevos polipéptidos biespecíficos contra CD137
|
US20190125826A1
(en)
|
2016-04-22 |
2019-05-02 |
Inserm (Institut National De La Santé Et De La Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
EP3448997B1
(en)
|
2016-04-27 |
2020-10-14 |
Massachusetts Institute of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
JP6871948B2
(ja)
|
2016-04-27 |
2021-05-19 |
アッヴィ・インコーポレイテッド |
抗il−13抗体を使用する、il−13活性が有害である疾患の治療方法
|
CN109310385A
(zh)
|
2016-04-27 |
2019-02-05 |
免疫医疗公司 |
抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
|
US11514331B2
(en)
|
2016-04-27 |
2022-11-29 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
EP3452512B1
(en)
|
2016-05-03 |
2023-03-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of tissue lesions
|
EP3452092B1
(en)
|
2016-05-06 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
|
SG11201809793UA
(en)
|
2016-05-09 |
2018-12-28 |
Bristol Myers Squibb Co |
Tl1a antibodies and uses thereof
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
US11142548B2
(en)
|
2016-05-10 |
2021-10-12 |
Sorbonne Universite |
Agents that activate CD47 and their use in the treatment of inflammation
|
KR20230124093A
(ko)
|
2016-05-10 |
2023-08-24 |
제넨테크, 인크. |
폴리펩타이드의 재조합 생산 동안 트리설파이드 결합을감소시키기 위한 방법
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Hdac抑制劑與pd-l1抑制劑之組合治療
|
AU2017263454B2
(en)
|
2016-05-11 |
2023-02-09 |
Amgen Inc. |
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
|
CN109476745B
(zh)
|
2016-05-13 |
2023-11-24 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
US11254742B2
(en)
|
2016-05-13 |
2022-02-22 |
Bioatla, Inc. |
Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
CA3022481A1
(en)
|
2016-05-16 |
2017-11-23 |
James Richard BERENSON |
Methods for monitoring immune status of a subject
|
MX2018014047A
(es)
|
2016-05-17 |
2019-06-20 |
Genentech Inc |
Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
|
WO2017201204A1
(en)
|
2016-05-17 |
2017-11-23 |
Abbvie Biotherapeutics Inc. |
ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
JP2019527535A
(ja)
|
2016-05-18 |
2019-10-03 |
上海開拓者生物医薬有限公司Shanghai Pharmaexplorer Co., Ltd. |
Il−13抗体およびその製造方法と使用
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
EP3463452A1
(en)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
WO2017202814A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
|
WO2017202813A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
IL245861A0
(en)
|
2016-05-25 |
2016-09-04 |
Yeda Res & Dev |
Use of substances to treat drug-resistant tumors
|
KR20230128144A
(ko)
|
2016-05-25 |
2023-09-01 |
인바이오모션 에스.엘. |
c-MAF 상태에 기초한 유방암의 치료
|
WO2017203051A1
(en)
|
2016-05-26 |
2017-11-30 |
University College Cork - National University Of Ireland, Cork |
An engineered gram positive bacterium
|
AU2017269675A1
(en)
|
2016-05-26 |
2019-01-17 |
Merck Patent Gmbh |
PD-1 / PD-L1 inhibitors for cancer treatment
|
SG10201912563XA
(en)
|
2016-05-27 |
2020-02-27 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
HUE056670T2
(hu)
|
2016-05-27 |
2022-02-28 |
Abbvie Biotherapeutics Inc |
Anti-CD40 antitestek és alkalmazásaik
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CA3025894A1
(en)
|
2016-06-02 |
2017-12-07 |
Immunocore Limited |
Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
AU2017274442B2
(en)
|
2016-06-02 |
2021-08-19 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
US10851159B2
(en)
|
2016-06-02 |
2020-12-01 |
Bloom Diagnostics Ag |
Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
|
BR112019022558A2
(pt)
|
2016-06-02 |
2020-05-19 |
Hoffmann La Roche |
anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
|
IL262996B2
(en)
|
2016-06-06 |
2024-03-01 |
Hoffmann La Roche |
Fusion proteins for ophthalmology with increased grip in the eye
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
CA3026778A1
(en)
|
2016-06-07 |
2017-12-14 |
Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
BR112018075644A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de anticorpo e fármaco
|
EP3469000A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
BR112018075630A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de fármaco de anticorpo
|
CA3027047A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019526529A
(ja)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
抗b7−h3抗体及び抗体薬物コンジュゲート
|
DK3458479T3
(da)
|
2016-06-08 |
2021-02-08 |
Abbvie Inc |
Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
|
US10626184B2
(en)
|
2016-06-09 |
2020-04-21 |
Omeros Corporation |
Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer
|
BR112018075222A2
(pt)
|
2016-06-09 |
2019-03-19 |
Pelican Therapeutics, Inc |
anticorpos anti-tnfrsf25
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
EP3468597A1
(en)
|
2016-06-12 |
2019-04-17 |
Millennium Pharmaceuticals, Inc. |
Method of treating inflammatory bowel disease
|
CA3027209C
(en)
|
2016-06-13 |
2022-08-16 |
I-Mab |
Anti-pd-l1 antibodies and uses thereof
|
IL309975A
(en)
|
2016-06-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against C5 and their uses
|
PE20190416A1
(es)
|
2016-06-14 |
2019-03-19 |
Merck Sharp & Dohme |
Anticuerpos antifactor de la coagulacion xi
|
EP3919518A1
(en)
|
2016-06-15 |
2021-12-08 |
Bayer Pharma Aktiengesellschaft |
Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
|
KR102492057B1
(ko)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
EP3472210A1
(en)
|
2016-06-17 |
2019-04-24 |
Life Technologies Corporation |
Site-specific crosslinking of antibodies
|
AR108800A1
(es)
|
2016-06-17 |
2018-09-26 |
Genentech Inc |
Purificación de anticuerpos multiespecíficos
|
CA3027612A1
(en)
|
2016-06-20 |
2017-12-28 |
F-Star Delta Limited |
Binding molecules binding pd-l1 and lag-3
|
KR20190053835A
(ko)
|
2016-06-21 |
2019-05-20 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
WO2017221255A1
(en)
|
2016-06-23 |
2017-12-28 |
Memed Diagnostics Ltd. |
Measuring trail by lateral flow immunoassay
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
FR3053042B1
(fr)
|
2016-06-24 |
2018-08-10 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
|
DK3264087T3
(da)
|
2016-06-27 |
2020-07-20 |
Chimera Biotec Gmbh |
Fremgangsmåde og indretning til kvantificering af målmolekyler
|
JP2019530848A
(ja)
|
2016-06-28 |
2019-10-24 |
ソシエテ・デ・プロデュイ・ネスレ・エス・アー |
血液脳関門機能不全のバイオマーカー
|
EP3478721A1
(en)
|
2016-07-01 |
2019-05-08 |
Five Prime Therapeutics, Inc. |
Combined anti tumor therapy with a gitr agonist and cpg
|
GB201611530D0
(en)
|
2016-07-01 |
2016-08-17 |
Alligator Bioscience Ab |
Novel polypeptides
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
EA038617B1
(ru)
*
|
2016-07-06 |
2021-09-23 |
Онкоиммьюн, Инк. |
Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование
|
CA3030219A1
(en)
|
2016-07-07 |
2018-01-11 |
Berg Llc |
Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
|
JP2019525772A
(ja)
|
2016-07-08 |
2019-09-12 |
スターテン・バイオテクノロジー・ベー・フェー |
抗apoc3抗体およびその使用方法
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
CN109789092A
(zh)
|
2016-07-13 |
2019-05-21 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
AU2017297404A1
(en)
|
2016-07-13 |
2019-01-24 |
Biogen Ma Inc. |
Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
TW201821093A
(zh)
|
2016-07-13 |
2018-06-16 |
英商4D製藥有限公司 |
包含細菌菌株之組合物
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
WO2018013936A1
(en)
|
2016-07-15 |
2018-01-18 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
US11708421B2
(en)
|
2016-07-18 |
2023-07-25 |
Ramot At Tel-Aviv University Ltd. |
Modular platform for targeted therapeutics
|
EP3487883B1
(en)
|
2016-07-20 |
2023-01-04 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
CN109641947B
(zh)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
WO2018017814A1
(en)
|
2016-07-20 |
2018-01-25 |
President And Fellows Of Harvard College |
Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
CN109641961A
(zh)
|
2016-07-22 |
2019-04-16 |
德国神经退行性疾病研究中心 |
Trem2切割调节剂及其用途
|
CN109689689B
(zh)
|
2016-07-22 |
2022-12-06 |
丹娜法伯癌症研究所公司 |
糖皮质激素诱导肿瘤坏死因子受体(gitr)抗体及其使用方法
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
BR112019001615A2
(pt)
|
2016-07-27 |
2019-04-30 |
Acceleron Pharma Inc. |
métodos e composições para tratar mielofibrose
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491387A1
(en)
|
2016-07-28 |
2019-06-05 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
KR102553195B1
(ko)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
GB201613167D0
(en)
|
2016-07-29 |
2016-09-14 |
Univ Southampton |
Cancer and b-cell related disease therapy
|
US11186634B2
(en)
|
2016-07-29 |
2021-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies targeting tumor associated macrophages and uses thereof
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
JP7148493B2
(ja)
|
2016-08-01 |
2022-10-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
副甲状腺ホルモン受容体1(pth1r)抗体およびその使用
|
MX2019001469A
(es)
|
2016-08-01 |
2019-10-02 |
Novartis Ag |
Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
BR112019001989A2
(pt)
|
2016-08-02 |
2019-08-20 |
Visterra Inc |
polipeptídeos projetados e usos dos mesmos
|
WO2018026600A1
(en)
|
2016-08-03 |
2018-02-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy
|
WO2018025168A1
(en)
|
2016-08-03 |
2018-02-08 |
Pfizer Inc. |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
JP6527643B2
(ja)
|
2016-08-05 |
2019-06-05 |
中外製薬株式会社 |
Il−8関連疾患の治療用又は予防用組成物
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
AU2017306709A1
(en)
|
2016-08-05 |
2019-03-14 |
Humabs, BioMed SA |
Anti-o2 antibodies and uses thereof
|
WO2018029586A1
(en)
|
2016-08-07 |
2018-02-15 |
Novartis Ag |
Mrna-mediated immunization methods
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
TW201808343A
(zh)
|
2016-08-09 |
2018-03-16 |
美商西雅圖遺傳學公司 |
具有改善之生理化學性質之具自我穩定連接子之藥物結合物
|
ES2919927T3
(es)
|
2016-08-10 |
2022-07-29 |
Pasteur Institut |
Métodos y reactivos para la detección del paludismo por Plasmodium falciparum resistente a la piperaquina
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
CN109689102A
(zh)
|
2016-08-12 |
2019-04-26 |
基因泰克公司 |
Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
|
US10759848B2
(en)
|
2016-08-12 |
2020-09-01 |
Arsanis Biosciences Gmbh |
Klebsiella pneumoniae O3 specific antibodies
|
US20190161534A1
(en)
|
2016-08-12 |
2019-05-30 |
Arsanis Biosciences Gmbh |
Anti-galactan ii monoclonal antibodies targeting klebsiella pneumoniae
|
US10947268B2
(en)
|
2016-08-12 |
2021-03-16 |
Bristol-Myers Squibb Company |
Methods of purifying proteins
|
KR20200136503A
(ko)
|
2016-08-15 |
2020-12-07 |
노파르티스 아게 |
오파투무맙을 사용한 다발성 경화증의 치료 요법 및 방법
|
EP3497440A1
(en)
|
2016-08-15 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US11225689B2
(en)
|
2016-08-17 |
2022-01-18 |
The Broad Institute, Inc. |
Method for determination and identification of cell signatures and cell markers
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
US10676537B2
(en)
|
2016-08-22 |
2020-06-09 |
Fudan University |
Antibody targeted to tissue factor, preparation method therefor, and use thereof
|
CN106938051B
(zh)
|
2016-08-22 |
2019-10-11 |
复旦大学 |
靶向于组织因子的抗体-药物偶联物
|
EP3502250B1
(en)
|
2016-08-22 |
2024-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Gene-modified rodent expressing human gpc3 polypeptide
|
WO2018037000A1
(en)
|
2016-08-23 |
2018-03-01 |
Medimmune Limited |
Anti-vegf-a and anti-ang2 antibodies and uses thereof
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
CN106967172B
(zh)
|
2016-08-23 |
2019-01-08 |
康方药业有限公司 |
抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
|
EP3504236B1
(en)
|
2016-08-23 |
2020-09-23 |
Medimmune Limited |
Anti-vegf-a antibodies and uses thereof
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
MX2019002437A
(es)
|
2016-08-30 |
2019-10-09 |
Regeneron Pharma |
Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.
|
GB201614627D0
(en)
|
2016-08-30 |
2016-10-12 |
Glaxosmithkline Ip Dev Ltd |
Antigen binding proteins
|
SG10202100683RA
(en)
|
2016-08-31 |
2021-03-30 |
Oncotherapy Science Inc |
Monoclonal antibody against melk and utilization thereof
|
WO2018045210A1
(en)
|
2016-09-02 |
2018-03-08 |
Therapeutics Lp 180 |
Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
EP3506920A4
(en)
|
2016-09-02 |
2020-05-27 |
180 Therapeutics LP |
METHOD OF TREATING SYSTEMIC FIBROSIS USING A BISPECIFIC ANTIBODY AGAINST IL-33 AND TNF
|
MX2019002696A
(es)
|
2016-09-06 |
2019-09-27 |
Dana Farber Cancer Inst Inc |
Metodos para tratar o prevenir una infeccion del virus del zika.
|
US11168148B2
(en)
|
2016-09-07 |
2021-11-09 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
EP3510047A1
(en)
|
2016-09-07 |
2019-07-17 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Anti-nkp46 antibodies and therapeutic use of same
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
EP3293271A1
(en)
|
2016-09-12 |
2018-03-14 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Marker and target as a diagnostic variable and target for therapy of metastatic cancer
|
WO2018053032A1
(en)
|
2016-09-13 |
2018-03-22 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
WO2018053142A2
(en)
|
2016-09-14 |
2018-03-22 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
UA124631C2
(uk)
|
2016-09-14 |
2021-10-20 |
Еббві Байотерапьютікс Інк. |
Антитіло до pd-1
|
DK4050034T3
(da)
|
2016-09-14 |
2024-06-03 |
Teneoone Inc |
Cd3-bindende antistoffer
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
CA3037144A1
(en)
|
2016-09-16 |
2018-03-22 |
Shanghai Henlius Biotech, Inc. |
Anti-pd-1 antibodies
|
BR112019005274A2
(pt)
|
2016-09-19 |
2019-06-04 |
I Mab |
anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratar uma doença ou condição inflamatória ou autoimune, para tratar um câncer, para reduzir ou aliviar dor e para detectar expressão de gm-csf em uma amostra.
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
US11052149B2
(en)
|
2016-09-19 |
2021-07-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for inducing an immune response
|
KR102257154B1
(ko)
|
2016-09-19 |
2021-05-28 |
셀진 코포레이션 |
Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
EP3515559A4
(en)
|
2016-09-20 |
2020-07-15 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS
|
CA3037230A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
CN110035769A
(zh)
|
2016-09-21 |
2019-07-19 |
奈斯科尔公司 |
针对siglec-15的抗体及其使用方法
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
ES2873377T3
(es)
|
2016-09-22 |
2021-11-03 |
Inst Nat Sante Rech Med |
Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón
|
WO2018056825A1
(en)
|
2016-09-23 |
2018-03-29 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Manipulation of immune activity by modulation of expression
|
BR112019005823A2
(pt)
|
2016-09-23 |
2019-06-25 |
Teva Pharmaceuticals Int Gmbh |
tratamento para enxaqueca refratária
|
AU2017330405B2
(en)
|
2016-09-23 |
2024-02-01 |
Genentech, Inc. |
Uses of IL-13 antagonists for treating atopic dermatitis
|
EP3515488A1
(en)
|
2016-09-23 |
2019-07-31 |
Teva Pharmaceuticals International GmbH |
Treating cluster headache
|
EP3515936A1
(en)
|
2016-09-23 |
2019-07-31 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
CN110023339A
(zh)
|
2016-09-23 |
2019-07-16 |
Csl有限公司 |
凝血因子结合蛋白及其应用
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
CA3038526A1
(en)
|
2016-09-27 |
2018-04-05 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
CN109862913B
(zh)
|
2016-09-29 |
2023-09-05 |
加利福尼亚大学董事会 |
用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
|
IL307684A
(en)
|
2016-09-29 |
2023-12-01 |
Amgen Inc |
Low viscosity antigen binding proteins and methods for their preparation
|
JP2019534251A
(ja)
|
2016-09-29 |
2019-11-28 |
ジェネンテック, インコーポレイテッド |
Mek阻害剤、pd−1軸阻害剤、及びタキサンを用いた併用療法
|
AU2017336799B2
(en)
|
2016-09-30 |
2023-08-31 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL23 specific antibody
|
AU2017339858B2
(en)
|
2016-10-03 |
2022-02-17 |
Abbott Laboratories |
Improved methods of assessing GFAP status in patient samples
|
US10941195B2
(en)
|
2016-10-04 |
2021-03-09 |
Fairbanks Pharmaceuticals, Inc. |
Anti-follistatin-like 3 antibodies and treatment of diabetes
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
CN116650622A
(zh)
|
2016-10-05 |
2023-08-29 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
CN109952369B
(zh)
|
2016-10-05 |
2024-03-22 |
弗罗里达中央大学研究基金会 |
涉及nk细胞和抗pdl1癌症治疗的方法和组合物
|
TWI762516B
(zh)
|
2016-10-06 |
2022-05-01 |
日商腫瘤療法 科學股份有限公司 |
針對fzd10之單株抗體及其用途
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
KR20190062515A
(ko)
|
2016-10-06 |
2019-06-05 |
화이자 인코포레이티드 |
암의 치료를 위한 아벨루맙의 투약 용법
|
DK3445787T3
(da)
|
2016-10-07 |
2021-03-01 |
Tcr2 Therapeutics Inc |
Sammensætninger og fremgangsmåder til omprogrammering af t-cellereceptorer under anvendelse af fusionsproteiner
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
WO2018071597A1
(en)
|
2016-10-12 |
2018-04-19 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
TWI773695B
(zh)
|
2016-10-12 |
2022-08-11 |
美商生物維瑞提夫美國公司 |
抗C1s抗體及其使用方法
|
EP3848390A1
(en)
|
2016-10-14 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Methods of treating diseases
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
WO2018071809A1
(en)
|
2016-10-14 |
2018-04-19 |
Ariad Pharmaceuticals, Inc. |
Inducible t-cell system and uses thereof
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
US11957713B2
(en)
|
2016-10-14 |
2024-04-16 |
Children's Medical Center Corporation |
Compositions and methods for treating diseases and disorders of the central nervous system
|
EP3525821A4
(en)
|
2016-10-17 |
2020-09-09 |
University of Maryland |
MULTI-SPECIFIC ANTIBODIES TARGETING THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR METHODS OF USE
|
BR112019006778A2
(pt)
|
2016-10-18 |
2019-10-15 |
Seattle Genetics Inc |
Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco
|
CN110267982B
(zh)
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
JP7160484B2
(ja)
|
2016-10-19 |
2022-10-25 |
メディミューン,エルエルシー |
抗o1抗体およびその使用
|
US11286295B2
(en)
|
2016-10-20 |
2022-03-29 |
Sanofi |
Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
|
US20190248895A1
(en)
|
2016-10-21 |
2019-08-15 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
EP3529262B1
(en)
|
2016-10-21 |
2021-07-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for promoting t cells response
|
AR109621A1
(es)
|
2016-10-24 |
2018-12-26 |
Janssen Pharmaceuticals Inc |
Formulaciones de vacunas contra glucoconjugados de expec
|
WO2018077926A1
(en)
|
2016-10-25 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the cd160 transmembrane isoform
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
EP3532496A1
(en)
|
2016-10-28 |
2019-09-04 |
Banyan Biomarkers, Inc. |
Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
MY195110A
(en)
|
2016-11-02 |
2023-01-10 |
Jounce Therapeutics Inc |
Antibodies to PD-1 and uses Thereof
|
CN110167964B
(zh)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
|
KR20190107656A
(ko)
|
2016-11-02 |
2019-09-20 |
이뮤노젠 아이엔씨 |
항체-약물 콘주게이트 및 parp 억제제로 병용 치료
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3040812A1
(en)
|
2016-11-04 |
2018-05-11 |
Novimmune Sa |
Anti-cd19 antibodies and methods of use thereof
|
WO2018144097A1
(en)
|
2016-11-04 |
2018-08-09 |
Akeagen Llc |
Genetically modified non-human animals and methods for producing heavy chain-only antibodies
|
KR102431830B1
(ko)
|
2016-11-07 |
2022-08-16 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
US20210115099A1
(en)
|
2016-11-07 |
2021-04-22 |
Immunocore Limited |
Peptides
|
JP7127859B2
(ja)
|
2016-11-09 |
2022-08-30 |
ノース カロライナ ステート ユニバーシティ |
キメラタンパク質を用いたアレルギー疾患の治療
|
AU2017358578B2
(en)
|
2016-11-09 |
2022-12-08 |
Philogen S.P.A |
IL2 and TNF mutant immunoconjugates
|
DK3321280T3
(da)
|
2016-11-10 |
2021-02-22 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Immunmodulatorer til reduktion af immunresistens i et melanom og andre proliferative sygdomme
|
WO2018087285A1
(en)
|
2016-11-10 |
2018-05-17 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Or10h1 antigen binding proteins and uses thereof
|
US11434301B2
(en)
|
2016-11-11 |
2022-09-06 |
The Regents Of The University Of California |
Anti-CD46 antibodies and methods of use
|
KR102459469B1
(ko)
|
2016-11-14 |
2022-10-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
US11008325B2
(en)
|
2016-11-14 |
2021-05-18 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
TWI791471B
(zh)
|
2016-11-15 |
2023-02-11 |
美商建南德克公司 |
用於用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
US11229662B2
(en)
|
2016-11-15 |
2022-01-25 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
MX2019005661A
(es)
|
2016-11-16 |
2019-10-07 |
Janssen Biotech Inc |
Método para tratar la psoriasis con el anticuerpo específico anti-il23.
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
JP7116059B2
(ja)
|
2016-11-21 |
2022-08-09 |
ジャスト-エヴォテック バイオロジックス、インコーポレイテッド |
アフリベルセプト製剤及びその使用
|
EP3468991A1
(en)
|
2016-11-21 |
2019-04-17 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
US11773163B2
(en)
|
2016-11-21 |
2023-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
CA3044274A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
BR112019010349A2
(pt)
|
2016-11-23 |
2019-10-08 |
Bioverativ Therapeutics Inc |
Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
WO2018098354A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
BR112019010602A2
(pt)
|
2016-11-23 |
2019-12-17 |
Harpoon Therapeutics Inc |
proteínas trispecíficas para psma e métodos de uso
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
TWI776827B
(zh)
|
2016-11-28 |
2022-09-11 |
日商中外製藥股份有限公司 |
能夠調節配體結合活性的配體結合分子
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
EP3548894B1
(en)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
US11198723B2
(en)
|
2016-12-05 |
2021-12-14 |
The Administrators Of The Tulane Educational Fund |
Arenavirus monoclonal antibodies and uses
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
JP2020511937A
(ja)
|
2016-12-07 |
2020-04-23 |
ジェネンテック, インコーポレイテッド |
抗tau抗体及び使用方法
|
AR110321A1
(es)
|
2016-12-07 |
2019-03-20 |
Genentech Inc |
Anticuerpos antitau y métodos de uso
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
AU2017373945A1
(en)
|
2016-12-07 |
2019-06-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
EP4252629A3
(en)
|
2016-12-07 |
2023-12-27 |
Biora Therapeutics, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
WO2018112033A1
(en)
|
2016-12-13 |
2018-06-21 |
President And Fellows Of Harvard College |
Methods and compositions for targeting tumor-infiltrating tregs
|
EP3554343A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
CN117045784A
(zh)
|
2016-12-14 |
2023-11-14 |
比奥拉治疗股份有限公司 |
使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
|
EP3554541B1
(en)
|
2016-12-14 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
WO2018112255A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
KR102616436B1
(ko)
|
2016-12-14 |
2023-12-27 |
비오라 쎄라퓨틱스, 인크. |
Tnf 저해제로의 위장관 질환의 치료
|
CA3045931A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
WO2018112223A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
EP4190318A1
(en)
|
2016-12-14 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
|
JP7252627B2
(ja)
|
2016-12-15 |
2023-04-05 |
デューク ユニバーシティ |
制御性b10細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
|
SG10201914126RA
(en)
|
2016-12-15 |
2020-02-27 |
Abbvie Biotherapeutics Inc |
Anti-ox40 antibodies and their uses
|
WO2018109770A1
(en)
|
2016-12-15 |
2018-06-21 |
The National Institute for Biotechnology in the Negev Ltd. |
Anti-pcna monoclonal antibodies and use thereof
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
MX2019007332A
(es)
|
2016-12-19 |
2019-11-18 |
Tolero Pharmaceuticals Inc |
Péptidos indicadores y métodos para caracterizar sensibilidad.
|
EP3555120A1
(en)
|
2016-12-19 |
2019-10-23 |
Abcam Plc |
Monovalent and divalent binding proteins
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
JP7030811B2
(ja)
|
2016-12-21 |
2022-03-07 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ksp阻害剤を有する特異的抗体-薬物コンジュゲート(adc)
|
CA3043158A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
GB201621806D0
(en)
|
2016-12-21 |
2017-02-01 |
Philogen Spa |
Immunocytokines with progressive activation mechanism
|
AU2017381657B2
(en)
|
2016-12-21 |
2020-07-23 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
EP3558388A1
(de)
|
2016-12-21 |
2019-10-30 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
|
WO2018114798A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Aktiengesellschaft |
Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
MX2019007019A
(es)
|
2016-12-22 |
2019-08-16 |
Univ Degli Studi Magna Graecia Catanzaro |
Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
|
EP3559037A1
(en)
|
2016-12-22 |
2019-10-30 |
Wake Forest University Health Sciences |
Sirp-gamma targeted agents for use in the treatment of cancer
|
CN110366557B
(zh)
|
2016-12-23 |
2024-04-09 |
威特拉公司 |
结合多肽及其制备方法
|
JP7062669B2
(ja)
|
2016-12-23 |
2022-05-06 |
ブリストル-マイヤーズ スクイブ カンパニー |
改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンg4の設計
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
CA3048211A1
(en)
|
2016-12-23 |
2018-06-28 |
Macrogenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
ES2912266T3
(es)
|
2016-12-23 |
2022-05-25 |
Immunogen Inc |
Inmunoconjugados dirigidos a ADAM9 y procedimientos de uso de los mismos
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
CN110088130A
(zh)
|
2016-12-27 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
新的生物素特异性单克隆抗体及其用途
|
KR102448439B1
(ko)
|
2016-12-27 |
2022-09-27 |
에프. 호프만-라 로슈 아게 |
신규한 비오틴-특이적 단일클론 항체 및 그 용도
|
KR20210123427A
(ko)
|
2016-12-27 |
2021-10-13 |
에프. 호프만-라 로슈 아게 |
신규한 비오틴-특이적 단일클론 항체 및 그 용도
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
EP3562844A1
(en)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
TWI673363B
(zh)
|
2016-12-29 |
2019-10-01 |
財團法人生物技術開發中心 |
製備醣蛋白-藥物共軛物之方法
|
WO2018129078A1
(en)
|
2017-01-04 |
2018-07-12 |
Research Institute At Nationwide Children's Hospital |
Dnabii vaccines and antibodies with enhanced activity
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
EP3565834A1
(en)
|
2017-01-04 |
2019-11-13 |
The Research Institute at Nationwide Children's Hospital |
Antibody fragments for the treatment of biofilm-related disorders
|
US20190350960A1
(en)
|
2017-01-04 |
2019-11-21 |
President And Fellows Of Harvard College |
Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
|
EP4032550A3
(en)
|
2017-01-05 |
2022-10-19 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
AU2018206279B2
(en)
|
2017-01-06 |
2020-09-03 |
Abl Bio Inc. |
Anti-alpha-syn antibody and use thereof
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3565845A4
(en)
|
2017-01-06 |
2020-10-07 |
Biosion, Inc. |
ERBB2 ANTIBODIES AND THEIR USES
|
EP4218817A3
(en)
|
2017-01-06 |
2023-09-06 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
US20180207267A1
(en)
|
2017-01-06 |
2018-07-26 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
|
GB201700345D0
(en)
|
2017-01-09 |
2017-02-22 |
F-Star Beta Ltd |
Conditional agonists of immune responses
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
US20190382462A1
(en)
|
2017-01-13 |
2019-12-19 |
Pietro P. Sanna |
Methods and compositions for treating hpa hyperactivity
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
EP3570670B1
(en)
|
2017-01-17 |
2024-03-06 |
Children's Medical Center Corporation |
Compositions and methods for treating lysosomal storage diseases and disorders
|
EP3570884B1
(en)
|
2017-01-17 |
2020-09-30 |
Genentech, Inc. |
Subcutaneous her2 antibody formulations
|
US11890319B2
(en)
|
2017-01-18 |
2024-02-06 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
CA3050009A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
WO2018133842A1
(zh)
|
2017-01-20 |
2018-07-26 |
大有华夏生物医药集团有限公司 |
人程序性死亡受体pd-1的单克隆抗体及其片段
|
WO2018138591A1
(en)
|
2017-01-24 |
2018-08-02 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
UA126571C2
(uk)
|
2017-01-24 |
2022-11-02 |
Ай-Маб Байофарма Юес Лімітед |
Антитіло до cd73 та його застосування
|
US11377492B2
(en)
|
2017-01-24 |
2022-07-05 |
Innate Pharma |
NKp46 binding agents
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
WO2018138257A1
(en)
|
2017-01-27 |
2018-08-02 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
EP3574012A1
(en)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
AU2018213716A1
(en)
|
2017-01-27 |
2019-08-15 |
A-Clip Institute, Co. ltd. |
Prophylactic and/or therapeutic agent of infectious disease or inflammatory disease
|
EP3573658A4
(en)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
CN110234658B
(zh)
|
2017-01-31 |
2024-03-12 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
WO2018144425A1
(en)
|
2017-01-31 |
2018-08-09 |
Vanderbilt University |
Generation of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
|
ES2865511T3
(es)
|
2017-02-02 |
2021-10-15 |
Hoffmann La Roche |
Inmunoanálisis que usa al menos dos agentes de unión específica a analito pegilado
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
EP3577137A1
(en)
|
2017-02-02 |
2019-12-11 |
Merck Patent GmbH |
Preferred pairing of antibody domains
|
KR20240046168A
(ko)
|
2017-02-03 |
2024-04-08 |
액티코어 바이오테크 |
항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
|
US20180221476A1
(en)
|
2017-02-06 |
2018-08-09 |
Oncoquest Nc. |
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
UA123889C2
(uk)
|
2017-02-08 |
2021-06-16 |
Ейдісі Терапьютікс Са |
Кон'югати піролобензодіазепін-антитіло
|
AU2018218557B9
(en)
|
2017-02-08 |
2021-06-24 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
CA3052291A1
(en)
|
2017-02-09 |
2018-08-16 |
Memorial Sloan Kettering Cancer Center |
Anti-kir3dl1 antibodies
|
JP7341060B2
(ja)
|
2017-02-10 |
2023-09-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
|
AR110873A1
(es)
|
2017-02-10 |
2019-05-08 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
JP7136790B2
(ja)
|
2017-02-17 |
2022-09-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
アルファ-シヌクレインに対する抗体およびその使用
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
WO2018156777A1
(en)
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
SG10201913833PA
(en)
|
2017-02-28 |
2020-03-30 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
CN110337305A
(zh)
|
2017-02-28 |
2019-10-15 |
赛诺菲 |
治疗性rna
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
SG11201907714UA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Adeno-associated virus (aav) clade f vector and uses therefor
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
EP3597217A4
(en)
|
2017-03-01 |
2021-01-13 |
Institute for Rheumatic Diseases Co., Ltd. |
PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE AND VACCINE
|
WO2018160654A2
(en)
|
2017-03-02 |
2018-09-07 |
Genentech, Inc. |
Adjuvant treatment of her2-positive breast cancer
|
JP7195262B2
(ja)
|
2017-03-02 |
2022-12-23 |
ベス イスラエル デアコネス メディカル センター インコーポレイティッド |
カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
|
WO2018158719A1
(en)
|
2017-03-02 |
2018-09-07 |
Novartis Ag |
Engineered heterodimeric proteins
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
AU2018226646A1
(en)
|
2017-03-03 |
2019-09-19 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
US11857608B2
(en)
|
2017-03-09 |
2024-01-02 |
Diamedica Inc. |
Dosage forms of tissue kallikrein 1
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
JP7048629B2
(ja)
|
2017-03-10 |
2022-04-05 |
エンベラ ニューロセラピューティクス,インコーポレイティド |
医薬組成物およびその使用
|
JP7021245B2
(ja)
|
2017-03-10 |
2022-02-16 |
エフ.ホフマン-ラ ロシュ アーゲー |
多重特異性抗体を生産するための方法
|
CA3055781A1
(en)
|
2017-03-14 |
2018-09-20 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases and disorders
|
EP3596118A4
(en)
|
2017-03-15 |
2021-04-07 |
Cue Biopharma, Inc. |
PROCESSES FOR MODULATING AN IMMUNE RESPONSE
|
CA3056088A1
(en)
|
2017-03-15 |
2018-09-20 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
CN114940713B
(zh)
|
2017-03-15 |
2024-04-30 |
清华大学 |
抗trkb抗体
|
JP7278595B2
(ja)
|
2017-03-16 |
2023-05-22 |
ユニベルシテ リブレ デ ブリュッセル |
Cd321マーカーの発現に基づく循環腫瘍細胞の検出、定量化、及び/又は単離
|
US20200056190A1
(en)
|
2017-03-16 |
2020-02-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
JP7308150B2
(ja)
|
2017-03-16 |
2023-07-13 |
イナート・ファルマ・ソシエテ・アノニム |
癌を処置するための組成物及び方法
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
US10941178B2
(en)
|
2017-03-17 |
2021-03-09 |
Gilead Sciences, Inc. |
Method of purifying an antibody
|
US20200085944A1
(en)
|
2017-03-17 |
2020-03-19 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
EP3378872A1
(en)
|
2017-03-20 |
2018-09-26 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antibodies against the human fshr extracellular domain
|
EP3602050A1
(en)
|
2017-03-20 |
2020-02-05 |
Celcuity Inc. |
Methods of measuring signaling pathway activity for selection of therapeutic agents
|
CA3056248A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
AU2018240375C1
(en)
|
2017-03-22 |
2024-02-01 |
Ascendis Pharma A/S |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
JP7346300B2
(ja)
|
2017-03-23 |
2023-09-19 |
アボット・ラボラトリーズ |
早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
|
JP7050333B2
(ja)
|
2017-03-24 |
2022-04-08 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
KR102628323B1
(ko)
|
2017-03-24 |
2024-01-22 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
CA3057676A1
(en)
|
2017-03-24 |
2018-09-27 |
The Regents Of The University Of California |
Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
|
IL269398B2
(en)
|
2017-03-24 |
2024-05-01 |
Seagen Inc |
A process for the preparation of glucuronide-drug binders and their intermediates
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
MX2019011624A
(es)
|
2017-03-27 |
2019-12-05 |
Celgene Corp |
Metodos y composiciones para la reduccion de la inmunogenicidad.
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
US20180273627A1
(en)
|
2017-03-27 |
2018-09-27 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
JP2020515543A
(ja)
|
2017-03-28 |
2020-05-28 |
ジェネンテック, インコーポレイテッド |
神経変性疾患の治療方法
|
JP7022328B2
(ja)
|
2017-03-30 |
2022-02-18 |
日油株式会社 |
自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
EP3600249A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
US11419946B2
(en)
|
2017-03-30 |
2022-08-23 |
Nof Corporation |
Heterobifunctional monodispersed polyethylene glycol and conjugate using same
|
US20210275543A1
(en)
|
2017-03-30 |
2021-09-09 |
Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
MX2019011599A
(es)
|
2017-03-30 |
2019-12-19 |
Univ Queensland |
Moleculas quimericas y usos de las mismas.
|
JP7166278B2
(ja)
|
2017-03-30 |
2022-11-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの治療のための抗pd-l1抗体およびdna-pkインヒビターの併用
|
WO2018183931A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
WO2018183941A2
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
US11656233B2
(en)
|
2017-03-30 |
2023-05-23 |
The Board of Trastees of the Leland Stanford Junior University |
Multiplex isotype-specific antibody detection
|
CA3057687A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
AU2018246873B2
(en)
|
2017-03-31 |
2021-05-06 |
Merus N.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
US20200024351A1
(en)
|
2017-04-03 |
2020-01-23 |
Jounce Therapeutics, Inc. |
Compositions and Methods for the Treatment of Cancer
|
EP3606954B1
(en)
|
2017-04-05 |
2022-07-20 |
F. Hoffmann-La Roche AG |
Anti-lag3 antibodies
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
US11040107B2
(en)
|
2017-04-07 |
2021-06-22 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
MA49122A
(fr)
|
2017-04-10 |
2021-03-24 |
Immatics Biotechnologies Gmbh |
Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
|
TW201841934A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於治療癌症免疫治療的新穎肽及其肽組合物
|
US10899819B2
(en)
|
2017-04-10 |
2021-01-26 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
EP3609915A1
(en)
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Antibodies having conditional affinity and methods of use thereof
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
JOP20190243A1
(ar)
|
2017-04-12 |
2019-10-13 |
Medimmune Llc |
علاج الربو بجسم مضاد لـ tslp
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
EP3610264A1
(en)
|
2017-04-13 |
2020-02-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
EP3609922A2
(en)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
CN110945128B
(zh)
|
2017-04-14 |
2023-11-03 |
代表亚利桑那大学的亚利桑那董事会 |
用于治疗肺纤维化的组合物和方法
|
KR20200014276A
(ko)
|
2017-04-14 |
2020-02-10 |
가마맵스 파마 |
암을 예방 또는 치료하기 위한 amhrii-결합 화합물
|
KR20200014277A
(ko)
|
2017-04-14 |
2020-02-10 |
가마맵스 파마 |
폐암을 예방 또는 치료하기 위한 amhrii-결합 화합물
|
WO2018191548A2
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
WO2018191531A1
(en)
|
2017-04-15 |
2018-10-18 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
WO2018192944A1
(en)
|
2017-04-18 |
2018-10-25 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
WO2018192974A1
(en)
|
2017-04-18 |
2018-10-25 |
Université Libre de Bruxelles |
Biomarkers and targets for proliferative diseases
|
US20200071417A1
(en)
|
2017-04-19 |
2020-03-05 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
US11207420B2
(en)
|
2017-04-19 |
2021-12-28 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Cytotoxin and conjugate, uses of same and preparation method therefor
|
EP3612234B1
(en)
|
2017-04-20 |
2024-03-13 |
ADC Therapeutics SA |
Combination therapy with an anti-axl antibody-drug conjugate
|
BR112019021680A2
(pt)
|
2017-04-20 |
2020-05-12 |
Adc Therapeutics Sa |
Terapia de combinação com conjugado anticorpo-fármaco anti-cd25??
|
MX2019012419A
(es)
|
2017-04-21 |
2019-12-05 |
Genentech Inc |
Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
US11203629B2
(en)
|
2017-04-22 |
2021-12-21 |
Immunomic Therapeutics, Inc. |
LAMP constructs
|
EP3396378A1
(en)
|
2017-04-24 |
2018-10-31 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
A method for determining myeloid natural killer (nk)-cells and use thereof
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
JP7295030B2
(ja)
|
2017-04-26 |
2023-06-20 |
ユーリカ セラピューティックス, インコーポレイテッド |
グリピカン3を特異的に認識するコンストラクト及びその使用
|
US11965021B2
(en)
|
2017-04-26 |
2024-04-23 |
Eureka Therapeutics, Inc. |
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
|
KR20190141181A
(ko)
|
2017-04-27 |
2019-12-23 |
시애틀 지네틱스, 인크. |
사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트
|
MA49288A
(fr)
|
2017-04-27 |
2020-03-04 |
Juno Therapeutics Gmbh |
Reactifs particulaires oligomères et leurs méthodes d'utilisation
|
CN110799541A
(zh)
|
2017-04-27 |
2020-02-14 |
特沙诺有限公司 |
针对淋巴细胞活化基因-3(lag-3)的抗体药剂及其用途
|
WO2018196782A1
(en)
|
2017-04-27 |
2018-11-01 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
JPWO2018199318A1
(ja)
|
2017-04-28 |
2020-03-12 |
国立大学法人高知大学 |
抗gpc−1抗体
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018200823A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
JP2020517715A
(ja)
|
2017-04-28 |
2020-06-18 |
メルク・シャープ・エンド・ドーム・コーポレイション |
がん療法のためのバイオマーカー
|
MX2019012749A
(es)
|
2017-04-28 |
2020-02-03 |
Millennium Pharm Inc |
Metodos para tratar trastornos pediatricos.
|
MA48461A
(fr)
|
2017-04-28 |
2020-03-04 |
Amgen Inc |
Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
|
MA50957A
(fr)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
AU2018263923A1
(en)
|
2017-05-02 |
2019-10-31 |
Immunomic Therapeutics, Inc. |
LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
US11845798B2
(en)
|
2017-05-02 |
2023-12-19 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
EP3618857A1
(en)
|
2017-05-04 |
2020-03-11 |
City of Hope |
Antibody variable domains and antibody constructs
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
MX2019013137A
(es)
|
2017-05-05 |
2020-07-14 |
Allakos Inc |
Metodos y composiciones para tratar enfermedades oculares alergicas.
|
IL252151A0
(en)
|
2017-05-07 |
2017-07-31 |
Fainzilber Michael |
Treatment of stress disorders
|
KR20200004880A
(ko)
|
2017-05-10 |
2020-01-14 |
아리엘 싸이언티픽 이노베이션스 엘티디. |
항체를 정제하는 방법
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
WO2018206644A1
(en)
|
2017-05-11 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of therapy selection for patient suffering from glioblastoma
|
GB201707561D0
(en)
|
2017-05-11 |
2017-06-28 |
Argenx Bvba |
GARP-TGF-beta antibodies
|
CN111201034A
(zh)
|
2017-05-11 |
2020-05-26 |
西托戴恩股份有限公司 |
涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法
|
US20200199168A1
(en)
|
2017-05-12 |
2020-06-25 |
Riken |
Class a gpcr-binding compound modifier
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
US11524999B2
(en)
|
2017-05-12 |
2022-12-13 |
The Trustees Of The University Of Pennsylvania |
Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
|
EP3625251A1
(en)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
EP3403649A1
(en)
|
2017-05-16 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Inhibitors and antagonists of gpr84 for the treatment of endometriosis
|
EP3624837A1
(en)
|
2017-05-16 |
2020-03-25 |
Five Prime Therapeutics, Inc. |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
CN110799536B
(zh)
|
2017-05-16 |
2024-04-26 |
拜奥迪斯私人有限公司 |
抗SIRPα抗体
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
KR102582297B1
(ko)
|
2017-05-19 |
2023-09-25 |
필립모리스 프로덕츠 에스.에이. |
대상체의 흡연 상태를 구별하기 위한 진단 테스트
|
TW201907928A
(zh)
|
2017-05-22 |
2019-03-01 |
英商4D製藥研究有限公司 |
包含細菌品系之組成物
|
US10914729B2
(en)
|
2017-05-22 |
2021-02-09 |
The Trustees Of Princeton University |
Methods for detecting protein binding sequences and tagging nucleic acids
|
CN110831976A
(zh)
|
2017-05-23 |
2020-02-21 |
斯索恩生物制药有限公司 |
用于制备抗体-药物缀合物的双重缀合方法
|
US20200172604A1
(en)
|
2017-05-23 |
2020-06-04 |
Technion Research & Development Foundation Limited |
Agents which inhibit gads dimerization and methods of use thereof
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
MA41708A
(fr)
|
2017-05-24 |
2020-04-08 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
EP3406253A1
(en)
|
2017-05-24 |
2018-11-28 |
Bayer Aktiengesellschaft |
Inhibitors and antagonists of human pycr1
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018217944A1
(en)
|
2017-05-24 |
2018-11-29 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
CA3063983A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
US10866251B2
(en)
|
2017-05-25 |
2020-12-15 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
CA3065008A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
US11129564B2
(en)
|
2017-05-30 |
2021-09-28 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
BR112019024604A2
(pt)
|
2017-06-02 |
2020-06-23 |
Pfizer Inc. |
Receptores de antígenos quiméricos que alvejam flt3
|
EP3630841A1
(en)
|
2017-06-02 |
2020-04-08 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
WO2018226690A1
(en)
|
2017-06-05 |
2018-12-13 |
The University Of Chicago |
Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
US11390666B2
(en)
|
2017-06-07 |
2022-07-19 |
Philogen S.P.A. |
Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
|
CN110996972A
(zh)
|
2017-06-08 |
2020-04-10 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的治疗性凋亡细胞
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
WO2018231944A1
(en)
|
2017-06-13 |
2018-12-20 |
Berenson James R |
Diagnostic, prognostic, and monitoring methods for solid tumor cancers
|
CN107271674B
(zh)
|
2017-06-13 |
2019-05-07 |
首都医科大学附属北京地坛医院 |
一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法
|
EP3638295A1
(en)
|
2017-06-13 |
2020-04-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
ES2841902T3
(es)
|
2017-06-14 |
2021-07-12 |
4D Pharma Res Ltd |
Composiciones que comprenden cepas bacterianas
|
AU2018283039A1
(en)
|
2017-06-14 |
2019-11-14 |
Dana-Farber Cancer Institute, Inc. |
B-cell maturation antigen (BCMA)-directed nanoparticles
|
MA49425A
(fr)
|
2017-06-14 |
2020-04-22 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
MX2019015042A
(es)
|
2017-06-14 |
2020-08-06 |
Adc Therapeutics Sa |
Regimen de dosificacion.
|
WO2018229218A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd25 adc
|
JP7469225B2
(ja)
|
2017-06-15 |
2024-04-16 |
キャンサー アドヴァンシーズ インク. |
腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
|
WO2018228875A1
(en)
|
2017-06-15 |
2018-12-20 |
Nestec S.A. |
Micro-rna biomarkers of blood-brain barrier dysfunction
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018236889A2
(en)
|
2017-06-19 |
2018-12-27 |
Massachusetts Institute Of Technology |
AUTOMATED PROCESSES FOR SYNTHESIZING AND MODIFYING PARALLELIZED AND EVOLUTIVE ENZYMA BIOPOLYMERS USING MICROFLUIDIC DEVICES
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
IL271194B1
(en)
|
2017-06-20 |
2024-06-01 |
Teneobio Inc |
Anti-BCMA antibodies containing only heavy chains
|
BR112019026803A2
(pt)
|
2017-06-20 |
2020-06-30 |
Teneoone, Inc. |
anticorpos apenas de cadeia pesada anti-bcma
|
WO2018237010A2
(en)
|
2017-06-20 |
2018-12-27 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
|
CR20190532A
(es)
|
2017-06-20 |
2020-01-10 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
US20210403573A1
(en)
|
2017-06-22 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
CN110869389B
(zh)
|
2017-06-25 |
2023-07-28 |
西雅图免疫公司 |
抗ror1抗体及其制备和使用方法
|
EP3645037A1
(en)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
WO2019005757A1
(en)
|
2017-06-27 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF CTLA4 ANTAGONIST RESISTANCE IN LEUKEMIA
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
US20210145828A1
(en)
|
2017-06-29 |
2021-05-20 |
Rutgers, The State University Of New Jersey |
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
|
JP2020530759A
(ja)
|
2017-07-07 |
2020-10-29 |
イマティクス バイオテクノロジーズ ゲーエムベーハー |
Nsclc、sclc、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
|
US10800823B2
(en)
|
2017-07-07 |
2020-10-13 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
|
JP2020527144A
(ja)
|
2017-07-10 |
2020-09-03 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
癌を処置するためのヒトsiglec−9に対する抗体およびヒトnkg2aに対する抗体を使用する組み合わせ療法
|
EP3652208A1
(en)
|
2017-07-10 |
2020-05-20 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
CA3069193A1
(en)
|
2017-07-10 |
2019-01-17 |
Bayer Pharma Aktiengesellschaft |
Prolactin receptor antibody for male and female pattern hair loss
|
EP3431496A1
(en)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
US20190048073A1
(en)
|
2017-07-20 |
2019-02-14 |
Pfizer Inc. |
Anti-gd3 antibodies and antibody-drug conjugates
|
WO2019018729A1
(en)
|
2017-07-20 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
KR20240006698A
(ko)
|
2017-07-21 |
2024-01-15 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
EP4218813A3
(en)
|
2017-07-27 |
2023-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-c5 antibody formulations
|
US20210032364A1
(en)
|
2017-07-27 |
2021-02-04 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
WO2019023525A1
(en)
|
2017-07-28 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
|
EP3658583A1
(en)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
US11680110B2
(en)
|
2017-07-31 |
2023-06-20 |
Hoffmann-La Roche Inc. |
Three-dimensional structure-based humanization method
|
BR112019023789A2
(pt)
|
2017-08-03 |
2020-07-28 |
Alector Llc |
anticorpos anti-cd33 e métodos de uso dos mesmos
|
BR112019022752A2
(pt)
|
2017-08-03 |
2020-05-19 |
Alector Llc |
anticorpos anti-trem2 e métodos de uso dos mesmos
|
US20210346513A1
(en)
|
2017-08-04 |
2021-11-11 |
Amgen Inc. |
Method of conjugation of cys-mabs
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
MX2020000903A
(es)
|
2017-08-11 |
2020-07-22 |
Genentech Inc |
Anticuerpos anti-cd8 y usos de los mismos.
|
US20200306516A1
(en)
|
2017-08-14 |
2020-10-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
|
TW202402809A
(zh)
|
2017-08-15 |
2024-01-16 |
美商歐米諾斯公司 |
用於治療和/或預防與造血幹細胞移植有關的移植物抗宿主病和/或瀰漫性肺泡出血和/或靜脈閉塞性病的方法
|
US20200256880A1
(en)
|
2017-08-16 |
2020-08-13 |
The Broad Institute, Inc. |
Neuronal Assay Method Involving Calcineurin
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
CA3067735A1
(en)
|
2017-08-17 |
2019-02-21 |
Just Biotherapeutics, Inc. |
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
AU2018316532B2
(en)
|
2017-08-18 |
2022-11-24 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
BR112020003622A2
(pt)
|
2017-08-21 |
2020-09-01 |
Adagene Inc. |
cadeia pesada de anticorpo, anticorpo, bibliotecas, kit, método de preparo de uma biblioteca, método de produção de uma biblioteca de anticorpos, fago, método de geração de um anticorpo biespecífico e anticorpo biespecífico
|
CN111511762A
(zh)
|
2017-08-21 |
2020-08-07 |
天演药业公司 |
抗cd137分子及其用途
|
US11585014B2
(en)
|
2017-08-21 |
2023-02-21 |
Adagene Inc. |
Dynamic human antibody light chain libraries
|
JP2020531532A
(ja)
|
2017-08-22 |
2020-11-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法
|
CN111094349A
(zh)
|
2017-08-23 |
2020-05-01 |
马克思-德布鲁克-分子医学中心亥姆霍兹联合会 |
嵌合抗原受体和结合cxcr5的car-t细胞
|
AU2018321893A1
(en)
|
2017-08-23 |
2020-03-19 |
Wayne State University |
In vivo immunoimaging of interferon-gamma
|
JP7241080B2
(ja)
|
2017-08-28 |
2023-03-16 |
アンジーエックス・インコーポレーテッド |
抗tm4sf1抗体およびそれを使用する方法
|
WO2019046600A1
(en)
|
2017-08-30 |
2019-03-07 |
Amgen Inc. |
INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE
|
US11085929B2
(en)
|
2017-08-31 |
2021-08-10 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
|
CN111107875A
(zh)
|
2017-08-31 |
2020-05-05 |
田边三菱制药株式会社 |
含有il-33拮抗剂的子宫内膜异位症治疗剂
|
EP3677267A4
(en)
|
2017-09-01 |
2021-06-02 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
|
WO2019051164A1
(en)
|
2017-09-07 |
2019-03-14 |
Augusta University Research Institute, Inc. |
ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
|
JP7268005B2
(ja)
|
2017-09-08 |
2023-05-02 |
武田薬品工業株式会社 |
拘束され、条件的に活性化された結合タンパク質
|
KR102125032B1
(ko)
|
2017-09-08 |
2020-06-19 |
주식회사 와이바이오로직스 |
인간 dlk1에 대한 항체 및 이의 용도
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
DK3681483T3
(da)
|
2017-09-15 |
2022-08-29 |
Amgen Inc |
Fremgangsmåde til lyofiliseret farmaceutisk formulering af et terapeutisk protein
|
DE112018005145T5
(de)
|
2017-09-15 |
2020-07-23 |
The Regents Of The University Of California |
Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
|
KR20200047702A
(ko)
|
2017-09-15 |
2020-05-07 |
브리스톨-마이어스 스큅 컴퍼니 |
관심 폴리펩티드 대규모 생산 동안의 온라인 바이오매스 정전용량 모니터링
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
US20200353076A1
(en)
|
2017-09-18 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
JP7279026B2
(ja)
|
2017-09-20 |
2023-05-22 |
メルサナ セラピューティクス インコーポレイテッド |
Napi2b標的化療法に対する応答を予測するための組成物および方法
|
US20200268837A1
(en)
|
2017-09-20 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating autophagy
|
CA3076547A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
Novel anti-hla-a2 antibodies and uses thereof
|
JP7226833B2
(ja)
|
2017-09-21 |
2023-02-21 |
イムチェック セラピューティクス エスエーエス |
Btn2に特異性を有する抗体及びその使用
|
KR20200053581A
(ko)
|
2017-09-22 |
2020-05-18 |
에프. 호프만-라 로슈 아게 |
분석 목적의 다가 단일- 또는 이특이성 재조합 항체
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
WO2019063958A1
(en)
|
2017-09-27 |
2019-04-04 |
The University Of York |
BIOCONJUGATION OF POLYPEPTIDES
|
CN111511769B
(zh)
|
2017-09-27 |
2024-05-24 |
埃皮辛特瑞柯斯公司 |
免疫调节性融合蛋白
|
EP3687629A4
(en)
|
2017-09-27 |
2021-10-06 |
University of Georgia Research Foundation |
TREATMENT AND DETECTION OF INFECTION AND DISEASE ASSOCIATED WITH DIFFERENT FUNGAL PATHOGENS
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
US20200354452A1
(en)
|
2017-09-29 |
2020-11-12 |
City Of Hope |
Cars and bispecific antibodies for treatment of mantle cell lymphoma
|
CA3071236A1
(en)
|
2017-09-29 |
2019-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
US11192943B2
(en)
|
2017-09-30 |
2021-12-07 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Protein binding to fibronectin B domain
|
US11945868B2
(en)
|
2017-10-02 |
2024-04-02 |
Visterra, Inc. |
Antibody molecules to CD138 and uses thereof
|
ES2759622T3
(es)
|
2017-10-02 |
2020-05-11 |
Certest Biotec S L |
Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
AU2018346264A1
(en)
|
2017-10-03 |
2020-04-23 |
Merck Patent Gmbh |
Cysteine engineered antigen-binding molecules
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
CA3078460A1
(en)
|
2017-10-04 |
2019-04-11 |
Opko Pharmaceuticals, Llc |
Articles and methods directed to personalized therapy of cancer
|
CA3077085A1
(en)
|
2017-10-06 |
2019-04-11 |
Oncotherapy Science, Inc. |
Screening of t lymphocytes for cancer-specific antigens
|
TW201930351A
(zh)
|
2017-10-06 |
2019-08-01 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
AU2018347796A1
(en)
|
2017-10-10 |
2020-05-07 |
Medicenna Therapeutics, Inc. |
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
|
EP4116327A1
(en)
|
2017-10-11 |
2023-01-11 |
Board Of Regents, The University Of Texas System |
Human pd-l1 antibodies and methods of use therefor
|
CA3078974A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
US10927180B2
(en)
|
2017-10-13 |
2021-02-23 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
RU2020113246A
(ru)
|
2017-10-13 |
2021-11-15 |
Мерк Патент Гмбх |
Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1
|
CN111212646A
(zh)
|
2017-10-13 |
2020-05-29 |
美国默沙东药厂 |
用于治疗弥漫性大b细胞淋巴瘤的组合物和方法
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
JP2020537668A
(ja)
|
2017-10-18 |
2020-12-24 |
シーエスエル リミティド |
ヒト血清アルブミン変異体およびその使用
|
BR112020007046A2
(pt)
|
2017-10-19 |
2020-11-17 |
Debiopharm International S.A. |
produto de combinação para o tratamento do câncer
|
BR112020004351A2
(pt)
|
2017-10-19 |
2020-09-08 |
Curevac Ag |
moléculas de ácido nucleico artificial
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
US20200283485A1
(en)
|
2017-10-20 |
2020-09-10 |
Institut Curie |
Hook fusion protein for regulating the cellular trafficking of a target protein
|
EP3697809A1
(en)
|
2017-10-20 |
2020-08-26 |
Institut Curie |
Dap10/12 based cars adapted for rush
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
US11826414B2
(en)
|
2017-10-23 |
2023-11-28 |
Cz Biohub Sf, Llc |
Measurement of afucosylated IgG Fc glycans and related vaccination methods
|
WO2019081456A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
WO2019084460A1
(en)
|
2017-10-26 |
2019-05-02 |
The Regents Of The University Of California |
INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY
|
KR20200078483A
(ko)
|
2017-10-27 |
2020-07-01 |
머크 샤프 앤드 돔 코포레이션 |
간암 치료를 위한 조성물 및 방법
|
BR112020007736A2
(pt)
|
2017-10-30 |
2020-10-20 |
F. Hoffmann-La Roche Ag |
composição e método de tratamento
|
US20190160089A1
(en)
|
2017-10-31 |
2019-05-30 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
MA50516A
(fr)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs procédés d'utilisation
|
WO2019088658A1
(ko)
|
2017-10-31 |
2019-05-09 |
주식회사 컴워스파마 |
Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
KR102559706B1
(ko)
|
2017-11-01 |
2023-07-25 |
에프. 호프만-라 로슈 아게 |
Trifab-콘톨스바디
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
BR112020008438A2
(pt)
|
2017-11-02 |
2020-10-20 |
Oxford Biotherapeutics Ltd |
anticorpos e métodos de uso
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
JP2021502125A
(ja)
|
2017-11-09 |
2021-01-28 |
ピンテオン セラピューティクス インコーポレイテッド |
ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
|
US10940171B2
(en)
|
2017-11-10 |
2021-03-09 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
JP7356435B2
(ja)
|
2017-11-14 |
2023-10-04 |
アーセルクス インコーポレイテッド |
多機能性免疫細胞療法
|
MA50102A
(fr)
|
2017-11-14 |
2020-07-15 |
Univ Virginia Patent Foundation |
Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
|
IL255664A0
(en)
|
2017-11-14 |
2017-12-31 |
Shachar Idit |
Hematopoietic stem cells with enhanced properties
|
CA3082643A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
MX2020005128A
(es)
|
2017-11-17 |
2020-07-27 |
Merck Sharp & Dohme |
Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
|
KR20200089282A
(ko)
|
2017-11-20 |
2020-07-24 |
저스트-에보텍 바이오로직스, 아이엔씨. |
등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
|
CA3082728A1
(en)
|
2017-11-22 |
2019-05-31 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-maf status
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
WO2019102456A1
(en)
|
2017-11-27 |
2019-05-31 |
University Of Rijeka Faculty Of Medicine |
Immunotoxins for treating cancer
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
AU2018376309A1
(en)
|
2017-11-28 |
2020-06-25 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand-binding activity
|
DK3717011T3
(da)
|
2017-11-29 |
2023-01-09 |
Csl Ltd |
Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
|
CA3082442A1
(en)
|
2017-11-30 |
2019-06-06 |
Genentech, Inc. |
Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
|
PT3717503T
(pt)
|
2017-11-30 |
2024-01-16 |
Ladrx Corp |
Profármacos de ligação a albumina de derivados de auristatina e
|
CN111712263A
(zh)
|
2017-11-30 |
2020-09-25 |
森托瑞恩生物制药公司 |
基于美登木素生物碱的药物递送系统
|
US10875915B2
(en)
|
2017-12-01 |
2020-12-29 |
Pfizer Inc. |
Anti-CXCR5 antibodies and compositions and uses thereof
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
WO2019110706A1
(en)
|
2017-12-08 |
2019-06-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
JP7344801B2
(ja)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
グリア原線維性酸性タンパク質(gfap)及び/又はユビキチンカルボキシ末端ヒドロラーゼl1(uch-l1)を使用する、整形外科損傷を負っており、軽度外傷性脳損傷(tbi)などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
|
WO2019112860A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
BR112020011810A2
(pt)
|
2017-12-12 |
2020-11-17 |
Macrogenics, Inc. |
molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
|
WO2019118318A1
(en)
|
2017-12-12 |
2019-06-20 |
Calico Biolabs, Inc. |
Recombinant antibody comprising heavy chain genetically fused to signature peptide and uses thereof
|
CN111630065A
(zh)
|
2017-12-13 |
2020-09-04 |
瑞泽恩制药公司 |
抗c5抗体组合及其用途
|
CA3080236A1
(en)
|
2017-12-15 |
2019-06-20 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Bioactive molecule conjugate, preparation method and use thereof
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
WO2019126329A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos Llc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
SG11202005654QA
(en)
|
2017-12-19 |
2020-07-29 |
Univ Rockefeller |
HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
WO2019120527A1
(en)
|
2017-12-20 |
2019-06-27 |
Michael Heneka |
Novel means and methods for treating neurodegenerative diseases
|
RU2756100C1
(ru)
|
2017-12-20 |
2021-09-28 |
Харбор Байомед (Шанхай) Ко., Лтд |
Антитела, связывающие ctla-4, и их применение
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
US11525165B2
(en)
|
2017-12-20 |
2022-12-13 |
Inserm |
Method of selection of an IRE1-inhibitor therapy for patient suffering from cancer
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
PE20201149A1
(es)
|
2017-12-21 |
2020-10-26 |
Hoffmann La Roche |
Anticuerpos de union a hla-a2/wt1
|
SG11202004806SA
(en)
|
2017-12-22 |
2020-06-29 |
Jounce Therapeutics Inc |
Antibodies to lilrb2
|
EA202091557A1
(ru)
|
2017-12-22 |
2020-11-18 |
Тенеобио, Инк. |
Антитела, содержащие только тяжелые цепи, которые связываются с cd22
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
SG11202006042SA
(en)
|
2017-12-27 |
2020-07-29 |
Teneobio Inc |
Cd3-delta/epsilon heterodimer specific antibodies
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
CA3082280A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
CN111511400A
(zh)
|
2017-12-29 |
2020-08-07 |
豪夫迈·罗氏有限公司 |
抗vegf抗体及其使用方法
|
WO2019134741A1
(en)
|
2018-01-03 |
2019-07-11 |
Albert-Ludwigs-Universität Freiburg |
Single-channel multianalyte biosensor
|
US20210072244A1
(en)
|
2018-01-04 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
AU2019205330A1
(en)
|
2018-01-04 |
2020-08-27 |
Iconic Therapeutics Llc |
Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
|
JP7426724B2
(ja)
|
2018-01-05 |
2024-02-02 |
エイシー イミューン ソシエテ アノニム |
ミスフォールドされたtdp-43結合分子
|
EP3735589A2
(en)
|
2018-01-05 |
2020-11-11 |
Vanderbilt University |
Antibody-mediated neutralization of chikungunya virus
|
BR112020013954A2
(pt)
|
2018-01-09 |
2020-12-01 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
composições e métodos para alvejamento de cânceres que expressam clec12a
|
CN111886255A
(zh)
|
2018-01-12 |
2020-11-03 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
CA3087951A1
(en)
|
2018-01-12 |
2019-07-18 |
Amgen Inc. |
Pac1 antibodies and uses thereof
|
KR20200110356A
(ko)
|
2018-01-15 |
2020-09-23 |
화이자 인코포레이티드 |
키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
|
TWI802633B
(zh)
|
2018-01-15 |
2023-05-21 |
大陸商南京傳奇生物科技有限公司 |
針對pd-1之單域抗體及其變異體
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
WO2019145413A1
(en)
|
2018-01-25 |
2019-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injury in an organ
|
WO2019147822A2
(en)
|
2018-01-24 |
2019-08-01 |
Northwestern University |
Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
|
BR112020013405A2
(pt)
|
2018-01-25 |
2020-12-01 |
Acm Biolabs Pte Ltd. |
polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
|
MA51676A
(fr)
|
2018-01-26 |
2021-05-05 |
Hoffmann La Roche |
Protéines de fusion il-22 fc et procédés d'utilisation
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
MD3638698T2
(ro)
|
2018-01-26 |
2021-07-31 |
Regeneron Pharma |
Anticorpi anti-TMPRSS2 și fragmente de legare al antigenului
|
KR20200125590A
(ko)
|
2018-01-26 |
2020-11-04 |
제넨테크, 인크. |
조성물 및 사용 방법
|
EP3743526A1
(en)
|
2018-01-28 |
2020-12-02 |
Enable Biosciences Inc. |
Reagents and methods for blocking non-specific interactions with nucleic acids
|
WO2019151418A1
(ja)
|
2018-01-31 |
2019-08-08 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
JP2021512103A
(ja)
|
2018-01-31 |
2021-05-13 |
バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft |
Nampt阻害剤を含む抗体薬物複合体(adcs)
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
AU2019214183B2
(en)
|
2018-02-01 |
2022-04-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
WO2019152705A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Antibodies specific for cd70 and their uses
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
FR3077574B1
(fr)
|
2018-02-07 |
2022-04-01 |
Commissariat Energie Atomique |
Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
TWI804572B
(zh)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
KR102417088B1
(ko)
|
2018-02-09 |
2022-07-07 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
WO2019155474A1
(en)
|
2018-02-12 |
2019-08-15 |
Hadasit Medical Research Services & Development Ltd. |
Modulation of slamf6 splice variants for cancer therapy
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
WO2019157772A1
(zh)
|
2018-02-13 |
2019-08-22 |
和元生物技术(上海)股份有限公司 |
抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
|
US11512127B2
(en)
|
2018-02-14 |
2022-11-29 |
Viela Bio, Inc. |
Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
|
WO2019158645A1
(en)
|
2018-02-14 |
2019-08-22 |
Abba Therapeutics Ag |
Anti-human pd-l2 antibodies
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス,インコーポレーテッド |
変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
EP3752134A1
(en)
|
2018-02-16 |
2020-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating vitiligo
|
SG11202007540SA
(en)
|
2018-02-20 |
2020-09-29 |
Seattle Genetics Inc |
Hydrophobic auristatin f compounds and conjugates thereof
|
EP3755712A1
(en)
|
2018-02-21 |
2020-12-30 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
MA51907A
(fr)
|
2018-02-21 |
2021-05-26 |
Hoffmann La Roche |
Posologie pour un traitement avec des protéines de fusion il-22 fc
|
CN111836831A
(zh)
|
2018-02-26 |
2020-10-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
|
EP3530282A1
(en)
|
2018-02-27 |
2019-08-28 |
Diaccurate |
Therapeutic methods
|
WO2019166946A1
(en)
|
2018-02-28 |
2019-09-06 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
WO2019168176A1
(ja)
|
2018-03-01 |
2019-09-06 |
国立大学法人広島大学 |
抗インテグリンα11モノクローナル抗体、およびその利用
|
WO2019169231A1
(en)
|
2018-03-02 |
2019-09-06 |
The University Of Chicago |
Methods and composition for neutralization of influenza
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
TW201946654A
(zh)
|
2018-03-05 |
2019-12-16 |
比利時商健生藥品公司 |
抗PHF-Tau抗體及其用途
|
WO2019171252A1
(en)
|
2018-03-05 |
2019-09-12 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
AU2019232630A1
(en)
|
2018-03-05 |
2020-09-24 |
Janssen Pharmaceutica Nv |
Assays to detect neurodegeneration
|
CN112292401A
(zh)
|
2018-03-06 |
2021-01-29 |
英凯尔生物科技有限责任公司 |
丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
|
WO2019170131A1
(zh)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
|
CA3093036A1
(en)
|
2018-03-07 |
2019-09-12 |
Pfizer Inc. |
Anti-pd-1 antibody compositions
|
CA3089049C
(en)
|
2018-03-08 |
2023-03-28 |
Purepharm Inc. |
Methods and compositions for preventing and treating conditions related to alpha-synuclein
|
WO2019177690A1
(en)
|
2018-03-12 |
2019-09-19 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
EP3765523A1
(en)
|
2018-03-12 |
2021-01-20 |
Memorial Sloan Kettering Cancer Center |
Bispecific binding agents and uses thereof
|
KR102542988B1
(ko)
|
2018-03-13 |
2023-06-13 |
니치유 가부시키가이샤 |
주쇄 및 측쇄에 단분산 폴리에틸렌 글리콜을 가지는 헤테로이관능성 화합물
|
CA3092345A1
(en)
|
2018-03-13 |
2019-09-19 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 2 beta 1 and methods of use
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
JP7377590B2
(ja)
|
2018-03-14 |
2023-11-10 |
ノビミューン エスアー |
抗cd3イプシロン抗体およびそれを使用する方法
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
JP2021515583A
(ja)
|
2018-03-14 |
2021-06-24 |
ベイジン シュアンイー ファーマサイエンシーズ カンパニー, リミテッド |
抗クローディン18.2抗体
|
CN112272674A
(zh)
|
2018-03-14 |
2021-01-26 |
勃林格殷格翰国际有限公司 |
抗-il-36r抗体用于治疗泛发性脓疱性银屑病的用途
|
US20190284273A1
(en)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
|
CN110272490B
(zh)
|
2018-03-14 |
2021-05-14 |
上海开拓者生物医药有限公司 |
靶向ctla-4抗体、其制备方法和用途
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
EP3765518A1
(en)
|
2018-03-15 |
2021-01-20 |
Biond Biologics Ltd. |
Methods and compositions for decreasing soluble immune receptor cd28
|
SG11202009010RA
(en)
|
2018-03-15 |
2020-10-29 |
Chugai Pharmaceutical Co Ltd |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
US20210010055A1
(en)
|
2018-03-16 |
2021-01-14 |
Bristol-Myers Squibb Company |
Metabolic enzyme activity and disulfide bond reduction during protein production
|
MX2020009774A
(es)
|
2018-03-21 |
2020-10-08 |
Alx Oncology Inc |
Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
CN116942851A
(zh)
|
2018-03-23 |
2023-10-27 |
布鲁塞尔自由大学 |
Wnt信号传递激动剂分子
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
WO2019182896A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
BR112020018691A2
(pt)
|
2018-03-26 |
2021-01-05 |
Regeneron Pharmaceuticals, Inc. |
Anticorpos anti-pfrh5 e fragmentos de ligação ao antígeno dos mesmos
|
US11993658B2
(en)
|
2018-03-26 |
2024-05-28 |
Sutro Biopharma, Inc. |
Anti-BCMA antibodies and treatment methods
|
LT3775909T
(lt)
|
2018-03-26 |
2023-08-10 |
Glycanostics S.R.O. |
Priemonės ir būdai, skirti baltymo glikozilinimo profilio nustatymui
|
EP3775206A1
(en)
|
2018-03-28 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
MX2020009991A
(es)
|
2018-03-28 |
2020-10-14 |
Axon Neuroscience Se |
Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
MX2020010028A
(es)
|
2018-03-29 |
2020-10-14 |
Genentech Inc |
Actividad lactogenica modulada en celulas de mamifero.
|
EP3774882A1
(en)
|
2018-03-29 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of purifying monomeric monoclonal antibodies
|
EP3774917A4
(en)
|
2018-03-30 |
2022-01-19 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
EA202092302A1
(ru)
|
2018-04-02 |
2021-02-02 |
Бристол-Майерс Сквибб Компани |
Антитела к trem-1 и их применения
|
CN110343178B
(zh)
|
2018-04-03 |
2022-07-22 |
上海开拓者生物医药有限公司 |
抗人lag-3单克隆抗体及其应用
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
US10633458B2
(en)
|
2018-04-10 |
2020-04-28 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
EP3552620A1
(en)
|
2018-04-11 |
2019-10-16 |
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center |
Methods of treatment for candida auris infections
|
WO2019197651A1
(en)
|
2018-04-12 |
2019-10-17 |
Mediapharma S.R.L. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
MX2020010808A
(es)
|
2018-04-13 |
2021-03-02 |
Sangamo Therapeutics France |
Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
|
US20210164984A1
(en)
|
2018-04-13 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
TW202344272A
(zh)
|
2018-04-13 |
2023-11-16 |
美商建南德克公司 |
穩定抗cd79b免疫結合物調配物
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
JP7465814B2
(ja)
|
2018-04-16 |
2024-04-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
高濃度タンパク質製剤の粘度低下
|
CN108623687A
(zh)
|
2018-04-17 |
2018-10-09 |
中山康方生物医药有限公司 |
神经生长因子的单克隆抗体及其编码基因和应用
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
US20210230245A1
(en)
|
2018-04-20 |
2021-07-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor and car-t cells that bind a herpes virus antigen
|
CN108373505B
(zh)
|
2018-04-20 |
2019-08-20 |
北京智仁美博生物科技有限公司 |
抗il-4r抗体及其用途
|
US11471506B2
(en)
|
2018-04-23 |
2022-10-18 |
Emory University |
VIP antagonists and uses in treating cancer
|
IT201800004853A1
(it)
|
2018-04-24 |
2019-10-24 |
|
Metodi per trattare il cancro
|
KR20210027254A
(ko)
|
2018-04-24 |
2021-03-10 |
앰프소스 바이오파마 상하이 인코포레이티드 |
Tim-3에 대한 항체 및 그의 용도
|
WO2019207066A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for the treatment of sjögren's syndrome
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
US20210230255A1
(en)
|
2018-04-27 |
2021-07-29 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
SG11202010423VA
(en)
|
2018-05-04 |
2020-11-27 |
Merck Patent Gmbh |
COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
|
US10647755B2
(en)
|
2018-05-09 |
2020-05-12 |
The Hong Kong University Of Science And Technology |
Photoresponsive protein hydrogels and methods and uses thereof
|
JP2021522801A
(ja)
|
2018-05-09 |
2021-09-02 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
ヒトネクチン4に特異的な抗体
|
CN112119091A
(zh)
|
2018-05-10 |
2020-12-22 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
US11292840B2
(en)
|
2018-05-14 |
2022-04-05 |
Jounce Therapeutics, Inc. |
Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist
|
MX2020012252A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
|
FI3794024T3
(fi)
|
2018-05-14 |
2023-08-10 |
Werewolf Therapeutics Inc |
Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
WO2019222281A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunomic Therapeutics, Inc |
Improved lamp constructs comprising allergens
|
CN110483639A
(zh)
|
2018-05-15 |
2019-11-22 |
复旦大学 |
靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
|
KR20210013091A
(ko)
|
2018-05-16 |
2021-02-03 |
시에스엘 리미티드 |
가용성 보체 수용체 1형 변이체 및 이의 용도
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
AU2019274654B2
(en)
|
2018-05-23 |
2023-07-20 |
Pfizer Inc. |
Antibodies specific for CD3 and uses thereof
|
US20220111065A1
(en)
|
2018-05-23 |
2022-04-14 |
Adc Therapeutics Sa |
Molecular adjuvant
|
KR20230146098A
(ko)
|
2018-05-23 |
2023-10-18 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
AU2019272885A1
(en)
|
2018-05-25 |
2020-11-26 |
Alector Llc |
Anti-SIRPA antibodies and methods of use thereof
|
EP3575320A1
(en)
|
2018-05-29 |
2019-12-04 |
Heinrich-Pette-Institut Leibniz-Institut für Experimentelle Virologie |
New therapy for treating graft-versus-host-disease
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
CN110551215A
(zh)
|
2018-05-30 |
2019-12-10 |
中山康方生物医药有限公司 |
抗白细胞介素-17a抗体、其药物组合物及其用途
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019230868A1
(ja)
|
2018-05-30 |
2019-12-05 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
BR112020023380A2
(pt)
|
2018-05-31 |
2021-02-09 |
Glyconex Inc. |
anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo isolado, vetor recombinante, célula hospedeira, método para produzir um anticorpo ou um fragmento de aglutinação ao antígeno do mesmo e para tratar ou detectar câncer, conjugado de anticorpo ,e, composição farmacêutica
|
WO2019232321A1
(en)
|
2018-06-01 |
2019-12-05 |
NanoView Biosciences, Inc. |
Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
|
JOP20200268A1
(ar)
|
2018-06-01 |
2020-10-26 |
Eisai R&D Man Co Ltd |
تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
|
JP2021525806A
(ja)
|
2018-06-01 |
2021-09-27 |
タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド |
疾患または状態を処置するための組成物およびそれらの使用
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
EP3805400A4
(en)
|
2018-06-04 |
2022-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
EP3801613A1
(en)
|
2018-06-04 |
2021-04-14 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
AU2019282264A1
(en)
|
2018-06-05 |
2020-11-26 |
Amgen Inc. |
Modulating antibody dependent cellular phagocytosis
|
EP3804759A4
(en)
|
2018-06-06 |
2022-07-20 |
Osaka University |
METHODS OF TREATMENT OF DANDRUFF OR PREVENTION OF GNASE 1 SECONDARY DISEASES
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
US20210246204A1
(en)
|
2018-06-08 |
2021-08-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
US20210163983A1
(en)
|
2018-06-08 |
2021-06-03 |
Crystal Bioscience Inc. |
Transgenic animal for producing diversified antibodies that have the same light chain ii
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
CN112469440A
(zh)
|
2018-06-18 |
2021-03-09 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
CN112334486A
(zh)
|
2018-06-18 |
2021-02-05 |
先天制药公司 |
用于治疗癌症的组合物和方法
|
WO2019245269A1
(ko)
|
2018-06-18 |
2019-12-26 |
연세대학교 산학협력단 |
Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물
|
WO2019243159A1
(de)
|
2018-06-18 |
2019-12-26 |
Bayer Aktiengesellschaft |
Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil
|
PE20210418A1
(es)
|
2018-06-19 |
2021-03-08 |
Atarga Llc |
Moleculas de anticuerpo de componente de complemento 5 y sus usos
|
JP7084057B2
(ja)
|
2018-06-20 |
2022-06-14 |
株式会社ファーマフーズ |
新規抗pad2抗体
|
US20210363233A1
(en)
|
2018-06-20 |
2021-11-25 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
EP3810085A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
US20210276971A1
(en)
|
2018-06-20 |
2021-09-09 |
The Research Foundation For The State University Of New York |
Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
|
WO2019246273A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
TW202016144A
(zh)
|
2018-06-21 |
2020-05-01 |
日商第一三共股份有限公司 |
包括cd3抗原結合片段之組成物及其用途
|
EP3810777A4
(en)
|
2018-06-21 |
2022-03-30 |
Yumanity Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
|
TW202016081A
(zh)
|
2018-06-21 |
2020-05-01 |
英商克拉德夫製藥有限公司 |
人類sting之小分子調節劑、結合物及治療應用
|
WO2019245039A1
(ja)
|
2018-06-22 |
2019-12-26 |
株式会社Junten Bio |
感染性免疫寛容を惹起するための組成物
|
US20210269529A1
(en)
|
2018-06-22 |
2021-09-02 |
Junten Bio Co., Ltd. |
Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
|
EP3811952A4
(en)
|
2018-06-22 |
2022-06-01 |
JUNTEN BIO Co., Ltd. |
IMMUNTOLERANCE-INDUCING ANTIBODIES PRODUCED USING A COMPLEX CONDITION CELL MIXTURE AND INDUCED LYMPHOCYTE OR CELL THERAPEUTIC MEDICATION AND CELL THERAPY METHODS EACH USING THE INDUCED LYMPHOCYTE
|
US20200030443A1
(en)
|
2018-06-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
SG11202012257VA
(en)
|
2018-06-26 |
2021-01-28 |
Immunogen Inc |
Immunoconjugates targeting adam9 and methods of use thereof
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
EP3841124A4
(en)
|
2018-06-29 |
2022-03-23 |
ApitBio, Inc. |
ANTI-L1CAM ANTIBODIES AND THEIR USES
|
US20210395329A1
(en)
|
2018-06-29 |
2021-12-23 |
City Of Hope |
Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
EP3813884A4
(en)
|
2018-06-29 |
2022-03-23 |
North Carolina State University |
IN SITU SPRAYED BIORESPONSIVE IMMUNOTHERAPEUTIC GEL FOR POSTOPERATIVE TREATMENT
|
SG11202010990TA
(en)
|
2018-06-29 |
2020-12-30 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
MX2020013885A
(es)
|
2018-06-29 |
2021-03-09 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd40 para su uso en el tratamiento de enfermedades autoinmunes.
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
SG11202013217PA
(en)
|
2018-07-03 |
2021-01-28 |
Catalent Pharma Solutions Llc |
Multifunctional protein molecules comprising decorin and use thereof
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
EP3820896A1
(en)
|
2018-07-11 |
2021-05-19 |
Scholar Rock, Inc. |
TGFbeta1 INHIBITORS AND USE THEREOF
|
MA52165A
(fr)
|
2018-07-11 |
2021-06-02 |
Scholar Rock Inc |
Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée
|
GB201811364D0
(en)
|
2018-07-11 |
2018-08-29 |
Adc Therapeutics Sa |
Combination therapy
|
TW202005981A
(zh)
|
2018-07-11 |
2020-02-01 |
美商供石公司 |
高親和性、異構體選擇性之TGFβ1抑制劑及其用途
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
BR112021000282A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a cd137 e ox40
|
CA3106046A1
(en)
|
2018-07-12 |
2020-01-16 |
F-Star Beta Limited |
Antibody molecules that bind pd-l1 and cd137
|
JP7447388B2
(ja)
|
2018-07-13 |
2024-03-12 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
感染性疾患の治療のための共受容体システム
|
WO2020012435A1
(en)
|
2018-07-13 |
2020-01-16 |
Lausanne University Hospital |
Hiv binding agents
|
SI3618928T1
(sl)
|
2018-07-13 |
2023-04-28 |
Alector Llc |
Protitelesa proti sortilinu in postopki za uporabo le-teh
|
CN110713537B
(zh)
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
WO2020018503A2
(en)
|
2018-07-16 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-il36r antibodies
|
JP2021530237A
(ja)
|
2018-07-17 |
2021-11-11 |
ウーマブス ビオメド エセアー |
Campylobacterの種に対する抗体
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
WO2020018789A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
MX2021000708A
(es)
|
2018-07-20 |
2021-03-25 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al cd19.
|
MX2021000745A
(es)
|
2018-07-20 |
2021-03-26 |
Surface Oncology Inc |
Composiciones anti-cd112r y metodos.
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
AU2019311077A1
(en)
|
2018-07-23 |
2021-02-25 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CN112752768A
(zh)
|
2018-07-27 |
2021-05-04 |
艾利妥 |
抗siglec-5抗体及其使用方法
|
US20210308170A1
(en)
|
2018-07-27 |
2021-10-07 |
Osaka University |
Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发(慕尼黑)股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
CN110898226B
(zh)
|
2018-07-31 |
2023-05-05 |
苏州亚盛药业有限公司 |
Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法
|
EP3829647A1
(en)
|
2018-07-31 |
2021-06-09 |
Astrazeneca AB |
Linkers and conjugates
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
PE20211400A1
(es)
|
2018-08-03 |
2021-07-27 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
SG11202101152QA
(en)
|
2018-08-03 |
2021-03-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
KR20210041571A
(ko)
|
2018-08-07 |
2021-04-15 |
인3바이오 리미티드 |
역형성 림프종 키나아제 억제제와 조합하여 egf/egfr 경로를 억제하기 위한 방법 및 조성물
|
WO2020033485A1
(en)
|
2018-08-08 |
2020-02-13 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
CN110317267B
(zh)
|
2018-08-09 |
2020-11-20 |
北京智仁美博生物科技有限公司 |
针对狂犬病病毒的双特异性抗体及其用途
|
CN112839960A
(zh)
|
2018-08-10 |
2021-05-25 |
中外制药株式会社 |
抗cd137抗原结合分子及其应用
|
US20210292389A1
(en)
|
2018-08-10 |
2021-09-23 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
TW202019968A
(zh)
|
2018-08-13 |
2020-06-01 |
美商英伊布里克斯公司 |
Ox40結合多肽及其用途
|
IL261156A
(en)
|
2018-08-14 |
2020-02-27 |
Fass Deborah |
Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
|
CN110818793A
(zh)
|
2018-08-14 |
2020-02-21 |
中山康方生物医药有限公司 |
抗IL-1β的抗体、其药物组合物及其用途
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
WO2020037225A1
(en)
|
2018-08-17 |
2020-02-20 |
Mersana Therapeutics, Inc. |
Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof
|
JP2021534735A
(ja)
|
2018-08-21 |
2021-12-16 |
アルバート アインシュタイン カレッジ オブ メディスンAlbert Einstein College Of Medicine |
ヒトTim−3に対するモノクローナル抗体
|
US11548938B2
(en)
|
2018-08-21 |
2023-01-10 |
Quidel Corporation |
DbpA antibodies and uses thereof
|
US20220363763A1
(en)
|
2018-08-21 |
2022-11-17 |
Abl Bio Inc. |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
AU2019324170A1
(en)
|
2018-08-23 |
2021-02-18 |
Seagen, Inc. |
Anti-TIGIT antibodies
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
CN113227359A
(zh)
|
2018-08-24 |
2021-08-06 |
耶达研究及发展有限公司 |
调节m2巨噬细胞极化的方法及其在治疗中的用途
|
WO2020043670A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
US20210253666A1
(en)
|
2018-08-30 |
2021-08-19 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
MX2021001908A
(es)
|
2018-08-31 |
2021-08-19 |
Adc Therapeutics Sa |
Terapia de combinacion.
|
WO2020047345A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
|
AU2019331018A1
(en)
|
2018-08-31 |
2021-03-11 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3847650A1
(en)
|
2018-09-06 |
2021-07-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
EP3847194A1
(en)
|
2018-09-07 |
2021-07-14 |
Pfizer Inc. |
Anti-avb8 antibodies and compositions and uses thereof
|
WO2020048607A1
(en)
|
2018-09-07 |
2020-03-12 |
Université Libre de Bruxelles |
Srsf2 as rna epigenetic factor
|
WO2020053147A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
CA3110530A1
(en)
|
2018-09-11 |
2020-03-19 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
EP3849600A1
(en)
|
2018-09-12 |
2021-07-21 |
ACM Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
AU2019339469A1
(en)
|
2018-09-13 |
2021-03-11 |
Immune-Onc Therapeutics, Inc. |
Novel LILRB4 antibodies and uses thereof
|
US10899826B1
(en)
|
2018-09-13 |
2021-01-26 |
Teva Pharmaceuticals International Gmbh |
Pharmaceutical compositions for an anti-CGRP antagonist antibody
|
JP7407723B2
(ja)
|
2018-09-14 |
2024-01-04 |
田辺三菱製薬株式会社 |
ヒト抗il-33モノクローナル抗体含有医薬用組成物
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
JP2022502076A
(ja)
|
2018-09-18 |
2022-01-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗tnfr2抗体およびその使用
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
JP2022501388A
(ja)
|
2018-09-19 |
2022-01-06 |
ラホヤ インスティチュート フォー イミュノロジー |
関節リウマチにおけるptprs及びプロテオグリカン
|
KR20210063330A
(ko)
|
2018-09-19 |
2021-06-01 |
제넨테크, 인크. |
방광암에 대한 치료 및 진단 방법
|
MX2021003169A
(es)
|
2018-09-21 |
2021-08-11 |
Teneobio Inc |
Metodos para purificar anticuerpos multiespecificos, heterodimericos.
|
AU2019343952A1
(en)
|
2018-09-21 |
2021-04-22 |
Mucommune, Llc |
Synthetic binding agents for limiting permeation through mucus
|
JP7475687B2
(ja)
|
2018-09-21 |
2024-04-30 |
国立大学法人 東京医科歯科大学 |
ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
JP7475336B2
(ja)
|
2018-09-21 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
CA3113837C
(en)
|
2018-09-24 |
2022-07-12 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
IL297931A
(en)
|
2018-09-25 |
2023-01-01 |
Harpoon Therapeutics Inc |
dll3 binding proteins and methods of use
|
US20220033486A1
(en)
|
2018-09-25 |
2022-02-03 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
EP3856343A1
(en)
|
2018-09-25 |
2021-08-04 |
Biolegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
CA3114024A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Csf1r/ccr2多特異性抗体
|
TWI828767B
(zh)
|
2018-09-27 |
2024-01-11 |
美商提聖納醫療公司 |
抗hla-g抗體、包含抗hla-g抗體之組成物及使用抗hla-g抗體之方法
|
SG11202103025PA
(en)
|
2018-09-27 |
2021-04-29 |
Phosphogam Inc |
Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
|
WO2020069398A1
(en)
|
2018-09-27 |
2020-04-02 |
Akrevia Therapeutics Inc. |
Masked cytokine polypeptides
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
WO2020069433A1
(en)
|
2018-09-28 |
2020-04-02 |
Imaginab, Inc. |
Cd8 imaging constructs and methods of use thereof
|
CN112771071A
(zh)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
胶原蛋白定位的免疫调节分子及其方法
|
EP3856781A1
(en)
|
2018-09-28 |
2021-08-04 |
Amgen Inc. |
Antibodies against soluble bcma
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210380675A1
(en)
|
2018-09-28 |
2021-12-09 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
JP2022512626A
(ja)
|
2018-10-04 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
粘膜炎症性疾患の処置のための方法及び医薬組成物
|
AU2019354101A1
(en)
|
2018-10-05 |
2021-04-15 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
|
AU2019355194A1
(en)
|
2018-10-05 |
2021-04-22 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for enzymatic disruption of bacterial biofilms
|
TW202028244A
(zh)
|
2018-10-09 |
2020-08-01 |
美商建南德克公司 |
用於確定突觸形成之方法及系統
|
JP2022512648A
(ja)
|
2018-10-09 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
心筋線維化の処置のためのαV-インテグリン(CD51)阻害剤の使用
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
US20210380923A1
(en)
|
2018-10-10 |
2021-12-09 |
Boehringer Ingelheim International Gmbh |
Method for membrane gas transfer in high density bioreactor culture
|
CN113329769A
(zh)
|
2018-10-11 |
2021-08-31 |
斯克里普斯研究学院 |
具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
TW202021986A
(zh)
|
2018-10-11 |
2020-06-16 |
美商英伊布里克斯公司 |
5t4單域抗體及其治療性組合物
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
JP7453219B2
(ja)
|
2018-10-11 |
2024-03-19 |
インヒブリックス, インコーポレイテッド |
Pd-1単一ドメイン抗体およびその治療用組成物
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
US11674961B2
(en)
|
2018-10-12 |
2023-06-13 |
Quidel Corporation |
Extraction reagent for use in an assay for detection of group A Streptococcus
|
US20210369705A1
(en)
|
2018-10-15 |
2021-12-02 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
US20220010016A1
(en)
|
2018-10-17 |
2022-01-13 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
WO2020081905A1
(en)
|
2018-10-18 |
2020-04-23 |
Jounce Therapeutics, Inc |
Methods for treating cancer
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
CN112955462B
(zh)
|
2018-10-18 |
2024-05-07 |
国家医疗保健研究所 |
用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
|
WO2020079647A1
(en)
|
2018-10-18 |
2020-04-23 |
Dh Technologies Development Pte. Ltd. |
Functionalizing a sampling element for use with a mass spectrometry system
|
CA3112977A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
CA3115136A1
(en)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
KR20210093879A
(ko)
|
2018-10-22 |
2021-07-28 |
상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. |
항-cldn18.2 항체 및 이의 용도
|
SG11202104010PA
(en)
|
2018-10-23 |
2021-05-28 |
Scholar Rock Inc |
Rgmc-selective inhibitors and use thereof
|
WO2020086802A1
(en)
|
2018-10-24 |
2020-04-30 |
Jounce Therapeutics, Inc. |
Methods and compositions for the treatment of cancer and infectious diseases
|
JP2022505450A
(ja)
|
2018-10-24 |
2022-01-14 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
コンジュゲート化された化学的分解誘導物質および使用方法
|
TWI824043B
(zh)
|
2018-10-25 |
2023-12-01 |
西班牙商瑪製藥股份有限公司 |
藥物抗體共軛物
|
KR20200047937A
(ko)
|
2018-10-26 |
2020-05-08 |
재단법인 목암생명과학연구소 |
Ids를 포함하는 융합 단백질 및 이의 용도
|
WO2020086943A1
(en)
|
2018-10-26 |
2020-04-30 |
Jounce Therapeutics, Inc. |
Methods of treating cancer
|
AU2019367218A1
(en)
|
2018-10-26 |
2021-06-03 |
TeneoFour, Inc. |
Heavy chain antibodies binding to CD38
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020089841A1
(en)
|
2018-10-31 |
2020-05-07 |
Garcia Joe G N |
Biomarkers and methods of use for radiation-induced lung injury
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
US20220195024A1
(en)
|
2018-11-02 |
2022-06-23 |
Oklahoma Medical Research Foundation |
Monoclonal Antibodies to ELTD1 and Uses Thereof
|
US20200140533A1
(en)
|
2018-11-02 |
2020-05-07 |
Annexon, Inc. |
Compositions and methods for treating brain injury
|
US20210388074A1
(en)
|
2018-11-05 |
2021-12-16 |
Ludwig Institute For Cancer Research Ltd. |
Humanized and variant tgf-beta3 specific antibodies and methods and uses thereof
|
AU2019375036A1
(en)
|
2018-11-05 |
2021-06-03 |
Centre Hospitalier Universitaire Vaudois |
Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof
|
AU2019375413A1
(en)
|
2018-11-05 |
2021-05-27 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
EP3878869A4
(en)
|
2018-11-07 |
2023-04-19 |
Shanghai Hyamab Biotech Co., Ltd. |
NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE
|
CA3117945A1
(en)
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
JP7451520B2
(ja)
|
2018-11-15 |
2024-03-18 |
ビョンディス・ビー.ブイ. |
ヒト化抗SIRPα抗体
|
US20220011301A1
(en)
|
2018-11-16 |
2022-01-13 |
Roche Diagnostics Operations, Inc. |
Streptavidin-coated solid phases with a member of a binding pair
|
MX2021005751A
(es)
|
2018-11-16 |
2021-10-01 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos contra mucina 16 y métodos de uso de los mismos.
|
US11274150B2
(en)
|
2018-11-16 |
2022-03-15 |
Bristol-Myers Squibb Company |
Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
|
WO2020099663A1
(en)
|
2018-11-16 |
2020-05-22 |
S-biomedic N.v. |
Compositions for treating oxidative stress-associated skin diseases and skin ageing and diagnosis of oxidative stress-associated skin diseases
|
KR20210095165A
(ko)
|
2018-11-19 |
2021-07-30 |
프로제너티, 인크. |
바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
|
WO2020106358A1
(en)
|
2018-11-20 |
2020-05-28 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
WO2020104531A1
(en)
|
2018-11-20 |
2020-05-28 |
Bavarian Nordic A/S |
Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
EP3883607A4
(en)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
|
CN113348180B
(zh)
|
2018-11-20 |
2023-05-26 |
上海开拓者生物医药有限公司 |
Ox40抗体及其制备方法和应用
|
CN111196851B
(zh)
|
2018-11-20 |
2021-11-16 |
厦门万泰凯瑞生物技术有限公司 |
针对人抗缪勒管激素的特异性抗体及其应用
|
EP3884276A2
(en)
|
2018-11-23 |
2021-09-29 |
Katholieke Universiteit Leuven |
Predicting a treatment response in inflammatory bowel disease
|
WO2020109251A1
(en)
|
2018-11-29 |
2020-06-04 |
Adc Therapeutics Sa |
Dosage regime
|
CN111234018A
(zh)
|
2018-11-29 |
2020-06-05 |
上海开拓者生物医药有限公司 |
全人抗gitr抗体及其制备方法
|
CN111253485A
(zh)
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
PE20211778A1
(es)
|
2018-11-30 |
2021-09-08 |
Abl Bio Inc |
Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos
|
EP3892637A1
(en)
|
2018-12-03 |
2021-10-13 |
Shanghai Pharmaexplorer Co., Ltd. |
Cd47 antibody, preparation method therefor and uses thereof
|
US20210403602A1
(en)
|
2018-12-03 |
2021-12-30 |
Bristol-Myers Squibb Company |
Anti-ido antibody and uses thereof
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
MX2021006573A
(es)
|
2018-12-06 |
2021-07-15 |
Genentech Inc |
Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020115655A1
(en)
|
2018-12-06 |
2020-06-11 |
Pfizer Inc. |
Cells with reduced inhibitor production and methods of use thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
KR102396194B1
(ko)
|
2018-12-07 |
2022-05-10 |
서울대학교 산학협력단 |
항 c-Met 아고니스트 항체 및 이의 용도
|
KR102433184B1
(ko)
|
2018-12-07 |
2022-08-17 |
서울대학교 산학협력단 |
항 c-Met 아고니스트 항체 및 이의 용도
|
TWI821474B
(zh)
|
2018-12-07 |
2023-11-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Cd3抗體及其藥物用途
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
KR20210148076A
(ko)
|
2018-12-11 |
2021-12-07 |
큐32 바이오 인크. |
보체 연관 질환을 위한 융합 단백질 작제물
|
CN111303283A
(zh)
|
2018-12-12 |
2020-06-19 |
上海君实生物医药科技股份有限公司 |
抗il-17a抗体及其应用
|
US20220010008A1
(en)
|
2018-12-12 |
2022-01-13 |
Shanghai Pharmaexplorer Co., Ltd. |
Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
|
JP2022512401A
(ja)
|
2018-12-13 |
2022-02-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
WO2020120786A1
(en)
|
2018-12-14 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
US20220064325A1
(en)
|
2018-12-17 |
2022-03-03 |
Alligator Bioscience Ab |
Novel polypeptides
|
CN113677703A
(zh)
|
2018-12-17 |
2021-11-19 |
鳄鱼生物科学公司 |
多肽
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
EP3898688A1
(en)
|
2018-12-18 |
2021-10-27 |
Catapult Therapeutics B.V. |
The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
US20220347309A1
(en)
|
2018-12-19 |
2022-11-03 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine resistance
|
EP3898687A1
(en)
|
2018-12-20 |
2021-10-27 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
WO2020128892A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Extended low dose regimens for mdm2 inhibitors
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
KR20210107025A
(ko)
|
2018-12-21 |
2021-08-31 |
제넨테크, 인크. |
세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
AU2019406712A1
(en)
|
2018-12-21 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Antibody that binds to VEGF and IL-1beta and methods of use
|
WO2020127864A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
US20220090125A1
(en)
|
2018-12-21 |
2022-03-24 |
Compass Therapeutics Llc |
Transgenic mouse expressing common human light chain
|
GB201820983D0
(en)
|
2018-12-21 |
2019-02-06 |
Pirbright Inst |
Virus
|
US20220096518A1
(en)
|
2018-12-21 |
2022-03-31 |
Aim Immunotech Inc. |
Compositions and methods for cancer therapy
|
CA3120474A1
(en)
|
2018-12-21 |
2020-06-25 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
BR112021012536A2
(pt)
|
2018-12-26 |
2021-09-14 |
City Of Hope |
Proteínas de ligação anti-ctla4 mascaradas ativáveis
|
EP3902828A1
(en)
|
2018-12-26 |
2021-11-03 |
Innate Pharma |
Compounds and methods for treatment of head and neck cancer
|
CN116813770A
(zh)
|
2018-12-27 |
2023-09-29 |
中山康方生物医药有限公司 |
抗人il-4ra的抗体及其用途
|
BR112021010789A2
(pt)
|
2018-12-27 |
2021-08-31 |
Boehringer Ingelheim International Gmbh |
Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
|
JP2022516505A
(ja)
|
2018-12-28 |
2022-02-28 |
スパークス・セラピューティクス・インコーポレイテッド |
癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法
|
CN113166246A
(zh)
|
2018-12-28 |
2021-07-23 |
四川科伦博泰生物医药股份有限公司 |
一种抗体及其用途
|
JP2022515473A
(ja)
|
2018-12-28 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
免疫応答が増幅された患者における治療的使用のためのペプチド-mhc-i-抗体融合タンパク質
|
CN111378045B
(zh)
|
2018-12-28 |
2022-08-02 |
长春金赛药业有限责任公司 |
二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
CA3125476A1
(en)
|
2019-01-03 |
2020-07-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
BR112021012294A2
(pt)
|
2019-01-07 |
2021-09-08 |
Inhibrx, Inc. |
Polipeptídeos compreendendo polipeptídeos de il-2 modificada e usos dos mesmos
|
CN111434688A
(zh)
|
2019-01-11 |
2020-07-21 |
上海开拓者生物医药有限公司 |
Cd73抗体及其制备方法和应用
|
WO2020146795A1
(en)
|
2019-01-11 |
2020-07-16 |
Omeros Corporation |
Methods and compositions for treating cancer
|
KR20210117277A
(ko)
|
2019-01-13 |
2021-09-28 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴-2에 특이적인 항체
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
TW202043272A
(zh)
|
2019-01-14 |
2020-12-01 |
美商建南德克公司 |
使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
CN109762067B
(zh)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|
US20220111034A1
(en)
|
2019-01-18 |
2022-04-14 |
Université Catholique de Louvain |
Virus compositions
|
MX2021008605A
(es)
|
2019-01-21 |
2021-10-26 |
Sanofi Sa |
Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
|
WO2020154405A2
(en)
|
2019-01-22 |
2020-07-30 |
Genentech, Inc. |
Immunoglobulin a antibodies and methods of production and use
|
SG11202107951YA
(en)
|
2019-01-22 |
2021-08-30 |
Bristol Myers Squibb Co |
Antibodies against il-7r alpha subunit and uses thereof
|
KR20210119454A
(ko)
|
2019-01-22 |
2021-10-05 |
이나뜨 파르마 에스.에이. |
T 세포 림프종의 치료
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
EP3914615A1
(en)
|
2019-01-23 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Methods of producing multimeric proteins in eukaryotic host cells
|
BR112021014574A2
(pt)
|
2019-01-23 |
2021-10-05 |
Encefa |
Competidores cd31 e usos dos mesmos
|
EP3914289A1
(en)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US11419932B2
(en)
|
2019-01-24 |
2022-08-23 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
EP3915581A4
(en)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
|
EP3917957A1
(en)
|
2019-01-28 |
2021-12-08 |
Maple Biotech LLC |
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
AU2019427766A1
(en)
|
2019-01-30 |
2021-09-16 |
Nomocan Pharmaceuticals Llc |
Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
|
PE20220279A1
(es)
|
2019-01-30 |
2022-02-25 |
Scholar Rock Inc |
Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
|
CA3126117A1
(en)
|
2019-02-01 |
2020-08-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
EP3918333A1
(en)
|
2019-02-01 |
2021-12-08 |
NanoView Biosciences, Inc. |
Systems and methods for vesicle cargo labeling and detection
|
EP3693063A1
(en)
|
2019-02-06 |
2020-08-12 |
Diaccurate |
Methods and compositions for treating cancer
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
IL264768A
(en)
|
2019-02-10 |
2020-08-31 |
Sagi Irit |
ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
|
CA3129818A1
(en)
|
2019-02-11 |
2020-08-20 |
Zumutor Biologics, Inc. |
Anti-clec2d antibodies and methods of use thereof
|
EP3924739A1
(en)
|
2019-02-12 |
2021-12-22 |
Biogen MA Inc. |
Biomarkers of progressive multifocal leukoencephalopathy
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
US11478553B2
(en)
|
2019-02-15 |
2022-10-25 |
Wuxi Biologies Ireland Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
WO2020168315A1
(en)
|
2019-02-15 |
2020-08-20 |
Just-Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
SG11202108281UA
(en)
|
2019-02-15 |
2021-08-30 |
Integral Molecular Inc |
Claudin 6 antibodies and uses thereof
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
CA3130240A1
(en)
|
2019-02-18 |
2020-08-27 |
Pfizer Inc. |
Method of treatment of chronic low back pain
|
BR112021016348A2
(pt)
|
2019-02-18 |
2021-11-23 |
Atb Therapeutics |
Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira
|
US20220275059A1
(en)
|
2019-02-20 |
2022-09-01 |
Harbour Antibodies Bv |
Antibodies
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
WO2020172597A1
(en)
|
2019-02-21 |
2020-08-27 |
Tizona Therapeutics |
Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
KR20210142638A
(ko)
|
2019-02-22 |
2021-11-25 |
우한 이지 바이오파마 씨오., 엘티디. |
Cd3 항원 결합 단편 및 이의 응용
|
CA3131033A1
(en)
|
2019-02-22 |
2020-08-27 |
Wuhan Yzy Biopharma Co., Ltd. |
Modified fc fragment, antibodies containing the same and use thereof
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
JP2022521428A
(ja)
|
2019-02-25 |
2022-04-07 |
ザ・ユニバーシティ・オブ・シカゴ |
抗炎症剤に連結されたecm親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
|
EP4378958A2
(en)
|
2019-02-26 |
2024-06-05 |
Inspirna, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
JP2022522185A
(ja)
|
2019-02-27 |
2022-04-14 |
エピアクシス セラピューティクス プロプライエタリー リミテッド |
T細胞機能を評価して治療法に対する応答を予測するための方法および薬剤
|
EP3931220A1
(en)
|
2019-02-27 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
MX2021010441A
(es)
|
2019-03-01 |
2021-09-21 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
|
US20220281990A1
(en)
|
2019-03-01 |
2022-09-08 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
EP3935391B1
(en)
|
2019-03-05 |
2024-04-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Biomarkers for renal cell carcinoma
|
US20200283796A1
(en)
|
2019-03-05 |
2020-09-10 |
Massachusetts Institute Of Technology |
Dna launched rna replicon system (drep) and uses thereof
|
JP2022524338A
(ja)
|
2019-03-05 |
2022-05-02 |
武田薬品工業株式会社 |
拘束され、条件的に活性化された結合タンパク質
|
WO2020180121A1
(ko)
|
2019-03-06 |
2020-09-10 |
주식회사 레고켐 바이오사이언스 |
인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
CA3126728A1
(en)
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
CN113784990A
(zh)
|
2019-03-08 |
2021-12-10 |
丹尼斯科美国公司 |
融合多肽
|
EP3938396A1
(en)
|
2019-03-11 |
2022-01-19 |
Jounce Therapeutics, Inc. |
Anti-icos antibodies for the treatment of cancer
|
CN114040799A
(zh)
|
2019-03-12 |
2022-02-11 |
哈佛大学校长及研究员协会 |
治疗癌症的方法和组合物
|
WO2020182807A1
(en)
|
2019-03-13 |
2020-09-17 |
Merck Patent Gmbh |
Process for the preparation of lipidated proteinaceous structures
|
EA202192508A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
WO2020186176A1
(en)
|
2019-03-14 |
2020-09-17 |
Genentech, Inc. |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
KR20210141990A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
|
JP2022525407A
(ja)
|
2019-03-14 |
2022-05-13 |
ビオンド バイオロジクス リミテッド |
低分子脱落遮断剤
|
WO2020183011A1
(en)
|
2019-03-14 |
2020-09-17 |
Institut Curie |
Htr1d inhibitors and uses thereof in the treatment of cancer
|
US11541086B2
(en)
|
2019-03-14 |
2023-01-03 |
Northwestern Univeristy |
Compositions and methods for treating Alzheimer's disease
|
JP2022524880A
(ja)
|
2019-03-15 |
2022-05-10 |
メドイミューン・リミテッド |
がんの治療における使用のための、アゼチドベンゾジアゼピン二量体及びこれを含む複合体
|
WO2020191082A1
(en)
|
2019-03-18 |
2020-09-24 |
Janssen Pharmaceuticals, Inc. |
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
|
MA55383A
(fr)
|
2019-03-18 |
2022-01-26 |
Janssen Biotech Inc |
Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
|
JP2022525535A
(ja)
|
2019-03-19 |
2022-05-17 |
アルベルト・アインシュタイン・カレッジ・オブ・メディシン |
単純ヘルペスウイルス感染の予防及び処置のためのモノクローナル抗体
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
SG11202109932WA
(en)
|
2019-03-20 |
2021-10-28 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btn2 and uses thereof
|
CN113490502A
(zh)
|
2019-03-21 |
2021-10-08 |
艾洛基治疗公司 |
用于提高TCRαβ+细胞耗竭效率的方法
|
EP3942026A1
(en)
|
2019-03-22 |
2022-01-26 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
CN113661177B
(zh)
|
2019-03-22 |
2024-04-16 |
里珍纳龙药品有限公司 |
EGFR x CD28多特异性抗体
|
CN113631573B
(zh)
|
2019-03-25 |
2024-06-04 |
国家医疗保健研究所 |
抗Tau抗体及其在制备用于治疗疾病的药物中的用途
|
ES2967879T3
(es)
|
2019-03-25 |
2024-05-06 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9
|
CN113811547B
(zh)
|
2019-03-27 |
2024-06-25 |
国家医疗保健研究所 |
具有cd40激活特性的重组蛋白
|
WO2020194317A1
(en)
|
2019-03-28 |
2020-10-01 |
Yeda Research And Development Co. Ltd. |
Method of treating lipid-related disorders
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
WO2020201073A1
(en)
|
2019-03-29 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
KR20210144819A
(ko)
|
2019-03-29 |
2021-11-30 |
브리스톨-마이어스 스큅 컴퍼니 |
크로마토그래피 수지의 소수성을 측정하는 방법
|
PT3946464T
(pt)
|
2019-03-29 |
2022-11-16 |
Medimmune Ltd |
Compostos e seus conjugados
|
AU2020253833A1
(en)
|
2019-03-29 |
2021-10-28 |
Atarga, Llc |
Anti FGF23 antibody
|
CA3133652A1
(en)
|
2019-04-01 |
2020-10-08 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
WO2020201442A1
(en)
|
2019-04-03 |
2020-10-08 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
CA3135032A1
(en)
|
2019-04-03 |
2020-10-08 |
Genzyme Corporation |
Anti-alpha beta tcr binding polypeptides with reduced fragmentation
|
GB201904717D0
(en)
|
2019-04-03 |
2019-05-15 |
Univ London Queen Mary |
Treatment and diagnosis of mental disorders
|
TW202102544A
(zh)
|
2019-04-04 |
2021-01-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
EP3946416A2
(en)
|
2019-04-04 |
2022-02-09 |
Bayer Aktiengesellschaft |
Agonists of adiponectin
|
EP3947470A1
(en)
|
2019-04-05 |
2022-02-09 |
TeneoBio, Inc. |
Heavy chain antibodies binding to psma
|
JP2022528721A
(ja)
|
2019-04-09 |
2022-06-15 |
アブクロ,インク. |
キラー細胞レクチン様受容体サブファミリーgメンバー1(klrg1)除去抗体
|
WO2020208150A1
(en)
|
2019-04-09 |
2020-10-15 |
Hospital For Special Surgery |
Protein binders for irhom2
|
AU2020270920A1
(en)
|
2019-04-12 |
2021-11-04 |
Geltor, Inc. |
Recombinant elastin and production thereof
|
KR20210153092A
(ko)
|
2019-04-15 |
2021-12-16 |
퀴셀 세라퓨틱스 엘엘씨 |
암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물
|
CN117186232A
(zh)
|
2019-04-16 |
2023-12-08 |
四川科伦博泰生物医药股份有限公司 |
抗FXI/FXIa抗体及其用途
|
KR20210148349A
(ko)
|
2019-04-17 |
2021-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
크로마토그래피 수지의 재생 방법
|
JP7501876B2
(ja)
|
2019-04-17 |
2024-06-18 |
国立大学法人広島大学 |
Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
|
WO2020212593A1
(en)
|
2019-04-18 |
2020-10-22 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
EP3956664A1
(en)
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antibody potency assay
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
MX2021012506A
(es)
|
2019-04-19 |
2022-01-24 |
Chugai Pharmaceutical Co Ltd |
Receptor quimerico que reconoce un sitio modificado geneticamente en anticuerpo.
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
MX2021012961A
(es)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
|
JP2022529741A
(ja)
|
2019-04-26 |
2022-06-23 |
アロジーン セラピューティクス,インコーポレイテッド |
同種car t細胞を製造する方法
|
EP3963099A1
(en)
|
2019-04-30 |
2022-03-09 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
|
CN114007642A
(zh)
|
2019-04-30 |
2022-02-01 |
森迪生物科学公司 |
嵌合受体及其使用方法
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
WO2020222573A1
(ko)
|
2019-05-02 |
2020-11-05 |
주식회사 레고켐 바이오사이언스 |
트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
SG11202112120WA
(en)
|
2019-05-03 |
2021-11-29 |
Celgene Corp |
Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
|
EP3962924A1
(en)
|
2019-05-03 |
2022-03-09 |
Genentech, Inc. |
Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3966242A1
(en)
|
2019-05-04 |
2022-03-16 |
Inhibrx, Inc. |
Cd123-binding polypeptides and uses thereof
|
MX2021013417A
(es)
|
2019-05-04 |
2021-12-10 |
Inhibrx Inc |
Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
|
MX2021013416A
(es)
|
2019-05-04 |
2021-12-10 |
Inhibrx Inc |
Polipeptidos de union al antigeno cd33 y sus usos.
|
AR122266A1
(es)
|
2019-05-09 |
2022-08-31 |
Boehringer Ingelheim Int |
Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
|
GB201906578D0
(en)
|
2019-05-09 |
2019-06-26 |
Cancer Research Tech Ltd |
Detection of fusion protein
|
KR20220005568A
(ko)
|
2019-05-09 |
2022-01-13 |
제넨테크, 인크. |
항체의 제조 방법
|
TW202108177A
(zh)
|
2019-05-10 |
2021-03-01 |
日商武田藥品工業股份有限公司 |
抗體藥物結合物
|
CA3137512A1
(en)
|
2019-05-14 |
2020-11-19 |
Werewolf Therapeutics, Inc. |
Separation moieties and methods and use thereof
|
MX2021013825A
(es)
|
2019-05-14 |
2022-01-18 |
Genentech Inc |
Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
|
KR20220009428A
(ko)
|
2019-05-15 |
2022-01-24 |
네오티엑스 테라퓨틱스 엘티디. |
암 치료
|
EP3821250B1
(en)
|
2019-05-16 |
2022-05-04 |
ProciseDx Inc. |
An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
|
JP2022532381A
(ja)
|
2019-05-16 |
2022-07-14 |
プロサイセデクス インコーポレイティド |
Vcam-1及びカルプロテクチンのための分析検出方法
|
TW202100184A
(zh)
|
2019-05-20 |
2021-01-01 |
瑞士商諾華公司 |
Mcl-1抑制劑抗體-藥物結合物及使用方法
|
EP3973281A1
(en)
|
2019-05-20 |
2022-03-30 |
Albert-Ludwigs-Universität Freiburg |
Disposable wearable sensor for continuous monitoring of breath biochemistry
|
JP2022538733A
(ja)
|
2019-05-20 |
2022-09-06 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
新規抗cd25抗体
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
CU20210096A7
(es)
|
2019-05-21 |
2022-06-06 |
Novartis Ag |
Moléculas de unión a cd19
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
US20220251538A1
(en)
|
2019-05-23 |
2022-08-11 |
Matjaz Vogelsang |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
BR112021023487A2
(pt)
|
2019-05-23 |
2022-02-08 |
Ac Immune Sa |
Moléculas de ligação anti-tdp-43 e usos das mesmas
|
US20220235117A1
(en)
|
2019-05-23 |
2022-07-28 |
Xiamen University |
Novel anti-hepatitis b virus antibody and uses thereof
|
WO2020236528A1
(en)
|
2019-05-23 |
2020-11-26 |
Procisedx Inc. |
Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
|
WO2020240360A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
CN113891729A
(zh)
|
2019-05-24 |
2022-01-04 |
赛诺菲 |
治疗系统性硬化症的方法
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
CN114599675A
(zh)
|
2019-05-28 |
2022-06-07 |
上海科技大学 |
用于治疗clouston型外胚层发育不良2的组合物和方法
|
JP2022535534A
(ja)
|
2019-06-03 |
2022-08-09 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
EP3976648A1
(en)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
WO2020247973A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
TW202112799A
(zh)
|
2019-06-05 |
2021-04-01 |
美商建南德克公司 |
過載層析管柱之再生方法
|
EP3980779A1
(en)
|
2019-06-06 |
2022-04-13 |
ProciseDx Inc. |
Detection of hemoglobin a1c (hba1c) in blood
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN114302746A
(zh)
|
2019-06-10 |
2022-04-08 |
Adc治疗有限公司 |
包含抗cd25抗体药物缀合物和另一剂的组合疗法
|
WO2020249528A1
(en)
|
2019-06-10 |
2020-12-17 |
Adc Therapeutics Sa |
Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
CA3140023A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Anti-sortilin antibodies for use in therapy
|
WO2020252257A1
(en)
|
2019-06-12 |
2020-12-17 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
KR20220019785A
(ko)
|
2019-06-12 |
2022-02-17 |
노파르티스 아게 |
나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
TW202108628A
(zh)
|
2019-06-14 |
2021-03-01 |
美商泰尼歐生物公司 |
與c d 2 2 及c d 3 結合之多特異性重鏈抗體
|
US20220259202A1
(en)
|
2019-06-17 |
2022-08-18 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
BR112021025421A2
(pt)
|
2019-06-17 |
2022-02-01 |
Visterra Inc |
Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
|
WO2020254861A1
(en)
|
2019-06-19 |
2020-12-24 |
Ovatrition Ltd. |
Antibody-mediated neutralization of beta-lactamases
|
WO2020257640A1
(en)
|
2019-06-21 |
2020-12-24 |
Vaccinex, Inc. |
Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
|
EP3990922A1
(en)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Detection of anti-tnf alpha drug biologics and anti-drug antibodies
|
GB201909135D0
(en)
|
2019-06-25 |
2019-08-07 |
Institute Of Cancer Res Royal Cancer Hospital |
Means and methods for treating cancer
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
KR20220025829A
(ko)
|
2019-06-25 |
2022-03-03 |
액토움 게엠베하 |
2-구성요소 시스템에서 분석물을 측정하기 위한 방법 및 키트, 및 그 용도
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
KR20220016957A
(ko)
|
2019-06-26 |
2022-02-10 |
에프. 호프만-라 로슈 아게 |
Sirt-1 유전자 녹아웃을 갖는 포유류 세포주
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
MX2021015694A
(es)
|
2019-06-28 |
2022-03-11 |
Genentech Inc |
Composición y métodos para estabilizar formulaciones líquidas de proteínas.
|
GB201909393D0
(en)
|
2019-06-28 |
2019-08-14 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
MX2021015193A
(es)
|
2019-06-28 |
2022-01-18 |
Hoffmann La Roche |
Metodo para la produccion de un anticuerpo.
|
JP2022538674A
(ja)
|
2019-07-01 |
2022-09-05 |
トニックス ファーマ リミテッド |
抗cd154抗体およびその使用
|
EP3994172A1
(en)
|
2019-07-03 |
2022-05-11 |
Oxford BioTherapeutics Ltd |
Antibodies and methods of use
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Pd-1/cd3二重特異性タンパク質による血液がん治療
|
GB2585252A
(en)
|
2019-07-05 |
2021-01-06 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
US20220273810A1
(en)
|
2019-07-08 |
2022-09-01 |
Imcare Biotech, Llc |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
WO2021006212A1
(ja)
|
2019-07-08 |
2021-01-14 |
テルモ株式会社 |
ハイブリドーマおよびその製造方法、並びにモノクローナル抗体およびその製造方法
|
CA3145385A1
(en)
|
2019-07-08 |
2021-01-14 |
Steven D. Goodman |
Antibody compositions for disrupting biofilms
|
TW202116805A
(zh)
|
2019-07-10 |
2021-05-01 |
日商中外製藥股份有限公司 |
Claudin-6結合分子以及其用途
|
BR112022000416A2
(pt)
|
2019-07-11 |
2022-03-03 |
Wuhan Yzy Biopharma Co Ltd |
Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico
|
WO2021005232A1
(en)
|
2019-07-11 |
2021-01-14 |
Umc Utrecht Holding B.V. |
Intranasal administration of neutralising antiviral antibodies
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
WO2021010326A1
(ja)
|
2019-07-12 |
2021-01-21 |
中外製薬株式会社 |
抗変異型fgfr3抗体およびその使用
|
AU2020314129A1
(en)
|
2019-07-15 |
2022-02-24 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-tigit antibodies and application thereof
|
JP2022541900A
(ja)
|
2019-07-15 |
2022-09-28 |
ローザンヌ ユニヴァーシティ ホスピタル |
Hiv結合剤
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
CN114174337A
(zh)
|
2019-07-15 |
2022-03-11 |
英特维特国际股份有限公司 |
针对犬ctla-4的犬源化抗体
|
US20220251234A1
(en)
|
2019-07-16 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
WO2021009740A1
(en)
|
2019-07-16 |
2021-01-21 |
Ramot At Tel-Aviv University Ltd. |
Compositions and methods for the treatment of tuberculosis
|
IL268111A
(en)
|
2019-07-16 |
2021-01-31 |
Fainzilber Michael |
Methods of treating pain
|
KR102489531B1
(ko)
|
2019-07-18 |
2023-01-17 |
주식회사 큐어바이오테라퓨틱스 |
Wrs 단백질에 특이적으로 결합하는 항체 및 이의 용도
|
JP7302093B2
(ja)
|
2019-07-18 |
2023-07-03 |
ジェイダブリュ バイオサイエンス |
Wrsタンパク質に特異的に結合する抗体及びその用途
|
WO2021016062A1
(en)
|
2019-07-19 |
2021-01-28 |
The Children's Hospital Of Philadelphia |
Chimeric antigen receptors containing glypican 2 binding domains
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
EP4004018A1
(en)
|
2019-07-24 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Modified human cytomegalovirus proteins
|
CA3147407A1
(en)
|
2019-07-25 |
2021-01-28 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
WO2021021605A1
(en)
|
2019-07-26 |
2021-02-04 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
JP2022542890A
(ja)
|
2019-07-26 |
2022-10-07 |
アムジエン・インコーポレーテツド |
抗il13抗原結合タンパク質
|
JP7483857B2
(ja)
|
2019-07-26 |
2024-05-15 |
ビステラ, インコーポレイテッド |
インターロイキン-2作用物質およびその使用
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
EP4004548A1
(en)
|
2019-07-29 |
2022-06-01 |
Yeda Research and Development Co. Ltd |
Methods of treating and diagnosing lung cancer
|
TW202118790A
(zh)
|
2019-07-30 |
2021-05-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
EP4008727A4
(en)
|
2019-07-30 |
2024-01-17 |
Akeso Biopharma, Inc. |
HUMANIZED ANTIBODY DIRECTED AGAINST THE P40 PROTEIN DOMAIN AND ITS USE
|
CN114341186A
(zh)
|
2019-07-30 |
2022-04-12 |
魁尔斯弗生物治疗股份有限公司 |
双特异性抗LRRC15和CD3ε抗体
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
WO2021022083A2
(en)
|
2019-07-31 |
2021-02-04 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
BR112022002013A2
(pt)
|
2019-08-02 |
2022-03-29 |
Akeso Pharmaceuticals Inc |
Anticorpo biespecífico anti-ctla4/anti-pd-1 e uso do mesmo
|
WO2021023644A1
(en)
|
2019-08-02 |
2021-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
JP2022543259A
(ja)
|
2019-08-02 |
2022-10-11 |
オレガ・バイオテック |
新規il-17b抗体
|
CA3146474A1
(en)
|
2019-08-02 |
2021-02-11 |
Denis BURGER |
Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
|
CA3146777A1
(en)
|
2019-08-02 |
2021-02-11 |
CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. |
Anti-pd-1 antibody and pharmaceutical use thereof
|
CA3148740A1
(en)
|
2019-08-06 |
2021-02-11 |
Aprinoia Therapeutics Limited |
Antibodies that bind to pathological tau species and uses thereof
|
EP4031658A1
(en)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Improved horseradish peroxidase polypeptides
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
MX2022001732A
(es)
|
2019-08-12 |
2022-05-06 |
Purinomia Biotech Inc |
Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
|
WO2021028921A1
(en)
|
2019-08-12 |
2021-02-18 |
Biond Biologics Ltd. |
Antibodies against ilt2 and use thereof
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
KR20220047826A
(ko)
|
2019-08-16 |
2022-04-19 |
리제너론 파마슈티칼스 인코포레이티드 |
고 농도의 항-c5 제형
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
US20240140988A1
(en)
|
2019-08-22 |
2024-05-02 |
Ariel Scientific Innovations Ltd. |
Scaled-up methods for purifying antibodies
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
EP3789401A1
(en)
|
2019-09-03 |
2021-03-10 |
Gamamabs Pharma |
Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
|
US20220348650A1
(en)
|
2019-09-03 |
2022-11-03 |
Bio-Thera Solutions, Ltd. |
Anti-tigit immunosuppressant and application thereof
|
KR20220053665A
(ko)
|
2019-09-03 |
2022-04-29 |
아케소 바이오파마, 인크. |
항-cd47 단일클론 항체 및 이의 용도
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
WO2021044009A1
(en)
|
2019-09-04 |
2021-03-11 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) |
Herv inhibitors for use in treating tauopathies
|
KR20220084033A
(ko)
|
2019-09-04 |
2022-06-21 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Il20-rb에 대해 특이적인 항체 및 만성 폐쇄성 폐 질환의 급성 악화를 치료하기 위한 이의 용도
|
AR119887A1
(es)
|
2019-09-04 |
2022-01-19 |
Genentech Inc |
Agentes de unión a cd8 y sus usos
|
CN114615999B
(zh)
|
2019-09-05 |
2024-03-08 |
法马马有限公司 |
药物抗体偶联物
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
CN114901699A
(zh)
|
2019-09-11 |
2022-08-12 |
英凯尔生物科技有限责任公司 |
抗丝氨酸蛋白酶抑制剂kazal(spik)抗体的表位
|
WO2021048852A1
(en)
|
2019-09-11 |
2021-03-18 |
Yeda Research And Development Co. Ltd. |
Methods of treating breast cancer
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP4028053A1
(en)
|
2019-09-11 |
2022-07-20 |
Bausch Health Ireland Limited |
Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
|
EP4028054A1
(en)
|
2019-09-12 |
2022-07-20 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP3792632A1
(en)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immunotherapy markers
|
BR112022004674A2
(pt)
|
2019-09-17 |
2022-06-07 |
Merck Patent Gmbh |
Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
JP2022548078A
(ja)
|
2019-09-18 |
2022-11-16 |
モレキュラー テンプレーツ,インク. |
志賀毒素aサブユニット足場を含むpd-l1結合分子
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
KR20220084056A
(ko)
|
2019-09-19 |
2022-06-21 |
씨젠 인크. |
내재화된 생물학적 활성 화합물 컨쥬게이트로부터의 선택적 약물 방출
|
WO2021055694A1
(en)
|
2019-09-20 |
2021-03-25 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
US20230125690A1
(en)
|
2019-09-20 |
2023-04-27 |
Jae-sung Bae |
Antibody for detecting acetylation of cox2 protein, and uses thereof
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
WO2021060439A1
(ja)
|
2019-09-26 |
2021-04-01 |
日油株式会社 |
ペプチドリンカーを有するヘテロ二官能性単分散ポリエチレングリコール
|
CN114729045A
(zh)
|
2019-09-26 |
2022-07-08 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
EP4034561A2
(en)
|
2019-09-27 |
2022-08-03 |
Starkage Therapeutics |
Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
PE20221110A1
(es)
|
2019-09-27 |
2022-07-11 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
WO2021058744A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
CN114450304B
(zh)
|
2019-09-27 |
2023-12-12 |
国家医疗保健研究所 |
抗苗勒管抑制物质抗体及其用途
|
US11760801B2
(en)
|
2019-09-27 |
2023-09-19 |
Janssen Biotech, Inc. |
Anti-CEACAM antibodies and uses thereof
|
US20220281997A1
(en)
|
2019-09-27 |
2022-09-08 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-VHH Domain Antibodies and Use Thereof
|
CA3151450A1
(en)
|
2019-09-30 |
2021-04-08 |
Matthias Schneider |
Protein binders to irhom2 epitopes
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
KR20220070201A
(ko)
|
2019-09-30 |
2022-05-30 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
항-pd-1 항체 및 이의 용도
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
EP4041397A1
(en)
|
2019-10-01 |
2022-08-17 |
Epsilogen Ltd |
Hybrid antibody
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
WO2021064180A1
(en)
|
2019-10-03 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
CA3152316A1
(en)
|
2019-10-04 |
2021-04-08 |
Scott C. Jeffrey |
Camptothecin peptide conjugates
|
IL291902A
(en)
|
2019-10-04 |
2022-06-01 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific binding properties
|
KR20220078634A
(ko)
|
2019-10-04 |
2022-06-10 |
메르크 파텐트 게엠베하 |
단백질 a 친화성 크로마토그래피에서 모노클로날 항체의 용리
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
CA3156649A1
(en)
|
2019-10-04 |
2021-04-08 |
Merck Patent Gmbh |
PROTEIN PURIFICATION AND VIRAL INACTIVATION
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
US20220370605A1
(en)
|
2019-10-08 |
2022-11-24 |
Luxembourg Institute Of Health (Lih) |
Inhibitor of DJ-1 for Use in Treating Immunoaging
|
JP2022552282A
(ja)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
グリコシル化lag3に対して特異的な抗体およびその使用方法
|
EP3804754A1
(en)
|
2019-10-09 |
2021-04-14 |
OSE Immunotherapeutics |
Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
EP4045090A1
(en)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CA3153850A1
(en)
|
2019-10-18 |
2021-04-22 |
Teri Heiland |
Improved lamp constructs comprising cancer antigens
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
GB201915163D0
(en)
|
2019-10-18 |
2019-12-04 |
Univ Southampton |
Cancer vaccine
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
US20240123081A1
(en)
|
2019-10-25 |
2024-04-18 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
EP4048691A1
(en)
|
2019-10-25 |
2022-08-31 |
Regeneron Pharmaceuticals, Inc. |
Dosing regimens for treating or preventing c5-associated diseases
|
TW202137984A
(zh)
|
2019-10-29 |
2021-10-16 |
日商衛材R&D企管股份有限公司 |
用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
|
CA3154413A1
(en)
|
2019-11-01 |
2021-05-06 |
Yan Lan |
Combined inhibition of pd-1, tgf.beta. and atm together with radiotherapy for the treatment of cancer
|
EP4054591A1
(en)
|
2019-11-04 |
2022-09-14 |
Astrazeneca AB |
Combination therapy for treating cancer
|
WO2021091960A1
(en)
|
2019-11-05 |
2021-05-14 |
Jounce Therapeutics, Inc. |
Methods of treating cancer with anti-pd-1 antibodies
|
IL292757A
(en)
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Tigit antibodies and their uses
|
CA3155219A1
(en)
|
2019-11-05 |
2021-05-14 |
Merck Patent Gmbh |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
AU2020380603A1
(en)
|
2019-11-07 |
2022-06-02 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
JP2023500889A
(ja)
|
2019-11-07 |
2023-01-11 |
イン3バイオ・リミテッド |
非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
AU2020382621A1
(en)
|
2019-11-13 |
2022-06-02 |
Amunix Pharmaceuticals, Inc. |
Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same
|
MX2022005904A
(es)
|
2019-11-15 |
2022-09-07 |
Pliant Therapeutics Inc |
Composiciones y metodos para la activacion de integrinas.
|
EP4057980A1
(en)
|
2019-11-15 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in aqueous protein solutions
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
KR20220106775A
(ko)
|
2019-11-20 |
2022-07-29 |
버베리안 노딕 에이/에스 |
암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
|
US11774451B2
(en)
|
2019-11-21 |
2023-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Molecular vibrational spectroscopic markers for detection of cancer
|
CN114787181A
(zh)
|
2019-11-21 |
2022-07-22 |
Inserm(法国国家健康医学研究院) |
用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
|
JP2023503429A
(ja)
|
2019-11-22 |
2023-01-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる、急性骨髄性白血病の処置のための、アドレノメデュリン阻害剤
|
CA3162748A1
(en)
|
2019-11-25 |
2021-06-03 |
Akeso Biopharma, Inc. |
Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
|
CN110894238B
(zh)
|
2019-11-25 |
2021-01-19 |
华道(上海)生物医药有限公司 |
Car-t细胞的检测用单克隆抗体、试剂盒及应用
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
IL293545A
(en)
|
2019-12-04 |
2022-08-01 |
Univ Leland Stanford Junior |
Improving blood-brain barrier drug transport by targeting endogenous regulators
|
US20230034584A1
(en)
|
2019-12-04 |
2023-02-02 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
US20210221886A1
(en)
|
2019-12-05 |
2021-07-22 |
Sorrento Therapeutics, Inc. |
Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
|
EP3986937A1
(en)
|
2019-12-05 |
2022-04-27 |
Alector LLC |
Methods of use of anti-trem2 antibodies
|
MX2022006751A
(es)
|
2019-12-06 |
2022-08-19 |
Regeneron Pharma |
Minitrampas de vegf y metodos de uso de las mismas.
|
JP2023504736A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Gprc5d標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
WO2021111005A1
(en)
|
2019-12-06 |
2021-06-10 |
Thoas Fioretos |
Novel agents and uses thereof
|
EP4073516A1
(en)
|
2019-12-09 |
2022-10-19 |
Celcuity Inc. |
Methods of treating cancer patients with ras node or rtk targeted therapeutic agents
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
EP4073120A2
(en)
|
2019-12-09 |
2022-10-19 |
Genentech, Inc. |
Anti-pd-l1 antibody formulations
|
IL293772A
(en)
|
2019-12-12 |
2022-08-01 |
Alector Llc |
Methods for using anti-cd33 antibodies
|
IL293827A
(en)
|
2019-12-13 |
2022-08-01 |
Alector Llc |
Anti-mertko antibodies and methods of using them
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
BR112022012075A2
(pt)
|
2019-12-17 |
2022-08-30 |
Chinook Therapeutics Inc |
Métodos para tratar nefropatia por iga com atrasentan
|
MX2022006578A
(es)
|
2019-12-17 |
2022-07-04 |
Pfizer |
Anticuerpos especificos para cd47, pd-l1 y sus usos.
|
MX2022007613A
(es)
|
2019-12-18 |
2022-07-19 |
Teneofour Inc |
Union de anticuerpos de cadena pesada a cd38.
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
JP2023507083A
(ja)
|
2019-12-19 |
2023-02-21 |
クイデル コーポレーション |
モノクローナル抗体融合物
|
JP2023509373A
(ja)
|
2019-12-20 |
2023-03-08 |
ノヴァロック バイオセラピューティクス, リミテッド |
抗インターロイキン-23 p19抗体およびそれの使用方法
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
EP4077380A1
(en)
|
2019-12-20 |
2022-10-26 |
Intervet International B.V. |
Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
|
CA3162031A1
(en)
|
2019-12-20 |
2021-06-24 |
Mohamad Morsey |
Canine interleukin-4 receptor alpha antibodies
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
MX2022007798A
(es)
|
2019-12-23 |
2022-07-19 |
Eisai R&D Man Co Ltd |
Metodo de produccion de conjugado de anticuerpo-farmaco a base de eribulina.
|
PE20221186A1
(es)
|
2019-12-23 |
2022-08-05 |
Genentech Inc |
Anticuerpos especificos de apolipoproteina l1 y metodos de uso
|
IL294218A
(en)
|
2019-12-27 |
2022-08-01 |
Chiome Bioscience Inc |
Antibody against cdcp1
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
AU2020414409A1
(en)
|
2019-12-27 |
2022-06-16 |
Affimed Gmbh |
Method for the production of bispecific FcyRIIl x CD30 antibody construct
|
EP4084808A1
(en)
|
2019-12-30 |
2022-11-09 |
City of Hope |
Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
CN115243763A
(zh)
|
2020-01-08 |
2022-10-25 |
里珍纳龙药品有限公司 |
治疗进行性骨化性纤维发育不良
|
EP4087657A1
(en)
|
2020-01-08 |
2022-11-16 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
AU2021205433A1
(en)
|
2020-01-11 |
2022-08-18 |
Scholar Rock, Inc. |
Tgfß inhibitors and use thereof
|
EP4087659A2
(en)
|
2020-01-11 |
2022-11-16 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
JP2023510847A
(ja)
|
2020-01-13 |
2023-03-15 |
ジャウンス セラピューティックス, インク. |
癌の治療方法
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
WO2021144426A1
(en)
|
2020-01-17 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
EP4090681A1
(en)
|
2020-01-17 |
2022-11-23 |
Biolegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのtim-3阻害剤と低メチル化剤とを含む組合せ
|
CN113138276B
(zh)
|
2020-01-19 |
2022-09-16 |
厦门万泰凯瑞生物技术有限公司 |
用于检测HBcAg的方法及抗体
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
IL272194A
(en)
|
2020-01-22 |
2021-07-29 |
Yeda Res & Dev |
Multi-target antibodies for use in the treatment of diseases
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
MX2022009052A
(es)
|
2020-01-22 |
2022-08-15 |
Medimmune Ltd |
Compuestos y conjugados de estos.
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods of treating cancer with an antibody to an anti-ti antagonist
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021151974A1
(en)
|
2020-01-28 |
2021-08-05 |
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis |
Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
|
JP2023513003A
(ja)
|
2020-01-29 |
2023-03-30 |
インヒブルクス インコーポレイテッド |
Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
|
IL272390A
(en)
|
2020-01-30 |
2021-08-31 |
Yeda Res & Dev |
Cancer treatment methods
|
IL272389A
(en)
|
2020-01-30 |
2021-08-31 |
Yeda Res & Dev |
Kits containing antibodies to PD-L1 and their uses in therapy
|
EP4096647A1
(en)
|
2020-01-30 |
2022-12-07 |
Yeda Research and Development Co. Ltd |
Treating acute liver disease with tlr-mik inhibitors
|
MX2022009391A
(es)
|
2020-01-31 |
2022-09-26 |
Genentech Inc |
Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
BR102020002165A2
(pt)
|
2020-01-31 |
2021-11-30 |
Fundação Oswaldo Cruz |
Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas.
|
CA3160557A1
(en)
|
2020-01-31 |
2021-08-05 |
Innate Pharma |
Treatment of cancer
|
JP2023513059A
(ja)
|
2020-01-31 |
2023-03-30 |
ザ クリーブランド クリニック ファウンデーション |
抗ミューラー管ホルモン受容体2抗体及び使用方法
|
JP2023512684A
(ja)
|
2020-02-03 |
2023-03-28 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Sars-cov-2に対する抗体およびそれを使用する方法
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
WO2021156329A1
(en)
|
2020-02-05 |
2021-08-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
AU2021218927A1
(en)
|
2020-02-10 |
2022-09-22 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
EP4105237A4
(en)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co., Ltd. |
ANTI-CLDN18.2 ANTIBODIES AND ITS USE
|
EP4103619A1
(en)
|
2020-02-10 |
2022-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-tmprss2 antibodies and antigen-binding fragments
|
CA3166949A1
(en)
|
2020-02-11 |
2021-08-19 |
James E. Crowe |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
JP2023513312A
(ja)
|
2020-02-13 |
2023-03-30 |
アムジェン インコーポレイテッド |
ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法
|
WO2021163588A1
(en)
|
2020-02-13 |
2021-08-19 |
Amgen Inc. |
Treatment of atopic dermatitis with anti-tslp antibody
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
US11692038B2
(en)
|
2020-02-14 |
2023-07-04 |
Gilead Sciences, Inc. |
Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
AR121368A1
(es)
|
2020-02-18 |
2022-06-01 |
Amgen Inc |
Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
|
CN115484971A
(zh)
|
2020-02-19 |
2022-12-16 |
艾琳治疗公司 |
靶向蛋白的分子
|
KR20220143701A
(ko)
|
2020-02-19 |
2022-10-25 |
에린 테라퓨틱스 |
돌연변이체 ras 단백질을 표적화하는 분자
|
JP2023527609A
(ja)
|
2020-02-21 |
2023-06-30 |
ハープーン セラピューティクス,インク. |
Flt3結合タンパク質および使用方法
|
JP2023515480A
(ja)
|
2020-02-21 |
2023-04-13 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗il-2抗体、その抗原結合断片及びその医薬用途
|
US20230159637A1
(en)
|
2020-02-24 |
2023-05-25 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2021173773A1
(en)
|
2020-02-25 |
2021-09-02 |
Mediboston, Inc. |
Camptothecin derivatives and conjugates thereof
|
MX2022010537A
(es)
|
2020-02-26 |
2022-09-21 |
Vir Biotechnology Inc |
Anticuerpos contra el coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2) y metodos de uso de los mismos.
|
KR20220147642A
(ko)
|
2020-02-27 |
2022-11-03 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Il4r에 결합하는 항체 및 이의 용도
|
WO2021170071A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
BR112022016999A2
(pt)
|
2020-02-28 |
2022-10-25 |
Genzyme Corp |
Polipeptídeos de ligação modificados para conjugação de fármacos otimizada
|
CN115427458A
(zh)
|
2020-02-28 |
2022-12-02 |
塔拉克治疗公司 |
转谷氨酰胺酶介导的缀合
|
EP4110810A1
(en)
|
2020-02-28 |
2023-01-04 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
MX2022010955A
(es)
|
2020-03-03 |
2022-10-07 |
Array Biopharma Inc |
Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida.
|
AU2021229611A1
(en)
|
2020-03-03 |
2022-10-27 |
Active Biotech Ab |
Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
|
WO2021175954A1
(en)
|
2020-03-04 |
2021-09-10 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btnl8 and uses thereof
|
WO2021176034A1
(en)
|
2020-03-05 |
2021-09-10 |
Umc Utrecht Holding B.V. |
Membrane ubiquitin ligases to target protein degradation
|
US20230184745A1
(en)
|
2020-03-05 |
2023-06-15 |
Umc Utrecht Holding B.V. |
Screening method for effective target - E3 ligase combinations
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
US20230126689A1
(en)
|
2020-03-06 |
2023-04-27 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
JP2023517611A
(ja)
|
2020-03-10 |
2023-04-26 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
Il-6/il-6r抗体の組成物及びその使用方法
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
NPM1c陽性がんの免疫療法のための組成物および方法
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
IL296256A
(en)
|
2020-03-13 |
2022-11-01 |
Genentech Inc |
Antibodies against interleukin-33 and uses thereof
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
CN117551194A
(zh)
|
2020-03-19 |
2024-02-13 |
基因泰克公司 |
同种型选择性抗TGF-β抗体及使用方法
|
IL296546A
(en)
|
2020-03-20 |
2022-11-01 |
Inst Nat Sante Rech Med |
Chimeric receptor for human cd45rc-specific antigen and its uses
|
WO2021186024A1
(en)
|
2020-03-20 |
2021-09-23 |
Centre National De La Recherche Scientifique (Cnrs) |
New anti-vegfc antibodies and uses thereof
|
WO2021194860A1
(en)
|
2020-03-23 |
2021-09-30 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
GB202004189D0
(en)
|
2020-03-23 |
2020-05-06 |
Bergenbio As |
Combination therapy
|
WO2021194861A1
(en)
|
2020-03-23 |
2021-09-30 |
Genentech, Inc. |
Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
|
US20240025991A1
(en)
|
2020-03-23 |
2024-01-25 |
Genentech, Inc. |
Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
|
TW202144419A
(zh)
|
2020-03-24 |
2021-12-01 |
美商建南德克公司 |
Tie2結合劑及其使用方法
|
CN113444171A
(zh)
|
2020-03-25 |
2021-09-28 |
兴盟生物医药(苏州)有限公司 |
金黄色葡萄球菌α-毒素特异性抗体及其应用
|
LT4045533T
(lt)
|
2020-03-26 |
2024-02-26 |
Vanderbilt University |
Žmogaus monokloniniai antikūnai prieš sunkaus ūminio respiracinio sindromo koronavirusą 2 (sars-cov-2)
|
WO2021195464A2
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
EP4130036A4
(en)
|
2020-03-30 |
2024-05-15 |
National Cancer Center |
ANTIBODY-DRUG CONJUGATE
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
US11045546B1
(en)
|
2020-03-30 |
2021-06-29 |
Cytodyn Inc. |
Methods of treating coronavirus infection
|
EP4126940A1
(en)
|
2020-03-30 |
2023-02-08 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and pdgf-b and methods of use
|
WO2021197340A1
(zh)
|
2020-03-31 |
2021-10-07 |
百奥泰生物制药股份有限公司 |
用于治疗冠状病毒的抗体、融合蛋白及其应用
|
GB202004677D0
(en)
|
2020-03-31 |
2020-05-13 |
Alligator Bioscience Ab |
Methods and compositions
|
CA3173519A1
(en)
|
2020-03-31 |
2021-10-07 |
Vishnu Priyanka Reddy CHICHILI |
Method for producing multispecific antigen-binding molecules
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
CA3170570A1
(en)
|
2020-04-01 |
2021-10-07 |
James J. KOBIE |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
US20210311054A1
(en)
|
2020-04-01 |
2021-10-07 |
Institut Pasteur |
Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
|
US11815513B2
(en)
|
2020-04-01 |
2023-11-14 |
Institut Pasteur |
Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
|
JP7116256B1
(ja)
|
2020-04-02 |
2022-08-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗sars-cov-2-スパイク糖タンパク質抗体および抗原結合断片
|
US20240183826A9
(en)
|
2020-04-02 |
2024-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
CN116710146A
(zh)
|
2020-04-03 |
2023-09-05 |
威特拉公司 |
抗体分子-药物偶联物及其用途
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
MX2022012182A
(es)
|
2020-04-03 |
2022-12-08 |
Alector Llc |
Metodos de uso de anticuerpos anti-trem2.
|
CA3179348A1
(en)
|
2020-04-06 |
2021-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
KR20210124867A
(ko)
|
2020-04-06 |
2021-10-15 |
하. 룬드벡 아크티에셀스카브 |
항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
|
CA3179416A1
(en)
|
2020-04-07 |
2021-10-14 |
Albert Einstein College Of Medicine |
Method of treating and preventing ocular disease with hsv-2 delta gd
|
US20230132275A1
(en)
|
2020-04-08 |
2023-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cdon inhibitors for the treatment of endothelial dysfunction
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
WO2021204713A1
(en)
|
2020-04-08 |
2021-10-14 |
Bergenbio Asa |
Axl inhibitors for antiviral therapy
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
US20230173093A1
(en)
|
2020-04-10 |
2023-06-08 |
Seagen Inc. |
Charge variant linkers
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
BR112022020706A2
(pt)
|
2020-04-14 |
2022-11-29 |
Vir Biotechnology Inc |
Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
|
EP4135841A1
(en)
|
2020-04-15 |
2023-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
GB2594084A
(en)
|
2020-04-17 |
2021-10-20 |
Bertrand Marie Rene Joseph |
Medical methods and medical uses
|
JP2023522030A
(ja)
|
2020-04-17 |
2023-05-26 |
ゾエティス・サービシーズ・エルエルシー |
ネコ科動物抗体バリアント
|
WO2021209824A1
(en)
|
2020-04-17 |
2021-10-21 |
Institut Pasteur |
Methods and products for serological analysis of sars-cov-2 infection
|
CN113527485A
(zh)
|
2020-04-17 |
2021-10-22 |
上海麦济生物技术有限公司 |
抗人白细胞介素-4受体α抗体及其制备方法和应用
|
US20230242635A1
(en)
|
2020-04-17 |
2023-08-03 |
Zoetis Services Llc |
Canine antibody variants
|
EP4139358A1
(en)
|
2020-04-20 |
2023-03-01 |
Jounce Therapeutics, Inc. |
Compositions and methods for vaccination and the treatment of infectious diseases
|
GB202005779D0
(en)
|
2020-04-21 |
2020-06-03 |
Scancell Ltd |
Anti-tumour immune responses
|
IL297028A
(en)
|
2020-04-21 |
2022-12-01 |
Pharma Mar Sa |
Drug-antibody conjugates
|
WO2021213475A1
(zh)
|
2020-04-22 |
2021-10-28 |
中山康方生物医药有限公司 |
抗cd73-抗pd-1双特异性抗体及其用途
|
BR112022021397A2
(pt)
|
2020-04-22 |
2023-02-07 |
Akeso Biopharma Inc |
Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
GB202006072D0
(en)
|
2020-04-24 |
2020-06-10 |
Bergenbio Asa |
Method of selecting patients for treatment with cmbination therapy
|
WO2021214221A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
|
KR20230005176A
(ko)
|
2020-04-24 |
2023-01-09 |
사노피 |
항-ceacam5 항체 콘쥬게이트 및 세툭시맙을 함유하는 항종양 조합물
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods for using anti-cd79b immunoconjugates
|
WO2021214222A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
|
MX2022013173A
(es)
|
2020-04-24 |
2022-11-30 |
Hoffmann La Roche |
Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
|
CN115427082A
(zh)
|
2020-04-24 |
2022-12-02 |
赛诺菲 |
含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
EP3921034A2
(en)
|
2020-04-28 |
2021-12-15 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
CN115885050A
(zh)
|
2020-04-28 |
2023-03-31 |
基因泰克公司 |
用于非小细胞肺癌免疫疗法的方法和组合物
|
TW202330622A
(zh)
|
2020-04-29 |
2023-08-01 |
美商泰尼歐生物公司 |
具有經修飾重鏈恆定區之多特異性重鏈抗體
|
EP4142791A1
(en)
|
2020-04-29 |
2023-03-08 |
TeneoOne, Inc. |
Methods of treating multiple myeloma
|
US20230203161A1
(en)
|
2020-04-29 |
2023-06-29 |
Teneobio, Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
BR112022022045A2
(pt)
|
2020-04-30 |
2023-01-10 |
Sairopa B V |
Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
TW202204420A
(zh)
|
2020-04-30 |
2022-02-01 |
美商建南德克公司 |
Kras特異性抗體及其用途
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
US11643388B2
(en)
|
2020-05-01 |
2023-05-09 |
The Regents Of The University Of California |
Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
EP4146283A1
(en)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
US20230331846A1
(en)
|
2020-05-04 |
2023-10-19 |
Inhibrx, Inc. |
Canine PD-1-Binding Polypeptides and Uses Thereof
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
KR20230010676A
(ko)
|
2020-05-08 |
2023-01-19 |
비르 바이오테크놀로지, 인코포레이티드 |
Sars-cov-2에 대한 항체
|
EP4146327A1
(en)
|
2020-05-08 |
2023-03-15 |
Novocure GmbH |
Compositions and methods of applying alternating electric fields to pluripotent stem cells
|
EP3909601A1
(en)
|
2020-05-11 |
2021-11-17 |
LeukoCom GmbH |
A novel antibody binding specifically to human ceacam1/3/5 and use thereof
|
EP4151652A4
(en)
|
2020-05-12 |
2024-06-05 |
Biotheus Inc. |
ANTI-CD73 ANTIBODIES AND USE THEREOF
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
MX2022014243A
(es)
|
2020-05-12 |
2022-12-02 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Proteina de union al antigeno st2.
|
JP2023524854A
(ja)
|
2020-05-13 |
2023-06-13 |
ファイザー・インク |
がんを処置するための方法、治療、および使用
|
US20230183366A1
(en)
|
2020-05-13 |
2023-06-15 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Recombinant proteins with ox40 activating properties
|
WO2021228141A1
(zh)
|
2020-05-15 |
2021-11-18 |
四川科伦博泰生物医药股份有限公司 |
抗体药物缀合物及其制备方法和用途
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
JP2023526529A
(ja)
|
2020-05-19 |
2023-06-21 |
アンスティテュ・クリー |
サイトカイン放出症候群の診断及び処置の方法
|
WO2021233853A1
(en)
|
2020-05-19 |
2021-11-25 |
F. Hoffmann-La Roche Ag |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4389146A2
(en)
|
2020-05-22 |
2024-06-26 |
Philogen S.p.A. |
Tnf-a immunoconjugate therapy for the treatment of brain tumors
|
EP4157343A2
(en)
|
2020-05-26 |
2023-04-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
|
CA3179819A1
(en)
|
2020-05-26 |
2021-12-02 |
Alina Baum |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
WO2021239666A1
(en)
|
2020-05-26 |
2021-12-02 |
Diaccurate |
Therapeutic methods
|
MX2022014974A
(es)
|
2020-05-26 |
2023-01-11 |
Boehringer Ingelheim Int |
Anticuerpos anti-pd-1.
|
EP4157881A1
(en)
|
2020-05-27 |
2023-04-05 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
FR3110838B1
(fr)
|
2020-05-28 |
2022-06-24 |
Commissariat Energie Atomique |
Complexe immunomodulateur et ses applications pour la thérapie
|
KR20230018425A
(ko)
|
2020-05-29 |
2023-02-07 |
23앤드미 인코포레이티드 |
항-cd200r1 항체 및 이의 사용 방법
|
EP4157874A2
(en)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
CN113754766A
(zh)
|
2020-06-02 |
2021-12-07 |
明慧医药(上海)有限公司 |
抗b7-h3抗体及其制备和应用
|
CA3185858A1
(en)
|
2020-06-02 |
2021-12-09 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
WO2021245224A1
(en)
|
2020-06-05 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
IL298053A
(en)
|
2020-06-05 |
2023-01-01 |
Eisai R&D Man Co Ltd |
Antibody-drug conjugates against bcma and methods of use
|
US20230398116A1
(en)
|
2020-06-08 |
2023-12-14 |
Y's Ac Co., Ltd. |
Agent for reversing resistance to anticancer drugs
|
US20220119513A1
(en)
|
2020-06-08 |
2022-04-21 |
Zoetis Services Llc |
Anti-tgfb antibodies and therapeutic uses thereof
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
WO2021250026A1
(en)
|
2020-06-08 |
2021-12-16 |
Acticor Biotech |
Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
AU2021288224A1
(en)
|
2020-06-11 |
2023-01-05 |
Novartis Ag |
ZBTB32 inhibitors and uses thereof
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
EP4163301A4
(en)
|
2020-06-11 |
2023-12-06 |
National University Corporation Kochi University |
HUMANIZED ANTI-GPC-1 ANTIBODY
|
WO2021252708A1
(en)
|
2020-06-11 |
2021-12-16 |
President And Fellows Of Harvard College |
Stabilized trioxacarcin antibody drug conjugates and uses thereof
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
EP4165077A1
(en)
|
2020-06-12 |
2023-04-19 |
VIR Biotechnology, Inc. |
Antibody therapies for sars-cov-2 infection
|
WO2021257497A1
(en)
|
2020-06-15 |
2021-12-23 |
Sarepta Therapeutis, Inc. |
Adeno-associated virus antibodies and fragments thereof
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
CA3175784A1
(en)
|
2020-06-17 |
2021-12-23 |
Kunwar Shailubhai |
Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
|
BR112022025801A2
(pt)
|
2020-06-18 |
2023-10-03 |
Hoffmann La Roche |
Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
JP2023531678A
(ja)
|
2020-06-22 |
2023-07-25 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
加齢筋肉、萎縮性筋肉、または異栄養性筋肉の処置のためのtsp-1阻害物質
|
WO2021259963A1
(en)
|
2020-06-23 |
2021-12-30 |
Pandora Endocrine Innovation B.V. |
Immunization against wnt4 for treatment and prophylaxis of breast cancer
|
BR112022026639A2
(pt)
|
2020-06-24 |
2023-05-09 |
Visterra Inc |
Moléculas de anticorpos para april e seus usos
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
US20230305023A1
(en)
|
2020-06-25 |
2023-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment and diagnostic of pathological conditions associated with intense stress
|
US20230265175A1
(en)
|
2020-06-25 |
2023-08-24 |
Merck Sharp & Dohme Llc |
High affinity antibodies targeting tau phosphorylated at serine 413
|
BR112022025667A2
(pt)
|
2020-06-26 |
2023-03-07 |
Pfizer |
Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
|
WO2022005883A1
(en)
|
2020-06-29 |
2022-01-06 |
Zoetis Services Llc |
Feline antibody variants for improving stability
|
CN115916834A
(zh)
|
2020-06-29 |
2023-04-04 |
基因泰克公司 |
帕妥珠单抗加曲妥珠单抗的固定剂量组合
|
CA3189297A1
(en)
|
2020-06-30 |
2022-01-06 |
Nathan Trinklein |
Multi-specific antibodies binding to bcma
|
US20230250173A1
(en)
|
2020-07-01 |
2023-08-10 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
JP2023532904A
(ja)
|
2020-07-02 |
2023-08-01 |
インヒブルクス インコーポレイテッド |
修飾il-2ポリペプチドを含むポリペプチド及びその使用
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
EP3933035A1
(en)
|
2020-07-03 |
2022-01-05 |
Aarhus Universitet |
Compositions comprising extracellular vesicles and sting stimulatory agents
|
WO2022010798A1
(en)
|
2020-07-06 |
2022-01-13 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
WO2022010797A2
(en)
|
2020-07-07 |
2022-01-13 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
CN116133689A
(zh)
|
2020-07-07 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
作为治疗性蛋白质制剂的稳定剂的替代表面活性剂
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
EP4178530A1
(en)
|
2020-07-09 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Concentrated compositions of proteins, their preparation and use thereof
|
EP4178618A1
(en)
|
2020-07-10 |
2023-05-17 |
Universiteit Gent |
Dyes for use in a method of photoporation of the inner limiting membrane
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
AU2021303508A1
(en)
|
2020-07-10 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
CN115812149A
(zh)
|
2020-07-13 |
2023-03-17 |
基因泰克公司 |
用于预测多肽免疫原性的基于细胞的方法
|
AU2021307516A1
(en)
|
2020-07-13 |
2023-03-02 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-CLDN-18.2 antibody and use thereof
|
KR20230037560A
(ko)
|
2020-07-14 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
고정 용량 조합에 대한 분석
|
JP2023535162A
(ja)
|
2020-07-15 |
2023-08-16 |
ユニヴェルシテ リーブル ド ブリュッセル |
抗新生物薬に対する感受性を決定するための方法
|
IL299586A
(en)
|
2020-07-16 |
2023-03-01 |
Novartis Ag |
Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
|
CN116323668A
(zh)
|
2020-07-17 |
2023-06-23 |
辉瑞公司 |
治疗性抗体及其用途
|
EP4182475A2
(en)
|
2020-07-17 |
2023-05-24 |
Onena Medicines S.L. |
Antibodies against lefty proteins
|
WO2022016037A1
(en)
|
2020-07-17 |
2022-01-20 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
EP4201958A1
(en)
|
2020-07-21 |
2023-06-28 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-ctla-4 antibody and use thereof
|
EP4185610A2
(en)
|
2020-07-21 |
2023-05-31 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
TW202216215A
(zh)
|
2020-07-21 |
2022-05-01 |
美商建南德克公司 |
Brm降解之抗體結合化學誘導物及其方法
|
IL300068A
(en)
|
2020-07-23 |
2023-03-01 |
Univ Erasmus Med Ct Rotterdam |
S100 proteins as new therapeutic targets in myeloproliferative catalysis
|
BR112023001209A2
(pt)
|
2020-07-24 |
2023-02-14 |
Hoffmann La Roche |
Método para produzir um polipeptídeo de fusão-anticorpo-multímero
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
AU2021315665A1
(en)
|
2020-07-29 |
2023-03-16 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
JP2023535792A
(ja)
|
2020-07-30 |
2023-08-21 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
コロナウイルス治療のための抗cd3抗体
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
AR123085A1
(es)
|
2020-07-31 |
2022-10-26 |
Genentech Inc |
FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS
|
CN114057876A
(zh)
|
2020-07-31 |
2022-02-18 |
百奥泰生物制药股份有限公司 |
Cd47抗体及其应用
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
US20220043000A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Methods and kits for detecting sars-cov-2 protein in a sample
|
KR20230084469A
(ko)
|
2020-08-04 |
2023-06-13 |
애보트 라피드 다이어그노스틱스 인터내셔널 언리미티드 컴퍼니 |
Sars-cov-2를 검출하기 위한 검정법
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
GB202012161D0
(en)
|
2020-08-05 |
2020-09-16 |
Adc Therapeutics Sa |
Combination therapy
|
JP2023536904A
(ja)
|
2020-08-06 |
2023-08-30 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体が媒介する疾患を有する対象における炎症性サイトカインおよび疲労
|
WO2022031948A1
(en)
|
2020-08-07 |
2022-02-10 |
Genentech, Inc. |
T cell-based methods for predicting polypeptide immunogenicity
|
WO2022028608A1
(zh)
|
2020-08-07 |
2022-02-10 |
百奥泰生物制药股份有限公司 |
抗pd-l1抗体及其应用
|
JP2023534765A
(ja)
|
2020-08-07 |
2023-08-10 |
フォーティス セラピューティクス,インク. |
免疫複合体を標的とするcd46およびその使用方法
|
WO2022033419A2
(en)
|
2020-08-10 |
2022-02-17 |
Shanghai Xbh Biotechnology Co., Ltd. |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
US20230303654A1
(en)
|
2020-08-11 |
2023-09-28 |
City Of Hope |
Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
|
JP2023537396A
(ja)
|
2020-08-12 |
2023-08-31 |
ビオンド バイオロジクス リミテッド |
Ilt2に対する抗体およびその使用
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2023537751A
(ja)
|
2020-08-14 |
2023-09-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
オクレリズマブで多発性硬化症を治療するための方法
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
EP4197555A1
(en)
|
2020-08-17 |
2023-06-21 |
Akeso Biopharma, Inc. |
Anti-cd73 antibody and use thereof
|
EP4196593A1
(en)
|
2020-08-17 |
2023-06-21 |
ATB Therapeutics |
Recombinant immunotoxin comprising a ribotoxin or rnase
|
US20230331862A1
(en)
|
2020-08-21 |
2023-10-19 |
Shanghai GenBase Biotechnology Co., Ltd. |
Antibody specifically bound to glycosylated ceacam5
|
JP2023540023A
(ja)
|
2020-08-24 |
2023-09-21 |
シャリテ-ウニベルジテーツメディツィン ベルリン |
Ceaを認識するキメラ抗原受容体(car)発現細胞
|
EP4199959A1
(en)
|
2020-08-24 |
2023-06-28 |
Charité - Universitätsmedizin Berlin |
A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
WO2022043863A1
(en)
|
2020-08-26 |
2022-03-03 |
Citius Pharmaceuticals, Inc. |
Combination for use in methods of treating cancer
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
CN114106190A
(zh)
|
2020-08-31 |
2022-03-01 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204806A1
(en)
|
2020-08-31 |
2023-07-05 |
Genentech, Inc. |
Methods for producing antibodies
|
WO2022047359A1
(en)
|
2020-08-31 |
2022-03-03 |
Berg Llc |
Protein biomarkers for pancreatic cancer
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023539528A
(ja)
|
2020-09-01 |
2023-09-14 |
メルック・パテント・ゲーエムベーハー |
Nkp30結合体
|
CN116963779A
(zh)
|
2020-09-02 |
2023-10-27 |
国立大学法人东京大学 |
癌症免疫微环境的调节物质及其预防、诊断或治疗
|
AU2021337223A1
(en)
|
2020-09-02 |
2023-03-16 |
Msd International Gmbh |
Combination therapy of a PD-1 antagonist and an antagonist for VEGFR-2 for treating patients with cancer
|
IL300616A
(en)
|
2020-09-04 |
2023-04-01 |
Hoffmann La Roche |
Antibody that binds to VEGF-A and ANG2 and methods of use
|
WO2022049223A1
(en)
|
2020-09-04 |
2022-03-10 |
Pamgene B.V. |
Methods for predicting the response of a patient to treatment with a pd-1 or pd-l1 immune checkpoint inhibitor
|
AU2021335257A1
(en)
|
2020-09-04 |
2023-03-09 |
Merck Patent Gmbh |
Anti-CEACAM5 antibodies and conjugates and uses thereof
|
CA3192526A1
(en)
|
2020-09-04 |
2022-03-10 |
Rutgers, The State University Of New Jersey |
Sars-cov-2 vaccines and antibodies
|
JP2023540526A
(ja)
|
2020-09-04 |
2023-09-25 |
ノヴァロック バイオセラピューティクス, リミテッド |
ネクチン-4抗体およびそれの使用
|
US20230340149A1
(en)
|
2020-09-07 |
2023-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
KR102528412B1
(ko)
|
2020-09-08 |
2023-05-04 |
클립스비엔씨 주식회사 |
신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
|
CA3193594A1
(en)
|
2020-09-11 |
2022-03-17 |
Medimmune Limited |
Therapeutic b7-h4 binding molecules
|
CA3194182A1
(en)
|
2020-09-12 |
2022-03-17 |
Medimmune Limited |
A scoring method for an anti-b7h4 antibody-drug conjugate therapy
|
AU2021341526A1
(en)
|
2020-09-14 |
2023-04-27 |
Ichnos Sciences SA |
Antibodies that bind to il1rap and uses thereof
|
JP2023540795A
(ja)
|
2020-09-14 |
2023-09-26 |
ファイザー・インク |
がんを処置するための方法、治療、および使用
|
CA3194792A1
(en)
|
2020-09-15 |
2022-03-24 |
Bayer Aktiengesellschaft |
Novel anti-a2ap antibodies and uses thereof
|
AU2021344422A1
(en)
|
2020-09-16 |
2023-05-04 |
Gordon J. Freeman |
Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
|
CN114195900B
(zh)
|
2020-09-17 |
2024-02-23 |
普米斯生物技术(珠海)有限公司 |
一种抗4-1bb/pd-l1双特异性抗体及其用途
|
CN114195894A
(zh)
|
2020-09-17 |
2022-03-18 |
普米斯生物技术(珠海)有限公司 |
一种靶向4-1bb的抗体及其应用
|
WO2022060412A1
(en)
|
2020-09-17 |
2022-03-24 |
Genentech, Inc. |
Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
AU2021342566A1
(en)
|
2020-09-21 |
2023-03-02 |
Genentech, Inc. |
Purification of multispecific antibodies
|
TW202229344A
(zh)
|
2020-09-21 |
2022-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
抗-cd40抗體用於治療發炎病況之用途
|
US20240053339A1
(en)
|
2020-09-21 |
2024-02-15 |
Theravectys |
High throughput methods and products for sars-cov-2 sero-neutralization assay
|
US11225508B1
(en)
|
2020-09-23 |
2022-01-18 |
The University Of North Carolina At Chapel Hill |
Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
|
JP2023542528A
(ja)
|
2020-09-24 |
2023-10-10 |
フレッド ハッチンソン キャンサー センター |
Sox2抗原を標的とする免疫療法
|
CN116472290A
(zh)
|
2020-09-24 |
2023-07-21 |
默沙东有限责任公司 |
程序性死亡受体1(pd-1)抗体和透明质酸酶变体及其片段的稳定制剂及其使用方法
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
JP2023542228A
(ja)
|
2020-09-24 |
2023-10-05 |
エフ. ホフマン-ラ ロシュ アーゲー |
遺伝子ノックアウトを有する哺乳動物細胞株
|
GB202015226D0
(en)
|
2020-09-25 |
2020-11-11 |
Adc Therapeutics S A |
Pyrrol obenzodiazepine-antibody conugates and uses thereof
|
EP4217385A2
(en)
|
2020-09-28 |
2023-08-02 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
IL301413A
(en)
|
2020-09-28 |
2023-05-01 |
Zoetis Services Llc |
Canine antibody variants
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
PE20240110A1
(es)
|
2020-09-29 |
2024-01-22 |
Zoetis Services Llc |
Variantes de anticuerpos felinos
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202214294A
(zh)
|
2020-09-30 |
2022-04-16 |
美商碩騰服務公司 |
具有hyaC及nanP缺失之新穎多殺性巴斯德氏菌株及疫苗
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
JP2023544387A
(ja)
|
2020-10-05 |
2023-10-23 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのgdf3
|
CA3198362A1
(en)
|
2020-10-07 |
2022-04-14 |
Zoetis Services Llc |
Anti-ngf antibodies and methods of use thereof
|
GB202015916D0
(en)
|
2020-10-07 |
2020-11-18 |
Adc Therapeutics Sa |
Combination therapy
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
EP3981789A1
(en)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb antibodies and uses thereof
|
US12006550B2
(en)
|
2020-10-12 |
2024-06-11 |
University Of South Carolina |
Targeting treatment for ADAM30 in pathological cells
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
WO2022079139A1
(en)
|
2020-10-15 |
2022-04-21 |
Intervet International B.V. |
Caninized antibodies to canine interleukin-31 receptor alpha
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
EP4228670A1
(en)
|
2020-10-15 |
2023-08-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
|
WO2022081895A1
(en)
|
2020-10-16 |
2022-04-21 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
EP4229082A1
(en)
|
2020-10-16 |
2023-08-23 |
AC Immune SA |
Antibodies binding to alpha-synuclein for therapy and diagnosis
|
US11440952B2
(en)
|
2020-10-16 |
2022-09-13 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
CN116670169A
(zh)
|
2020-10-16 |
2023-08-29 |
魁尔斯弗生物治疗股份有限公司 |
与pd-l1结合的多特异性结合化合物
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022084399A1
(en)
|
2020-10-21 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
US20220127344A1
(en)
|
2020-10-23 |
2022-04-28 |
Boehringer Ingelheim International Gmbh |
Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
JP2023546743A
(ja)
|
2020-10-23 |
2023-11-07 |
中山康方生物医▲藥▼有限公司 |
抗cd73抗体及びその使用
|
CA3199806A1
(en)
|
2020-10-26 |
2022-05-05 |
Janssen Pharmaceutica Nv |
Methods of reducing tau in human subjects
|
MX2023004808A
(es)
|
2020-10-26 |
2023-05-10 |
Akeso Biopharma Inc |
Anticuerpo anti-tigit y composicion farmaceutica y uso del mismo.
|
TW202231661A
(zh)
|
2020-10-26 |
2022-08-16 |
比利時商健生藥品公司 |
安全投予抗tau抗體之方法
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
US20220135620A1
(en)
|
2020-10-30 |
2022-05-05 |
Genentech, Inc. |
Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
EP4237441A1
(en)
|
2020-11-02 |
2023-09-06 |
F. Hoffmann-La Roche AG |
Sars-cov-2 nucleocapsid antibodies
|
CN116801906A
(zh)
|
2020-11-02 |
2023-09-22 |
阿雷斯贸易股份有限公司 |
癌症的联合治疗
|
EP4237435A1
(en)
|
2020-11-02 |
2023-09-06 |
Ares Trading S.A. |
Combination treatment of cancer
|
MX2023005132A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
WO2022098628A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
AR123997A1
(es)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
|
WO2022096547A1
(en)
|
2020-11-05 |
2022-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
WO2022096716A2
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
US20230406929A1
(en)
|
2020-11-06 |
2023-12-21 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
CN114437212B
(zh)
|
2020-11-06 |
2023-03-14 |
上海麦济生物技术有限公司 |
抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
|
US20240067728A1
(en)
|
2020-11-06 |
2024-02-29 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
JP2023548421A
(ja)
|
2020-11-06 |
2023-11-16 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
多のう胞性卵巣症候群(pcos)を診断および処置するための方法
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
JP2023548538A
(ja)
|
2020-11-08 |
2023-11-17 |
シージェン インコーポレイテッド |
併用療法
|
US20220168330A1
(en)
|
2020-11-09 |
2022-06-02 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
MX2023005570A
(es)
|
2020-11-12 |
2023-05-29 |
Inst Nat Sante Rech Med |
Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
CR20230253A
(es)
|
2020-11-16 |
2023-07-26 |
Hoffmann La Roche |
Glucoformas de fab ricas en manosa
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
KR20230118108A
(ko)
|
2020-11-20 |
2023-08-10 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-cd25 항체
|
EP4247496A1
(en)
|
2020-11-20 |
2023-09-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Anti-cd25 antibodies
|
GB202105804D0
(en)
|
2020-11-20 |
2021-06-09 |
Univ Cape Town |
Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
|
EP4247851A1
(en)
|
2020-11-20 |
2023-09-27 |
Zoetis Services LLC |
Bovine antibody variants
|
CA3199429A1
(en)
|
2020-11-23 |
2022-05-27 |
Davide Corti |
Anti-influenza antibodies and combinations thereof
|
IL302938A
(en)
|
2020-11-23 |
2023-07-01 |
Vir Biotechnology Inc |
Antibodies against influenza A viruses
|
WO2022106726A2
(en)
|
2020-11-23 |
2022-05-27 |
Norimun As |
IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES
|
GB202018395D0
(en)
|
2020-11-23 |
2021-01-06 |
Scancell Ltd |
Immunotherapy
|
WO2022109309A1
(en)
|
2020-11-23 |
2022-05-27 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibodies against influenza neuraminidase
|
AU2021385349A1
(en)
|
2020-11-24 |
2023-06-22 |
Les Laboratoires Servier |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
KR20230143605A
(ko)
|
2020-11-24 |
2023-10-12 |
노파르티스 아게 |
Bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
|
AU2021387795A1
(en)
|
2020-11-25 |
2023-06-01 |
Innate Pharma |
Treatment of cancer
|
EP4251279A1
(en)
|
2020-11-25 |
2023-10-04 |
VIR Biotechnology, Inc. |
Antibodies that bind to multiple betacoronaviruses
|
EP4251282A1
(en)
|
2020-11-27 |
2023-10-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
US20240042024A1
(en)
|
2020-11-27 |
2024-02-08 |
David A. Horwitz |
Methods and compositions for treatment of immune-mediated diseases
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022120352A1
(en)
|
2020-12-02 |
2022-06-09 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
KR20230117189A
(ko)
|
2020-12-02 |
2023-08-07 |
맵웰 (상하이) 바이오사이언스 컴퍼니, 리미티드 |
항-인간 b7-h3 항체 및 이의 응용
|
JP2023553038A
(ja)
|
2020-12-02 |
2023-12-20 |
セバスチャン バウマー |
静電ナノ粒子およびその使用
|
AU2021391924A1
(en)
|
2020-12-04 |
2023-06-22 |
The General Hospital Corporation |
Methods of using interleukin-2 agents
|
WO2022120216A1
(en)
|
2020-12-04 |
2022-06-09 |
Qiagen Sciences Llc |
Compositions and methods for diagnosing sars-cov-2 (covid-19) and for monitoring sars-cov-2-specific immunological memory
|
WO2022122652A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
MX2023006650A
(es)
|
2020-12-07 |
2023-06-21 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos.
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
JPWO2022124247A1
(xx)
|
2020-12-09 |
2022-06-16 |
|
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
CA3200770A1
(en)
|
2020-12-14 |
2022-06-23 |
Lillian SEU |
Methods and reagents for characterizing car t cells for therapies
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
MX2023007181A
(es)
|
2020-12-16 |
2023-08-30 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
JP2024500747A
(ja)
|
2020-12-18 |
2024-01-10 |
キニクサ ファーマシューティカルズ, リミテッド |
タンパク質組成物ならびにそれを産生及び使用するための方法
|
CN112500491B
(zh)
|
2020-12-18 |
2022-04-08 |
深圳市迈加瑞生物技术有限公司 |
一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
|
EP4263596A1
(en)
|
2020-12-18 |
2023-10-25 |
Zoetis Services LLC |
Mutations in feline antibody constant regions
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
AU2021405730A1
(en)
|
2020-12-23 |
2023-07-06 |
Cantargia Ab |
Anti-il1rap antibody
|
EP4267176A1
(en)
|
2020-12-23 |
2023-11-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
EP4273167A1
(en)
|
2020-12-30 |
2023-11-08 |
Bio-Thera Solutions, Ltd. |
Anti-cldn18.2 antibody, and preparation method therefor and use thereof
|
CN114685669A
(zh)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
结合trop2的抗体及其用途
|
EP4271482A2
(en)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
EP4274658A1
(en)
|
2021-01-06 |
2023-11-15 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
AU2022205313A1
(en)
|
2021-01-06 |
2023-07-20 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
KR20230131204A
(ko)
|
2021-01-12 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
암 세포에 결합하여 방사성핵종을 상기 세포에 표적화하는분할 항체
|
CN114763381A
(zh)
|
2021-01-13 |
2022-07-19 |
博生吉医药科技(苏州)有限公司 |
B7-h3嵌合抗原受体修饰的t细胞及其应用
|
MX2023008285A
(es)
|
2021-01-13 |
2023-09-12 |
Memorial Sloan Kettering Cancer Center |
Conjugado de anticuerpo anti-dll3-farmaco.
|
JP2024503657A
(ja)
|
2021-01-13 |
2024-01-26 |
メモリアル スローン-ケタリング キャンサー センター |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
BR112023014128A2
(pt)
|
2021-01-15 |
2023-10-31 |
Seagen Inc |
Conjugados de anticorpo-fármaco imunomodulatórios
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022159575A1
(en)
|
2021-01-20 |
2022-07-28 |
Bioentre Llc |
Ctla4-binding proteins and methods of treating cancer
|
US20220226442A1
(en)
|
2021-01-20 |
2022-07-21 |
Visterra, Inc. |
Interleukin-2 agents and uses thereof
|
WO2022159984A1
(en)
|
2021-01-22 |
2022-07-28 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
CA3208998A1
(en)
|
2021-01-22 |
2022-07-28 |
Steven Kerrigan |
Treatment of coronavirus
|
WO2022159842A1
(en)
|
2021-01-25 |
2022-07-28 |
Vir Biotechnology, Inc. |
Antibody combination therapies for sars-cov-2 infection
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
KR20230136604A
(ko)
|
2021-01-28 |
2023-09-26 |
조에티스 서비시즈 엘엘씨 |
개과 항체 불변 영역에서의 돌연변이
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
CN117157320A
(zh)
|
2021-01-29 |
2023-12-01 |
国家健康科学研究所 |
沙眼衣原体抗原性多肽及其用于疫苗目的的用途
|
JP2024505524A
(ja)
|
2021-01-29 |
2024-02-06 |
メルク・シャープ・アンド・ドーム・エルエルシー |
プログラム死受容体1(pd-1)抗体の組成物及びその組成物を得る方法
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
KR20230152679A
(ko)
|
2021-02-03 |
2023-11-03 |
씨젠 인크. |
면역자극 화합물 및 접합체
|
CN113501878B
(zh)
|
2021-02-03 |
2022-12-02 |
北京智仁美博生物科技有限公司 |
针对人tslp的多种抗体及其用途
|
TW202245811A
(zh)
|
2021-02-03 |
2022-12-01 |
美商異基因治療有限公司 |
用於car t細胞藥物產品的調配物與製程
|
JP2024505674A
(ja)
|
2021-02-05 |
2024-02-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗il1rap抗体
|
TW202246317A
(zh)
|
2021-02-09 |
2022-12-01 |
瑞士商休曼生物醫藥股份公司 |
針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
|
EP4292611A1
(en)
|
2021-02-09 |
2023-12-20 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-cd112r antibody and use thereof
|
JP2024508081A
(ja)
|
2021-02-09 |
2024-02-22 |
メディリンク セラピューティクス(スーチョウ)カンパニー,リミティド |
生物活性物質コンジュゲート、その調製方法及びその使用
|
WO2022171030A1
(zh)
|
2021-02-10 |
2022-08-18 |
厦门大学 |
用于预防和治疗eb病毒感染及相关疾病的表位肽及抗体
|
CA3206413A1
(en)
|
2021-02-11 |
2022-08-18 |
Pinchas TSUKERMAN |
Antibodies against cd112r and uses thereof
|
IL305181A
(en)
|
2021-02-15 |
2023-10-01 |
Takeda Pharmaceuticals Co |
Cell therapy compositions and methods for modulating TGF-B signaling
|
WO2022177394A1
(ko)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
|
EP4047016A1
(en)
|
2021-02-19 |
2022-08-24 |
Université de Strasbourg |
Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
JP2024513643A
(ja)
|
2021-02-19 |
2024-03-27 |
シャペロン インク. |
Pd-l1に対する単一ドメイン抗体及びその用途
|
JP2024506931A
(ja)
|
2021-02-19 |
2024-02-15 |
インヒブルクス インコーポレイテッド |
Dr5結合性ポリペプチドの製剤
|
BR112023016713A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
EP4298130A2
(en)
|
2021-02-25 |
2024-01-03 |
Teneobio, Inc. |
Anti-psma antibodies and car-t structures
|
JP2024508808A
(ja)
|
2021-02-26 |
2024-02-28 |
テネオバイオ, インコーポレイテッド |
抗muc1-c抗体及びcar-t構造
|
KR20230150287A
(ko)
|
2021-02-26 |
2023-10-30 |
바이엘 악티엔게젤샤프트 |
비정상적 자궁 출혈의 치료에 사용하기 위한 il-11 또는 il-11ra의 억제제
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
BR112023017035A2
(pt)
|
2021-03-01 |
2024-02-06 |
New York Soc For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surger |
Anticorpos humanizados contra irhom2, ácido nucleico, uso do anticorpo, composição farmacêutica, composição, método de tratamento e kit terapêutico
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
US20240139171A1
(en)
|
2021-03-02 |
2024-05-02 |
Cgrp Diagnostics Gmbh |
Treatment and/or reduction of occurrence of migraine
|
EP4301777A1
(en)
|
2021-03-02 |
2024-01-10 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating red blood cell disorders
|
US20240181073A1
(en)
|
2021-03-03 |
2024-06-06 |
Sorrento Therapeutics, Inc. |
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
|
CA3209006A1
(en)
|
2021-03-04 |
2022-09-09 |
Boehringer Ingelheim International Gmbh |
Methods for the treatment of gpp
|
EP4301472A1
(en)
|
2021-03-05 |
2024-01-10 |
Dynamicure Biotechnology LLC |
Anti-vista constructs and uses thereof
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
CA3212530A1
(en)
|
2021-03-05 |
2022-09-09 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-cldn6 antibody and use thereof
|
KR20230156021A
(ko)
|
2021-03-09 |
2023-11-13 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
Ror1 결합 단백질 및 이의 용도
|
CN114933649B
(zh)
|
2021-03-10 |
2023-04-21 |
北京智仁美博生物科技有限公司 |
抗水痘-带状疱疹病毒的抗体及其用途
|
JP2024518013A
(ja)
|
2021-03-10 |
2024-04-24 |
イミュノウェイク インコーポレイテッド |
免疫調節分子及びその使用
|
JP2024514284A
(ja)
|
2021-03-12 |
2024-04-01 |
トリンス ビーブイ |
カーゴの細胞への送達方法
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
WO2022191306A1
(ja)
|
2021-03-12 |
2022-09-15 |
中外製薬株式会社 |
重症筋無力症の治療または予防用の医薬組成物
|
CN115068603A
(zh)
|
2021-03-12 |
2022-09-20 |
中山康方生物医药有限公司 |
含有抗pd-1-抗vegfa双特异性抗体的药物组合及其用途
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
US20220306700A1
(en)
|
2021-03-17 |
2022-09-29 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
GB202103706D0
(en)
|
2021-03-17 |
2021-04-28 |
Ucl Business Ltd |
CD160 binding domain
|
EP4308118A1
(en)
|
2021-03-17 |
2024-01-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating melanoma
|
JP2024511078A
(ja)
|
2021-03-17 |
2024-03-12 |
レセプトス エルエルシー |
抗il-13抗体を用いてアトピー性皮膚炎を処置する方法
|
US20240174746A1
(en)
|
2021-03-18 |
2024-05-30 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
US20230091653A1
(en)
|
2021-03-18 |
2023-03-23 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2022195051A1
(en)
|
2021-03-18 |
2022-09-22 |
Université De Genève |
Peptides and use thereof for diagnosing and treating antiphospholipid syndrome
|
MX2023010819A
(es)
|
2021-03-18 |
2023-09-28 |
Seagen Inc |
Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
MX2023010917A
(es)
|
2021-03-18 |
2023-09-27 |
Medimmune Ltd |
Molecula de union terapeutica que se une a ccr9.
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
IL305828A
(en)
|
2021-03-22 |
2023-11-01 |
Novimmune Sa |
Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
|
JP2024511137A
(ja)
|
2021-03-22 |
2024-03-12 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗tmem106b抗体
|
GB202104037D0
(en)
|
2021-03-23 |
2021-05-05 |
Bergenbio Asa |
Combination therapy
|
EP4313317A1
(en)
|
2021-03-23 |
2024-02-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
CN117616041A
(zh)
|
2021-03-25 |
2024-02-27 |
当康生物技术有限责任公司 |
抗-igfbp7构建体及其用途
|
WO2022204514A1
(en)
|
2021-03-26 |
2022-09-29 |
Abcuro, Inc. |
Anti-klrg1 antibodies
|
WO2022201123A1
(en)
|
2021-03-26 |
2022-09-29 |
Janssen Biotech, Inc. |
Anti-tau antibodies and uses thereof
|
WO2022204529A1
(en)
|
2021-03-26 |
2022-09-29 |
Abcuro, Inc. |
Anti-klrg1 antibodies
|
JP2024513172A
(ja)
|
2021-03-26 |
2024-03-22 |
ヤンセン バイオテツク,インコーポレーテツド |
対らせん状細線維タウに対するヒト化抗体及びその使用
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
WO2022207652A1
(en)
|
2021-03-29 |
2022-10-06 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
KR20230162800A
(ko)
|
2021-03-30 |
2023-11-28 |
바이엘 악티엔게젤샤프트 |
항-sema3a 항체 및 그의 용도
|
TW202304508A
(zh)
|
2021-03-31 |
2023-02-01 |
美商百歐維拉提夫美國公司 |
減少冷凝集素疾病患者之手術相關溶血
|
IL307236A
(en)
|
2021-03-31 |
2023-11-01 |
Hoffmann La Roche |
Purification of antibodies by mixed-mode chromatography
|
WO2022212836A1
(en)
|
2021-04-01 |
2022-10-06 |
Pyxis Oncology, Inc. |
Gpnmb antibodies and methods of use
|
AU2022246675A1
(en)
|
2021-04-02 |
2023-10-19 |
Amgen Inc. |
Mageb2 binding constructs
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗il-2r抗體及使用方法
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
US20240190992A1
(en)
|
2021-04-05 |
2024-06-13 |
University Public Corporation Osaka |
Antibody against pancreatic cancer stem cells
|
EP4320441A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
CA3214833A1
(en)
|
2021-04-06 |
2022-10-13 |
Bpgbio, Inc. |
Protein markers for the prognosis of breast cancer progression
|
EP4320440A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
AU2022255709A1
(en)
|
2021-04-06 |
2023-09-28 |
Teneobio, Inc. |
Anti-cd19 antibodies and car-t structures
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
EP4319739A2
(en)
|
2021-04-08 |
2024-02-14 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
BR112023020662A2
(pt)
|
2021-04-09 |
2024-02-06 |
Seagen Inc |
Métodos de tratamento de câncer com anticorpos anti-tigit
|
WO2022216898A1
(en)
|
2021-04-09 |
2022-10-13 |
Genentech, Inc. |
Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
CA3214934A1
(en)
|
2021-04-12 |
2022-10-20 |
Madhavan Nallani |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
CR20230523A
(es)
|
2021-04-14 |
2024-01-23 |
Villaris Therapeutics Inc |
Anticuerpos anti-cd122 y usos de estos
|
EP4190816A1
(en)
|
2021-04-14 |
2023-06-07 |
Akeso Biopharma, Inc. |
Anti-cd47 monoclonal antibody and use thereof
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
CN115215937B
(zh)
|
2021-04-15 |
2023-05-26 |
上海麦济生物技术有限公司 |
抗人masp-2抗体及其制备方法和应用
|
CA3215241A1
(en)
|
2021-04-16 |
2022-10-20 |
Teneobio, Inc. |
Anti-cd20 antibodies and car-t structures
|
EP4323404A1
(en)
|
2021-04-16 |
2024-02-21 |
Tiziana Life Sciences PLC |
Subcutaneous administration of antibodies for the treatment of disease
|
WO2022223488A1
(en)
|
2021-04-19 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
JP2024514673A
(ja)
|
2021-04-20 |
2024-04-02 |
シージェン インコーポレイテッド |
抗体依存性細胞傷害の調節
|
CR20230531A
(es)
|
2021-04-23 |
2024-01-08 |
Amgen Inc |
Composiciones de anticuerpos anti-tslp y usos de las mismas
|
CN117177992A
(zh)
|
2021-04-23 |
2023-12-05 |
美国安进公司 |
经修饰的抗tslp抗体
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
TW202305010A
(zh)
|
2021-04-25 |
2023-02-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗masp2抗體、其抗原結合片段及醫藥用途
|
AU2022266934A1
(en)
|
2021-04-26 |
2023-10-26 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal user thereof
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
TW202243689A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
IL308100A
(en)
|
2021-05-03 |
2023-12-01 |
UCB Biopharma SRL |
Antibodies
|
EP4333900A2
(en)
|
2021-05-03 |
2024-03-13 |
Merck Patent GmbH |
Her2 targeting fc antigen binding fragment-drug conjugates
|
JP2024517844A
(ja)
|
2021-05-04 |
2024-04-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性fgf21受容体アゴニスト及びそれらの使用
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
CD20 and CD22 targeting antigen-binding molecules for use in proliferative diseases
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
TW202310876A
(zh)
|
2021-05-12 |
2023-03-16 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
WO2022241057A1
(en)
|
2021-05-12 |
2022-11-17 |
Applied Biomedical Science Institute |
Binding polypeptides against sars cov-2 and uses thereof
|
TW202310871A
(zh)
|
2021-05-14 |
2023-03-16 |
美商建南德克公司 |
用莫蘇妥珠單抗及帕羅托珠單抗維多汀治療cd20陽性增生性失調之方法
|
TW202306993A
(zh)
|
2021-05-14 |
2023-02-16 |
美商建南德克公司 |
Trem2之促效劑
|
WO2022245920A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
EP4340876A1
(en)
|
2021-05-19 |
2024-03-27 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate combination therapy with bevacizumab
|
AU2022276189A1
(en)
|
2021-05-20 |
2024-01-18 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
JP2024521107A
(ja)
|
2021-05-21 |
2024-05-28 |
ジェネンテック, インコーポレイテッド |
目的の組換え産物を産生するための修飾細胞
|
KR20240012502A
(ko)
|
2021-05-21 |
2024-01-29 |
세바스티안 보이머 |
프로타민 기반 나노입자의 표적 화합물로서의 항체-프로타민 융합
|
KR20240035758A
(ko)
|
2021-05-24 |
2024-03-18 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 폴리펩타이드
|
CN117999101A
(zh)
|
2021-05-25 |
2024-05-07 |
默克专利股份公司 |
靶向EGFR的Fc抗原结合片段-药物缀合物
|
EP4348263A1
(en)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2022248268A1
(en)
|
2021-05-28 |
2022-12-01 |
Adc Therapeutics Sa |
Combination therapy
|
GB202107709D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
GB202107706D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
GB202107713D0
(en)
|
2021-05-28 |
2021-07-14 |
Medimmune Ltd |
Combination therapy
|
AU2022283467A1
(en)
|
2021-05-28 |
2023-12-07 |
Seagen Inc. |
Anthracycline antibody conjugates
|
JP2022184105A
(ja)
|
2021-05-31 |
2022-12-13 |
ワイズ・エー・シー株式会社 |
抗cd26抗体と免疫チェックポイント阻害剤との併用療法
|
EP4347647A1
(en)
|
2021-06-01 |
2024-04-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of b cell depleting agents for the treatment of rheumatic heart disease
|
CA3220167A1
(en)
|
2021-06-02 |
2022-12-08 |
Marc Derive |
Anti-trem-1 antibodies
|
EP4348260A2
(en)
|
2021-06-03 |
2024-04-10 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
TW202307006A
(zh)
|
2021-06-03 |
2023-02-16 |
美商表面腫瘤學公司 |
用抗cd39抗體及派姆單抗治療癌症之方法
|
EP4346904A1
(en)
|
2021-06-03 |
2024-04-10 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
|
BR112023025194A2
(pt)
|
2021-06-04 |
2024-02-27 |
Boehringer Ingelheim Int |
Anticorpos anti-sirp-alfa
|
TW202306994A
(zh)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
抗ddr2抗體及其用途
|
GB202108055D0
(en)
|
2021-06-04 |
2021-07-21 |
Univ Court Of The Univ Of Aberdeen |
Antibodies and methods for generating the same
|
EP4351640A1
(en)
|
2021-06-07 |
2024-04-17 |
Ares Trading S.A. |
Combination treatment of cancer
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
EP4351582A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
AU2022289017A1
(en)
|
2021-06-11 |
2023-11-30 |
Genentech, Inc. |
Method for treating chronic obstructive pulmonary disease with an st2 antagonist
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗il-9抗体及びその使用方法
|
WO2022266034A1
(en)
|
2021-06-14 |
2022-12-22 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
EP4355786A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
CN117500826A
(zh)
|
2021-06-17 |
2024-02-02 |
基因泰克公司 |
抗泛素化抗体及其使用方法
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
JP2024521967A
(ja)
|
2021-06-18 |
2024-06-04 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
抗il-36r抗体及びその使用
|
WO2022263632A1
(en)
|
2021-06-18 |
2022-12-22 |
Alligator Bioscience Ab |
Novel combination therapies and uses thereof
|
IL308959A
(en)
|
2021-06-18 |
2024-01-01 |
Nammi Therapeutics Inc |
Fusion protein composition(s) containing masked type I interferons (IFNalpha and IFNbeta) for use in cancer therapy and methods thereof
|
WO2022269473A1
(en)
|
2021-06-23 |
2022-12-29 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
CA3221555A1
(en)
|
2021-06-23 |
2022-12-29 |
Kimberly LONG |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
EP4359439A1
(en)
|
2021-06-24 |
2024-05-01 |
Yeda Research and Development Co. Ltd |
Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor
|
TW202311291A
(zh)
|
2021-06-25 |
2023-03-16 |
日商中外製藥股份有限公司 |
抗ctla-4抗體的用途
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
KR20240025597A
(ko)
|
2021-06-29 |
2024-02-27 |
씨젠 인크. |
비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
|
IL309780A
(en)
|
2021-07-02 |
2024-02-01 |
Merck Patent Gmbh |
Antibodies and antiprotec complexes
|
CN115558023A
(zh)
|
2021-07-02 |
2023-01-03 |
安源医药科技(上海)有限公司 |
抗cd3抗体及其用途
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
WO2023283611A1
(en)
|
2021-07-08 |
2023-01-12 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
EP4367137A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
EP4368640A1
(en)
|
2021-07-09 |
2024-05-15 |
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
Cd19 antibody and application thereof
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
EP4367130A1
(en)
|
2021-07-09 |
2024-05-15 |
Luxembourg Institute of Health (LIH) |
Dimeric protein complexes and uses thereof
|
TW202306985A
(zh)
|
2021-07-12 |
2023-02-16 |
美商建南德克公司 |
降低抗體-脂酶結合之結構
|
EP4370550A1
(en)
|
2021-07-12 |
2024-05-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
US20230197278A1
(en)
|
2021-07-13 |
2023-06-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
KR20240058075A
(ko)
|
2021-07-14 |
2024-05-03 |
스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 |
Cd40을 특이적으로 식별하는 항체 및 이의 응용
|
TW202309097A
(zh)
|
2021-07-14 |
2023-03-01 |
美商建南德克公司 |
抗c-c模體趨化因子受體8(ccr8)抗體及其使用方法
|
AU2022310862A1
(en)
|
2021-07-14 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
BR112024000744A2
(pt)
|
2021-07-14 |
2024-04-30 |
Regeneron Pharma |
Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
|
WO2023285620A2
(en)
|
2021-07-14 |
2023-01-19 |
Alchemab Therapeutics Ltd. |
Compositions and methods for targeting viral proteins
|
EP4370647A1
(en)
|
2021-07-15 |
2024-05-22 |
Just-Evotec Biologics, Inc. |
Bidirectional tangential flow filtration (tff) perfusion system
|
EP4372006A1
(en)
|
2021-07-16 |
2024-05-22 |
Brightpath Biotherapeutics Co., Ltd. |
Anti-tim-3 antigen antibody or antibody derivative, and use thereof
|
TW202321283A
(zh)
|
2021-07-20 |
2023-06-01 |
美商英伊布里克斯公司 |
Cd8結合多肽及其用途
|
WO2023004305A1
(en)
|
2021-07-20 |
2023-01-26 |
Inhibrx, Inc. |
Cd8-targeted modified il-2 polypeptides and uses thereof
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
CN116059341A
(zh)
|
2021-07-23 |
2023-05-05 |
中山康方生物医药有限公司 |
药物组合物及用途
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
GB202110726D0
(en)
|
2021-07-26 |
2021-09-08 |
Cambridge Entpr Ltd |
Conjugating reagents and conjugates thereof
|
CN115991744A
(zh)
|
2021-07-26 |
2023-04-21 |
北京万泰生物药业股份有限公司 |
人鼻病毒的通用亲和表位多肽、抗体及其用途
|
AU2022320627A1
(en)
|
2021-07-26 |
2024-02-08 |
Abcuro, Inc. |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
AU2022318161A1
(en)
|
2021-07-29 |
2024-02-08 |
Centre Leon Berard |
HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
|
AU2022320667A1
(en)
|
2021-07-30 |
2024-03-14 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Anti-pvrig/anti-tigit bispecific antibody and application
|
WO2023006975A2
(en)
|
2021-07-30 |
2023-02-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric proteins and methods of immunotherapy
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
EP4380604A1
(en)
|
2021-08-05 |
2024-06-12 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
WO2023012343A1
(en)
|
2021-08-06 |
2023-02-09 |
Institut Du Cancer De Montpellier |
Methods for the treatment of cancer
|
EP4386003A1
(en)
|
2021-08-09 |
2024-06-19 |
Biotheus Inc. |
Anti-tigit antibody and use thereof
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
KR20240046224A
(ko)
|
2021-08-18 |
2024-04-08 |
바이오세우스 인크. |
이중특이성 항체 및 그 용도
|
CN117858905A
(zh)
|
2021-08-19 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
多价抗变体fc区抗体及使用方法
|
CA3227725A1
(en)
|
2021-08-20 |
2023-02-23 |
Mohamad Morsey |
Homodimer fusion proteins for treating atopic dermatitis
|
EP4388004A1
(en)
|
2021-08-20 |
2024-06-26 |
Intervet International B.V. |
Antibodies and igg fusion proteins with an extended half-life
|
KR20240046905A
(ko)
|
2021-08-20 |
2024-04-11 |
아케소 바이오파마, 인크. |
항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
WO2023026205A1
(en)
|
2021-08-24 |
2023-03-02 |
Cgrp Diagnostics Gmbh |
Preventative treatment of migraine
|
TW202327642A
(zh)
|
2021-08-25 |
2023-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種含融合蛋白的醫藥組成物
|
WO2023025303A1
(zh)
|
2021-08-26 |
2023-03-02 |
上海君实生物医药科技股份有限公司 |
抗cldn-18.2抗体药物偶联物及其用途
|
AU2022335718A1
(en)
|
2021-08-26 |
2024-03-28 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
KR20240049348A
(ko)
|
2021-08-27 |
2024-04-16 |
메디뮨 리미티드 |
항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료
|
IL310382A
(en)
|
2021-08-27 |
2024-03-01 |
Genentech Inc |
Methods for treating tau pathologies
|
KR20240049275A
(ko)
|
2021-08-27 |
2024-04-16 |
하. 룬드벡 아크티에셀스카브 |
항-cgrp 항체를 사용한 군발성 두통의 치료
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
WO2023032955A1
(ja)
|
2021-08-31 |
2023-03-09 |
大正製薬株式会社 |
抗成長ホルモン抗体
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
WO2023034866A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
IL310773A
(en)
|
2021-09-02 |
2024-04-01 |
Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts |
Anti-CECAM6 antibodies with reduced side effects
|
AU2022339819A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
TW202328188A
(zh)
|
2021-09-03 |
2023-07-16 |
美商Go治療公司 |
抗醣化-cmet抗體及其用途
|
WO2023039442A1
(en)
|
2021-09-08 |
2023-03-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibody combination therapies for sars-cov-2 infection
|
EP4148067A1
(en)
|
2021-09-08 |
2023-03-15 |
F. Hoffmann-La Roche AG |
Method for the expression of an antibody-multimer-fusion
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
CA3231761A1
(en)
|
2021-09-13 |
2023-03-16 |
Qiong Wang |
Anti-human cd3 antibody and use thereof
|
CA3231890A1
(en)
|
2021-09-14 |
2023-03-23 |
Jan Tkac |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
IL286430A
(en)
|
2021-09-14 |
2023-04-01 |
Yeda Res & Dev |
Multispecific antibodies for use in the treatment of diseases
|
CA3231944A1
(en)
|
2021-09-16 |
2023-03-23 |
Carole GUILLONNEAU |
Anti-human cd45rc binding domains and uses thereof
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023048111A1
(ja)
|
2021-09-21 |
2023-03-30 |
国立研究開発法人 農業・食品産業技術総合研究機構 |
無莢膜株を抗原として含むワクチン
|
CN115838424A
(zh)
|
2021-09-22 |
2023-03-24 |
上海康岱生物医药技术股份有限公司 |
靶向tigit的单克隆抗体
|
CN115925929A
(zh)
|
2021-09-22 |
2023-04-07 |
上海康岱生物医药技术股份有限公司 |
抗tnfr2单克隆抗体及其应用
|
US20230192834A1
(en)
|
2021-09-27 |
2023-06-22 |
Zoetis Services Llc |
Anti- tgfb1,2,3 antibodies and therapeutic uses thereof
|
JPWO2023053282A1
(xx)
|
2021-09-29 |
2023-04-06 |
|
|
CN115873116A
(zh)
|
2021-09-29 |
2023-03-31 |
中山康方生物医药有限公司 |
抗lag3抗体、药物组合物及用途
|
GB202113904D0
(en)
|
2021-09-29 |
2021-11-10 |
Alligator Bioscience Ab |
Methods and compositions
|
US11879010B2
(en)
|
2021-09-30 |
2024-01-23 |
The Charlotte Mecklenburg Hospital Authority |
Methods and compositions for pretargeted immunotherapy
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
CN115894689A
(zh)
|
2021-09-30 |
2023-04-04 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
US20230190806A1
(en)
|
2021-10-06 |
2023-06-22 |
Immatics Biotechnologies Gmbh |
Methods of treating metastatic lesions and compositions thereof
|
KR20240082388A
(ko)
|
2021-10-08 |
2024-06-10 |
추가이 세이야쿠 가부시키가이샤 |
프리필드 시린지 제제의 조제 방법
|
TW202323281A
(zh)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
WO2023064942A1
(en)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Methods of suppressing microglial activation
|
AU2022364888A1
(en)
|
2021-10-14 |
2024-05-30 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
|
IL311963A
(en)
|
2021-10-15 |
2024-06-01 |
Regenxbio Inc |
Antibodies and methods of using them
|
EP4166150A1
(en)
|
2021-10-15 |
2023-04-19 |
Exeliom Biosciences |
Association of a faecalibacterium prausnitzii strain and anti-pd-1, anti-pd-l1 or anti-ctla-4 antibodies for the treatment of cancer
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023072904A1
(en)
|
2021-10-26 |
2023-05-04 |
F. Hoffmann-La Roche Ag |
Monoclonal antibodies specific for sars-cov-2 rbd
|
WO2023073084A1
(en)
|
2021-10-27 |
2023-05-04 |
Imcheck Therapeutics |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
CA3236522A1
(en)
|
2021-10-28 |
2023-05-04 |
In3Bio Ltd. |
Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
|
CN118251491A
(zh)
|
2021-10-28 |
2024-06-25 |
瑞泽恩制药公司 |
用于敲除C5的CRISPR/Cas相关方法及组合物
|
IL312401A
(en)
|
2021-10-29 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023081471A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
AU2022381977A1
(en)
|
2021-11-05 |
2024-05-23 |
Alligator Bioscience Ab |
Novel peptides
|
AU2022379952A1
(en)
|
2021-11-05 |
2024-05-16 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
TW202323285A
(zh)
|
2021-11-05 |
2023-06-16 |
大陸商正大天晴藥業集團股份有限公司 |
抗cldn18.2抗體及其用途
|
KR20230066257A
(ko)
|
2021-11-05 |
2023-05-15 |
서울대학교병원 |
리지스틴 특이적 항체 및 이의 용도
|
AU2022382383A1
(en)
|
2021-11-05 |
2024-06-20 |
Eli Lilly And Company |
Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
|
WO2023081925A1
(en)
|
2021-11-08 |
2023-05-11 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
WO2023081486A1
(en)
|
2021-11-08 |
2023-05-11 |
Nurix Therapeutics, Inc. |
Toll-like receptor therapy combinations with cbl-b inhibitor compounds
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
AU2022386323A1
(en)
|
2021-11-09 |
2024-05-16 |
Sensei Biotherapeutics, Inc. |
Anti-vista antibodies and uses thereof
|
EP4180061A1
(en)
|
2021-11-10 |
2023-05-17 |
Nerviano Medical Sciences S.r.l. |
Anthracycline derivative linker reagents, antibody-drug conjugates and methods
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
TW202330613A
(zh)
|
2021-11-12 |
2023-08-01 |
美商建南德克公司 |
使用整聯蛋白β7拮抗劑治療克隆氏病之方法
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
TW202334202A
(zh)
|
2021-11-16 |
2023-09-01 |
瑞士商Ac免疫有限公司 |
用於治療和診斷的新分子
|
WO2023088968A1
(en)
|
2021-11-17 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Universal sarbecovirus vaccines
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
AU2022392804A1
(en)
|
2021-11-19 |
2024-05-02 |
Mirobio Limited |
Engineered PD-1 antibodies and uses thereof
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023088966A1
(en)
|
2021-11-19 |
2023-05-25 |
Adc Therapeutics Sa |
Anti-psma conjugates
|
WO2023088963A1
(en)
|
2021-11-19 |
2023-05-25 |
Adc Therapeutics Sa |
Anti-il-13ralpha2 conjugates
|
CA3239216A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
CA3238936A1
(en)
|
2021-11-24 |
2023-06-01 |
Wayne A. Marasco |
Antibodies against ctla-4 and methods of use thereof
|
WO2023096904A2
(en)
|
2021-11-24 |
2023-06-01 |
President And Fellows Of Harvard College |
C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
|
US20230348614A1
(en)
|
2021-11-24 |
2023-11-02 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
CN118159286A
(zh)
|
2021-11-25 |
2024-06-07 |
正大天晴药业集团股份有限公司 |
抗Siglec-15抗体及其应用
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023102463A1
(en)
|
2021-12-01 |
2023-06-08 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
AU2022402850A1
(en)
|
2021-12-01 |
2024-06-06 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023104904A2
(en)
|
2021-12-08 |
2023-06-15 |
Genclis |
The sars-cov-2 and variants use two independent cell receptors to replicate
|
GB202117928D0
(en)
|
2021-12-11 |
2022-01-26 |
Cancer Research Tech Ltd |
Immunotherapy for cancer
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
CA3239267A1
(en)
|
2021-12-15 |
2023-06-22 |
Ronnie M. RUSSELL |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
WO2023111128A1
(en)
|
2021-12-16 |
2023-06-22 |
Intervet International B.V. |
Caninized antibodies to canine interleukin-31 receptor alpha ii
|
WO2023111157A1
(en)
|
2021-12-16 |
2023-06-22 |
Intervet International B.V. |
Caninized and felinized antibodies to human ngf
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
CA3241395A1
(en)
|
2021-12-17 |
2023-06-22 |
Barbel SCHROFELBAUER |
Antibodies and uses thereof
|
WO2023111168A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
A novel antibody for detection of amyloid beta 42 (aβ42)
|
AU2022413677A1
(en)
|
2021-12-17 |
2024-06-27 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
CA3241407A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118241A1
(en)
|
2021-12-20 |
2023-06-29 |
Vetoquinol Sa |
Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
AU2022420788A1
(en)
|
2021-12-22 |
2024-05-16 |
Boehringer Ingelheim International Gmbh |
Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
|
WO2023118508A1
(en)
|
2021-12-23 |
2023-06-29 |
Bavarian Nordic A/S |
Recombinant mva viruses for intraperitoneal administration for treating cancer
|
WO2023129942A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023133393A1
(en)
|
2022-01-05 |
2023-07-13 |
Inhibrx, Inc. |
Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
|
WO2023133394A1
(en)
|
2022-01-05 |
2023-07-13 |
Inhibrx, Inc. |
Gamma delta t-cell-binding polypeptides and uses thereof
|
AR128222A1
(es)
|
2022-01-07 |
2024-04-10 |
Johnson & Johnson Entpr Innovation Inc |
MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023139293A1
(en)
|
2022-01-24 |
2023-07-27 |
Novimmune Sa |
Composition and methods for the selective activation of cytokine signaling pathways
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023144665A1
(en)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
TW202332767A
(zh)
|
2022-02-02 |
2023-08-16 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗TfR:GAA及抗CD63:GAA插入
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
US20230383010A1
(en)
|
2022-02-07 |
2023-11-30 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023152637A1
(en)
|
2022-02-08 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralization of acyl-coa binding protein confers autophagy-dependent organ protection
|
WO2023152633A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
|
WO2023154780A1
(en)
|
2022-02-09 |
2023-08-17 |
Martell Diagnostic Laboratories, Inc. |
Anti-her2/neu antibodies and methods of use
|
CN114181310B
(zh)
|
2022-02-14 |
2022-07-05 |
中山康方生物医药有限公司 |
抗tigit抗体、其药物组合物及用途
|
TW202348252A
(zh)
|
2022-02-16 |
2023-12-16 |
英商梅迪繆思有限公司 |
用治療性結合分子治療癌症的組合療法
|
AR128540A1
(es)
|
2022-02-16 |
2024-05-22 |
Ac Immune Sa |
Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
|
WO2023156634A1
(en)
|
2022-02-17 |
2023-08-24 |
Atb Therapeutics |
Recombinant immunotoxin comprising a ribosome inactivating protein
|
EP4230222A1
(en)
|
2022-02-17 |
2023-08-23 |
Oxsonics Limited |
Combination therapy with an anti-axl antibody-pbd conjugate and nanocups
|
TW202337497A
(zh)
|
2022-02-18 |
2023-10-01 |
中國大陸商重慶明道浩悅生物科技有限公司 |
鼻內調配物及抗sars-cov-2棘蛋白抗體
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
WO2023156683A1
(en)
|
2022-02-21 |
2023-08-24 |
Acticor Biotech |
Treatment of cardiovascular diseases using anti-human gpvi antibodies
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023161412A1
(en)
|
2022-02-25 |
2023-08-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for preventing the cleavage of cd95l by metalloproteases
|
WO2023166420A1
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
US20240002544A1
(en)
|
2022-03-07 |
2024-01-04 |
Novimmune Sa |
Cd28 bispecific antibodies for targeted t cell activation
|
WO2023172968A1
(en)
|
2022-03-09 |
2023-09-14 |
Merck Patent Gmbh |
Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
|
WO2023170207A1
(en)
|
2022-03-09 |
2023-09-14 |
Alderaan Biotechnology |
Anti-cd160 transmembrane isoform antibodies
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170240A1
(en)
|
2022-03-09 |
2023-09-14 |
Merck Patent Gmbh |
Anti-ceacam5 antibodies and conjugates and uses thereof
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023170434A1
(en)
|
2022-03-11 |
2023-09-14 |
Macomics Limited |
Compositions and methods for modulation of macrophage activity
|
WO2023174925A1
(en)
|
2022-03-14 |
2023-09-21 |
Novimmune Sa |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
GB202203588D0
(en)
|
2022-03-15 |
2022-04-27 |
Argonaut Therapeutics Ltd |
Cancer diagnostic
|
TW202400137A
(zh)
|
2022-03-17 |
2024-01-01 |
美商思進公司 |
喜樹鹼偶聯物
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
TW202402790A
(zh)
|
2022-03-25 |
2024-01-16 |
英商梅迪繆思有限公司 |
減少呼吸系統感染之方法
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
TW202405009A
(zh)
|
2022-03-30 |
2024-02-01 |
瑞士商諾華公司 |
使用抗利尿鈉肽受體1(npr1)抗體治療障礙之方法
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
US20230365708A1
(en)
|
2022-04-01 |
2023-11-16 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023187176A1
(en)
|
2022-04-01 |
2023-10-05 |
Trince bv |
Method for delivering a cargo into cell
|
WO2023196866A1
(en)
|
2022-04-06 |
2023-10-12 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
WO2023196937A1
(en)
|
2022-04-06 |
2023-10-12 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring frataxin replacement therapy
|
TW202404636A
(zh)
|
2022-04-08 |
2024-02-01 |
美商英伊布里克斯公司 |
Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法
|
WO2023193239A1
(en)
|
2022-04-08 |
2023-10-12 |
Peter Peizhi Luo |
Anti-cd28 antibodies and methods of use thereof
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
TW202400243A
(zh)
|
2022-04-12 |
2024-01-01 |
日商衛材R&D企管股份有限公司 |
基於艾日布林的抗體–藥物軛合物及其使用方法
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023201291A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of mosunetuzumab and methods of use
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023209716A1
(en)
|
2022-04-25 |
2023-11-02 |
Biond Biologics Ltd. |
Anti-ilt3 antibodies and use thereof
|
TW202400637A
(zh)
|
2022-04-25 |
2024-01-01 |
美商威特拉公司 |
April之抗體分子及其用途
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
US20230407252A1
(en)
|
2022-04-28 |
2023-12-21 |
Allogene Therapeutics, Inc. |
Methods for donor cell analysis
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
WO2023215810A1
(en)
|
2022-05-05 |
2023-11-09 |
Inhibrx, Inc. |
Albumin-binding polypeptides and uses thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
WO2023217904A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
WO2023217933A1
(en)
|
2022-05-11 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf-a and il6 and methods of use
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023223092A1
(en)
|
2022-05-18 |
2023-11-23 |
Institut Pasteur |
Identification of a human circovirus
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023225336A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
WO2023225359A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
EP4279090A1
(en)
|
2022-05-20 |
2023-11-22 |
ADC Therapeutics SA |
Composition comprising a pyrrolobenzodiazepine-based antibody drug conjugate
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023230432A1
(en)
|
2022-05-23 |
2023-11-30 |
Inhibrx, Inc. |
Dr5 agonist and iap antagonist combination therapy
|
TW202411247A
(zh)
|
2022-05-23 |
2024-03-16 |
瑞士商休曼生物醫藥股份公司 |
針對流感神經胺酸酶的廣泛中和抗體
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
WO2023227202A1
(en)
|
2022-05-24 |
2023-11-30 |
Trince bv |
T cells, compositions comprising t cells and use thereof
|
GB202207691D0
(en)
|
2022-05-25 |
2022-07-06 |
Cambridge Entpr Ltd |
Quinone protected forms and conjugates
|
WO2023230554A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
|
WO2023228082A1
(en)
|
2022-05-26 |
2023-11-30 |
Pfizer Inc. |
Anti-tnfr2 antibodies and methods of use thereof
|
TW202405002A
(zh)
|
2022-05-31 |
2024-02-01 |
美商輝瑞大藥廠 |
抗-bmp9抗體及其使用方法
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023237431A1
(en)
|
2022-06-07 |
2023-12-14 |
Esocap Ag |
Drug delivery system comprising an agent effective in the treatment or prevention of an esophageal disease for the application to esophageal mucous membranes
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023240201A1
(en)
|
2022-06-08 |
2023-12-14 |
Larimar Therapeutics, Inc. |
Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
WO2023240218A1
(en)
|
2022-06-09 |
2023-12-14 |
Allogene Therapeutics Inc. |
Methods for detecting genomic abnormalities in cells
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|
WO2023240216A1
(en)
|
2022-06-11 |
2023-12-14 |
Inhibrx, Inc. |
Fcrn-binding polypeptides and uses thereof
|
WO2023245008A1
(en)
|
2022-06-13 |
2023-12-21 |
Genentech, Inc. |
Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
WO2023245048A1
(en)
|
2022-06-15 |
2023-12-21 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023242769A1
(en)
|
2022-06-17 |
2023-12-21 |
Pfizer Inc. |
Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
US20240043553A1
(en)
|
2022-06-22 |
2024-02-08 |
Genentech, Inc. |
Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide
|
CN117257934A
(zh)
|
2022-06-22 |
2023-12-22 |
中山康方生物医药有限公司 |
药物组合物及其用途
|
EP4296279A1
(en)
|
2022-06-23 |
2023-12-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-transthyretin (ttr) binding proteins and uses thereof
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024003114A1
(en)
|
2022-06-29 |
2024-01-04 |
Actome Gmbh |
Detection of biomolecules in single cells
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
WO2024006961A1
(en)
|
2022-07-01 |
2024-01-04 |
Neoleukin Therapeutics, Inc. |
Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
|
WO2024008274A1
(en)
|
2022-07-04 |
2024-01-11 |
Universiteit Antwerpen |
T regulatory cell modification
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024015993A1
(en)
|
2022-07-15 |
2024-01-18 |
Fibrogen, Inc. |
Modified anti-galectin-9 antibody and uses thereof
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024020429A1
(en)
|
2022-07-22 |
2024-01-25 |
Lyell Immunopharma, Inc. |
Immune cell therapy
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
EP4309733A1
(en)
|
2022-07-22 |
2024-01-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction
|
GB202210957D0
(en)
|
2022-07-27 |
2022-09-07 |
Alligator Bioscience Ab |
Novel dosages
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
GB202210965D0
(en)
|
2022-07-27 |
2022-09-07 |
Alligator Bioscience Ab |
Novel dosages
|
WO2024026411A1
(en)
|
2022-07-27 |
2024-02-01 |
Humabs Biomed Sa |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
WO2024023735A1
(en)
|
2022-07-27 |
2024-02-01 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
US20240052051A1
(en)
|
2022-07-29 |
2024-02-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
TW202405020A
(zh)
|
2022-07-29 |
2024-02-01 |
美商阿列克特有限責任公司 |
轉鐵蛋白受體抗原結合域及其用途
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024030982A2
(en)
|
2022-08-02 |
2024-02-08 |
Diadem Spa |
Device for detection and prognostic assessment of neurodegenerative disorders
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024028773A1
(en)
|
2022-08-03 |
2024-02-08 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024033362A1
(en)
|
2022-08-08 |
2024-02-15 |
Atb Therapeutics |
Humanized antibodies against cd79b
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
US20240085403A1
(en)
|
2022-08-16 |
2024-03-14 |
Allogene Therapeutics, Inc. |
Method for inhibiting adventitious viral infection
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024038193A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
WO2024038198A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038183A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Limited |
Multi-domain binding molecules
|
WO2024038186A1
(en)
|
2022-08-19 |
2024-02-22 |
Medimmune Limited |
Treatment of acute respiratory failure
|
WO2024040216A2
(en)
|
2022-08-19 |
2024-02-22 |
Fibrogen, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2024042212A1
(en)
|
2022-08-26 |
2024-02-29 |
Medimmune Limited |
Treatment of asthma with an anti-interleukin-33 antibody
|
WO2024044687A1
(en)
|
2022-08-26 |
2024-02-29 |
Valo Health, Inc. |
Biomarker combinations for prognosis and management of diabetic retinopathy
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
CN117679505A
(zh)
|
2022-09-09 |
2024-03-12 |
中山康方生物医药有限公司 |
药物组合及用途
|
WO2024052685A1
(en)
|
2022-09-09 |
2024-03-14 |
MyricX Pharma Limited |
Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059183A1
(en)
|
2022-09-14 |
2024-03-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of piezo1 in the treatment of cancer
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064752A2
(en)
|
2022-09-20 |
2024-03-28 |
Yale University |
Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
|
WO2024062019A1
(en)
|
2022-09-21 |
2024-03-28 |
Synabs |
Anti-ccr8 antibodies and uses thereof
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
WO2024062420A1
(en)
|
2022-09-22 |
2024-03-28 |
Pfizer Inc. |
METHODS OF TREATMENT WITH IFNß ANTIBODIES
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|
WO2024074571A1
(en)
|
2022-10-05 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
WO2024074649A1
(en)
|
2022-10-05 |
2024-04-11 |
Alcea Therapeutics, Inc. |
Notch4 antibodies, compositions, and methods for treating airway inflammation
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
GB202215115D0
(en)
|
2022-10-13 |
2022-11-30 |
Univ Nottingham |
VEGF antibodies
|
WO2024079310A1
(en)
|
2022-10-14 |
2024-04-18 |
Ebbil, Ltd. |
Sil-6r and ctgf binding proteins and methods of use thereof
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
WO2024089418A1
(en)
|
2022-10-24 |
2024-05-02 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|
WO2024089417A1
(en)
|
2022-10-24 |
2024-05-02 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
WO2024091437A1
(en)
|
2022-10-25 |
2024-05-02 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024089180A1
(en)
|
2022-10-26 |
2024-05-02 |
Eximmium Biotechnologies Gmbh |
Method to determine extracellular vesicle recovery
|
WO2024092240A1
(en)
|
2022-10-28 |
2024-05-02 |
Chinook Therapeutics, Inc. |
Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
WO2024097796A1
(en)
|
2022-11-02 |
2024-05-10 |
Kira Pharmaceuticals (Us) Llc |
Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
|
WO2024097441A1
(en)
|
2022-11-02 |
2024-05-10 |
Kira Pharmaceuticals (Us) Llc |
Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024097741A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100200A1
(en)
|
2022-11-09 |
2024-05-16 |
Cis Pharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
WO2024100663A1
(en)
|
2022-11-10 |
2024-05-16 |
Famewave Ltd. |
Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024107759A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
WO2024105205A1
(en)
|
2022-11-17 |
2024-05-23 |
Bayer Aktiengesellschaft |
Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
|
WO2024105244A1
(en)
|
2022-11-18 |
2024-05-23 |
Universiteit Antwerpen |
Igfbp2 as biomarker for thoracic aortic aneurysm and dissections
|
WO2024108178A1
(en)
|
2022-11-18 |
2024-05-23 |
Genentech, Inc. |
Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
|
WO2024110493A1
(en)
|
2022-11-21 |
2024-05-30 |
Thabor Therapeutics |
Humanized anti-agr2 antibody
|
WO2024112818A1
(en)
|
2022-11-22 |
2024-05-30 |
Humabs Biomed Sa |
Engineered anti-sars-cov-2 antibodies and uses thereof
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024115935A1
(en)
|
2022-11-29 |
2024-06-06 |
Inserm |
Methods for the treatment of b-cell lymphoma using cd39 inhibitors
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
WO2024118998A2
(en)
|
2022-12-01 |
2024-06-06 |
Vir Biotechnology, Inc. |
Engineered anti-sars-cov-2 antibodies and methods of using the same
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2024129628A1
(en)
|
2022-12-14 |
2024-06-20 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|
WO2024127332A1
(en)
|
2022-12-14 |
2024-06-20 |
Pheon Therapeutics Ltd |
Cytotoxic compounds
|